**National Cervical Screening Programme**

**Monitoring Report 49**

**1 January – 30 June 2018**

Technical report 49

Prepared April 2019

Revised November 2019

Finalised January 2020

By Megan Smith, Leanne Rumlee, Maddison Sherrah and Karen Canfell

Cancer Research Division, Cancer Council NSW Australia, Sydney NSW Australia

Suggested citation:

Smith M, Rumlee L, Sherrah M, Canfell K. National Cervical Screening Programme Monitoring Report Number 49 (1 January – 30 June 2018). National Screening Unit: Wellington, 2020.

**Acknowledgements**

This report was prepared by the authors in collaboration with the National Screening Unit (NSU), Ministry of Health, in particular Ivan Rowe, Senior Analyst, Sector Development, of the National Screening Unit.

We would like to acknowledge the contribution from Ronnie de Does, NCSP Register Central Team, for data extraction; and Simon Edwards, Robert Walker, Sarsha Yap and Dr Mark Clements for assistance with code development and importing data for analysis.

**About the authors**

The authors are based at Cancer Research Division at Cancer Council NSW, Sydney, Australia. They are part of a research group (led by Prof Karen Canfell) which has as its core research focus the epidemiology of cervical cancer, cervical screening and human papillomavirus (HPV) vaccination. This research group has established an extensive track record both in research publication and in successful completion of commissioned projects related to national cervical screening programmes in New Zealand, Australia and England. The group has extensive experience in the analysis of descriptive data from cervical cancer screening programmes. The team also has a range of related skills in the analysis of linked datasets, systematic review and meta-analysis, biostatistics, health economics, and advanced statistical modelling techniques.

Contents

[1. Executive Summary 1](#_Toc29555034)

[2. Background 12](#_Toc29555035)

[3. Methods 13](#_Toc29555036)

[Data used 13](#_Toc29555037)

[Age 13](#_Toc29555038)

[Hysterectomy-adjusted population 13](#_Toc29555039)

[Ethnicity analysis 14](#_Toc29555040)

[Calculating NCSP coverage 14](#_Toc29555041)

[4. Biannual NCSP Monitoring Indicators 16](#_Toc29555042)

[Indicator 1 – Coverage 17](#_Toc29555043)

[Indicator 1.1 – Three-year coverage 18](#_Toc29555044)

[Indicator 1.2 – Regularity of screening 34](#_Toc29555045)

[Indicator 2 – First screening events 35](#_Toc29555046)

[Indicator 3 – Withdrawal rates 41](#_Toc29555047)

[Indicator 4 – Early re-screening 45](#_Toc29555048)

[Indicator 5 – Laboratory indicators 51](#_Toc29555049)

[Indicator 5.1 – Laboratory cytology reporting 52](#_Toc29555050)

[Indicator 5.2 – Accuracy of cytology predicting HSIL 65](#_Toc29555051)

[Indicator 5.3 – Accuracy of negative cytology reports 74](#_Toc29555052)

[Indicator 5.4 – Histology Reporting 75](#_Toc29555053)

[Indicator 5.5 - Laboratory turnaround times 86](#_Toc29555054)

[Indicator 6 – Follow-up women high-grade cytology, no histology 93](#_Toc29555055)

[Indicator 7 – Colposcopy Indicators 107](#_Toc29555056)

[Indicator 7.1 – Timeliness of colposcopic assessment – high-grade cytology 108](#_Toc29555057)

[Indicator 7.2 – Timeliness of colposcopic assessment – low-grade cytology 115](#_Toc29555058)

[Indicator 7.3 – Adequacy of documenting colposcopy assessment 121](#_Toc29555059)

[Indicator 7.4 – Timeliness and appropriateness of treatment 127](#_Toc29555060)

[Indicator 7.5 – Timely discharging of women after treatment 132](#_Toc29555061)

[Indicator 8 – HPV tests 136](#_Toc29555062)

[Indicator 8.1 – Triage of low-grade cytology 137](#_Toc29555063)

[Indicator 8.2 – HPV test volumes 150](#_Toc29555064)

[Indicator 8.3 – HPV tests for follow-up of women with a historical high -grade abnormality 161](#_Toc29555065)

[Appendix A – Additional data 168](#_Toc29555066)

[Indicator 1 - Coverage 168](#_Toc29555067)

[Indicator 1.1 – Three-year coverage 168](#_Toc29555068)

[Indicator 2 – First screening events 182](#_Toc29555069)

[Indicator 3 – Withdrawal rates 185](#_Toc29555070)

[Indicator 4 – Early re-screening 186](#_Toc29555071)

[Indicator 5 – Laboratory indicators 188](#_Toc29555072)

[Indicator 5.1 – Laboratory cytology reporting 188](#_Toc29555073)

[Indicator 5.2 – Accuracy of cytology predicting HSIL 189](#_Toc29555074)

[Indicator 5.4 – Histology Reporting 194](#_Toc29555075)

[Indicator 5.5 – Laboratory turnaround time 200](#_Toc29555076)

[Indicator 6 – Follow-up of women with high-grade cytology 203](#_Toc29555077)

[Indicator 7 – Colposcopy indicators 205](#_Toc29555078)

[Indicator 7.1 – Timeliness of colposcopic assessment – high-grade cytology 205](#_Toc29555079)

[Indicator 7.2 – Timeliness of colposcopic assessment – low-grade cytology 207](#_Toc29555080)

[Indicator 7.3 – Adequacy of documenting colposcopic assessment 209](#_Toc29555081)

[Indicator 7.5 – Timely discharge of women after treatment 212](#_Toc29555082)

[Indicator 8 – HPV tests 214](#_Toc29555083)

[Indicator 8.1 – Triage of low-grade cytology 214](#_Toc29555084)

[Indicator 8.2 – HPV test volumes 217](#_Toc29555085)

[Indicator 8.3 –HPV tests for follow-up of women with a historical high-grade abnormality 221](#_Toc29555086)

[Appendix B – Bethesda 2001 New Zealand Modified 226](#_Toc29555087)

[Appendix C – SNOMED categories for histological samples 228](#_Toc29555088)

[Appendix D – Indicator Definitions Targets and Reporting Details 230](#_Toc29555089)

[Positive predictive value calculations 230](#_Toc29555090)

[Appendix E – DHB assignment for colposcopy clinics 231](#_Toc29555091)

[Appendix F – Glossary 233](#_Toc29555092)

[References 234](#_Toc29555093)

List of Tables

[Table 1 - Satisfactory and unsatisfactory cytology reporting by laboratory (1 January – 30 June 2018) 59](#_Toc29555094)

[Table 2 - Laboratory cytology reporting by general result (1 January – 30 June 2018) – percentage of satisfactory samples 59](#_Toc29555095)

[Table 3 - Laboratory cytology reporting by type of cytological category (1 January – 30 June 2018) – counts of all satisfactory samples 60](#_Toc29555096)

[Table 4 - Laboratory cytology reporting by cytological category (1 January – 30 June 2018) – percentage of all satisfactory samples 60](#_Toc29555097)

[Table 5 - Laboratory reporting of cytological category by five-year age group (1 January – 30 June 2018) – counts of all satisfactory samples 61](#_Toc29555098)

[Table 6 - Laboratory reporting of cytological category by five-year age group () – percentage of all satisfactory samples in women of that age group 62](#_Toc29555099)

[Table 7 - Histology results reporting by SNOMED category 79](#_Toc29555100)

[Table 8 - Histology results reporting by diagnostic category 80](#_Toc29555101)

[Table 9 - Histology results by age – counts 81](#_Toc29555102)

[Table 10 - Histology results by age – percentages 82](#_Toc29555103)

[Table 11 - Histology results reporting by diagnostic category excluding samples from partial\* or total hysterectomy specimens and where the result was negative/ benign. 83](#_Toc29555104)

[Table 12 - Women with a histology report within 90 and 180 days of a high-grade cytology report, by DHB 100](#_Toc29555105)

[Table 13 - Women with a histology report within 90 and 180 days of a high-grade cytology report, by age 100](#_Toc29555106)

[Table 14 - Women with a histology report within 90 days of a high -grade cytology report, by DHB and ethnicity 101](#_Toc29555107)

[Table 15 - Women with a histology report within 180 days of a high-grade cytology report, by DHB and ethnicity 102](#_Toc29555108)

[Table 16 - Women with high-grade cytology who have follow-up within 90 and 180 days recorded on the NCSP Register, by urgency of referral and type of follow-up 102](#_Toc29555109)

[Table 17 - Women without any follow-up test within 90 and 180 days of a high-grade cytology report, by DHB 104](#_Toc29555110)

[Table 18 - Women without any follow-up test within 180 days of a high -grade cytology report, by ethnicity 104](#_Toc29555111)

[Table 19 - Women with a high-grade cytology report (suspicion of invasive disease), accepted referral and colposcopy visit, by ethnicity 113](#_Toc29555112)

[Table 20 - Timeliness and appropriateness of treatment, by DHB 131](#_Toc29555113)

[Table 21 - HPV triage test results following ASC-US cytology, by age and cytology laboratory 144](#_Toc29555114)

[Table 22 - HPV triage test results following LSIL cytology, by age and cytology laboratory 145](#_Toc29555115)

[Table 23 - Three-year coverage by DHB (women 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted) 168](#_Toc29555116)

[Table 24 - Three-year coverage by ethnicity (women 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted) 168](#_Toc29555117)

[Table 25 – Three-year coverage by age (women 20-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted) 169](#_Toc29555118)

[Table 26 – Three-year coverage (women aged 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and DHB 170](#_Toc29555119)

[Table 27 – Three-year coverage (women aged 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and age 171](#_Toc29555120)

[Table 28 – Five-year coverage by DHB (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted) 172](#_Toc29555121)

[Table 29 – Five-year coverage by ethnicity (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted) 173](#_Toc29555122)

[Table 30 - Five-year coverage by age (women 20-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted) 173](#_Toc29555123)

[Table 31 - Five-year coverage (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and DHB 175](#_Toc29555124)

[Table 32 - Women under 20 years of age, and aged 15-19 years, screened in the three years prior to 30 June 2018, by DHB. 176](#_Toc29555125)

[Table 33 - Women screened under 20 years of age, as a proportion of all women screened in the three years to 30 June 2018, by DHB 177](#_Toc29555126)

[Table 34 - Women screened under 20 years of age, and women aged 18-19 years when they were screened, in the three years to 30 June 2018, by DHB 178](#_Toc29555127)

[Table 35 – Estimated age-specific prevalence of hysterectomy in New Zealand, used to perform hysterectomy adjustment 178](#_Toc29555128)

[Table 36 - Women (25-69 years) screened in the three years to 30 June 2018, as a percentage of the i) hysterectomy-adjustment NZ female population and ii) total NZ female population, by DHB 179](#_Toc29555129)

[Table 37 - Trends in three-year coverage by DHB (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population) 180](#_Toc29555130)

[Table 38 - Trends in three-year coverage by age (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population) 180](#_Toc29555131)

[Table 39 - Trends in three-year coverage by ethnicity (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population) 181](#_Toc29555132)

[Table 40 - Age distribution of first screening events for period 1 January – 30 June 2018 182](#_Toc29555133)

[Table 41 - Women (aged 20-69 years) with first screening events as a proportion of i) total number of women with screening events, and ii) eligible women, by DHB, for period 1 January – 30 June 2018 183](#_Toc29555134)

[Table 42 - Women (ages 20-69 years) with first screening events as a proportion of i) total number of women with screening events, and ii) eligible women, by ethnicity, for period 1 January – 30 June 2018 183](#_Toc29555135)

[Table 43 - Median age of women with a first screening event, by ethnicity, for period 1 January – 30 June 2018 184](#_Toc29555136)

[Table 44 - Number of women who withdrew from the NCSP Register 1 January – 30 June 2018 by age, and proportion of women who were enrolled at the start of the monitoring period who withdrew 185](#_Toc29555137)

[Table 45 - Number of women (aged 20-69 years) who withdrew from the NCSP Register 1 January – 30 June 2018 by ethnicity, and proportion of women who were enrolled at the start of the monitoring period who withdrew 185](#_Toc29555138)

[Table 46 - Early re-screening by five-year age group 186](#_Toc29555139)

[Table 47 - Early re-screening by DHB 186](#_Toc29555140)

[Table 48 - Early re-screening by ethnicity 187](#_Toc29555141)

[Table 49 - Age-standardised percentage of satisfactory smears reported as HSIL, by laboratory 188](#_Toc29555142)

[Table 50 - Positive predictive value of a report of HSIL + SC cytology, excluding samples from colposcopy, by laboratory 189](#_Toc29555143)

[Table 51 – Comparison of PPV based on original method vs updated method excluding samples from colposcopy, by cytology category and laboratory 189](#_Toc29555144)

[Table 52 - Positive predictive value of a report of HSIL + SC cytology (original method), by laboratory 190](#_Toc29555145)

[Table 53 - Positive predictive value of a report of ASC-H cytology, excluding samples from colposcopy, by laboratory 190](#_Toc29555146)

[Table 54 - Positive predictive value of a report of ASC-H cytology (original method), by laboratory 191](#_Toc29555147)

[Table 55 - Positive predictive value of a report of ASC-H + HSIL + SC cytology, excluding samples from colposcopy, by laboratory 191](#_Toc29555148)

[Table 56 - Positive predictive value of a report of ASC-H + HSIL + SC cytology (original method), by laboratory 192](#_Toc29555149)

[Table 57 – Change in categorisation of women with high grade cytology results between the original and updated method excluding samples from colposcopy 192](#_Toc29555150)

[Table 58 - Rate of women with CIN 2/3 per 1,000 women screened, by age and ethnicity and for NZ overall, 1 January – 30 June 2018 195](#_Toc29555151)

[Table 59 - Rate of women, per 1,000 women screened, with CIN 2/3 histology, by age and ethnicity, July-Dec 2008 to Jan-Jun 2018 196](#_Toc29555152)

[Table 60 - Number of women screened, by age and ethnicity, July-Dec 2008 to Jan-Jun 2018 198](#_Toc29555153)

[Table 61 - Timeliness of cytology reporting by laboratory, 1 January – 30 June 2018 200](#_Toc29555154)

[Table 62 - Timeliness of histology reporting by laboratory, 1 January – 30 June 2018 201](#_Toc29555155)

[Table 63 - Timeliness of reporting for cytology with associated HPV testing by laboratory, 1 January – 30 June 2018 202](#_Toc29555156)

[Table 64 - Women with a histology report within 90 days of a high-grade cytology report, by DHB and age 203](#_Toc29555157)

[Table 65 - Women with a histology report within 180 days of a high-grade cytology report, by DHB and age 204](#_Toc29555158)

[Table 66 - Women with high -grade cytology (including cytological suspicion of invasive disease), by DHB 205](#_Toc29555159)

[Table 67 - Women with a high -grade cytology report (no suspicion of invasive disease), accepted referral and a colposcopy visit within 20 and 40 working days, by ethnicity 205](#_Toc29555160)

[Table 68 - Women with a high-grade cytology report (no suspicion of invasive disease), accepted referral and a colposcopy visit within 20 and 40 working days, by DHB 206](#_Toc29555161)

[Table 69 - Women with cytological suspicion of invasive disease, by cytology result subcategory 206](#_Toc29555162)

[Table 70 - Follow-up of women with persistent low -grade cytology/ low -grade cytology and positive hrHPV test, by DHB 207](#_Toc29555163)

[Table 71 - Follow-up of women with persistent low -grade cytology/ low-grade cytology and positive hrHPV test, by ethnicity 208](#_Toc29555164)

[Table 72 - Completion of colposcopic assessment fields, by DHB 209](#_Toc29555165)

[Table 73 - Summary of colposcopic appearance findings, by DHB 210](#_Toc29555166)

[Table 74 - Biopsies by colposcopic appearance and DHB 211](#_Toc29555167)

[Table 75 - Follow-up of treated women with colposcopy and cytology in the period up to nine months post-treatment, and discharge of eligible women 212](#_Toc29555168)

[Table 76 - Follow-up of treated women in the period up to nine months post-treatment 213](#_Toc29555169)

[Table 77 - Triage testing of women with ASC-US cytology 214](#_Toc29555170)

[Table 78 - Triage testing of women with LSIL cytology 215](#_Toc29555171)

[Table 79 - Histological outcomes within 12 months in women with ASC-US cytology and positive HPV triage test 215](#_Toc29555172)

[Table 80 - Histological outcomes within 12 months in women with LSIL cytology and positive HPV triage test 216](#_Toc29555173)

[Table 81 - Volume of HPV test samples received during the monitoring period, by laboratory 217](#_Toc29555174)

[Table 82 - Invalid HPV tests, by laboratory 217](#_Toc29555175)

[Table 83 - Validity of HPV triage tests, by test technology 217](#_Toc29555176)

[Table 84 - Volume of HPV test samples received during the monitoring period, by purpose and ethnicity 218](#_Toc29555177)

[Table 85 - Volume of HPV test samples received during the monitoring period, by purpose and age 218](#_Toc29555178)

[Table 86 - Volume of HPV test samples received during the monitoring period, by purpose and laboratory 219](#_Toc29555179)

[Table 87 - HPV test samples collected at colposcopy, in relation to total colposcopies performed in the period, by DHB 220](#_Toc29555180)

[Table 88 - Women eligible for and proportion who have received HPV testing for a historical high-grade abnormality, by age at 30 June 2018 221](#_Toc29555181)

[Table 89 - Women eligible for and proportion who have received historical HPV testing, by DHB 222](#_Toc29555182)

[Table 90 - Women eligible for and proportion who have received historical HPV testing, by ethnicity 222](#_Toc29555183)

[Table 91 - Women screened in the previous five years and proportion of women with historical round 1 and 2 tests recorded, by DHB 225](#_Toc29555184)

[Table 92 - Definition used for positive predictive value calculations 230](#_Toc29555185)

List of Figures

[Figure 1 - Three-year coverage by ethnicity (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population) 23](#_Toc29821684)

[Figure 2 - Three-year coverage by five-year age group (women 20-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population) 23](#_Toc29821685)

[Figure 3 - Three-year coverage by DHB (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population) 24](#_Toc29821686)

[Figure 4 - Three-year coverage in Māori women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 24](#_Toc29821687)

[Figure 5 - Three-year coverage in Pacific women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 25](#_Toc29821688)

[Figure 6 - Three-year coverage in Asian women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 25](#_Toc29821689)

[Figure 7 - Three-year coverage in European/ Other women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 26](#_Toc29821690)

[Figure 8 - Three-year coverage (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by ethnicity and five-year age group 26](#_Toc29821691)

[Figure 9 - Five-year coverage by DHB (women screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population) 27](#_Toc29821692)

[Figure 10 - Five-year coverage by five-year age-group (women screened in the five years prior to 30 June 2018, as proportion of hysterectomy-adjusted female population) 27](#_Toc29821693)

[Figure 11 - Five-year coverage by ethnicity (women screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population) 28](#_Toc29821694)

[Figure 12 - Five-year coverage in Māori women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 28](#_Toc29821695)

[Figure 13 - Five-year coverage in Pacific women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 29](#_Toc29821696)

[Figure 14 - Five-year coverage in Asian women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 29](#_Toc29821697)

[Figure 15 - Five-year coverage in European/ Other women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB 30](#_Toc29821698)

[Figure 16 - Number of women screened who were aged less than 20 years at the time of their cervical sample in the three years to 30 June 2018, by DHB 30](#_Toc29821699)

[Figure 17 - Trends in three-year coverage by DHB (women aged 25-69 years screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\* 31](#_Toc29821700)

[Figure 18 - Trends in three-year coverage by age (women screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\* 32](#_Toc29821701)

[Figure 19 - Trends in three-year coverage by ethnicity (women aged 25-69 years screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\* 32](#_Toc29821702)

[Figure 20 - Trends in the number of women screened in the preceding three years who were aged less than 20 years at the time of their cervical sample, by DHB 33](#_Toc29821703)

[Figure 21 - Trends in the percent of women aged less than 20 years at the time of their cervical sample who were aged 18 or 19 years, by DHB 33](#_Toc29821704)

[Figure 22 - Women with first screening events during the monitoring period, by five-year age group (women aged 20-69 years at 30 June 2018) 37](#_Toc29821705)

[Figure 23 - Women with first screening events as a proportion of all women screened in that age group during the monitoring period, by five-year age group (women aged 20-69 years at 30 June 2018) 37](#_Toc29821706)

[Figure 24 - Women with first screening events as a proportion of all women screened during the monitoring period, by DHB (women aged 20-69 years at 30 June 2018) 38](#_Toc29821707)

[Figure 25 - Women with first screening events as a proportion of all women screened during the monitoring period, by ethnicity (women aged 20-69 years at 30 June 2018) 38](#_Toc29821708)

[Figure 26 - Trends in the number of women with a first screening event, by age 39](#_Toc29821709)

[Figure 27 - Trends in the number of women with a first screening event, by DHB 39](#_Toc29821710)

[Figure 28 - Trends in the number of women with a first screening event, by ethnicity 40](#_Toc29821711)

[Figure 29 - Number of women (aged 20-69 years) who withdrew from the NCSP Register by DHB, 1 January – 30 June 2018 43](#_Toc29821712)

[Figure 30 - Number of women who withdrew from the NCSP Register by age, 1 January – 30 June 2018 43](#_Toc29821713)

[Figure 31 - Number of women (aged 20-69 years) who withdrew from the NCSP Register by ethnicity, 1 January – 30 June 2018 44](#_Toc29821714)

[Figure 32 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by DHB 48](#_Toc29821715)

[Figure 33 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by five-year age group 48](#_Toc29821716)

[Figure 34 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by ethnicity 49](#_Toc29821717)

[Figure 35 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by DHB 49](#_Toc29821718)

[Figure 36 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by age 50](#_Toc29821719)

[Figure 37 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by ethnicity 50](#_Toc29821720)

[Figure 38 - Proportion of total LBC samples reported as unsatisfactory by laboratory, 1 January – 30 June 2018 57](#_Toc29821721)

[Figure 39 - Proportion of total satisfactory samples reported as negative by laboratory, 1 January – 30 June 2018 57](#_Toc29821722)

[Figure 40 - Proportion of total satisfactory samples reported as abnormalities by laboratory, 1 January – 30 June 2018 58](#_Toc29821723)

[Figure 41 - Proportion of total satisfactory samples reported as HSIL by laboratory, 1 January – 30 June 2018 58](#_Toc29821724)

[Figure 42 - Trends in the proportion of total satisfactory samples reported as HSIL (last four monitoring periods), by age 63](#_Toc29821725)

[Figure 43 - Longer term trends in the proportion of total satisfactory samples reported as HSIL (to 1 January – 30 June 2018), by age 63](#_Toc29821726)

[Figure 44 - Trends in the proportion of total satisfactory samples reported as HSIL, by laboratory 64](#_Toc29821727)

[Figure 45 - Positive predictive value for CIN 2+ in women with HSIL or SC cytology reports (cytology sample collected 1 January – 30 June 2018), excluding samples from colposcopy, by laboratory 70](#_Toc29821728)

[Figure 46 – Comparison of positive predictive value for CIN 2+ in women with HSIL or SC cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory 70](#_Toc29821729)

[Figure 47 - Comparison of positive predictive value for CIN 2+ in women with ASC-H cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory 71](#_Toc29821730)

[Figure 48 - Comparison of positive predictive value for CIN 2+ in women with ASC-H, HSIL or SC cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory 71](#_Toc29821731)

[Figure 49 - Trends in the positive predictive value for CIN 2+ in women with HSIL or SC cytology results (based on original method), by laboratory 72](#_Toc29821732)

[Figure 50 - Trends in the positive predictive value for CIN 2+ in women with HSIL or SC cytology results (based on original method), by laboratory, Jul-Dec 2008 – Jan-Jun 2018 72](#_Toc29821733)

[Figure 51 - Trends in the positive predictive value for CIN 2+ in women with ASC-H cytology results (based on original method), by laboratory 73](#_Toc29821734)

[Figure 52 - Trends in the positive predictive value for CIN 2+ in women with ASC-H, HSIL or SC cytology results (based on original method), by laboratory 73](#_Toc29821735)

[Figure 53 - Rate of women with CIN 2/3 per 1,000 women screened, by age and ethnicity for the period 1 January – 30 June 2018 84](#_Toc29821736)

[Figure 54 - Trends in the age standardised rate of women with CIN 2/3 per 1,000 women screened, by ethnicity 84](#_Toc29821737)

[Figure 55 - Trends in the rate of women with CIN 2/3 per 1,000 women screened, by age 85](#_Toc29821738)

[Figure 56 - Trends in the rate of women with CIN 2/3 per 1,000 women screened, by ethnicity and selected ages 85](#_Toc29821739)

[Figure 57 - Proportion of cytology samples reported within seven working days by laboratory, 1 January – 30 June 2018 90](#_Toc29821740)

[Figure 58 - Proportion of cytology samples reported within 15 working days by laboratory, 1 January – 30 June 2018 90](#_Toc29821741)

[Figure 59 - Proportion of histology samples reported within ten working days by laboratory, 1 January – 30 June 2018 91](#_Toc29821742)

[Figure 60 - Proportion of histology samples reported within 15 working days by laboratory, 1 January – 30 June 2018 91](#_Toc29821743)

[Figure 61 - Proportion of cytology samples with associated HPV triage testing and of all cytology samples reported within 15 days by laboratory, 1 January – 30 June 2018 92](#_Toc29821744)

[Figure 62 - Proportion of women with a histology report within 90 days, and within 180 days of their high -grade cytology report, by DHB 99](#_Toc29821745)

[Figure 63 - Proportion of women without any follow-up test within 90 days and within 180 days of a high-grade cytology report, by DHB 103](#_Toc29821746)

[Figure 64 - Proportion of women without any follow-up test within 90 days and within 180 days of a high-grade cytology report, by ethnicity 103](#_Toc29821747)

[Figure 65 – Trends in the proportion of women with high-grade cytology who have follow-up within 90 days recorded on the NCSP Register, by DHB 105](#_Toc29821748)

[Figure 66 – Trends in the proportion of women with high-grade cytology who have follow-up within 180 days recorded on the NCSP Register, by DHB 105](#_Toc29821749)

[Figure 67 - Trends in the proportion of women with high-grade cytology who have follow-up within 90 days recorded on the NCSP Register, by ethnicity 106](#_Toc29821750)

[Figure 68 - Trends in the proportion of women with high-grade cytology who have follow-up within 180 days recorded on the NCSP Register, by ethnicity 106](#_Toc29821751)

[Figure 69 - Percentage of women with a high-grade cytology (no suspicion of invasive disease) with a colposcopy visit within 20 and 40 working days, by ethnicity 113](#_Toc29821752)

[Figure 70 - Percentage of women with a high-grade cytology (no suspicion of invasive disease) with a colposcopy visit within 20 and 40 working days, by DHB 114](#_Toc29821753)

[Figure 71 – Trends of the proportion of women with a high -grade cytology report (no suspicion of invasive disease) seen within 4 weeks (20 working days), by ethnicity 114](#_Toc29821754)

[Figure 72 - Follow-up recorded\* for women with persistent LG cytology/ LG cytology and positive hrHPV test, by DHB 118](#_Toc29821755)

[Figure 73 - Follow-up recorded\* for women with persistent LG cytology/ LG cytology and positive hrHPV test, by ethnicity 118](#_Toc29821756)

[Figure 74 - Women with persistent LG cytology/ LG cytology and positive hrHPV test and an accepted referral for colposcopy: percentage with a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by DHB 119](#_Toc29821757)

[Figure 75 - Women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy: percentage with a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by ethnicity 119](#_Toc29821758)

[Figure 76 - Trends in the proportion of women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy who have a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by DHB 120](#_Toc29821759)

[Figure 77 - Trends in proportion of women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy who have a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by ethnicity 120](#_Toc29821760)

[Figure 78 - Completion of colposcopic assessment fields, by DHB 125](#_Toc29821761)

[Figure 79 - Trends in the completion of all required colposcopic assessment fields, by DHB 125](#_Toc29821762)

[Figure 80 - Trends in the number of colposcopies recorded on the NCSP Register, by DHB 126](#_Toc29821763)

[Figure 81 - Proportion of women treated within eight weeks of histological confirmation of HSIL, by DHB 130](#_Toc29821764)

[Figure 82 - Trends in the proportion of women treated within eight weeks of histological confirmation of HSIL, by DHB 130](#_Toc29821765)

[Figure 83 - Percentage of women treated with colposcopy, and both colposcopy and cytology, within nine months post-treatment, by DHB 135](#_Toc29821766)

[Figure 84 - Percentage of women discharged appropriately within 12 months of treatment, by DHB 135](#_Toc29821767)

[Figure 85 - Proportion of women (aged 30 years or more) with low-grade cytology who have a subsequent HPV test, by laboratory and cytology result 142](#_Toc29821768)

[Figure 86 - Proportion of HPV triage tests which are positive following ASC-US cytology (women aged 30 years or more), by cytology laboratory 142](#_Toc29821769)

[Figure 87 - Proportion of HPV triage tests which are positive following LSIL cytology (women aged 30 years or more), by cytology laboratory 143](#_Toc29821770)

[Figure 88 - Proportion of women with an HPV triage test who are HPV positive, by age and cytology result 143](#_Toc29821771)

[Figure 89 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of all women with histology, by laboratory 146](#_Toc29821772)

[Figure 90 – Triage-positive *women with histologically-confirmed* CIN 2+ within 12 months, as a percentage of all women who attended colposcopy, by laboratory 146](#_Toc29821773)

[Figure 91 - Women with histologically-confirmed CIN 2+ within 12 months, as a percentage of all women who attended colposcopy, by laboratory and referral cytology 147](#_Toc29821774)

[Figure 92 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with histology recorded, by age 147](#_Toc29821775)

[Figure 93 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by age 148](#_Toc29821776)

[Figure 94 –Trends in ASC-US triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by laboratory 148](#_Toc29821777)

[Figure 95 – Trends in LSIL triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by laboratory 149](#_Toc29821778)

[Figure 96 - Volume of HPV test samples received by laboratories during the monitoring period, by age 156](#_Toc29821779)

[Figure 97 - Volume of HPV test samples received by laboratories during the monitoring period, by laboratory 156](#_Toc29821780)

[Figure 98 - HPV test samples as a percentage of cytology test samples received during the monitoring period, by laboratory 157](#_Toc29821781)

[Figure 99 - Volume of HPV test samples received during the monitoring period, by purpose 157](#_Toc29821782)

[Figure 100 - HPV test samples received during the monitoring period, by purpose and age 158](#_Toc29821783)

[Figure 101 - HPV test samples received during the monitoring period, by purpose and laboratory 158](#_Toc29821784)

[Figure 102 - HPV test samples collected at colposcopy, in relation to total colposcopies\* performed in the period, by DHB 159](#_Toc29821785)

[Figure 103 - Trends in volumes of HPV test samples received, by laboratory 159](#_Toc29821786)

[Figure 104 - Trends in volumes of HPV test samples received, by purpose 160](#_Toc29821787)

[Figure 105 - Trends in HPV test samples collected at colposcopy, in relation to total colposcopies\* performed in the period, by DHB 160](#_Toc29821788)

[Figure 106 - Proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by age at 30 June 2018 165](#_Toc29821789)

[Figure 107 - Proportion of eligible women with squamous high -grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by DHB at 30 June 2018 165](#_Toc29821790)

[Figure 108 - Proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by ethnicity at 30 June 2018 166](#_Toc29821791)

[Figure 109 – Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by DHB 166](#_Toc29821792)

[Figure 110 - Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by ethnicity 167](#_Toc29821793)

[Figure 111 - Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by age 167](#_Toc29821794)

[Figure 112 - Proportion of population\* in that age group with their first screening event during the monitoring period (women aged 20-69 years at 30 June 2018) 182](#_Toc29821795)

[Figure 113 - Trends in histologically-confirmed HSIL as a percentage of all women with histology (to 1 January – 30 June 2018) 194](#_Toc29821796)

[Figure 114 - Rate of women with CIN 2/3 per 1,000 women screened, by age, 1 January 2008 – 30 June 2018 194](#_Toc29821797)

[Figure 115 - Number of women eligible for historical testing within a DHB versus the percentage with a Round 1 historical HPV test recorded 223](#_Toc29821798)

[Figure 116 - Relationship between women screened in the previous five years and proportion of women with historical tests recorded, by DHB 223](#_Toc29821799)

[Figure 117 - Relationship between women screened in the previous five years and proportion of women with historical tests recorded, by ethnicity 224](#_Toc29821800)

# Executive Summary

|  |  |
| --- | --- |
| **Purpose** | This report provides data on performance indicators of the National Cervical Screening Programme (NCSP) for the period 1 January to 30 June 2018. |
| **Key points on performance/trends** | |
| Indicator 1 | Coverage |
| Indicator 1.1 | Three-year coverage  **Target:** 80% of eligible women screened within the previous three years.   * Among an estimated 1,291,580 eligible women aged 25-69 years at the end of the monitoring period, 931,546 (72.1%) had a screening test in the previous three years. * The coverage target was not met nationally (80% of women aged 25-69 years screened in the previous three years). * The coverage target was not met in any five-year age group. * No DHBs met the coverage target. * Nationally, coverage targets were not met for any ethnicity including European/ Other women, Māori, Pacific, or Asian women (78.0%, 61.8%, 68.6%, 59.1% respectively screened within the previous three years). * Five-year coverage among women aged 25-69 years exceeded 80% in all DHBs, in Pacific and European/ Other women, and in women in all five-year age groups between 30-69 years.   Changes in the estimates of the eligible population (the denominator) between reports has occurred between this and the previous report (see comments section for this indicator in the main body of the report for more information). Caution must therefore be taken when interpreting these results as differences between reports may not be a true reflection of changes in coverage but due to more accurate estimates in the eligible population.   * Differences were seen in three-year coverage among women aged 25-69 years, with a coverage of 72.1% in this report and 74.8% in the previous report. A change in more than one percentage point was seen for all ethnicities except Māori women. * Three-year coverage has changed by more than one percentage point in each of the 5-year age groups between 20 and 69 years. * Three-year coverage has not changed by more than one percentage point in any DHB. * Five-year coverage among women aged 25-69 years was found to be 85.8% in this report and 88.6% in the previous monitoring report.   *Screens in women aged less than 20 years*  **Target:** None   * In the three years to 30 June 2018, 5,309 women had a cervical sample taken when they were aged less than 20 years. This is fewer than in the previous monitoring period (5,682 women). * This represents 0.6% of all women (of any age) who were screened in the three-year period (which is similar to the previous monitoring period, 0.5%). * Most of these women (89.4%) were aged 18-19 years at the time of their cervical sample. |
| Indicator 1.2 | Regularity of screening  **Target:** Not yet defined  This indicator is assessed annually, in the report that relates to the second half of each calendar year, and so is not assessed in this report. This indicator was last assessed in Report 48 and will be next assessed in Report 50. |
| Indicator 2 | First screening events  **Target:** None   * There were 23,911 women who had their first screening event during the current monitoring period – an increase compared to the previous monitoring period. * First screening events generally occur among young women (median age 26 years). * Asian women appear to have their first screening event at a later age (median age of Asian women attending for their first screening event was 31 years). * The proportion of women attending for screening who are attending for their first test is highest in Asian women. |
| Indicator 3 | Withdrawal rates  **Target:** Zero between ages 20-69 years   * There were 22 women aged between 20-69 years who withdrew from the NCSP Register during this six-month period. This is similar to the number of women in this age range who withdrew during the previous monitoring period (20 women). |
| Indicator 4 | Early re-screening  **Target:** Not yet defined  Currently reporting on the percentage of women in routine screening (previous smear negative and recommended to return in 36 months (3 years)) who returned for a smear within 30 months (2.5 years) of their index smear.   * 12.1% of a cohort of women with a recommendation to return at the routine interval had at least one cytology sample within 30 months of their index cytology sample. * Early re-screening varies widely between DHBs, from 6.5% in West Coast to 16.7% in Wairarapa. * Early re-screening occurs in all ethnic groups but is most common among European/ Other (12.5%) and least common among Pacific women (8.4%). * Early re-screening occurs in all age groups but is most common in women aged 20-24 years at the end of the period (15.9%) and least common in women aged 65-69 years at the end of the period (7.7%). * Early re-screening has decreased slightly overall since the previous report, from 12.6% to 12.1%. |
| Indicator 5 | Laboratory Indicators |
| Indicator 5.1 | Cytology reporting  *Unsatisfactory cytology*  **Target:** 0.1% - 3% for LBC   * The target for the percentage of LBC samples reported as unsatisfactory was met by five of the six laboratories and was met nationally (1.3%). * The rate of unsatisfactory LBC samples is similar to that in the previous report (1.4%).   *Negative cytology*  **Target:** No more than 96% of satisfactory cytology samples   * The target for the percent of samples reported as negative was met nationally (93.3%) and met in all six laboratories. * Nationally, the percent of samples which are negative (93.3%) is similar to what was reported in the previous period (93.5%).   *Abnormal cytology*  **Target:** No more than 10% of satisfactory cytology samples   * The target for the percent of samples reported as abnormal was met nationally (6.7%) and by four of six laboratories. * Nationally, the percent of samples which are abnormal (6.7%) is similar to what was reported in the previous period (6.5%).   *HSIL cytology*  **Target:** No less than 0.5% of satisfactory cytology samples   * The target for the percent of HSIL samples was met nationally and met by all six laboratories. * Nationally the percent of HSIL samples (0.8%) was slightly higher than in the last monitoring report (0.7%). * In women aged 20-24 years the rate of HSIL samples is again lower than has ever been previously reported. |
| Indicator 5.2 | Cytology positive predictive value  *An updated method was used in the current report that excluded high grade cytology samples collected at a colposcopy visit from this indicator. Results from this updated method are not directly comparable to those derived via the original method in previous reports for trends reporting.*  *HSIL + SC*  **Target:** 65% - 85% of HSIL+SC cytology samples should be histologically confirmed as high-grade   * Five of six laboratories met the target range for HSIL + SC. * Nationally, the positive predictive value of HSIL + SC is 80.2%, and ranges across laboratories from 77.4% to 85.9%. * When results derived using the original method (not excluding cytology collected at colposcopy) are compared with previous reports, the positive predictive value of HSIL + SC was higher in this monitoring period than in the previous report.   *Other cytological abnormalities*  **Target:** None   * Nationally, the positive predictive value of ASC-H is 55.4%, and ranges across laboratories from 53.2% to 62.7%. * Nationally, the positive predictive value of the combination of ASC-H + HSIL + SC is 70.5%, and ranges across laboratories from 62.2% to 74.1%. * Nationally, the percent of glandular cytological abnormalities identified as histological high-grade is 50.0% (however this measure is generally based on a comparatively small number of samples; 156 samples with histology in the current report). * When results derived using the original method (not excluding cytology collected at colposcopy) are compared with previous reports, the positive predictive values of ASC-H, the combination of ASC-H + HSIL + SC, and for glandular abnormalities have all increased. |
| Indicator 5.3 | Accuracy of negative cytology reports  Among cytology slides within the 42 months preceding a histological diagnosis of high-grade/ invasive disease originally reported as negative, benign/ reactive or unsatisfactory:  **Target:** Not more than 10% identified as HS1, HS2, SC, AIS or AC1-AC5 (HSIL+) on review  Data for this indicator is provided annually and so this indicator is reported annually (in the report that relates to the second half of each calendar year) and is not assessed in this report. This indicator was last assessed in Report 48 and will be next assessed in Report 50. |
| Indicator 5.4 | Histology reporting  **Target:** None   * 12,467 histology samples were taken during the current monitoring period. 431 (3.5%) of these were insufficient for diagnosis. * Results for most severe histology from 10,553 women with samples which were sufficient for diagnosis are presented. * 56.1% of women had histology samples which were negative/ benign. This reduced to 45.1% of women when negative/ benign hysterectomy samples (total hysterectomy and partial hysterectomy with cervical component) were excluded. * 19.4% of women had CIN 2/3 or HSIL histology results. * 67 (0.63%) women had histology results indicating adenocarcinoma in situ (AIS). * 51 (0.48%) women had invasive squamous cell carcinoma (ISCC) histology results, 39 (0.37%) women had adenocarcinomas not arising from the endocervix and four women (<0.05%) adenocarcinoma arising from the endocervix histology results. Two women (<0.05%) had adenosquamous carcinoma histology results. |
| Indicator 5.5 | Turnaround times  *Cytology*  **Target:** 90% within seven working days; 98% within 15 working days   * The seven-working-days target for cytology was met nationally (94.9%) and was met by four of six laboratories. * The 15-working-days target was met nationally (99.0%) and was also met in all six laboratories. * Performance against the seven-working-days target is lower when compared to the previous report (96.3% to 94.9% in the current monitoring period). * The overall percent of cytology samples reported within 15-working-days (99.0%) is similar to the previous monitoring period (99.2%).   *Histology*  **Target:** 90% within 10 working days; 98% within 15 working days   * Turnaround time target for histology was met nationally for reporting within 10 working days (92.3%). * The target was not met for reporting within 15 working days (96.9%). * Targets were met by eight of 14 laboratories (10-working-day target) and five of 14 laboratories (15-working-day target). * The overall proportion of histology samples reported within 15 days (96.9%) was similar to what was reported in the previous report (97.2%).   *Low-grade cytology with associated HPV triage testing*  **Target:** 98% within 15 working days   * There were 3,063 cytology samples with associated HPV triage testing in the current monitoring period. * The 15-working-days target for turnaround time for cytology with associated HPV triage testing was met nationally (99.3%). * Four of the six laboratories met the target. |
| Indicator 6 | Follow-up of women with high -grade cytology – histology  *Histological follow-up*  **Target:** 90% of women should have a histology report within 90 days of their high-grade cytology report date; 99% should have a histology report within 180 days of their cytology report.   * Targets were not met nationally (for either 90 days or 180 days). * 84.0% of women had a histology report within 90 days of their high-grade cytology report; 89.1% of women had one within 180 days. * Three DHBs met the target for histological follow-up within 90 days and no DHBs met the target for 180 days. * Nationally, the proportion of women with histological follow-up has increased at 90 days (from 83.0% to 84.0%) and at 180 days (from 88.3% to 89.1%) since the previous monitoring period. * Compared to the previous monitoring period, the proportion of women with follow-up histology within 90 days has increased for Māori women (from 78.9% to 80.3%), Pacific (from 68.6% to 71.1%) and Asian women (from 77.6% to 86.5%). European/ Other women had similar rates between both reports (from 85.7% to 85.4%). * The proportion of women with follow-up histology within 180 days has increased for Pacific and Asian women and is similar to the previous report for Māori and European/ Other women.   *Women with no follow-up tests*  **Target:** None   * Nationally, 140 (8.2%) women have no report of a follow-up test of any kind (colposcopy, subsequent cytology, histology or HPV test) within 90 days of their high-grade cytology report, and 94 (5.5%) women have no follow-up test report within 180 days. * Nationally, the proportion of women with no record of a follow-up test report at 90 days (from 8.5% to 8.2%) and for 180 days (from 5.7% to 5.5%) were similar over the last two reports. * Compared to the previous monitoring period, the proportion of women with no follow-up test recorded at 180 days has increased for Pacific (from 10.5% to 12.0%) and Asian women (from 7.1% to 8.2%), decreased for Māori women (from 9.5% to 8.2%) and remained similar for European/ Other women (from 4.3% to 4.1%). |
| Indicator 7 | Colposcopy |
| Indicator 7.1 | Timeliness of colposcopic assessment – high -grade cytology  **Target:** 95% or more of women who have evidence of clinical suspicion of invasive carcinoma, or a suspicion of invasive disease (TBS codes HS2, SC, AC1-AC5), receive colposcopy or a gynaecological assessment within 10 working days of receipt of referral. 95% or more of women who have other high-grade smear abnormalities (TBS codes ASH, HS1, AG1-AG5, AIS) receive colposcopy within 20 working days of receipt of referral.     * There were 1,706 women with high-grade cytology results who were not already under specialist management (the same women reported on in Indicator 6). * This comprised 43 women with high-grade results indicating a suspicion of invasive disease and 1,663 women with other high-grade results. * Nationally, the proportion of women with accepted referrals recorded on the NCSP Register (90.2%) is similar to the previous report (88.2%).   *Suspicion of Invasive Disease*   * Among the 43 women with high-grade cytology results indicating a suspicion of invasive disease, 30 (69.8%) had an accepted referral. Of the women with an accepted referral, 83.3% were seen within 10 working days of their referral being accepted. This is higher than in the previous report (65.0%). * A colposcopy visit was recorded for 41 (95.3%) of these women as of 30 June 2018 (follow-up time of at least six and up to 12 months).   *No Suspicion of Invasive Disease*   * Among the 1,663 women with other high-grade cytology results, 1,509 (90.7%) had an accepted referral. Of the women with an accepted referral, 75.7% were seen within 20 working days of their referral being accepted. This is similar to the proportion seen within 20 working days in the previous monitoring period (75.6%). * A colposcopy visit is recorded for 1,576 (94.8%) of these women as of 30 June 2018 (follow-up time of at least six and up to 12 months). |
| Indicator 7.2 | Timeliness of colposcopic assessment – low-grade cytology  **Target**: 95% of women who have persistent low-grade abnormalities or a low-grade abnormality and positive HPV test, must receive a date for a colposcopy appointment within a period that does not exceed 26 weeks of the colposcopy unit accepting the referral from the sample taker.   * There were 3,488 women with persistent low-grade cytology or low-grade cytology and a positive hrHPV test collected (the 6-month period ending 12 months prior to the end of the current monitoring period, i.e. between 1 January – 30 June 2017). * Subsequent accepted referrals are recorded for 3,017 (86.5%) of these women, and subsequent colposcopy (by 30 June 2018) for 3,198 (91.7%) of these women. * Nationally, 88.8% of women attended for colposcopy within 26 weeks of their accepted referral. This is higher than in the previous monitoring report (85.1%). |
| Indicator 7.3 | Adequacy of reporting colposcopy  **Target:** 100% of medical notes will accurately record colposcopic findings including visibility of the squamo-columnar junction, presence or absence of a visible lesion, and colposcopic opinion regarding the nature of the abnormality.   * Based on 12,198 colposcopy visits in the current monitoring period recorded on the NCSP Register, no DHB nor the aggregate of colposcopy visits to private practice met the target of 100% completion of all recommended fields. * All items (degree of visibility of the squamo-columnar junction, presence or absence of a lesion and colposcopic opinion regarding abnormality) were documented for 92.6% of colposcopy visits. * The type of recommended follow-up was recorded for 95.6% of colposcopy visits, and the recommended timeframe for this follow-up was recorded for 94.9% of colposcopy visits. * Colposcopic appearance was reported as abnormal in 54.0% of colposcopies, and inconclusive in 4.9% of colposcopies. * Completion of most recommended fields is broadly similar to what was reported in the previous monitoring period. * Overall completion is similar in this monitoring period (92.6%) to the previous monitoring period (92.2%). * The number of colposcopies recorded on the NCSP Register was similar to what had been reported in the previous report (0.7% increase). * All DHBs were reporting colposcopy data electronically to the NCSP Register throughout the current monitoring period. |
| Indicator 7.4 | Timeliness and appropriateness of treatment  **Target:** 90% or more of women with HSIL should be treated within eight weeks of histological confirmation.   * 63.8% of 2,130 women with HSIL (CIN 2/3) histology during the period 1 July to 31 December 2017 have a record of treatment within eight weeks of their histology report. * The proportion of women with histologically-confirmed CIN 2/3 who were treated within eight weeks of their histology result being reported (63.8%) was similar to the previous monitoring period (63.2%). * One DHB met the target. |
| Indicator 7.5 | Timeliness of discharge following treatment  **Target:** 90% or more of women treated for CIN 2/3 should have a colposcopy and cytology within the nine-month period post treatment.   * Based on NCSP Register records, 1,392 women were treated for high-grade lesions in the period 1 January to 30 June 2017. * 76.4% of women treated have a record of both colposcopy and cytology within the nine months after their treatment visit. 77.5% have a record of at least a colposcopy visit (with or without cytology) in the same time period. * One DHB met the target for follow-up within nine months post-treatment.   **Target:** 90% or more of women treated for CIN 2/3 should be discharged back to the sample taker as appropriate.   * There were 1,021 women who were eligible for appropriate discharge within 12 months of their treatment (73.3% of all women treated for CIN 2/3). Of these women, 879 (86.1%) were discharged to their sample taker within 12 months. * Ten DHBs met the target of discharging 90% or more women who were eligible for discharge within 12 months. |
| Indicator 8 | HPV testing |
| Indicator 8.1 | HPV triage of low -grade cytology  **Target:** None set.  *HPV triage*   * Nationally, 97.3% of women aged 30 years or more with an eligible ASC-US cytology result, and 96.7% of women aged 30 years or more with an eligible LSIL cytology result, are recorded as having a subsequent HPV triage test. * Small numbers of HPV triage tests occur in women aged under 30 years (in 1.0% of women with an ASC-US result, and 0.6% of women with an LSIL result; 22 women in total). * The proportion of women aged 30 years and over who were eligible for HPV triage of low-grade cytology who subsequently received a triage test is similar in the previous monitoring period for women with ASC-US results (97.3%, compared to 97.4% in the previous report) and for women with LSIL results (96.7%, compared to 97.6% in the previous report).   *Positive triage tests*   * Among women aged 30 years or more with a valid HPV triage test results, 24.5% of women with ASC-US results and 58.5% of women with LSIL results were positive for high risk HPV. * Positivity for high risk HPV varied by laboratory (from 13.5% to 29.7% for ASC-US, and from 38.5% to 67.1% for LSIL). * Positivity for high risk HPV generally decreased with increasing age. * The proportion of women whose HPV tests were positive decreased compared to the previous monitoring period for ASC-US (24.5%, compared to 25.5% in the previous period), and LSIL (58.5%, compared to 60.1%, in the previous period).   *Histological outcomes in triage-positive women who attended colposcopy*   * Among women with ASC-US cytology and a positive HPV triage test in the six-month period one year prior to the current monitoring period, 95.4% of women have a record of colposcopy and 63.5% have a record of histology within 12 months of their triage test. The corresponding percentages for LSIL are 91.5% with colposcopy and 67.0% with histology within 12 months. * Among women with colposcopy recorded within 12 months of a positive triage test, the proportion of women that had a CIN 2 or more severe outcome (CIN 2+) was 15.3% for women with ASC-US cytology and 14.1% for women with LSIL cytology. This corresponded to 48 of the women with ASC-US cytology and 103 of the women with LSIL cytology. * Among women with histology recorded within 12 months of a triage test, 23.0% of women with ASC-US cytology and 19.3% of women with LSIL cytology had a histological outcome of CIN 2+. |
| Indicator 8.2 | HPV test volumes  **Target:** None set.   * Nationally, there were 18,302 cervical samples received at laboratories for HPV testing during the current monitoring period. * Nationally, 14.7% of HPV tests were taken for follow-up of women treated for confirmed high-grade squamous abnormalities in the previous four years (post-treatment follow-up), 36.6% were taken to manage women with high-grade squamous cytology or histology more than three years ago (historical testing), 7.6% were taken at colposcopy (potentially to assist in resolving discordant results), and 15.7% were taken for HPV triage of low-grade cytology in women aged 30 years or more. The remaining 25.4% of HPV tests did not fit into any of the previously described categories, and so the reason for testing was unclear. * The proportion of HPV tests which are invalid is very small (0.07%). * Overall HPV test volumes have been similar between the last two reports with a 0.4% increase since the previous monitoring period. |
| Indicator 8.3 | Historical HPV tests for follow-up of women with previous high-grade abnormality  Target: None set.   * This analysis followed up 49,193 women who were eligible for historical HPV testing as at 1 October 2009 to ascertain how many women had received an HPV test for management of their historical (more than three years prior) high-grade squamous abnormality. * There were 33,472 women (68.0%) with a Round 1 historical HPV test recorded, and 28,102 women (57.1%) with a Round 2 historical HPV test recorded. * The proportion of women who had received a historical HPV test varied by DHB, from 56.3% to 79.8% for Round 1 tests and from 43.5% to 72.5% for Round 2 tests. * For women aged 25 to 69 years this varied from 43.2% (25-29 years) to 71.0% (60-64 years) for Round 1 tests, and from 37.8% (25-29 years) to 61.1% (60-64 years) for Round 2 tests. * The proportion of women who had received a historical HPV test varied somewhat by ethnicity, from 48.4% (Pacific women) to 70.1% (European/ Other women) for Round 1 tests and from 37.9% (Pacific women) to 59.8% (European/ Other women) for Round 2 tests. * The proportion of eligible women with an HPV test recorded has increased since the previous report from 66.5% to 68.0% for Round 1 tests, and from 54.8% to 57.1% for Round 2 tests. |

# 

# Background

An organised National Cervical Screening Programme (NCSP) was established in New Zealand in 1990, to reduce the number of women who develop cervical cancer and the number who die from it. The Programme recommends regular cervical screening at three-year intervals for women aged between 20 and 69 years who have ever been sexually active. Part 4A of the Health Act 1956, which came into effect in 2005, underpins the NCSP’s operations to ensure the co-ordination of a high-quality screening programme for all women in New Zealand.

Ongoing systematic monitoring is a requirement of an organised screening programme. Such monitoring allows the performance of the Programme to be evaluated and corrective action to be taken as required. Monitoring is carried out through a set of key indicators which cover all aspects of the screening pathway, including participation by women, their clinical outcomes, NCSP provider performance and the Programme overall.

Monitoring reports were produced quarterly from December 2000 to June 2007 (Report 27); and six-monthly thereafter. The audience for these monitoring reports includes the general public, NCSP providers, and the Programme itself.

Technical information on the indicators are available from the Ministry of Health on request.

From Report 30 (July-December 2008) onwards, monitoring has been undertaken with the technical assistance of researchers based at the Cancer Research Division at Cancer Council NSW, Sydney, Australia. This has coincided with the use of a new reporting format, incorporating more explicit definitions and utilising data from the newly developed NCSP Register, so earlier reports are not fully comparable with Report 30 onwards.

The development of these reports has been ongoing, however it is anticipated that from Report 44 going forward, there will be minimal further changes until the NCSP transitions to primary HPV screening in the near future.

NCSP biannual monitoring reports are reviewed by a multidisciplinary advisory and monitoring group, representing NCSP providers and consumers. The group may make recommendations to the NSU for follow-up actions.

Further information about the NCSP Advisory Group and the monitoring and performance of the NCSP is available on <https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/independent-monitoring-reports> and on request from the NCSP:

Email: [Ivan\_Rowe@moh.govt.nz](mailto:Ivan_Rowe@moh.govt.nz)

Phone: (04) 816 3345, 021 711 432 or Fax: (04) 816 4484

1. Methods

## Data used

The analyses in this report are based on data extracted from the NCSP Register on 17 August 2018.

## Age

Unless otherwise specified, age is defined as the woman’s age at the end of the monitoring period, i.e. the women’s age at 30 June 2018.

## Hysterectomy-adjusted population

Measures such as coverage require an estimate of the population eligible for cervical screening. This is approximated by applying a hysterectomy-adjustment to the estimated New Zealand female population, to exclude women with a hysterectomy from the eligible population. This is an imperfect adjustor of the proportion of the population eligible for screening, since women with a hysterectomy may or may not require further cervical smears, depending on the type of hysterectomy that they received.

The hysterectomy-adjustment used in this report uses estimates of the hysterectomy prevalence in the New Zealand population from Cleary and Wright.[1](#_ENREF_1) Cleary and Wright used similar modelling techniques to those used by Gray[2](#_ENREF_2" \o "Gray, 2011 #9020) to provide hysterectomy estimates used in previous monitoring reports. Alterations to the methods used by Gray[2](#_ENREF_2" \o "Gray, 2011 #9020) include: slight modifications to the model used; additional procedure data and procedure codes were included (to include previously overlooked procedures where the cervix is removed, but did not include sub-total hysterectomies which leave part of the cervix intact); and attempts to account for mortality and migration. Hysterectomy incidence was estimated by fitting models to observed data on hysterectomies obtained from public and private hospital discharge data from the National Minimum Dataset and the Mortality collection and applied these incidence estimates to estimates of the usually resident female population from Statistics New Zealand. The New Zealand Health Survey was used to calibrate the estimates. The resulting estimates of hysterectomy incidence and survival in single-year age groups by calendar year were then used to estimate the prevalence of hysterectomy by five-year age group (among women aged 20-69 years) and calendar year (1957 to 2018). The 30 June 2018 estimates that were employed in this monitoring report have been updated to include actual hysterectomy data to 31 December 2016 (supplemented by New Zealand Health Survey data) in five-year age groups to better reflect the hysterectomy prevalence in the population, and have been projected forward using similar the methods similar to previously applied. A known limitation of previous estimates of hysterectomy prevalence is that they did not take into account deaths or women who leave New Zealand after they have a hysterectomy (which would tend to result in an overestimate of hysterectomy prevalence), nor women who migrate to New Zealand who have previously had a hysterectomy (which would tend to underestimate hysterectomy prevalence). In these new estimates attempts to account for mortality and migration have been applied, to reduce these limitations. The estimates of hysterectomy prevalence used in the current report are included in an Appendix.

The hysterectomy prevalence data were applied to New Zealand population estimates from Statistics New Zealand so that estimates of the number of women in the New Zealand population (by age and ethnicity) who had not had a hysterectomy prior to 30 June 2018 were obtained. Hysterectomy prevalence figures for the whole population (the denominator) were age-specific hysterectomy adjustments, and were applied equally across the estimated population within each DHB and ethnicity grouping. These adjusted population estimates were then used as the denominator in the hysterectomy-adjusted calculations.

The estimates used for the New Zealand female population (as at 30 June 2018) were also updated in the current report, from projections made in 2016 based on 2013 Census data, to projections made in 2018, also based on 2013 Census data.

## Ethnicity analysis

The analysis by ethnicity considered four groups – Māori, Pacific, Asian, or European/ Other, based on women’s prioritised ethnicity derived from level two ethnicity codes recorded on the NCSP Register. Women for whom ethnicity information was not available were included in the “European/ Other” ethnicity category. The data download used for the current analysis (NCSP Register data as at mid-August 2018) contained ethnicity codes for approximately 99.1% of women on the NCSP Register.

Ethnicity data in New Zealand is collected during encounters with the health system, such as registering with primary care, during an admission to hospital, or during surveys. The Ministry of Health has undertaken a number of activities to improve the quality of ethnicity data, including the development in 2004 of protocols for the collection and recording of ethnicity data,[2](#_ENREF_2) updated in 2017.[3](#_ENREF_3) Coding of ethnicity on the NCSP Register follows the classification used by the Ministry of Health.[4](#_ENREF_4), [5](#_ENREF_5) The NCSP is continuing with work to improve the accuracy of ethnicity recording on the NCSP Register. This has included matching women’s NHIs for which there is no ethnicity on the register with the Ministry of Health’s NHI register to include ethnicities. This matching is done every three months.

## Calculating NCSP coverage

Revisions to calculations are made in accordance with changes to New Zealand statistics, such as the population census data and ethnicity recordings. These changes reflect Statistics New Zealand modifications to methods for estimating population statistics. Any changes to methods for numerators or denominators are discussed with and supported by the NCSP Advisory Group. These changes are then approved by the National Screening Unit.

In 2008 the NCSP Advisory Group agreed that NCSP report coverage for women aged 25-69 years at the end of the monitoring period. This includes women aged 22 and over at the beginning of the three-year period but excludes women aged 20 or 21 years at the beginning). This approach is consistent with practice in Australia and England. In England, until 2003, the target age range for screening was 20-64 years, but coverage was calculated for women aged 25-64 years, to ensure only women eligible throughout the period were included. Similarly, in Australia, women are eligible to start screening from 18 years, but coverage is measured among women aged 20-69 years. The difference between the starting ages (two years) is the same as the recommended screening interval in Australia.

The advantage of measuring coverage at ages 25-69 are that it provides a fairer estimate of coverage (by excluding women who are not eligible for the full three-year period) and allows international benchmarking with important peer group countries, including Australia and UK.

In addition to three-year coverage, (discussed above) we also report five-year coverage (as is also done internationally). The change in method is even more important here as women aged 20-24 all need to be excluded as they are not eligible for screening for the full five years prior to the end of the assessment period. Restricting the coverage estimate to the 25-69 age group rather than the 20-69 age group is even more advantageous with respect to the five-year coverage indicator than the three-year coverage indicator.

As with all indicators, coverage indicators and the statistics on which they are based continue to evolve and further changes in the construction of these are to be expected in the future.

# Biannual NCSP Monitoring Indicators

## Indicator 1 – Coverage

This indicator includes two sub-indicators – three-year coverage (Indicator 1.1) and regularity of screening (Indicator 1.2). Indicator 1.1 also describes participation at longer intervals (five-year coverage). These two sub-indicators complement each other, in that the first allows monitoring of women who are screened versus those who are not screened over various timeframes; whereas the second (regularity of screening) allows more detailed monitoring of the timeliness among women who have attended for screening.


This is a re-structure compared to reports prior to Report 44, where only three-year (and five-year) coverage were included in the biannual monitoring reports, and regularity of screening was included in the annual reports.

Indicator 1.2, regularity of screening, is analysed annually to allow for the full year to be examined, and so is only included in every second monitoring report.

### Indicator 1.1 – Three-year coverage


|  |  |
| --- | --- |
| **Definition** | The proportion of all 25-69 year old women who have had a screening event (cytology sample, HPV sample or histology sample) taken in the three years prior to the end of the monitoring period. This definition restricts the measure of coverage to the five-year age groups who were eligible for the entire duration of the three-year period, i.e. women aged 25-69 years at the end of the monitoring period. Screening coverage in women aged 20-69 years is also presented, for comparability with previous reports.  The denominator (eligible population) for this indicator is adjusted for the estimated proportion of women who have had a total hysterectomy. Women who have withdrawn from or are not enrolled on the NCSP Register are excluded from the counts of women screened.  Screening of women aged less than 20 years at the time of their cervical sample is also reported by DHB. |
| **Target** | 80% of eligible women (aged 25-69 years at the end of the period) within three years.  This target applies nationally, and also to each ethnicity group (80% for Māori, 80% for Asian, 80% for Pacific, 80% for European/ Other women). |
| **Current Situation** | ***Coverage***  931,546 (72.1%) women aged 25-69 at the end of the current monitoring period (30 June 2018) had at least one cervical sample taken during the previous three years. This does not yet meet the target of 80%. 1,108,338 (85.8%) women aged 25-69 at the end of the current monitoring period had at least one cervical sample taken during the previous five years.    Three-yearly coverage varied by ethnicity. Coverage targets of 80% were not met for any ethnicity group. Māori, Pacific, Asian women and European/ Other women coverage among women aged 25-69 years was 61.8%, 68.6%, 59.1% and 78.0% respectively (Figure 1, Table 24).  The target coverage of 80% of women screened at least once within the previous three years was not achieved in any of the five-year age groups between 25 and 69 years Among women aged 25-69 years at the end of the period, coverage was lowest for women aged 25-29 years (58.9%) and was highest for women aged 45-49 (78.3%) (Figure 2, Table 25). Coverage was also low for women aged 20-24 years (45.9%), however many women in this age group were not eligible for screening for the entire three-year period, and so the target is not applied to this age group.  Three-yearly coverage in women aged 25-69 years varied by DHB from 67.6% (Auckland) to 78.8% (Taranaki). The three Auckland DHBs have some of the lowest coverage rates (67.6%, 68.0% and 70.0% in Auckland, Counties Manukau and Waitemata, respectively). No DHBs achieved the 80% target for women aged 25-69 years at the end of the period (Figure 3, Table 23).  Coverage for each of Māori, Pacific, Asian or European/ Other women was also examined at the DHB level (Table 26), and by age group (Table 27).  Three-yearly coverage for Māori women ranged from 52.3% (Auckland) to 71.5% (Hawke's Bay) (Figure 4). The target level of 80% of Māori women screened within the previous three years was not achieved in any DHB. Three-yearly coverage for Pacific women ranged from 53.2% (Northland) to 91.7% of women in South Canterbury (Figure 5). The target level of 80% of Pacific women screened within the previous three years was achieved by three DHBs (Lakes, South Canterbury and Wairarapa). Three-yearly coverage in Asian women ranged from 45.6% (Southern) to 70.4% (Hutt Valley) (Figure 6). The target level of 80% of Asian women screened within the previous three years was not met in any DHB. Three-yearly coverage for European/ Other women ranged from 72.0% (Counties Manukau) to 86.3% (Bay of Plenty) (Figure 7). The target level of 80% of European/ Other women screened within the previous three years was achieved in six DHBs (Auckland, Bay of Plenty, Capital and Coast, Lakes, Southern, Taranaki). No DHB met the 80% target in all four ethnic groups.  Three-yearly coverage for Māori women ranged from 57.6% (25-29 years) to 66.2% (55-59 years) (Figure 8). The target level of 80% of Māori women screened within the previous three years was not achieved in any age group. Three-yearly coverage for Pacific women ranged from 52.7% (25-29 years) to 82.7% of women (60-64 years). The target level of 80% of Pacific women screened within the previous three years was met in one age group (60-64 years). Three-yearly coverage in Asian women ranged from 40.3% (25-29 years) to 66.0% (35-39 years). The target level of 80% of Asian women screened within the previous three years was not met in any age group. Three-yearly coverage for European/ Other women ranged from 66.6% (25-29 years) to 85.0% (35-39 years). The target level of 80% of European/ Other women screened within the previous three years was achieved in five age groups (each of the five-year age groups between ages 35 and 59 years).  When compared to the findings for three-year coverage, five-year coverage had broadly similar patterns of variation by age, DHB, and ethnicity. For women aged 25-69 years at the end of the monitoring period, five-year coverage varied from 81.3% for Auckland to 91.1% for Taranaki (Figure 9, Table 28); by age from 71.8% for women aged 25-29 years to 93.0% for women aged 45-49 years (Figure 10, Table 30) and from 69.5% (Asian) to 91.8% (European/ Other) (Figure 11, Table 29). Five-yearly coverage for Māori women ranged from 65.0% (Auckland) to 90.3% (Hawke's Bay) (Figure 12, Table 31). Five-yearly coverage for Pacific women ranged from 65.2% (Northland) to all women (South Canterbury and Wairarapa) (Figure 13, Table 31). Five-yearly coverage for Asian women ranged from 53.3% (Southern) to 82.7% (Hutt Valley) (Figure 14, Table 31). Five-yearly coverage in European/ Other women ranged from 85.7% (Counties Manukau) to 98.8% (Capital & Coast) (Figure 15, Table 31). Coverage was estimated to be over 100% of the eligible population in some cases (Table 31); this is likely to be due to limitations in the estimates for population and hysterectomy prevalence.  ***Screens in women aged less than 20 years***  In the three years to the 30 June 2018, a total of 5,308 women had a cervical sample taken when they were aged less than 20 years. This represents 0.5% of women who were screened at any age (Table 33).  The number of women who were aged less than 20 years at the time they were screened varied by DHB from 30 (Tairawhiti) to 999 (Canterbury), however some differences in counts are to be expected due to differences in population size and age structure between DHBs. In order to take differences in population size between DHBs into account, the number of women who were screened in the previous three years and aged 15-19 years at the time of their cervical sample in each DHB was divided by the estimated population of females aged 15-19 years in that DHB. Note that as the events occurred over a three-year period, and the population estimate is for a single year, this cannot be interpreted directly as the proportion of 15-19 year old females in each DHB who have been screened in the last three years. However, this does allow the variation in DHB populations to be partly accounted for, and thus can give an indication of where screening among women aged less than 20 years is more or less common. Estimates for this proportion ranged from 1.9% (Tairawhiti) to 5.7% (Canterbury). Some DHBs screen a relatively low number of women when they are younger than 20 years, but at a comparatively high rate, because their population is small (for example West Coast). Details of screens of women aged less than 20 years by DHB are presented in Figure 16, and Table 32 to Table 34.  Further exploratory analysis determined that a very high proportion of the women who were aged less than 20 years at the time of their cervical sample were aged 18-19 years at the time (89.4%; Table 34). This may represent opportunistic screening of women aged 18-19 years. This proportion varied from 83.3% in Tairawhiti to 94.9% in Capital & Coast. Where this proportion is higher, it indicates that a larger proportion of screening in women aged less than 20 years may be attributable to opportunistic screening of women aged 18-19 years; as this proportion decreases, it indicates that more of the screening in women aged under 20 years is occurring in women aged under 18 years, and less may be attributed to opportunistic screening of women aged 18-19 years. |
| **Trends** | ***Coverage***  Overall coverage in New Zealand among women aged 25-69 years is lower in the current monitoring report (72.1% within the last three years, and 85.8% within the last five years) compared to the previous monitoring report (74.8% within the last three years, and 88.6% within the last five years). These changes however are likely to be due to changes in the estimates of the eligible population (the denominator) between reports (see *Comments* section for more information). Caution must therefore be taken when interpreting these results, as in many cases differences between reports are potentially due to more accurate estimates in the eligible population, rather than a true reflection of changes in coverage.  The proportion of Asian women screened was 63.4% in the previous period and 59.1% in the current period. Small differences between reports also exist for Māori (62.0% in the previous report, 61.8% in the current report), European/ Other (80.4% in the previous report, 78.0% in the current report) and Pacific women (73.4% in the previous report, 68.6% in the current report) (Figure 19, Table 39). Caution must be taken when interpreting these results as these changes are likely to be mainly attributed to changes in the eligible population (denominator value).  Trends over the last four monitoring periods are shown by DHB in Figure 17 and Table 37, and by age in Figure 18 and Table 38, however caution must be taken when interpreting these results as these changes are likely to be mainly attributed to changes in the eligible population (denominator value).  ***Screens in women aged less than 20 years***  The number of women screened who were aged under 20 years has decreased from 5,682 in the previous monitoring period to 5,308 in the current monitoring period, with the proportion of all women with screening events who were aged less than 20 years at the time of the event being similar (at 0.5% in both reports). The number of women screened who were aged less than 20 years at the time of their cervical sample has decreased in 18 of the 20 DHBs over the last two monitoring periods (Figure 20).  The proportion of these women who were aged 18-19 years has remained similar to the previous monitoring period (89.4%, compared to 89.7% previously), with small increases occurring in 9 of 20 DHBs (Figure 21). |
| **Comments** | Low coverage in women aged 25-34 years is a concern. The transition to screening starting at age 25 years from November 2019 means there is a need for rapid uptake from age 25.  As noted in the *Trends* section, the estimates for the number of women eligible for screening including hysterectomy adjustment were updated in the previous and current report, and this change means that differences in coverage compared to prior reports should be interpreted with caution, as these may partially reflect differences in the population estimates. The estimates of age-specific hysterectomy prevalence used in the current report are included in Appendix A (Table 35). Table 35 also includes a comparison with the hysterectomy prevalence estimates used in the previous monitoring report.  Application of population projection changes from June 2017 to this monitoring period has also resulted in additional differences in estimates for this report compared to all previous reports. These changes not only have an influence on the overall coverage but also at an age, ethnicity and DHB level. This limits the comparability between this and the previous reports as the majority of the differences are most likely to be due to changes in the denominator (eligible population) rather than changes in the number of women who attend screening. In particular, the updated population projections were higher than earlier projections for Pacific and Asian women, while there were smaller decreases in the estimated population of Māori and European/ Other women.  As discussed in the Methods section of this report (*Hysterectomy-adjusted population*; page 13), the hysterectomy prevalence estimates used to make the adjustment includes all women with a total hysterectomy, some of whom may still require screening (for example, where treated with a total hysterectomy for histologically-confirmed cervical high grade). These women will have been removed from the denominator but may still appear in the numerator. As a result of these limitations, coverage must be interpreted with some caution. We explored the impact of the hysterectomy-adjustment on the results by calculating coverage as a proportion of the total New Zealand female population (i.e. regardless of whether they have had a hysterectomy or not). Results for this analysis appear in Table 36.  Counts of women screened used to estimate coverage (numerator) exclude women who are not enrolled on the NCSP Register, whereas the hysterectomy-adjusted population estimates (denominator) represent all women in New Zealand without a hysterectomy, regardless of whether they are enrolled on the NCSP Register. Therefore, the coverage estimates may be an underestimate of the actual coverage rates achieved; however, the impact is likely to be very small.  Concerns about under- and over-counting of different ethnicity groups have led the Ministry to use the NHI for ethnicities as other Ministry collections do. This report relies on NCSP Register ethnicities; however regular matching is done with the NHI register for women on the NCSP Register who have no ethnicity recorded on the NCSP Register.  Coverage in women aged 20-24 years is likely to remain lower than for other ages and coverage in this age group should be interpreted with caution, as many women will have had a shorter period in which they were eligible for screening. In 2019, National Cervical Screening Programme will be changing the starting age for cervical screening from 20 to 25 years, based on evidence that screening women between the ages of 20 and 24 provides little benefit to women and can cause harm.[6](#_ENREF_6) This change is in line with the screening start age in many other countries. |

Figure 1 - Three-year coverage by ethnicity (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population)




*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.* *Target: 80% for ages 25-69 years, hysterectomy adjusted. See also Table 24.*

Figure 2 - Three-year coverage by five-year age group (women 20-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population)



*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target: 80% for ages 25-69 years, hysterectomy adjusted. See also Table 25*.


Figure 3 - Three-year coverage by DHB (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population)



*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.*


*Target 80%, hysterectomy adjusted. See also Table 23.*

Figure 4 - Three-year coverage in Māori women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB




*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target 80%, hysterectomy adjusted.*

Figure 5 - Three-year coverage in Pacific women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB




*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target 80%, hysterectomy adjusted.*

Figure 6 - Three-year coverage in Asian women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB




*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target 80%, hysterectomy adjusted.*

Figure 7 - Three-year coverage in European/ Other women (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB




*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target 80%, hysterectomy adjusted.*

Figure 8 - Three-year coverage (women 25-69 years screened in the three years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by ethnicity and five-year age group



*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. Target 80%, hysterectomy adjusted.*

Figure 9 - Five-year coverage by DHB (women screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population)



*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. See also Table 28*.

Figure 10 - Five-year coverage by five-year age-group (women screened in the five years prior to 30 June 2018, as proportion of hysterectomy-adjusted female population)




* Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data. See also* ***Table 30****.*

Figure 11 - Five-year coverage by ethnicity (women screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population)




*Note: Coverage calculated using population projection for based on 2013 Census data. See also Table 29.*

Figure 12 - Five-year coverage in Māori women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB

****


*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.*

Figure 13 - Five-year coverage in Pacific women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB

****


*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.*

Figure 14 - Five-year coverage in Asian women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB

****


*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.*

Figure 15 - Five-year coverage in European/ Other women (women 25-69 years screened in the five years prior to 30 June 2018, as a proportion of hysterectomy-adjusted female population), by DHB

****


*Note: Coverage calculated using population projection for 30 June 2018 based on 2013 Census data.*

Figure 16 - Number of women screened who were aged less than 20 years at the time of their cervical sample in the three years to 30 June 2018, by DHB



*See also Table 32.*

Figure 17 - Trends in three-year coverage by DHB (women aged 25-69 years screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\*



*\*Note: Updated hysterectomy estimates and population projections were used to calculate coverage for 31 December 2017 and 30 June 2018 (2017 update 2013 Census and 2018 update 2013 Census, respectively). Original population projection estimates were used to calculate coverage for 30 June 2017 and prior.. Target 80%. See also Table 37*

Figure 18 - Trends in three-year coverage by age (women screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\*






Figure 19 - Trends in three-year coverage by ethnicity (women aged 25-69 years screened in the previous three years, as a proportion of hysterectomy-adjusted female population)\*




*\*Note: Updated hysterectomy estimates and population projections were used to calculate coverage for 31 December 2017 and 30 June 2018 (2017 update 2013 Census and 2018 update 2013 Census, respectively). Original population projection estimates were used to calculate coverage for 30 June 2017 and prior.. Target 80%. See also Table 39*

Figure 20 - Trends in the number of women screened in the preceding three years who were aged less than 20 years at the time of their cervical sample, by DHB



*See also Table 32.*

Figure 21 - Trends in the percent of women aged less than 20 years at the time of their cervical sample who were aged 18 or 19 years, by DHB



### Indicator 1.2 – Regularity of screening

|  |  |
| --- | --- |
| **Definition** | This indicator reports on the timeliness of attendance, both for women recommended to return at the routine time of three years, or at an earlier interval of 12 months (for example following a recent abnormality).  For women recommended to return at a three-year interval, on-time screening is defined as attending between 30-42 months of their previous test (that is, within +/- six months of their due date). Early and late screening are therefore respectively defined as women who attend either within 30 months (<2.5 years), or more than 42 months (>3.5 years) of their previous test. The timing of early re-screening in this context matches the definition used within Indicator 4 (the differences between early re-screening in this Indicator and in Indicator 4 are described in the *Comments* section).  For women recommended to return at a 12-month interval, on-time screening is defined as attending between 9-12 months of their previous test (that is, within +/- three months of their due date). Early and late screening are therefore respectively defined as women who attend either within 9 months, or more than 15 months of their previous test. |
| **Target** | Not yet defined, however aim to maximise on-time attendance. |
| **Current Situation** | This indicator is analysed annually to allow for the full year to be examined. Timeliness of screening was last reported for women who attended during 1 January to 31 December 2017 and was provided in Report 48. This indicator will next be reported for women attending during 2018 and will be provided again in Report 50. |
| **Trends** | - |
| **Comments** | - |

## Indicator 2 – First screening events

|  |  |
| --- | --- |
| **Definition** | Women with no cervical samples (cytology, histology, or HPV) taken prior to the current monitoring period, who have had a cervical sample taken during the monitoring period (first event).  A woman’s age is defined as her age at the end of the current monitoring period (i.e. the women’s age at 30 June 2018).  This indicator is presented as the number of women by age, DHB and ethnicity. It is also presented as a proportion of all women in the eligible population (defined as the hysterectomy-adjusted population, aged 20-69 years), and as a proportion of all women with a cervical sample taken during this monitoring period (screening event), by DHB. |
| **Target** | There are no targets for first screening events |
| **Current Situation** | There were 23,911 women aged 20-69 years at the end of the period who had their first screening event in the period 1 January - 30 June 2018. This constituted 11.0% of the 217,135 women aged 20-69 years with a cervical sample taken in the period (screening event), and 1.6% of the eligible population. The median age (at the end of the monitoring period) of women with a first event recorded was 26 years.  The age group with the highest number of first screening events was women aged 20-24. 10,546 women aged 20-24 had their first screening event recorded on the register during this monitoring period, accounting for 45.2% of all women aged 20-69 years with first screening events (Figure 22, Table 40). First screening events then tended to decrease with increasing age. Women aged 20-24 years also had the highest proportion of women screened in their age group who were being screened for the first time (44.1%; Figure 23), and the highest proportion of the eligible population at that age with a first screening event recorded in the current monitoring period (6.1%) (Figure 24).  The DHBs with the highest number of women aged 20-69 years with first screening events were Auckland (3,639) and Waitemata (3,237). The DHBs where women with first screening events, as a proportion of all women with screening events, were the highest in Auckland (14.7%) followed by Counties Manukau (13.0%) and Capital & Coast (12.8%). The DHBs where this proportion was lowest was Wairarapa (6.4%), and South Canterbury (6.7%) (Figure 24, Table 41).  The ethnic group with the highest number of women with first screening events was European/ Other (13,093 women; Figure 25, Table 42). The group with the highest proportion of their eligible population being screened for the first time was Asian women (2.8%), and the lowest was Māori women (1.3%) (Table 42). The proportion of women screened who were being screened for the first time was highest for Asian women (22.6%; Figure 25, Table 42). This proportion is likely to be related to the median age of women with a first screening event, which is comparatively high for Asian women (31 years, compared with 22 years for Māori women, 25 years for Pacific women, and 24 years for European/ Other women; Table 43). |
| **Trends** | The number of women with a first screening event recorded on the NCSP Register has increased from 22,618 women in the previous period to 23,911 in the current period. Across the overall eligible population aged 20-69 years, the proportion of women with screening events that are their first screening event being recorded on the NCSP Register is similar in this period (1.6%) and the previous period.  Patterns by age, DHB, and ethnicity are broadly similar to those seen in the previous report. Trends by age show a steady number of first screens in most five-year age groups when compared to the previous report. A noticeable increase in the number of first screens is seen in women aged 20-39 years. Small increases in the number of women with first screening events is seen in two ethnicities, Asian and European/ Other women (An increase from 22.4% to 22.6% for Asian women and 8.5% to 8.7% in European/ Other women). As was the case in previous reports, the median age of a first screening event was older for Asian women than for Māori, Pacific and European/ Other women, and in Asian women, those with a first screening event constituted a larger proportion of all women screened than in other ethnic groups.  Trends over the two years ending 30 June 2018 are shown in Figure 26 (by age), Figure 27 (by DHB), and Figure 28 (by ethnicity). |
| **Comments** | This indicator can only measure the number of women with their first screening event in New Zealand, recorded on the register since its introduction (1990). It does not capture screening events which occurred outside New Zealand, or among women who are not enrolled on the NCSP Register.  Some differences in counts and proportion of women with first screens among screened women between DHBs are to be expected due to differences in population size, immigration and age structure. Proportions have been provided to partially account for this, however they should be interpreted with caution. For example, a relatively low number of women with first screens as a proportion of all women screened could be due to either a lower number of women with first events, or a higher number of women with screening events. If coverage remains high, then this proportion will inevitably decrease, as fewer women are available to be screened for the first time. Conversely, a relatively high number of women with first screens as a proportion of all women screened could be due to either a higher number of women with first events (due to increasing coverage), or a lower number of women with screening events (for example due to less frequent screening among women who have been screened at least once since the inception of the NCSP Register). |

Figure 22 - Women with first screening events during the monitoring period, by five-year age group (women aged 20-69 years at 30 June 2018)




Figure 23 - Women with first screening events as a proportion of all women screened in that age group during the monitoring period, by five-year age group (women aged 20-69 years at 30 June 2018)




Figure 24 - Women with first screening events as a proportion of all women screened during the monitoring period, by DHB (women aged 20-69 years at 30 June 2018)




Figure 25 - Women with first screening events as a proportion of all women screened during the monitoring period, by ethnicity (women aged 20-69 years at 30 June 2018)




Figure 26 - Trends in the number of women with a first screening event, by age




Figure 27 - Trends in the number of women with a first screening event, by DHB






Figure 28 - Trends in the number of women with a first screening event, by ethnicity



## Indicator 3 – Withdrawal rates

|  |  |
| --- | --- |
| **Definition** | The number of women, by age-group, DHB, and ethnicity not currently enrolled in the NCSP Register and whose enrolment ended during the monitoring period (withdrawals). Withdrawals relate to active withdrawals, where women specifically elect to be removed from the NCSP Register.  Withdrawals are also reported as a proportion of women who were enrolled on the NCSP Register at 30 June 2017 (i.e. just prior to the commencement of the current monitoring period). This is also reported by age group, DHB, and ethnicity.  Age is defined as a woman’s age at the end of the monitoring period (i.e. at 30 June 2018). |
| **Target** | Zero for ages 20-69 years. |
| **Current Situation** | At the end of the previous monitoring period, 1,603,282 women aged 20-69 years were enrolled on the NCSP Register. During the current monitoring period, 22 of these women (0.001%) withdrew from the NCSP Register.  In all DHBs, the number and proportion of women who withdrew was extremely small (maximum four women in the Capital & Coast and Nelson Marlborough regions). No women withdrew in ten of the twenty DHB regions (Figure 29).  The number and proportion of women withdrawing was extremely small for all age groups, but were largest among women aged 60-64 years (4 women, 0.003% of those enrolled at the end of the previous monitoring period), 55-59 years (4 withdrawals, 0.002%) and 45-49 years (3 withdrawals, 0.001%) (Figure 30, Table 44).  The number and proportion of women withdrawing was extremely small for all ethnic groups. One Māori and One Pacific women withdrew in the current monitoring period (<0.001% and 0.001%, respectively), while 18 European/ Other women (0.002%) and two Asian women (0.001%) withdrew during the current monitoring period (Figure 31, Table 45). |
| **Trends** | The number of women who withdrew in the current monitoring period (22 women) is higher than in the previous monitoring period (20 women). The overall number of withdrawals and the withdrawals as a proportion of all women enrolled both continue to be extremely small. |
| **Comments** | The proportion of women choosing to withdraw from the NCSP Register is extremely small.  Withdrawals relate to active withdrawals, where women specifically elect to be removed from the NCSP Register. It does not include, for example, women who have moved overseas, or who have died during the period, and who therefore are not having tests recorded on the NCSP Register or who ask for no more communications but still participate in the Programme and have their results recorded on the NCSP Register. |

Figure 29 - Number of women (aged 20-69 years) who withdrew from the NCSP Register by DHB, 1 January – 30 June 2018



*Excludes 4 women who withdrew whose DHB was not recorded.*

Figure 30 - Number of women who withdrew from the NCSP Register by age, 1 January – 30 June 2018



****


Figure 31 - Number of women (aged 20-69 years) who withdrew from the NCSP Register by ethnicity, 1 January – 30 June 2018



## Indicator 4 – Early re-screening


|  |  |
| --- | --- |
| **Definition** | The proportion of women who returned for a smear within 30 months (2.5 years) of their index smear is calculated for a cohort of women. The cohort comprises of women with an index smear taken between 1 August – 31 September 2015 (inclusive), who i) were aged 20-66 years at the time the smear was taken (and hence remained within the screening target age throughout the period); and ii) were given a recommendation to return at the regular interval of three years as a result of their smear in February/ March 2015 (NZ Modified Bethesda code R1). Using this method of calculating the measure allows follow-up to be considered over 30 months for every individual woman.  This measure excludes women who return early but are being followed according to *Guidelines for Cervical Screening in New Zealand*, for example, those with a recent report of an abnormality. It also excludes from the count of women screened early those whose “early” smear recommended urgent referral regardless of cytological findings, in view of the abnormal clinical history provided (NZ Modified Bethesda code R14).  In some cases, early re-screening may be the result of women being re-screened early in response to clinical symptoms, and this is appropriate.  For the purposes of analysis by age group, a woman’s age is defined as her age at the end of the current monitoring period (i.e. a women’s age at 30 June 2018). |
| **Target** | A target has not been set for this cohort-based calculation method. |
| **Current Situation** | There were 45,037 women who had a smear taken in August or September 2015, were aged between 20-66 years at the time of their smear and were given a recommendation to return for their next smear at the routine interval of three years. Among these women, 5,466 (12.1%) had at least one subsequent smear in the following 30 months (6 months earlier than recommended).  There was wide variation in early re-screening by DHB. Early re-screening was most common in Wairarapa (16.7%) and Waitemata (16.2%), and was least common in West Coast (6.5%) (Figure 32, Table 47).  There was also variability by age. Younger women (aged 20-24 years at the end of the period) were most likely to be re-screened early (15.9%) and older women (aged 65-69 years) were the least likely to be re-screened early (7.7%)(Figure 33, Table 46). Rates of early re-screening tended to decrease with increasing age but were quite similar across five-year age groups from 30 to 54 years (between 13.0% and 12.4%).  Among the ethnic groups considered, European/ Other were the most likely to be re-screened early (12.5%), while early re-screening was least common among Pacific women (8.4%) (Figure 34, Table 48). |
| **Trends** | The level of early re-screening (12.1%) is slightly lower to what was reported in the previous monitoring period (12.6%) and has been declining over a number of reporting periods.  The DHB with the highest level of early rescreening in this report was Wairarapa (16.7%) followed by Waitemata (16.2%), the same DHBs reported in the previous report. In the majority of DHBs, early rescreening is decreasing; however early rescreening increased in the current report in nine DHBs (Bay of Plenty, Counties Manukau, Hawke's Bay, Mid Central, Nelson Marlborough, Southern, Tairawhiti, Taranaki and Waikato) with the greatest increases occurring in Taranaki (2.3% increase; from 9.8% to 12.1% in the current report) followed by Tairawhiti (1.8%; from 6.5% to 8.3% in the current report). Trends over the two years ending 30 June 2018 by DHB are shown in Figure 35.  A reduction in the level of early re-screening was seen for eight of the ten five-year age groups between 20 and 69 years since the previous report. A small increase was seen in one age group however: in women aged 20-24 years (from 15.3% to 15.9%) and women 40-44 remained at a similar percent between the two monitoring periods (12.9%). Trends over the two years ending 30 June 2018 by five-year age group are shown in Figure 36.  Small decreases in early re-screening were also seen in four of the 5 ethnic groups. The greatest drop was seen in Pacific women (from 9.8% to 8.4%) since the last monitoring period. Decreases to a lesser extent was seen for Asian and European/ Other women. Early rescreening in Māori women increase slightly from 10.9% to 11.4% in the current report. |
| **Comments** | Early re-screening was assessed based on cytology recommendation codes, in order to exclude from the early re-screening group women with a negative smear for whom an earlier screening visit is appropriate. Thus, only women with a recommendation that their next screening visit be in three years were eligible for inclusion in the early re-screening group (that is, in both the numerator and the denominator). Women excluded from the early re-screening group would include those who just had their first smear or more than five years have elapsed since their previous smear (NCSP policy is to recommend a one-year follow-up), women with atrophic changes for whom a repeat after oestrogen is recommended, women with an abnormal history or clinical symptoms, and those already under specialist care.  In some cases, early re-screening may be the result of women being re-screened early in response to clinical symptoms, and this is appropriate. We have used the NZ Modified Bethesda recommendation code for urgent referral regardless of cytological findings (R14) to try and exclude some of these cases from the count of women re-screened early, but this does not exclude all screens performed in response to clinical symptoms.  There are some similarities between Indicator 4 and Indicator 1.2, although they examine different groups of women and the proportions reported answer somewhat different questions (as is described in more detail in the *Definition* and Comments section of Indicator 1.2). Indicator 1.2 addresses the question – “*What proportion of women who are re-attending for routine screening in a particular time period are returning at least six months early?*”, and does not take into account women who did not attend for screening; whereas Indicator 4 addresses the question – “*What proportion of women recommended to return in three years for routine screening return at least six months early?*”, and takes into account all women given a routine screening recommendation, whether they re-attend or not. |

Figure 32 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by DHB




*See also Table 47.*

Figure 33 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by five-year age group



*See also Table 46.*

Figure 34 - Proportion of women recommended to return at the routine interval (three years) who were re-screened early, by ethnicity



*See also Table 48.*

Figure 35 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by DHB




Figure 36 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by age





Figure 37 - Trends in the proportion of women recommended to return at the routine interval (three years) who were re-screened early, by ethnicity



## Indicator 5 – Laboratory indicators

The indicators include cytology, histology reports (encompassing cytology and histology reporting rates, positive predictive value of cytology predicting HSIL), laboratory turnaround times, the accuracy of negative cytology reports, and unsatisfactory samples. Volumes of high-risk HPV (hrHPV) tests according to NCSP guidelines are included in Indicator 8.


### Indicator 5.1 – Laboratory cytology reporting

This includes the breakdown of cytology reporting by category for squamous and glandular abnormalities reported

|  |  |
| --- | --- |
| * Negative * ASC-US * LSIL * ASC-H * HSIL | * SC * AGC/AIS * Adenocarcinoma * Malignant neoplasm * Total abnormalities * Unsatisfactory samples |


|  |  |
| --- | --- |
| **Definition** | Bethesda codes used are provided in Appendix B.  The Bethesda reporting system (TBS), introduced in New Zealand on 1 July 2005, is a New Zealand modification of the Bethesda 2001 cytology reporting system.  The NCSP Register collects cytology results of samples taken from the cervix and vagina.  Total samples include all cytology samples (satisfactory and unsatisfactory) taken during the monitoring period. All NCSP cytology is liquid-based cytology (LBC).  Reporting rates for negative cytology, total abnormal cytology, and other reporting categories are as a percentage of all satisfactory cytology samples. |
| **Target** | 0.1% - 3.0% of LBC samples reported as unsatisfactory.  No more than 96% of satisfactory samples reported as negative.  No more than 10% of satisfactory samples reported as abnormal.  No less than 0.5% of satisfactory samples reported as HSIL (Bethesda HS1 or HS2). |
| **Current Situation** | Six laboratories reported on cytology taken during the current monitoring period, the same number as in the previous monitoring period. A total of 219,259 cytology samples were taken, all of which (100%) were coded as LBC samples.  ***Unsatisfactory cytology***  2,950 cytology samples (1.3%) were unsatisfactory. The unsatisfactory rate for LBC is within the 0.1% - 3.0% target range for LBC samples. Five of the six laboratories had unsatisfactory rates within the target range; the remaining laboratory had a rate that exceeded the maximum target of 3.0% (Anatomical Pathology Services; 3.2%). Pathlab had the lowest unsatisfactory percentage of 0.4% (Figure 38, Table 1).  Unsatisfactory samples are reported in more detail in Table 1 and Figure 38. The remaining satisfactory samples are reported on below and in more detail in Table 1 to Table 6.  ***Negative cytology reports***  93.3% of satisfactory cytology results were negative (Table 1), consistent with the target of no more than 96%. The proportion of samples which were negative varied by laboratory from 77.4% (LabPLUS) to 95.3% (Southern Community Laboratories) (Figure 39). All six laboratories met the target of no more than 96%.  ***Abnormal cytology reports***  Nationally, the proportion of satisfactory samples which were abnormal (6.7%) met the target of no more than 10% (Figure 40, Table 2). This varied by laboratory, from 4.7% (Southern Community Labs) to 22.6% (LabPLUS) (Figure 40). Two laboratories (LabPLUS and Canterbury Health Laboratories) exceeded the target (22.6% and 10.3%, respectively).  Abnormal cytology results were most common in younger women and LSIL was the most common abnormal result (Table 5, Table 6).  ***HSIL cytology reports***  Overall, 0.8% of satisfactory cytology samples were HSIL, consistent with the target of at least 0.5% of samples (Table 4). Rates varied by laboratory from 0.5% (Pathlab) to 2.3% (LabPLUS). All six laboratories met the HSIL target (Table 4, Figure 41).  Among women aged 20-69 years, rates of HSIL or worse were most common in women aged 25-29 years (Table 5, Table 6).  In the current report we additionally examined age-standardised rates of HSIL cytology reports. This was done to partially account for different rates which may arise in different laboratories due to differences in the age of the population whose cytology tests they process. The age-standardised HSIL rates were very similar to the crude rates, both nationally and within each laboratory, but tended to be slightly lower (Table 49). |
| **Trends** | ***Unsatisfactory cytology***  Overall, the percentage of unsatisfactory LBC samples for the current monitoring period (1.3%) is similar to that seen in the previous monitoring period (1.4%). One laboratory (Anatomical Pathology Services) has remained above the upper target of 3.0% for the last four monitoring periods.  ***Negative vs abnormal cytology reports***  The proportion of satisfactory cytology samples which are negative for intraepithelial lesion or malignancy (93.3%) is similar to the previous monitoring period (93.5%), and correspondingly the proportion of cytology samples reported as abnormal (6.7%) is also similar as in the previous monitoring period (6.5%). All six laboratories continued to meet the target for negative cytology. The same laboratories as previous reports had abnormal cytology rates above the target of 10% (Canterbury Health Laboratories and LabPLUS).  ***HSIL cytology reports***  The proportion of satisfactory cytology samples reported as HSIL (0.8%) is similar to that reported in the previous monitoring report (0.7%). All six laboratories met the target, which was the same number of laboratories that achieved the target in the previous report.  Longer term trends in the proportion of satisfactory cytology samples reported as HSIL are shown in Figure 42, Figure 43 (trends by age) and Figure 44 (trends by laboratory). Figure 42 and Figure 44 show trends over the last four monitoring report periods (two years), consistent with other trends presented in this report. Figure 43 shows longer term trends (1 July 2008 to 30 June 2018) in rates of HSIL cytology by age. The younger age groups in this figure would be the first to be potentially affected by HPV vaccination (the oldest birth cohorts eligible for vaccination through the publicly funded programme would be aged up to 28 years at the time of the current monitoring period). HSIL rates in women aged less than 20 years are quite variable; this is likely to be because far fewer women of this age group attend for screening, since routine screening is not recommended for women aged less than 20 years. HSIL reporting rates in women aged 20-24 years had been increasing prior to 2013 and reached a high of 2.2% for the July-December 2012 period (Report 38). HSIL rates then fell for four monitoring periods between January 2013 and December 2014. In the July-December 2015 monitoring period (Report 44) an increase was seen in virtually all age groups, including women aged 20-24 years (from 1.6% in January to June 2015, Report 43, to 2.0% in July to December 2015, Report 44), however this increase appeared to be driven by an increase in the percentage of satisfactory samples reported as HSIL at two laboratories (Anatomical Pathology Services and Southern Community Laboratories; which together accounted for 65.2% of all satisfactory cytology), and a coinciding decrease in the positive predictive value of HSIL + SC cytology for histologically-confirmed CIN2+ within six months from these two laboratories. Since then, there has been a consistent decline in HSIL rates observed over the last four monitoring reports up to December 2017, with rates being below what they were prior to the increase in the latter half of 2015 especially for women 20-24 years and 25-29 years. For women aged 20-24 years HSIL reporting rates remain lower than the latter half of 2008 (around the time that the HPV vaccination programme began). In this report small increases were seen in women aged 25-29 (increase of 0.2%). All other changes were very small being no more than 0.1% for women aged 20-24 and 30-69 years of age. |
| **Comments** | High rates of abnormal samples from LabPLUS are consistent with previous reports, and as discussed in previous monitoring reports, investigation into this has shown that the case-mix of this laboratory (i.e. a significant proportion of samples received from colposcopy clinics compared to other laboratories) is an underlying factor.  Workload catchments for laboratories may be regional or nationwide and may change because of laboratory service restructuring. As a result, it is not always straightforward to determine the catchment population for a laboratory. Rates of negative and abnormal results for individual laboratories therefore need to be interpreted with some care, to allow for this difference in workloads and case-mix.  The national Human Papillomavirus (HPV) Immunisation Programme was introduced in New Zealand in September 2008, and involves routine vaccination of girls 12-13 years and catch-up vaccination has previously been offered to young women born in 1990 or later. International and New Zealand data indicate that most high-grade squamous cytology reports are associated with HPV types which are potentially preventable by vaccination (approximately 53% by first generation vaccines against HPV16/18; >70% with 9-valent vaccines),[7-10](#_ENREF_7) and that this is particularly true for younger women.[7](#_ENREF_7), [11-13](#_ENREF_11) It is anticipated that data will also soon be available from New Zealand to further quantify the potential impact of the Human Papillomavirus Immunisation Programme in New Zealand. As vaccinated cohorts enter the screening programme, it is anticipated that the proportion of satisfactory cytology samples reported as HSIL will gradually reduce, and that this will occur in younger age groups first (the oldest birth cohorts eligible for vaccination through the publicly funded programme would be aged up to 28 years at the time of the current monitoring period, while the oldest birth cohorts offered vaccination at the target age of 12-13 years would be aged up to 22 years). Therefore, trends in the proportion of satisfactory cytology samples reported as HSIL by age are included in these monitoring reports, in order to monitor the impact of HPV vaccination over time. This proportion of satisfactory cytology samples reported as HSIL in the 20-24 years age group in the current report the lowest it has been since the latter half of 2008 (around the time that the HPV vaccination programme began), and is consistent with an HPV vaccine effect. At the current time, it is not possible to present HSIL rates separately for vaccinated and unvaccinated women, because information relating to whether or not individual women have been vaccinated is not available on the NCSP Register. This data therefore needs to be interpreted with some care, as they include results in all women, both vaccinated and unvaccinated.  In the current report we additionally examined age-standardised rates of HSIL cytology reports, in order to partially account for differences in the age of the population whose cytology tests each laboratory processes. This could be an additional factor in some laboratories having higher or lower HSIL reporting rates. As the target does not specifically relate to age-standardised rates, these results cannot be directly compared to the target; however, as the target was set in 2013, standardising was done using the 2013 Census population (females). As the age-standardised HSIL rates were very similar to the crude rates within each laboratory, differences in age distribution of cytology tests reported do not appear to be a factor in differences between laboratories in HSIL reporting rates, or in why some laboratories are outside the target range. |

Figure 38 - Proportion of total LBC samples reported as unsatisfactory by laboratory, 1 January – 30 June 2018




*Target for LBC: 0.1-3.0% (Red line-upper target limit; black line=lower target limit)*

Figure 39 - Proportion of total satisfactory samples reported as negative by laboratory, 1 January – 30 June 2018




*Note: Line shows negative target of no more than 96%*

Figure 40 - Proportion of total satisfactory samples reported as abnormalities by laboratory, 1 January – 30 June 2018



*Note: Line shows abnormal target of no more than 10%*

Figure 41 - Proportion of total satisfactory samples reported as HSIL by laboratory, 1 January – 30 June 2018



*Note: Line shows HSIL target of no less than 0.5%*

Table 1 - Satisfactory and unsatisfactory cytology reporting by laboratory (1 January – 30 June 2018)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All samples** | | **Satisfactory** | | **Unsatisfactory** | |
| **Laboratory** | **N** | **N** | | **%** | **N** | **%** |
| Anatomical Pathology Services | 46,159 | 44,670 | | 96.8 | 1,489 | 3.2 |
| Canterbury Health Laboratories | 10,592 | 10,482 | | 99.0 | 110 | 1.0 |
| LabPLUS | 8,400 | 8,222 | | 97.9 | 178 | 2.1 |
| Medlab Central Ltd. | 15,885 | 15,406 | | 97.0 | 479 | 3.0 |
| Pathlab | 28,163 | 28,056 | | 99.6 | 107 | 0.4 |
| Southern Community Laboratories | 110,060 | 109,473 | | 99.5 | 587 | 0.5 |
| ***Total*** | **219,259** | **216,309** | | **98.7** | **2,950** | **1.3** |

*Target total unsatisfactory: 0.1%-3.0% reported as unsatisfactory*

Table 2 - Laboratory cytology reporting by general result (1 January – 30 June 2018) – percentage of satisfactory samples

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Negative** | | **Abnormal** | | |
| **Laboratory** | **N** | **%** | | **N** | **%** |
| Anatomical Pathology Services | 41,633 | 93.2 | | 3,037 | 6.8 |
| Canterbury Health Laboratories | 9,406 | 89.7 | | 1,076 | 10.3 |
| LabPLUS | 6,361 | 77.4 | | 1,861 | 22.6 |
| Medlab Central Ltd. | 14,164 | 91.9 | | 1,242 | 8.1 |
| Pathlab | 25,899 | 92.3 | | 2,157 | 7.7 |
| Southern Community Laboratories | 104,351 | 95.3 | | 5,122 | 4.7 |
| ***Total*** | **201,814** | **93.3** | | **14,495** | **6.7** |

*Target total negative: ≤ 96% reported as negative*

*Target total abnormal: ≤ 10% reported as abnormal*

Table 3 - Laboratory cytology reporting by type of cytological category (1 January – 30 June 2018) – counts of all satisfactory samples

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Result** | | | | | | | | | |
| **Laboratory** | **Negative** | **ASC-US** | **LSIL** | **ASC-H** | **HSIL** | **SC** | **AGC/AIS** | **Adeno-carcinoma** | **Malignant Neoplasm** | **Total** |
| Anatomical Pathology Services | 41,633 | 901 | 1,669 | 156 | 254 | 4 | 45 | 8 | - | 44,670 |
| Canterbury Health Laboratories | 9,406 | 318 | 510 | 129 | 105 | - | 9 | 4 | 1 | 10,482 |
| LabPLUS | 6,361 | 630 | 760 | 253 | 191 | 1 | 20 | 5 | 1 | 8,222 |
| Medlab Central Ltd. | 14,164 | 423 | 499 | 129 | 162 | 1 | 22 | 5 | 1 | 15,406 |
| Pathlab | 25,899 | 689 | 1,174 | 139 | 128 | 2 | 22 | 2 | 1 | 28,056 |
| Southern Community Laboratories | 104,351 | 897 | 2,963 | 214 | 909 | 10 | 109 | 17 | 3 | 109,473 |
| ***Total*** | **201,814** | **3,858** | **7,575** | **1,020** | **1,749** | **18** | **227** | **41** | **7** | **216,309** |

Table 4 - Laboratory cytology reporting by cytological category (1 January – 30 June 2018) – percentage of all satisfactory samples

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Result** | | | | | | | | |
| **Laboratory** | **Negative** | **ASC-US** | **LSIL** | **ASC-H** | **HSIL** | **SC** | **AGC/AIS** | **Adeno-carcinoma** | **Malignant Neoplasm** |
| Anatomical Pathology Services | 93.2 | 2.0 | 3.7 | 0.3 | 0.6 | 0.01 | 0.10 | 0.02 | - |
| Canterbury Health Laboratories | 89.7 | 3.0 | 4.9 | 1.2 | 1.0 | - | 0.09 | 0.04 | 0.01 |
| LabPLUS | 77.4 | 7.7 | 9.2 | 3.1 | 2.3 | 0.01 | 0.24 | 0.06 | 0.01 |
| Medlab Central Ltd. | 91.9 | 2.7 | 3.2 | 0.8 | 1.1 | 0.01 | 0.14 | 0.03 | 0.01 |
| Pathlab | 92.3 | 2.5 | 4.2 | 0.5 | 0.5 | 0.01 | 0.08 | 0.01 | <0.005 |
| Southern Community Laboratories | 95.3 | 0.8 | 2.7 | 0.2 | 0.8 | 0.01 | 0.10 | 0.02 | <0.005 |
| ***Total*** | **93.3** | **1.8** | **3.5** | **0.5** | **0.8** | **0.01** | **0.10** | **0.02** | **<0.005** |

*Target: HSIL ≥ 0.5% reported as HSIL*

Table 5 - Laboratory reporting of cytological category by five-year age group (1 January – 30 June 2018) – counts of all satisfactory samples


|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cytology Result** | | | | | | | | |  | |
| **Age Group** | **Negative** | **ASC-US** | **LSIL** | **ASC-H** | **HSIL** | **SC** | **AGC/AIS** | **Adeno-carcinoma** | **Malignant Neoplasm** | | **Total** |
| <20 | 649 | 19 | 121 | 3 | 1 | - | - | - | - | | 793 |
| 20-24 | 20,572 | 683 | 2,434 | 203 | 295 | - | 1 | - | - | | 24,188 |
| 25-29 | 22,789 | 581 | 1,381 | 197 | 422 | - | 17 | - | - | | 25,387 |
| 30-34 | 23,522 | 479 | 845 | 178 | 342 | 3 | 19 | - | - | | 25,388 |
| 35-39 | 22,028 | 373 | 597 | 101 | 226 | 1 | 17 | 1 | - | | 23,344 |
| 40-44 | 21,437 | 370 | 482 | 69 | 140 | 4 | 19 | - | - | | 22,521 |
| 45-49 | 22,766 | 409 | 495 | 62 | 107 | - | 30 | 2 | 2 | | 23,873 |
| 50-54 | 20,416 | 347 | 379 | 60 | 51 | 3 | 31 | 7 | 2 | | 21,296 |
| 55-59 | 19,032 | 243 | 375 | 62 | 62 | - | 25 | 6 | 1 | | 19,806 |
| 60-64 | 14,998 | 175 | 250 | 42 | 47 | 3 | 23 | 5 | 1 | | 15,544 |
| 65-69 | 11,629 | 131 | 143 | 32 | 39 | - | 23 | 10 | 1 | | 12,008 |
| 70+ | 1,976 | 48 | 73 | 11 | 16 | 4 | 22 | 10 | - | | 2,160 |
| ***Total*** | **201,814** | **3,858** | **7,575** | **1,020** | **1,748** | **18** | **227** | **41** | **7** | | **216,308** |

*Note: excludes test results for one woman where date of birth was not available*

Table 6 - Laboratory reporting of cytological category by five-year age group () – percentage of all satisfactory samples in women of that age group


|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cytology Result** | | | | | | | | |
| **Age Group** | **Negative** | **ASC-US** | **LSIL** | **ASC-H** | **HSIL** | **SC** | **AGC/AIS** | **Adeno-carcinoma** | **Malignant Neoplasm** |
| <20 | 81.8 | 2.4 | 15.3 | 0.4 | 0.1 | - | - | - | - |
| 20-24 | 85.1 | 2.8 | 10.1 | 0.8 | 1.2 | - | <0.005 | - | - |
| 25-29 | 89.8 | 2.3 | 5.4 | 0.8 | 1.7 | - | 0.07 | - | - |
| 30-34 | 92.7 | 1.9 | 3.3 | 0.7 | 1.3 | 0.01 | 0.07 | - | - |
| 35-39 | 94.4 | 1.6 | 2.6 | 0.4 | 1.0 | <0.005 | 0.07 | <0.005 | - |
| 40-44 | 95.2 | 1.6 | 2.1 | 0.3 | 0.6 | 0.02 | 0.08 | - | - |
| 45-49 | 95.4 | 1.7 | 2.1 | 0.3 | 0.4 | - | 0.13 | 0.01 | 0.01 |
| 50-54 | 95.9 | 1.6 | 1.8 | 0.3 | 0.2 | 0.01 | 0.15 | 0.03 | 0.01 |
| 55-59 | 96.1 | 1.2 | 1.9 | 0.3 | 0.3 | - | 0.13 | 0.03 | 0.01 |
| 60-64 | 96.5 | 1.1 | 1.6 | 0.3 | 0.3 | 0.02 | 0.15 | 0.03 | 0.01 |
| 65-69 | 96.8 | 1.1 | 1.2 | 0.3 | 0.3 | - | 0.19 | 0.08 | 0.01 |
| 70+ | 91.5 | 2.2 | 3.4 | 0.5 | 0.7 | 0.19 | 1.02 | 0.46 | - |
| ***Total*** | **93.3** | **1.8** | **3.5** | **0.5** | **0.8** | **0.01** | **0.10** | **0.02** | **<0.005** |

Figure 42 - Trends in the proportion of total satisfactory samples reported as HSIL (last four monitoring periods), by age




*Note: women aged less than 20 years are not routinely screened*

Figure 43 - Longer term trends in the proportion of total satisfactory samples reported as HSIL (to 1 January – 30 June 2018), by age



*Note: women aged less than 20 years are not routinely screened*

Figure 44 - Trends in the proportion of total satisfactory samples reported as HSIL, by laboratory




*Note: Line shows HSIL target of no less than 0.5%.*

### Indicator 5.2 – Accuracy of cytology predicting HSIL

|  |  |
| --- | --- |
| **Definition** | The accuracy of cytology predicting HSIL/SC (positive predictive value; PPV) is defined as the probability of a high-grade histological report (CIN 2/3 or higher) given an HSIL/invasive squamous carcinoma cytology report.  Refer to Appendix D for detailed definitions of histological confirmation.  All satisfactory cytology samples collected in the six months prior to the current monitoring period (i.e. collected from 1 July – 31 December 2017 inclusive) were identified. In the current report, cytology samples were excluded if they were collected at a colposcopy visit (assessed by excluding cytology samples collected at the same facility and on the same date as either a colposcopy or a histology sample in the same woman; “excluding samples from colposcopy”). In previous reports, this restriction had not been applied (“original method”). Where a woman had multiple samples, or a cytology report had multiple interpretation codes, the most serious cytology result category reported was used. If there were two cytology test results for a woman of the same grade, the earliest one was used. Up until this report (original method), histology samples taken up to five days prior to and up to six months after the cytology sample were then retrieved for women with a high-grade cytology report. From this report onwards, histology samples taken up to six months after the cytology sample were included (histology prior to or on the same day as cytology are now excluded from the analysis). Where there were multiple histology reports for a woman in the period, the most serious abnormality category was used. |
| **Target** | Not less than 65% and not greater than 85% for cytology reported as HSIL or SC. |
| **Current Situation** | ***HSIL + SC***  When cytology samples collected at colposcopy were excluded, 935 women with HSIL or SC cytology reports were identified. 63 of these women (6.7%) had no histology taken in the six months after the cytology sample was taken. Among the remaining 872 for whom there was histology, 699 (80.2%) had their HSIL or SC cytology report confirmed as high-grade by histology (Figure 45, Table 50).  By laboratory, the proportion of HSIL + SC being confirmed as high-grade by histology ranged from 77.4% for Anatomical Pathology Services to 85.9% for Medlab Central Ltd. All six laboratories achieved the minimum target of at least 65% of cytological HSIL + SC being confirmed by histology. One of the six laboratories exceeded the 85% upper target margin of HSIL + SC being histologically confirmed (Medlab Central Ltd; Figure 45, Table 50).  Comparison of the results from the updated method excluding samples from colposcopy and the original method can be seen in Figure 46 and Table 51. In most laboratories, positive predictive value was relatively unaffected, but decreased at two laboratories (Canterbury Health Laboratories and LabPLUS). Detailed results based on the original method are reported in Table 52.  ***Other cytological abnormalities***  Similar calculations for positive predictive value were performed for ASC-H; glandular abnormalities (AG1-AG5, AIS, AC1-AC4); and the combination of ASC-H, HSIL and SC. There are no targets for these measures.  ***ASC-H***  After excluding samples from colposcopy, 667 women with a cytology report of ASC-H were identified. 111 (16.6%) had no histology taken in the period up to six months after the cytology sample. Among the remaining 556 women, 308 (55.4%) were histologically confirmed as high-grade. This proportion varied by laboratory, from 53.2% (LabPLUS) to 62.7% (Canterbury Health Laboratories) (Figure 47,Table 53).  Comparison of the results from the updated method excluding samples from colposcopy and the original method can be seen in Figure 47 and Table 51. In four laboratories, positive predictive value increased for ASC-H (Anatomical Pathology Services, LabPLUS, Pathlab, Southern Community Labs), and in two laboratories it decreased (Canterbury Health Laboratories, Medlab Central). The decreases were relatively small (less than two percentage points), whereas the increases tended to be larger and more variable (ranging from 3.3 to 11.2 percentage points). Detailed results based on the original method are reported in Table 54.  ***ASC-H + HSIL + SC***  After excluding samples from colposcopy, a total of 1602 women had a cytology report of ASC-H, HSIL or SC. 174 (10.9%) women had no histology taken in the period up to six months after the cytology sample. Among the remaining 1428 women, 1,007 (70.5%) were histologically confirmed as high-grade. This proportion varied by laboratory, from 62.2% (LabPLUS) to 74.1% (Southern Community Laboratories Dunedin) (Figure 48, Table 55).  Comparison of the results from the updated method excluding samples from colposcopy and the original method can be seen in Figure 48 and Table 51. The positive predictive value for ASC-H+HSIL+SC was somewhat lower with the updated method for five laboratories but was somewhat higher at one laboratory (Anatomical Pathology Services). Detailed results based on the original method are reported in Table 56.  ***Glandular abnormalities***  After excluding samples from colposcopy, there were 176 women with a glandular abnormality (AG1-AG5, AIS, AC1-AC4) identified. 52 women (29.5%) had no histology taken in the period up to six months after the cytology sample. Among the remaining 124 women, 62 (50.0%) were identified as having high-grade histology. This was not analysed by laboratory, as the number of samples reported on by some laboratories was small. These results from the updated method excluding samples from colposcopy compares with the original method as follows: 227 women identified with a glandular abnormality, 71 (31.3%) of whom had no histology taken in the period from five days prior to six months after the cytology sample; among the remaining 156 women, 80 (51.3%) were identified as having high-grade histology. Therefore the overall PPV for glandular abnormalities was relatively similar for both methods.  ***Overall comparison of PPV for updated method (excluding samples from colposcopy) vs original method***  In most laboratories, the PPV decreased for HSIL + SC results when cytology samples collected at colposcopy were excluded, but increased for ASC-H (Table 51). The improvement in ASC-H is largely because excluding cytology collected at colposcopy meant that some women moved from the HSIL category (based on the results of a cytology test collected at colposcopy), to the ASC-H category (the referring cytology result). In the original analysis, these women were included in the HSIL group (because the most severe cytology diagnosis is used when there are multiple cytology results). As shown in Table 57, women who moved into the ASC-H category, and out of the HSIL category (because the HSIL was based on cytology at collected colposcopy), overwhelmingly were those women with HSIL-confirmed histology (66 out of 71 women). This explains the increase in the PPV of ASC-H observed at most laboratories when cytology collected at colposcopy was excluded. Both the movement out of HSIL into ASC-H, and the exclusion of women whose only HSIL cytology result was one collected at colposcopy (both of whom were very likely to have HSIL-confirmed histology) explains why laboratories generally had a lower PPV when cytology collected at colposcopy was excluded. |
| **Trends** | The method for selecting cytology and histology tests for inclusion in this calculating this indicator changed in this monitoring period, but to allow for some continuation in monitoring trends, results based on the original method will be compared with previous monitoring periods.  ***HSIL + SC***  Positive predictive value for HSIL and SC cytology has increased when compared to the previous monitoring report (80.4% in the previous period; 82.3% in the current period). As in the previous monitoring period, all six laboratories had greater than 65% of their HSIL + SC cytology results confirmed by histology. The number of laboratories with PPVs above the upper target of 85% has increased from one to three. The proportion of cytology reports with histology available following HSIL or SC results is similar (92.9% in the current report; 92.2% in the previous report). Trends in the positive predictive value for HSIL and SC cytology by laboratory are shown in Figure 49 and Figure 50. Increases in the positive predictive value for HSIL and SC cytology were evident for all laboratories except Anatomical Pathology Services and Medlab Central Ltd (the latter of which was already above the upper target 85%).  ***ASC-H***  Positive predictive value for ASC-H cytology has increased, from 48.3% to 50.9%, however there is no target for this measure. The proportion of ASC-H cytology reports with histology available has increased in the current report compare to the previous monitoring report (80.3% in current report; 81.5% in previous report; Figure 50). Increases in the positive predictive value for ASC-H cytology were evident in four laboratories of the six.  ***ASC-H + HSIL + SC***  The positive predictive value for the combined group ASC-H, HSIL and SC has increased slightly in the current report (to 71.1%, compared to 69.5% in the previous report). Note that there is no target for the positive predictive value of this combined group. Trends in the positive predictive value for the combined group ASC-H, HSIL and SC cytology by laboratory are shown in Figure 52. Decreases in the positive predictive value for the combined group of ASC-H, HSIL and SC cytology were evident for three of six laboratories.  ***Glandular abnormalities***  The positive predictive value of glandular abnormalities increased (from 40.6% in the previous report to 51.3% in the current report). Compared to both ASC-H cytology, and the combined group of HSIL and SC cytology, there are far fewer glandular abnormalities, and an even smaller number with histology available. The proportion of glandular abnormalities with histology available (68.7%) is higher in this report than the previous monitoring period (67.8%), and remains less than ASC-H (80.3%) and HSIL + SC (92.9%). As a result, the positive predictive value of glandular abnormalities is more prone to fluctuations than positive predictive values for other high-grade abnormalities. Due to the small number of samples involved, glandular abnormalities were not analysed in further detail by laboratory. |
| **Comments** | This estimate does not take into account cytology predicting HSIL for which there is no histology available. Histology may be unavailable because the woman does not attend for follow-up colposcopy, or a biopsy may not be taken if the colposcopic impression is normal. When the monitoring period for this indicator is after all DHBs have started reporting in accordance the 2013 Colposcopy Standards (September 2017), it should be possible to better distinguish between these two possibilities. This can also be examined by calculating the probability of a high-grade histological report (CIN 2/3 or higher) among all women attending colposcopy after a high-grade cytology report (rather than only among the subset of women where a biopsy is taken). These results are presented in Figure 91, and compared with those for women with low-grade cytology results with a positive HPV triage test.  Previous calculations did not discriminate between cytology taken as a screening or diagnostic test. Since diagnostic test samples are, by definition, collected from women at a higher risk of disease than the general population attending for screening, this may be a contributing factor for some laboratories with a PPV that is higher than the upper end of the target range, particularly where the colposcopically-directed cytology and corresponding histology are reported by the same laboratory as best management practice. In the current report, the methodology was updated to try to restrict the analysis to screening or community-derived cytology samples, by excluding samples that appeared to have been collected at a colposcopy visit. This updated method should provide a clearer picture of positive predictive value of HSIL (and other reporting categories) in a screening setting. As samples collected at colposcopy are likely to have a higher PPV than screening samples (for the reasons above), this update led to a decrease in the PPV for HSIL + SC cytology samples in most laboratories, and the decrease was more pronounced for those laboratories with a higher proportion of samples originating from colposcopy clinics. After cytology collected at colposcopy was excluded, the number of laboratories that exceeded the upper target of 85% decreased from three to one.  The effect of the updated methodology on the estimates of the PPV for ASC-H were different than for HSIL + SC, because some women classified in the HSIL category in the original method, based on a sample collected at colposcopy, shifted into the ASC-H category, based on their referring cytology result (Table 57). Overwhelmingly, the women who shifted from the HSIL category to the ASC-H category were those with HSIL-confirmed histology. Potentially the result for the cytology sample collected at colposcopy (HSIL) differed from the referring cytology result (ASC-H) in these women because cytology could be colposcopically-directed and cytology and corresponding histology were reported by the same laboratory as best management practice. |

Figure 45 - Positive predictive value for CIN 2+ in women with HSIL or SC cytology reports (cytology sample collected 1 January – 30 June 2018), excluding samples from colposcopy, by laboratory



*Target: 65% - 85%.*

Figure – Comparison of positive predictive value for CIN 2+ in women with HSIL or SC cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory


**

Figure - Comparison of positive predictive value for CIN 2+ in women with ASC-H cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory





Figure - Comparison of positive predictive value for CIN 2+ in women with ASC-H, HSIL or SC cytology reports (cytology collected 1 January – 30 June 2018) between two calculation methods, by laboratory




Figure 49 - Trends in the positive predictive value for CIN 2+ in women with HSIL or SC cytology results (based on original method), by laboratory




*Time period relates to monitoring report period; cytology samples were collected in the period six months prior.*

Figure 50 - Trends in the positive predictive value for CIN 2+ in women with HSIL or SC cytology results (based on original method), by laboratory, Jul-Dec 2008 – Jan-Jun 2018

**


*Time period relates to monitoring report period; cytology samples were collected in the period six months prior. Samples labelled as Anatomical Pathology Services prior to Report 43 (Jan-Jun 2015) were reported by Diagnostic Medlab Ltd.*

Figure 51 - Trends in the positive predictive value for CIN 2+ in women with ASC-H cytology results (based on original method), by laboratory



*Time period relates to monitoring report period; cytology samples were collected in the period six months prior.*

Figure 52 - Trends in the positive predictive value for CIN 2+ in women with ASC-H, HSIL or SC cytology results (based on original method), by laboratory



*Time period relates to monitoring report period; cytology samples were collected in the period six months prior.*

### Indicator 5.3 – Accuracy of negative cytology reports

|  |  |
| --- | --- |
| **Definition** | This indicator currently has two parts to its definition.   1. For women with a histological diagnosis of CIN 2, CIN 3, invasive SCC, AIS or invasive endocervical adenocarcinoma, the proportion of cytology slides originally reported within the preceding 42 months as negative, benign/reactive or unsatisfactory which on review are consistent with high -grade or worse category (Standard 522). 2. The ability of a laboratory to correctly identify a negative sample.   All cases with a high-grade or invasive diagnosis on histology (CIN 2, CIN 3, invasive SCC, AIS or invasive endocervical adenocarcinoma) must have a review of any cytology slides that have been reported as negative, benign/reactive or unsatisfactory in the previous 42 months. Any abnormality identified as high -grade or worse on review of a previously reported negative or unsatisfactory cytology slide must be documented by the laboratory. Cumulative data must be forwarded to the National Screening Unit to help ensure the accuracy of submitted negative cytology reports. |
| **Target** | No more than 10% of cytology originally identified as negative is identified as consistent with a cytological interpretation of HS1, HS2, SC, AIS or AC1-AC5 (HSIL+) on review.  Aim for less than 15%, but not more than 20% of cytology originally identified as negative is identified as consistent with a cytological interpretation of ASC-H, HS1, HS2, SC, AG4-AG5, AIS or AC1-AC5 (ASC-H +) on review. |
| **Current Situation** | This indicator is analysed annually to allow for the full year to be examined. Data for women with a histological diagnosis of high-grade/ invasive disease in the period 1 January – 31 December 2017 2017 were provided in Report 48. Data for women with a histological diagnosis of high-grade/ invasive disease in the period 1 January – 31 December 2018 will be provided in Report 50. |
| **Trends** | - |
| **Comments** | - |

### Indicator 5.4 – Histology Reporting

|  |  |
| --- | --- |
| **Definition** | The NCSP Register collects histology results of samples taken from the cervix and vagina. Histology samples include diagnostic biopsies, treatment biopsies, cervical polyps and the cervical tissue of total hysterectomy specimens. All histology samples taken during the current monitoring period were retrieved. Where a histology sample had more than one SNOMED code, or a woman had more than one histology result, the most serious (highest ranked) code was used (see Appendix C).  Results are presented both according to the detailed SNOMED category, and by broader histology diagnostic category. The mapping between SNOMED codes and diagnostic category is detailed in Appendix C.  Two versions of SNOMED are used by laboratories (1986 and 1993) depending on the laboratory software. The NCSP Register accepts both versions and for statistical purposes maps the 1986 codes to the 1993 codes.  A woman’s age is defined as her age at the end of the monitoring period (i.e. a woman’s age at 30 June 2018). Where trends are shown, a woman’s age is her age at the end of the 6-month period in which the result was reported. |
| **Target** | None |
| **Current Situation** | 12,467 histology samples were taken during the current monitoring period. Of these, 431 (3.5%) were insufficient for diagnosis. These samples were taken from 427 women, 68 (15.9%) of whom have a record of a subsequent sufficient histology test. The remaining 12,036 samples were taken from 10,553 women.  Results for these women are reported on in Table 7 to Table 10.  Table 7 shows histology results by SNOMED category, based on the most serious (highest ranked) result for each woman in the monitoring period. Table 8 to Table 11 show histology results by broader histology diagnostic category.  56.1% of women with histology tests had negative or benign histology results (Table 8). 19.4% of women had high-grade squamous (CIN 2/3) histology results and 67 women (0.63%) had adenocarcinoma in situ. There were 51 women (0.48%) with invasive squamous cell carcinoma (ISCC) histology, 6 (0.06%) with microinvasive squamous cell carcinoma (SCC) histology and 43 (0.41%) with invasive adenocarcinoma; four (<0.05%) were adenocarcinomas arising from the endocervix and 39 (0.37%) were adenocarcinomas not arising from the endocervix. There were two women with adenosquamous carcinoma (<0.05%) as their most serious histology result.  The age group with the largest number of women with histology samples was women aged 45-49 years (1,427 women, Table 9). Among women aged 20-69 years, the age group with the lowest rate of women with results which were negative was women aged 25-29 years (34.6%; Table 10).  Histology samples were additionally analysed after excluding 2,120 women whose only histology result(s) originated from a hysterectomy (partial with cervical component or total hysterectomy) and were negative/ benign (non-neoplastic) (Table 11). This represented approximately 35.8% of the women with negative/ benign histology. This reduced the proportion with a histology result being negative/ benign from 56.1% to 45.1% of all women with a histology sample. After excluding negative/ benign histology from hysterectomy samples, this resulted in 0.51% women with histology having an invasive adenocarcinoma result, including with adenocarcinomas arising from the endocervix (<0.05%) and women with adenocarcinomas not arising from the endocervix (0.46%). The most severe histological abnormality detected was HSIL (CIN 2/3) for 24.2% of women; ISCC for 0.60% of women; microinvasive SCC for 0.07% of women; adenocarcinoma in situ for 0.79% of women; and adenosquamous carcinoma for <0.05% of women (Table 11).  The number of women with CIN 2/3 histology within the monitoring period was further explored as a rate per 1,000 women screened within the period (where a screening event included a cytology, histology or HPV event). There were 2,044 women with CIN 2/3 histology, corresponding to a rate of 10.0 women with CIN 2/3 histology per 1,000 women screened (age-standardised to WHO population aged 20-69 years). Among women aged 20-69, the rate of women with CIN 2/3 histology samples taken per 1,000 women screened was highest in women aged 25-29 (18.7 per 1,000 women screened) and lowest in women aged 60-64 years (2.4 per 1,000 women screened) (Figure 53). By ethnicity, Māori women had the highest rates of CIN2/3 histology per 1,000 women screened (12.0 women) and Asian women the lowest (6.1 women) (age-standardised to WHO population aged 20-69 years; Table 58, Figure 54). This difference was most apparent in younger women aged less than 35 years (Figure 53, Table 58). |
| **Trends** | The proportion of women with negative or benign histology (56.1%; or 45.1% if benign hysterectomy samples are excluded; Table 8, Table 11) is similar to that reported for the previous period (56.8%; 45.6% if benign hysterectomy samples are excluded).  The proportions were similar to those in the previous period for women with invasive adenocarcinoma not arising from the endocervix (0.37% in the current and previous period) and adenocarcinoma arising from the endocervix (<0.05% in both periods). An increase was seen in women with adenocarcinoma in situ (0.63% in this period and 0.57% last period) and for CIN1 (15.6% to 16.8% in the current period). The proportion slightly decreased for women with ISCC (0.48% in this period and 0.52% in the last period).  Rates of CIN 2/3 per 1,000 women screened were previously reported in Annual Reports (up to 2013), but have been re-analysed in six-month monitoring periods for the purpose of this report. These are shown by ethnicity in Figure 54, and by age in Figure 55. When looking at longer term changes, notable decreasing trends over time are seen in women aged 20-24 and 25-29, from the latter half of 2012 and early 2016, respectively (Figure 55).  Longer term trends by ethnicity are shown in Table 59, and for selected age groups (20-24 and 25-29) in Figure 56, based on those ages which would include a proportion of women who have been vaccinated against HPV. In both Māori and European/ Other women, there has been a consistent decline in CIN 2/3 cases per 1,000 women screened, since approximately 2012 for woman aged 20-24 years. More recently, rates also appear to have begun declining in European/ Other women aged 25-29 years, and potentially also in Māori women. Trends are less consistent in Pacific and Asian women. |
| **Comments** | Histology samples include diagnostic biopsies, treatment biopsies, cervical polyps and the cervical tissue of total hysterectomy specimens. Histology samples may also include samples from non-cervical sites, where there is also a cervical component in the sample, for example endometrial samples. Also, pathologists are not always able to determine the site of origin particularly in small biopsies. “Adenocarcinoma not endocervical type” is the code that pathologists use for adenocarcinomas involving the cervix, but not primarily arising from the cervix. This means that the code category of endocervical adenocarcinoma of endocervical type should equate much more closely with data held on the Cancer Registry. In addition, it has been identified that the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories. This is in the process of being corrected.  In the current report, a supplementary analysis was undertaken which excluded any samples which originated from a hysterectomy sample (partial with cervical component or total) which were negative/ benign. These supplementary results may more closely reflect the results of histology which were collected in relation to the NCSP.  In previous reports, trends in high grade abnormalities were examined by looking at the rate of women with CIN 2/3 histology, as a proportion of all women with histology. In the current report, this aspect of looking at trends in high-grade histological abnormalities has been updated to look at the rate of CIN 2/3 histology per 1,000 women screened. This is a more widely used and standard measure, and has been brought across from the NCSP Annual Reports. The previous measure has been included in this report in Figure 113, to allow comparison with earlier reports.  As discussed in Indicator 5.1, a decline in both cytological and histological HSIL would be expected to occur as a consequence of the introduction of HPV vaccination from September 2008, and this would be expected to occur in younger age groups first (the oldest birth cohorts eligible for vaccination through the publicly funded programme would be aged up to 28 years at the time of the current monitoring period, while the oldest birth cohorts offered vaccination at the target age of 12-13 years would be aged up to 22 years). Declines histological HSIL in younger women in this section of the current monitoring report are consistent with declines also seen in the proportion of satisfactory samples reported as HSIL, documented as part of Indicator 5.1. These results in New Zealand are consistent with findings from a number of other countries that have reported a reduction in population-level rates of histological HSIL since the introduction of HPV vaccination.[14](#_ENREF_14) They also contribute to a relatively smaller number of settings that have reported vaccine impact within specific ethnicity subgroups of the population.[15](#_ENREF_15), [16](#_ENREF_16) |

Table 7 - Histology results reporting by SNOMED category

|  |  |  |
| --- | --- | --- |
| **SNOMED category** | **Women with that diagnosis** | |
|  | **N** | **%** |
| Negative/normal | 3,230 | 30.6 |
| Inflammation | 649 | 6.1 |
| Microglandular hyperplasia | 7 | 0.07 |
| Squamous metaplasia | 290 | 2.7 |
| Polyp | 1,414 | 13.4 |
| Other\* | 329 | 3.1 |
| Atypia | 42 | 0.40 |
| Benign glandular atypia | 3 | <0.05 |
| HPV | 584 | 5.5 |
| Condyloma acuminatum | 3 | <0.05 |
| CIN 1 (LSIL) or VAIN 1 | 1,688 | 16.0 |
| Dysplasia/CIN NOS | 41 | 0.39 |
| Glandular dysplasia | 1 | <0.05 |
| CIN 2 (HSIL) or VAIN 2 | 788 | 7.5 |
| HSIL not otherwise specified | 41 | 0.39 |
| CIN 3 (HSIL) or VAIN 3 | 1,215 | 11.5 |
| Adenocarcinoma in situ | 67 | 0.63 |
| Microinvasive squamous cell carcinoma | 6 | 0.06 |
| Invasive squamous cell carcinoma | 51 | 0.48 |
| Adenocarcinoma (arising from the endocervix) | 4 | <0.05 |
| Invasive adenocarcinoma (not arising from the endocervix) | 39 | 0.37 |
| Adenosquamous carcinoma | 2 | <0.05 |
| Undifferentiated carcinoma | 3 | <0.05 |
| Sarcoma | 1 | <0.05 |
| Carcinosarcoma | 2 | <0.05 |
| Choriocarcinoma | - | - |
| Miscellaneous primary tumour | 5 | <0.05 |
| Metastatic tumour | 26 | 0.25 |
| Small cell carcinoma | 2 | <0.05 |
| Malignant tumour, small cell type | - | - |
| Melanoma | - | - |
| Other primary epithelial malignancy | 20 | 0.19 |
| **Total** | **10,553** | **100** |

*NOS = not otherwise specified; HSIL not otherwise specified = high -grade squamous intraepithelial lesion, not otherwise specified/ CIN 2/3 (SNOMED code M67017; see Appendix C)*

*\* Other morphologic abnormality, not dysplastic or malignant.*

*Note: the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories.*

Table 8 - Histology results reporting by diagnostic category

|  |  |  |
| --- | --- | --- |
| **Histology category** | **Women with that histology result** | |
|  | **N** | **%** |
| Negative/benign (non neoplastic) | 5,922 | 56.1 |
| HPV | 587 | 5.6 |
| CIN1 | 1,771 | 16.8 |
| Glandular dysplasia | 1 | <0.05 |
| CIN 2 | 788 | 7.5 |
| HSIL not otherwise specified | 41 | 0.39 |
| CIN 3 | 1,215 | 11.5 |
| Adenocarcinoma in situ | 67 | 0.63 |
| Microinvasive | 6 | 0.06 |
| Invasive squamous cell carcinoma | 51 | 0.48 |
| Adenocarcinoma (arising from the endocervix) | 4 | <0.05 |
| Invasive adenocarcinoma (not arising from the endocervix) | 39 | 0.37 |
| Adenosquamous carcinoma | 2 | <0.05 |
| Other cancer | 59 | 0.56 |
| **Total** | **10,553** | **100.0** |

*Details of mapping between SNOMED category and diagnostic category are included in Appendix C. HSIL not otherwise specified = high-grade squamous intraepithelial lesion, not otherwise specified/ CIN 2/3 (SNOMED code M67017; see Appendix C). Note: the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories.*

Table 9 - Histology results by age – counts

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Age group** | | | | | | | | | | | | |
| **Histology Diagnostic Category** | **<20** | **20-24** | **25-29** | **30-34** | **35-39** | **40-44** | **45-49** | **50-54** | **55-59** | **60-64** | **65-69** | **70+** | **Total** |
| Negative/benign (non neoplastic) | 14 | 321 | 355 | 429 | 555 | 853 | 1,076 | 830 | 544 | 366 | 269 | 310 | 5,922 |
| HPV | - | 93 | 82 | 73 | 68 | 64 | 62 | 58 | 37 | 25 | 17 | 8 | 587 |
| CIN1 | 3 | 396 | 328 | 296 | 223 | 148 | 137 | 91 | 74 | 37 | 24 | 14 | 1,771 |
| Glandular dysplasia | - | - | - | - | - | - | 1 | - | - | - | - | - | 1 |
| CIN 2 | 3 | 186 | 176 | 158 | 83 | 53 | 52 | 26 | 24 | 11 | 12 | 4 | 788 |
| HSIL not otherwise specified | - | 7 | 16 | 6 | 2 | 2 | 3 | 2 | 1 | 1 | - | 1 | 41 |
| CIN 3 | - | 134 | 285 | 292 | 173 | 113 | 76 | 42 | 40 | 26 | 19 | 15 | 1,215 |
| Adenocarcinoma in situ | - | 1 | 13 | 21 | 6 | 10 | 4 | 2 | 5 | 3 | 2 | - | 67 |
| Microinvasive | - | - | - | 2 | 1 | 1 | 1 | - | 1 | - | - | - | 6 |
| Invasive squamous cell carcinoma | - | - | 7 | 7 | 6 | 5 | 7 | 4 | 3 | 5 | 4 | 3 | 51 |
| Adenocarcinoma (arising from the endocervix) | - | - | - | - | - | 2 | 1 | 1 | - | - | - | - | 4 |
| Invasive adenocarcinoma (not arising from the endocervix) | - | - | 1 | 2 | 3 | 3 | 3 | 4 | 10 | 1 | 5 | 7 | 39 |
| Adenosquamous carcinoma | - | - | - | - | 1 | - | 1 | - | - | - | - | - | 2 |
| Other cancer | - | - | 1 | 4 | 2 | 1 | 3 | 8 | 5 | 6 | 10 | 19 | 59 |
| **Total** | **20** | **1,138** | **1,264** | **1,290** | **1,123** | **1,255** | **1,427** | **1,068** | **744** | **481** | **362** | **381** | **10,553** |

*HSIL not otherwise specified = high -grade squamous intraepithelial lesion, not otherwise specified/ CIN 2/3 (SNOMED code M67017; see Appendix C)*

*Note: the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories.*

Table 10 - Histology results by age – percentages

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Histology Diagnostic Category** | **Age group** | | | | | | | | | | | |
| **<20** | **20-24** | **25-29** | **30-34** | **35-39** | **40-44** | **45-49** | **50-54** | **55-59** | **60-64** | **65-69** | **70+** |
| Negative/benign  (non neoplastic) | 70.0 | 28.2 | 28.1 | 33.3 | 49.4 | 68.0 | 75.4 | 77.7 | 73.1 | 76.1 | 74.3 | 81.4 |
| HPV | - | 8.2 | 6.5 | 5.7 | 6.1 | 5.1 | 4.3 | 5.4 | 5.0 | 5.2 | 4.7 | 2.1 |
| CIN1 | 15.0 | 34.8 | 25.9 | 22.9 | 19.9 | 11.8 | 9.6 | 8.5 | 9.9 | 7.7 | 6.6 | 3.7 |
| Glandular dysplasia | - | - | - | - | - | - | 0.07 | - | - | - | - | - |
| CIN 2 | 15.0 | 16.3 | 13.9 | 12.2 | 7.4 | 4.2 | 3.6 | 2.4 | 3.2 | 2.3 | 3.3 | 1.0 |
| HSIL not otherwise specified | - | 0.62 | 1.27 | 0.47 | 0.18 | 0.16 | 0.21 | 0.19 | 0.13 | 0.21 | - | 0.3 |
| CIN 3 | - | 11.8 | 22.5 | 22.6 | 15.4 | 9.0 | 5.3 | 3.9 | 5.4 | 5.4 | 5.2 | 3.9 |
| Adenocarcinoma in situ | - | 0.09 | 1.0 | 1.6 | 0.53 | 0.80 | 0.28 | 0.19 | 0.67 | 0.62 | 0.55 | - |
| Microinvasive | - | - | - | 0.16 | 0.09 | 0.08 | 0.07 | - | 0.13 | - | - | - |
| Invasive squamous cell carcinoma | - | - | 0.55 | 0.54 | 0.53 | 0.40 | 0.49 | 0.37 | 0.40 | 1.04 | 1.1 | 0.8 |
| Adenocarcinoma (arising from the endocervix) | - | - | - | - | - | 0.16 | 0.07 | 0.09 | - | - | - | - |
| Invasive adenocarcinoma  (not arising from the endocervix) | - | - | 0.08 | 0.16 | 0.27 | 0.24 | 0.21 | 0.37 | 1.34 | 0.21 | 1.38 | 1.84 |
| Adenosquamous carcinoma | - | - | - | - | 0.09 | - | 0.07 | - | - | - | - | - |
| Other cancer | - | - | 0.08 | 0.31 | 0.18 | 0.08 | 0.21 | 0.75 | 0.67 | 1.25 | 2.8 | 5.0 |
| **Total** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** |

*HSIL not otherwise specified = high -grade squamous intraepithelial lesion, not otherwise specified/ CIN 2/3 (SNOMED code M67017; see Appendix C).*

*Note: the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories.*

Table 11 - Histology results reporting by diagnostic category excluding samples from partial\* or total hysterectomy specimens and where the result was negative/ benign.

|  |  |  |
| --- | --- | --- |
| **Histology category** | **Women with that histology result** | |
|  | **N** | **%** |
| Negative/benign (non neoplastic) | 3,802 | 45.1 |
| HPV | 587 | 7.0 |
| CIN1 | 1,771 | 21.0 |
| Glandular dysplasia | 1 | <0.05 |
| CIN 2 | 788 | 9.3 |
| HSIL not otherwise specified | 41 | 0.49 |
| CIN 3 | 1,215 | 14.4 |
| Adenocarcinoma in situ | 67 | 0.79 |
| Microinvasive | 6 | 0.07 |
| Invasive squamous cell carcinoma | 51 | 0.60 |
| Invasive adenocarcinoma (arising from the endocervix)† | 4 | <0.05 |
| Invasive adenocarcinoma (not arising from the endocervix)† | 39 | 0.46 |
| Adenosquamous carcinoma | 2 | <0.05 |
| Other cancer | 59 | 0.70 |
| **Total** | 8,433 | **100.0** |

*\*Partial with cervical component. Details of mapping between SNOMED category and diagnostic category are included in Appendix C.*

*HSIL not otherwise specified = high-grade squamous intraepithelial lesion, not otherwise specified/ CIN 2/3 (SNOMED code M67017; see Appendix C). Results differ from those in Table 8 due to the exclusion of negative/ benign results from partial/ total hysterectomy samples.*

*† Note: the SNOMED codes that distinguish the two categories of adenocarcinoma have not been utilised consistently by some laboratories. Consequently, “invasive adenocarcinoma not endocervical type” may be over reported and “invasive adenocarcinoma endocervical type” under-reported in these laboratories.*

Figure 53 - Rate of women with CIN 2/3 per 1,000 women screened, by age and ethnicity for the period 1 January – 30 June 2018



**

Figure 54 - Trends in the age standardised rate of women with CIN 2/3 per 1,000 women screened, by ethnicity

**

*Age-standardised rate, standardised to the WHO population (ages 20-69 years)*

Figure 55 - Trends in the rate of women with CIN 2/3 per 1,000 women screened, by age



**


Figure 56 - Trends in the rate of women with CIN 2/3 per 1,000 women screened, by ethnicity and selected ages

**

### Indicator 5.5 - Laboratory turnaround times


|  |  |
| --- | --- |
| **Definition** | Turnaround time is defined as the number of working days from the date a sample is received by a laboratory, and the date which it is reported to the sample taker (for cytology and hrHPV samples) or referring colposcopist (for histology samples). For the purposes of this measure, samples received and reported on the same day are defined as having a turnaround time of one day. |
| **Target** | ***Cytology***  Laboratories are required to report 90% of final gynaecological cytology results to sample takers within seven working days of receipt of the sample and 98% within 15 working days (Standard 513[17](#_ENREF_17)).  ***Histology***  Laboratories are required to report 90% of final histology results to referring colposcopists within ten working days of receipt of the sample and 98% of final histology results within 15 working days of receiving the sample (Standard 516[17](#_ENREF_17)).  ***Cytology with associated hrHPV testing***  Laboratories are required to report 98% of final cytology test results (including those associated with HPV test) within 15 working days of receiving the sample. Here, the turnaround time is measured specifically for cytology where HPV testing is performed for low-grade triage. Low-grade triage is defined further in Indicator 8; here it relates to cytology samples *received at the laboratory* in the monitoring period (as opposed to *samples collected* in the period, in Indicator 8). It is restricted to triage testing of women aged 30 years or more. These samples form a subset of those considered in the overall measure of turnaround time for cytology. Note that since reporting of cytology with adjunctive hrHPV testing requires that both test results be reported together (hrHPV test results must not be issued independently when adjunct to a cytology request), the turnaround time of the hrHPV test should not exceed that of the accompanying cytology, except where the HPV test was added after cytology was already reported. |
| **Current Situation** | ***Cytology***  Six laboratories received 218,755 cytology samples during the current monitoring period. Overall, 94.9% of cytology samples were reported on within seven working days, which meets the target of 90% (Table 61). Nationally, 99.0% were reported on within 15 working days, which meets the target of 98%.  Four of the six laboratories met the target for 90% of cytology samples to be reported to sample takers in seven working days or less (Anatomical Pathology Services, Canterbury Health Laboratories, Pathlab and Southern Community Labs Dunedin) while the remaining two laboratories (LabPLUS, Medlab Central Ltd.) reported on 70.9% and 89.3% of cytology samples within seven days (Figure 57, Table 61). All six laboratories also met the target of 98% of samples reported within 15 working days (Anatomical Pathology Services, Canterbury Health Laboratories, LabPLUS, Medlab Central Ltd, Pathlab and Southern Community Labs Dunedin) (Figure 58, Table 61).  ***Histology***  Fourteen laboratories received 12,446 histology samples in the current monitoring period. Overall 92.3% of samples were reported on within ten working days, which meets the target of 90%. Nationally 96.9% were reported on in 15 working days or less, which is below the target of 98% (Table 62). Eight of the 14 laboratories met the target of 90% of final histology results to referring colposcopists within ten working days of receipt of the sample (Anatomical Pathology Services, Medlab Central Ltd, Middlemore Hospital Laboratory, Nelson Hospital Laboratory, North Shore Hospital Laboratory, Southern Community Laboratories Dunedin, Southern Community Laboratories Wellington, Taranaki) (Figure 59). Five laboratories met the target of 98% of final histology results reported to the requestor within 15 working days of receiving the sample (Figure 60, Table 62). Among the eight remaining laboratories, six had reported on at least 95% of samples within 15 days (Figure 60, Table 62). The proportion of histology samples reported on within 15 days ranged from 79.4% (Waikato Hospital Laboratory) to all samples in Taranaki Medlab.  ***Low-grade cytology with associated HPV triage testing***  Six laboratories received 3,063 cytology samples during the current monitoring period which were associated with HPV testing for the purpose of triage of low-grade abnormalities. Overall, 99.3% of these cytology samples were reported on within 15 working days, which meets the target of 98%. The proportion of cytology samples with HPV triage tests reported on within 15 days ranged from 97.6% (LabPLUS) to 99.9% (Anatomical Pathology Services) (Figure 61, Table 63).  The target of 98% of tests reported within 15 working days was met by four of the six laboratories. Nationally, the proportion of cytology reported within 15 days for cytology associated with low-grade triage HPV testing (99.3%) was similar to the cytology reported overall (99.0%). At most laboratories, the proportion of cytology tests reported within 15 working days was similar regardless of whether there is an associated HPV triage test (Figure 61). LabPlus and Medlab Central Ltd. reported below the target level for cytology associated with low-grade triage HPV testing (97.6% and 97.7%, respectively) but achieved the target for cytology overall (98.2% and 98.5%, respectively). |
| **Trends** | ***Cytology***  The overall proportion of samples reported on within seven working days in the current report (94.9%) is lower than the proportion reported in the previous monitoring period (96.3%). Four laboratories met the target in this monitoring period which is one less laboratory compared to the previous reporting period. The proportion of samples reported on within 15 working days was similar in the previous monitoring period (99.0% compared to 99.2% in the previous monitoring period). All six laboratories met the target of reporting 98% of samples within 15 working days, which is one more than the previous report.  ***Histology***  The proportion of histology samples reported on within ten working days has decreased in this report (from 94.0% to 92.3%). Eight laboratories achieved the ten-working-days target in this monitoring period compared to nine in the last period. The proportion of histology samples reported on within 15 working days is similar to the previous report (96.9%, compared to 97.2% in the previous report). Five laboratories meet the target in this period compared to six in the previous report. In the current period, eleven of the 14 laboratories had reported on at least 95% of samples within 15 days, which is one more than achieved in the previous period.  ***Cytology with associated HPV triage testing***  The proportion of cytology samples with an associated HPV triage test reported within 15 working days is similar to the previous report – from 99.0% to 99.3%. The target of reporting 98% of final cytology test results within 15 working days was met by one less laboratory compared to the previous report. |
| **Comments** | Note that the total number of cytology samples reported on in this Indicator is different from that reported in Indicator 5.1, as the inclusion criteria for the current indicator was all cytology samples *received by laboratories* within the monitoring period, rather than cytology samples where the *specimen was* *collected* during the monitoring period, which is the criteria for Indicator 5.1.  The definition used by individual laboratories for turnaround time differs. For example, depending on the definition used by the laboratory, a turnaround time of one day can mean the results are reported within 24 hours, on the same day the sample is received, or on the day after the sample is received. Therefore, we have applied the same definition to all laboratories in these calculations, but because of the variation between laboratories in their internal definition, it has not been possible in this report to use a definition here which is consistent with what each individual laboratory uses.  Turnaround time performance may be underestimated due to limitations in the report date recorded on the NCSP Register. When amended reports are sent to the NCSP Register, the report date in the NCSP Register is updated to reflect the date on which the report was re-transmitted after the amendments are made. The occurrence of these amended reports can therefore distort (and lengthen) turnaround time, as in these cases the report date recorded in the NCSP Register does not reflect the date on which results were first communicated to the sample taker or colposcopist. The extent of this cannot be directly determined from the NCSP Register, however audit results (which invariably find better turnaround time performance) suggest that it is a factor which should be considered in interpretation of these results.  There are some possible explanations why in some laboratories the turnaround time for cytology with associated HPV triage testing is longer than for other cytology. As the HPV triage test is performed in response to low-grade cytology results in a subset of women (those aged 30 years or more without a recent cytological abnormality), the need for the HPV test is only apparent after the cytology result is available. Additionally, as HPV tests are generally performed in batches, laboratories with smaller HPV test volumes may take longer to accrue the required batch sizes, and therefore perform HPV tests less frequently.  Caution must be taken when comparing percentages of reporting from this monitoring period to previous monitoring periods due to changes in the number of reporting laboratories. Differences in percentages from this and previous monitoring reports may be due to differences in caseloads. |

Figure 57 - Proportion of cytology samples reported within seven working days by laboratory, 1 January – 30 June 2018




*Target: 90% within seven working days (red line)*

Figure 58 - Proportion of cytology samples reported within 15 working days by laboratory, 1 January – 30 June 2018

**


*Target: 98% within 15 working days (red line)*

Figure 59 - Proportion of histology samples reported within ten working days by laboratory, 1 January – 30 June 2018




*Target: 90% within ten working days (red line)*

Figure 60 - Proportion of histology samples reported within 15 working days by laboratory, 1 January – 30 June 2018



*Target: 98% within 15 working days (red line)*

Figure 61 - Proportion of cytology samples with associated HPV triage testing and of all cytology samples reported within 15 days by laboratory, 1 January – 30 June 2018


****

*Target: 98% within 15 working days (red line)*

## Indicator 6 – Follow-up women high-grade cytology, no histology

|  |  |
| --- | --- |
| **Definition** | The proportion of women who have had a cervical sample showing a high -grade cytology result for whom a histological report has been received by the NCSP Register. This proportion is a measure of the completeness of follow-up of women with high-grade cytology.  Each woman with a high-grade cytology result, relating to a cytology sample taken in the six months preceding the current monitoring period (i.e. sample taken in the period of 1 July - 31 December 2017), is followed for any histology samples taken on or after the date of the cytology sample. The period of time between the cytology and histology reports relating to these samples is calculated. The proportion of women with a histology report up to and including 90 days after their cytology report is calculated. Histology reports which occur prior to the cytology report are included, as long as the histology sample was not taken before the cytology sample, to allow for differences in turnaround times between cytology and histology.  Analyses were also performed which calculated the proportion of women with a high-grade cytology result who have a histology report within 180 days of their cytology report.  For the purposes of this indicator, the following Bethesda 2001 (New Zealand modified; TBS 2001 NZ modified)[18](#_ENREF_18) interpretation codes are included as high-grade cytology: ASH, HS1, HS2, SC, AG1-AG5, AIS, AC1-AC5. Within this group, women are considered as having an urgent referral, due to suspicion of invasive disease if they have an interpretation code of HS2, SC, or AC1-AC5 and/or a recommendation code of R10 or R14.  High-grade cytology reports that indicated women were already under specialist management (TBS 2001 NZ modified recommendation code R13) are excluded. After these are excluded, follow-up of women who have more than one high-grade cytology sample is based on the first cytology sample collected in the period.  Note that some women may be assessed at colposcopy but have no biopsy taken. The colposcopy visit data for this group of women (Indicator 7.1) will supplement this indicator. An exploratory analysis was also performed here which calculated the proportion of women with high-grade cytology who had no follow-up test of any kind (including colposcopy, histology sample, HPV sample, or subsequent cytology sample) within 180 days.  Note that the Programme also attempts to facilitate the follow-up of all women with absent histology so that they may receive appropriate care where possible.  A woman’s age is defined as her age at the end of the current monitoring period (i.e. A woman’s age at 30 June 2018). |
| **Target** | 90% of women should have a histology report within 90 days of their cytology report date.  99% of women should have a histology report within 180 days of their cytology report. |
| **Current Situation** | There were 2,819 high-grade cytology results relating to samples collected in the period 1 July - 31 December 2017; 1,110 of these cytology samples were collected at a colposcopy visit or the results indicated that a woman was already under specialist management. It was assumed that these results were already being followed up in the course of this management, and so the cytology tests were excluded from this measure. This left 1,709 cytology results, which related to 1,706 women. Histological follow-up for these 1,706 women is considered in this indicator. Where women had more than one high-grade cytology result relating to a sample taken in the period, histological follow-up of the earliest cytology sample taken in the period was assessed.  ***Histological follow-up***  Nationally, 1,433 women (84.0%) had a histology report within 90 days of their cytology report, and 1,520 (89.1%) had a histology report within 180 days. These were below the targets of 90% within 90 days and 99% within 180 days.  The proportion of women with a histology report varied by DHB from 72.7% (West Coast) to 93.8% (South Canterbury) within 90 days of their cytology report, and from 81.8% (Counties Manukau and West Coast) to 97.1% (Whanganui) within 180 days of their cytology report (Figure 62, Table 12). Three DHBs met the target for the proportion of women with histology within 90 days (Nelson Marlborough, South Canterbury and Whanganui with 91.2%, 93.8% and 91.4% of histology reported within 90 days of a high-grade cytology report, respectively), however no DHB met the target for 180 days. As shown in Table 12, some DHBs had a relatively small number of women with a high-grade cytology result recorded in the period (including Wairarapa and West Coast, with 14 and 11 women with a high-grade result respectively), and this should be taken into account when interpreting these results.    The proportion of women with a histology report also varied by age. Among women aged 20-69 years, the proportion varied from 57.9% (ages 60-64) to 91.0% (ages 40-44 years) within 90 days, with the target being met only for women in the 40-44 years age group. The target was not met in any age group for 180 days and ranged from 73.7% (ages 60-64 years) to 93.8% (ages 40-44 years) within 180 days (Table 13).  There was some variation by ethnicity in the proportion of women with histological follow-up, however the targets were not met for any group of women. At 90 days, the proportion of women with histological follow-up ranged from 71.1% (Pacific women) to 86.5% (Asian women; Table 14). By 180 days, however, the difference had narrowed, and the proportion with histology reports ranged from 80.7% (Pacific women) to 90.3% (European/ Other women; Table 15). Further breakdown by DHB and ethnicity is also shown in Table 14 and Table 15, and breakdown by DHB and age is shown in Table 64 and Table 65.  Among women with an urgent referral, due to a suspicion of invasive disease, (N=43), a histology report was available within 90 days for 86.0% of women and within 180 days for 93.0% of women (Table 16). Among the remaining women where there was no suspicion of invasive disease (TBS 2001 NZ modified Bethesda codes ASH, HS1, AG1-AG5, AIS), 83.9% had a histology report available within 90 days and 89.0% within 180 days.  ***Women with no follow-up tests***  When follow-up tests of any kind (colposcopy, histology, HPV test, or subsequent cytology test) were considered, there were 140 women (8.2%) who had no record of any subsequent follow-up within 90 days and 94 women (5.5%) who had no record of any subsequent follow-up within 180 days on the NCSP Register (Table 17).  This varied by DHB, from no women without follow-up (Whanganui) to 27.3% (West Coast) of women without a record of follow-up of some kind by 90 days, and from no women (Hawke's Bay, Lakes, Whanganui) to 18.2% (West Coast) of women without a record of follow-up of some kind by 180 days (Figure 63, Table 17). Among the DHBs where there remained women without a record of follow-up at 90 days, the number was generally small (ten or fewer women in 15 DHBs) and was a maximum of 23 women (14.9%) in Counties Manukau. At 180 days, the number remaining without a record of follow-up was ten or fewer in 17 DHBs, with a maximum of 17 women (11.0%) without a record of follow-up in Counties Manukau.  The proportion of women who had no record of any subsequent follow-up also varied by ethnicity, from 6.3% (European/ Other women) to 18.1% (Pacific women) at 90 days and from 4.1% (European/ Other women) to 12.0% (Pacific women) at 180 days (Table 18, Figure 64).  Among women with an urgent referral, due to a suspicion of invasive disease, a follow-up test of some kind was available within 90 days for 86.0% of women and 93.0% within 180 days (Table 16). At 180 days, there remained three women (7.0%) for whom no follow-up tests were recorded. Among women where there was no suspicion of invasive disease, 91.9% had a follow-up test report available within 90 days and 94.5% within 180 days (Table 16). At 180 days, there remained 91 women (5.5%) for whom no follow-up tests were recorded. |
| **Trends** | ***Histological follow-up***  The proportion of women with a histology report within 90 days has increased since the previous monitoring period (from 83.0% to 84.0% in the current period). The proportion of women with a histology report within 180 days has increased slightly (from 88.3% in the previous period to 89.1% in the current period).  While the proportion of women with histological follow-up at 90 days and 180 days has increased overall, this still varies for individual DHBs (Figure 65, Figure 66). In six DHBs the proportion of women with histological follow-up has decreased at 90 days and at 180 days (Canterbury, Hutt Valley, Northland, Southern, Tairawhiti and Taranaki). In eleven DHBs, the proportion of women with histological follow-up increased at both 90 days and at 180 days (Auckland, Bay of Plenty, Capital & Coast, Hawke's Bay, Lakes, Mid Central, Nelson Marlborough, South Canterbury, Waikato, Waitemata and Whanganui).  The proportion of women with follow-up histology at 90 days in the current monitoring period has increased since the previous report for Māori women (from 78.9% to 80.3%), Pacific women (from 68.6% to 71.1%) and Asian women (from 77.6% to 86.5%); and has remained similar for European/ Other women (from 85.7% to 85.4%) with follow-up histology within 90 days over the last two monitoring periods. The proportion of women with follow-up histology at 180 days has remained similar for Māori women (from 86.1% to 86.2%) and European/ Other women (from 90.2% to 90.3%) and has increased for the remaining ethnic groups (76.7% to 80.7% for Pacific; and 84.1% to 89.4% for Asian woman). The proportions of women with follow-up histology are quite variable within individual DHBs when broken down by DHB and ethnicity, as the number of women with high-grade cytology generally becomes comparatively small when broken down in those categories (except in some cases such as for European/ Other women, and Māori women in a few DHBs). Trend charts for ethnicity can be seen in Figure 67 and Figure 68.  As in previous reports, the proportion of women with histological follow-up varied substantially by age, and is generally lower in women aged 50 years or more, than in women younger than 50 years. Increases in the proportion of women with histological follow-up were seen in five of the ten age groups at 90 days follow-up, and in four age groups at 180 days. Decreases were seen in the five-year age groups between 30-49 and 60-64 years for both 90 and 180 days, and 55-59 years at 180 days.  ***Women with no follow-up tests***  The proportion of women with no record of a follow-up test has remained similar when compared to the previous report at 90 days (from 8.5% to 8.2% in the current report), and at 180 days (from 5.7% to 5.5%).  Trends by DHB were complex, but the proportion of women with no follow-up test recorded at 180 days reduced in nine of the 20 DHBs, and the reductions were greatest in Hawke's Bay (decrease of 6.6%). Increases were observed in the remaining 11 DHBs and was largest in West Coast (increase of 12.6%).  In the current monitoring period, the proportion of women for whom there was no follow-up test recorded has been stable at 90 days between the current and previous monitoring reports for all ethnics groups (Māori women from 13.3% to 12.6%; Pacific women from 17.4% to 18.1%; Asian women, 9.4% in both reports; and European/ Other women from 6.6% to 6.3%). At 180 days there was an increase in the number of women with no follow-up for Pacific women (by 1.5%, from 10.5% to 12.0%) and Asian women (by 1.1%, from 7.1% to 8.2%). For Māori women, however, a decrease was observed at 180 days from 9.5% to 8.2% but remained fairly consistent for European/ Other women (4.3% to 4.1% at 180 days). |
| **Comments** | The proportion of women with a follow-up test of any kind provides useful additional information. While 16.0% of women with high-grade cytology reports had no record of a histology report within 90 days, the proportion without a record of a follow-up test of any kind was much lower (8.2%). The same was also true at 180 days, where 10.9% of women with high-grade cytology reports had no record of a histology report within 180 days, but the proportion without a record of a follow-up test of any kind was much lower (5.5%). Consistent with previous monitoring reports, many of the women with no follow-up histology recorded do have a record of some follow-up test. This provides reassurance that many women without histology have not been lost to follow-up.  The measure of whether or not there has been a follow-up test of any sort considers cytology, colposcopy, histology and HPV tests. Therefore, changes in women with a follow-up test of any kind may also reflect changes in the completeness of reporting colposcopy data to the NCSP Register. This is expected to improve now that the time period of the data used to report on this indicator is after all DHBs began electronically reporting 2013 Colposcopy Standards data to the Register for the full reporting period.  Note that some women presenting with high grade glandular cytology or cancer may be referred directly to gynae-oncology and therefore not be recorded on the NCSP Register. While these represent a small number of women in absolute terms, they are potentially a noticeable proportion of the women with an urgent referral (for example, the three women with no follow-up within 180 days). This may have contributed to the lower rates of follow-up recorded for women with an urgent referral, due to a suspicion of invasive disease.  Note that while all *cytology results* which indicated that a woman was under specialist management were excluded from the measure of follow-up, not all *women* who had these cytology results were. If all cytology results for a woman indicated that she was under specialist management, she was excluded. However, any woman with at least one high-grade cytology result which did *not* indicate that she was under specialist management was included in the group in whom histological follow-up was measured. It was assumed that any high-grade cytology result without this indication should have been followed up in some way, regardless of other cytology results in the period. All of the cytology tests selected for follow-up indicated that referral or further assessment was recommended.  The risk level for women with no recorded biopsy is difficult to ascertain because a lack of histology can be due to a number of reasons, including:   1. examined but no biopsy taken, 2. did not attend (DNA) or refusal to attend 3. wait time issue 4. died or left New Zealand   Risk is also related to the degree of abnormality including microinvasive/ invasive carcinoma. Women who do not or refuse to attend are at highest risk due to no colposcopic examination. Due to the significant risk for this group of women if not followed up, NCSP Portfolio Managers ensure that priority is given to follow-up of these women through DHBs. |

Figure 62 - Proportion of women with a histology report within 90 days, and within 180 days of their high -grade cytology report, by DHB



*Target: 90% within 90 days; 99% within 180 days.*

Table 12 - Women with a histology report within 90 and 180 days of a high-grade cytology report, by DHB

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **DHB** | **High-grade cytology** | **Follow-up histology within 90 days** | | **Follow-up histology within 180 days** | |
| **N** | **N** | **%** | **N** | **%** |
| Auckland | 199 | 154 | 77.4 | 169 | 84.9 |
| Bay of Plenty | 84 | 70 | 83.3 | 73 | 86.9 |
| Canterbury | 197 | 174 | 88.3 | 182 | 92.4 |
| Capital & Coast | 87 | 69 | 79.3 | 75 | 86.2 |
| Counties Manukau | 154 | 118 | 76.6 | 126 | 81.8 |
| Hawke's Bay | 75 | 65 | 86.7 | 69 | 92.0 |
| Hutt Valley | 39 | 32 | 82.1 | 35 | 89.7 |
| Lakes | 39 | 34 | 87.2 | 36 | 92.3 |
| Mid Central | 71 | 62 | 87.3 | 66 | 93.0 |
| Nelson Marlborough | 68 | 62 | 91.2 | 64 | 94.1 |
| Northland | 48 | 36 | 75.0 | 41 | 85.4 |
| South Canterbury | 16 | 15 | 93.8 | 15 | 93.8 |
| Southern | 125 | 111 | 88.8 | 116 | 92.8 |
| Tairawhiti | 31 | 23 | 74.2 | 27 | 87.1 |
| Taranaki | 55 | 46 | 83.6 | 50 | 90.9 |
| Waikato | 155 | 134 | 86.5 | 137 | 88.4 |
| Wairarapa | 14 | 12 | 85.7 | 13 | 92.9 |
| Waitemata | 203 | 176 | 86.7 | 183 | 90.1 |
| West Coast | 11 | 8 | 72.7 | 9 | 81.8 |
| Whanganui | 35 | 32 | 91.4 | 34 | 97.1 |
| **Total** | **1,706** | **1,433** | **84.0** | **1,520** | **89.1** |

Table 13 - Women with a histology report within 90 and 180 days of a high-grade cytology report, by age

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Age (years)** | **High -grade cytology** | **Follow-Up histology Within 90 days** | | **Follow-up histology**  **Within 180 days** | |
|  | **N** | **N** | **%** | **N** | **%** |
| <20 | 2 | 2 | 100.0 | 2 | 100.0 |
| 20-24 | 255 | 220 | 86.3 | 232 | 91.0 |
| 25-29 | 330 | 295 | 89.4 | 304 | 92.1 |
| 30-34 | 315 | 270 | 85.7 | 285 | 90.5 |
| 35-39 | 212 | 189 | 89.2 | 195 | 92.0 |
| 40-44 | 144 | 131 | 91.0 | 135 | 93.8 |
| 45-49 | 110 | 87 | 79.1 | 95 | 86.4 |
| 50-54 | 98 | 75 | 76.5 | 81 | 82.7 |
| 55-59 | 95 | 71 | 74.7 | 76 | 80.0 |
| 60-64 | 57 | 33 | 57.9 | 42 | 73.7 |
| 65-69 | 52 | 39 | 75.0 | 44 | 84.6 |
| 70+ | 36 | 21 | 58.3 | 29 | 80.6 |
| **Total** | **1,706** | **1,433** | **84.0** | **1,520** | **89.1** |

Table 14 - Women with a histology report within 90 days of a high -grade cytology report, by DHB and ethnicity

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Māori** | | **Pacific** | | **Asian** | | **European/ Other** | |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| Auckland | 6 | 54.5 | 14 | 73.7 | 42 | 89.4 | 92 | 75.4 |
| Bay of Plenty | 13 | 86.7 | 1 | 100.0 | 1 | 100.0 | 55 | 82.1 |
| Canterbury | 10 | 76.9 | 2 | 66.7 | 10 | 100.0 | 152 | 88.9 |
| Capital & Coast | 6 | 85.7 | 4 | 66.7 | 9 | 90.0 | 50 | 78.1 |
| Counties Manukau | 21 | 67.7 | 20 | 64.5 | 17 | 77.3 | 60 | 85.7 |
| Hawke's Bay | 18 | 90.0 | 1 | 50.0 | 2 | 100.0 | 44 | 86.3 |
| Hutt Valley | 8 | 100.0 | 1 | 33.3 | 4 | 80.0 | 19 | 82.6 |
| Lakes | 13 | 100.0 | 1 | 100.0 | 1 | 100.0 | 19 | 79.2 |
| Mid Central | 17 | 85.0 | 1 | 100.0 | 3 | 100.0 | 41 | 87.2 |
| Nelson Marlborough | 4 | 66.7 | - | - | 2 | 100.0 | 56 | 93.3 |
| Northland | 6 | 66.7 | 1 | 100.0 | 2 | 66.7 | 27 | 77.1 |
| South Canterbury | 1 | 100.0 | - | - | 1 | 100.0 | 13 | 92.9 |
| Southern | 16 | 94.1 | 2 | 100.0 | 2 | 100.0 | 91 | 87.5 |
| Tairawhiti | 14 | 73.7 | - | - | - | - | 9 | 75.0 |
| Taranaki | 8 | 88.9 | 2 | 66.7 | 1 | 50.0 | 35 | 85.4 |
| Waikato | 26 | 86.7 | 2 | 100.0 | 7 | 58.3 | 99 | 89.2 |
| Wairarapa | 3 | 75.0 | - | - | - | - | 9 | 90.0 |
| Waitemata | 15 | 68.2 | 7 | 87.5 | 40 | 90.9 | 114 | 88.4 |
| West Coast | 0 | 0.0 | - | - | - | - | 8 | 88.9 |
| Whanganui | 11 | 91.7 | - | - | 3 | 100.0 | 18 | 90.0 |
| **Total** | **216** | **80.3** | **59** | **71.1** | **147** | **86.5** | **1,011** | **85.4** |

*‘ – ‘ indicates there were no women in this sub-category with a high -grade cytology report*

Table 15 - Women with a histology report within 180 days of a high-grade cytology report, by DHB and ethnicity


|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Māori** | | **Pacific** | | **Asian** | | **European/ Other** | |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| Auckland | 7 | 63.6 | 16 | 84.2 | 43 | 91.5 | 103 | 84.4 |
| Bay of Plenty | 13 | 86.7 | 1 | 100.0 | 1 | 100.0 | 58 | 86.6 |
| Canterbury | 12 | 92.3 | 3 | 100.0 | 10 | 100.0 | 157 | 91.8 |
| Capital & Coast | 7 | 100.0 | 4 | 66.7 | 9 | 90.0 | 55 | 85.9 |
| Counties Manukau | 23 | 74.2 | 24 | 77.4 | 19 | 86.4 | 60 | 85.7 |
| Hawke's Bay | 18 | 90.0 | 2 | 100.0 | 2 | 100.0 | 47 | 92.2 |
| Hutt Valley | 8 | 100.0 | 1 | 33.3 | 5 | 100.0 | 21 | 91.3 |
| Lakes | 13 | 100.0 | 1 | 100.0 | 1 | 100.0 | 21 | 87.5 |
| Mid Central | 18 | 90.0 | 1 | 100.0 | 3 | 100.0 | 44 | 93.6 |
| Nelson Marlborough | 5 | 83.3 | - | - | 2 | 100.0 | 57 | 95.0 |
| Northland | 8 | 88.9 | 1 | 100.0 | 2 | 66.7 | 30 | 85.7 |
| South Canterbury | 1 | 100.0 | - | - | 1 | 100.0 | 13 | 92.9 |
| Southern | 16 | 94.1 | 2 | 100.0 | 2 | 100.0 | 96 | 92.3 |
| Tairawhiti | 16 | 84.2 | - | - | - | - | 11 | 91.7 |
| Taranaki | 9 | 100.0 | 2 | 66.7 | 1 | 50.0 | 38 | 92.7 |
| Waikato | 27 | 90.0 | 2 | 100.0 | 7 | 58.3 | 101 | 91.0 |
| Wairarapa | 3 | 75.0 | - | - | - | - | 10 | 100.0 |
| Waitemata | 16 | 72.7 | 7 | 87.5 | 41 | 93.2 | 119 | 92.2 |
| West Coast | 0 | 0.0 | - | - | - | - | 9 | 100.0 |
| Whanganui | 12 | 100.0 | - | - | 3 | 100.0 | 19 | 95.0 |
| **Total** | **232** | **86.2** | **67** | **80.7** | **152** | **89.4** | **1069** | **90.3** |

*‘ – ‘ indicates there were no women in this sub-category with a high -grade cytology report*

Table 16 - Women with high-grade cytology who have follow-up within 90 and 180 days recorded on the NCSP Register, by urgency of referral and type of follow-up

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Urgent referral**  **(HS2, SC, AC1-AC5)** | | **No suspicion of invasion (ASH, HS1, AG1-AG5, AIS)** | |
|  | **N** | **%** | **N** | **%** |
| Follow-up within 90 days |  |  |  |  |
| - histology | 37 | 86.0 | 1,396 | 83.9 |
| - any follow-up | 37 | 86.0 | 1,529 | 91.9 |
| - no follow-up | *6* | *14.0* | *134* | *8.1* |
| Follow-up within 180 days |  |  |  |  |
| - histology | 40 | 93.0 | 1,480 | 89.0 |
| - any follow-up | 40 | 93.0 | 1,572 | 94.5 |
| - no follow-up | *3* | *7.0* | *91* | *5.5* |

Figure 63 - Proportion of women without any follow-up test within 90 days and within 180 days of a high-grade cytology report, by DHB



*There were no women without follow-up recorded within 180 days in Lakes, Nelson Marlborough, South Canterbury, Wairarapa and Whanganui.*

Figure 64 - Proportion of women without any follow-up test within 90 days and within 180 days of a high-grade cytology report, by ethnicity




Table 17 - Women without any follow-up test within 90 and 180 days of a high-grade cytology report, by DHB

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **High-grade cytology** | **Without a follow-up test by 90 days** | | **Without a follow-up test by 180 days** | |
| **DHB** | **N** | **N** | **%** | **N** | **%** |
| Auckland | 199 | 21 | 10.6 | 14 | 7.0 |
| Bay of Plenty | 84 | 6 | 7.1 | 5 | 6.0 |
| Canterbury | 197 | 12 | 6.1 | 8 | 4.1 |
| Capital & Coast | 87 | 6 | 6.9 | 4 | 4.6 |
| Counties Manukau | 154 | 23 | 14.9 | 17 | 11.0 |
| Hawke's Bay | 75 | 3 | 4.0 | - | 0.0 |
| Hutt Valley | 39 | 3 | 7.7 | 2 | 5.1 |
| Lakes | 39 | 1 | 2.6 | - | 0.0 |
| Mid Central | 71 | 5 | 7.0 | 2 | 2.8 |
| Nelson Marlborough | 68 | 3 | 4.4 | 3 | 4.4 |
| Northland | 48 | 5 | 10.4 | 4 | 8.3 |
| South Canterbury | 16 | 1 | 6.3 | 1 | 6.3 |
| Southern | 125 | 5 | 4.0 | 4 | 3.2 |
| Tairawhiti | 31 | 5 | 16.1 | 3 | 9.7 |
| Taranaki | 55 | 4 | 7.3 | 2 | 3.6 |
| Waikato | 155 | 13 | 8.4 | 9 | 5.8 |
| Wairarapa | 14 | 2 | 14.3 | 1 | 7.1 |
| Waitemata | 203 | 19 | 9.4 | 13 | 6.4 |
| West Coast | 11 | 3 | 27.3 | 2 | 18.2 |
| Whanganui | 35 | - | - | - | 0.0 |
| *Unspecified* | *-* | *-* |  | *-* |  |
| ***Total*** | **1,706** | **140** | **8.2** | **94** | **5.5** |

Table 18 - Women without any follow-up test within 180 days of a high -grade cytology report, by ethnicity

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **High -grade cytology** | **Without follow-up by 90 days** | | **Without follow-up by 180 days** | |
|  | **N** | **N** | **%** | **N** | **%** |
| Māori | 269 | 34 | 12.6 | 22 | 8.2 |
| Pacific | 83 | 15 | 18.1 | 10 | 12.0 |
| Asian | 170 | 16 | 9.4 | 14 | 8.2 |
| European/ Other | 1,184 | 75 | 6.3 | 48 | 4.1 |
| ***Total*** | **1,706** | **140** | **8.2** | **94** | **5.5** |

Figure 65 – Trends in the proportion of women with high-grade cytology who have follow-up within 90 days recorded on the NCSP Register, by DHB




Figure 66 – Trends in the proportion of women with high-grade cytology who have follow-up within 180 days recorded on the NCSP Register, by DHB




Figure 67 - Trends in the proportion of women with high-grade cytology who have follow-up within 90 days recorded on the NCSP Register, by ethnicity





Figure 68 - Trends in the proportion of women with high-grade cytology who have follow-up within 180 days recorded on the NCSP Register, by ethnicity



## Indicator 7 – Colposcopy Indicators

These indicators report on colposcopy, against the 2013 NCSP Policies and Standards, Section 6. They include the following aspects:

1. Timeliness of colposcopic assessment of high -grade cytology results (Standard 602)
2. Timeliness of colposcopic assessment of low -grade cytology results (Standard 602)
3. Adequacy of documenting colposcopy assessment (Standard 603)
4. Timeliness of treatment (Standard 605)
5. Timely discharging of women after treatment (Standard 608)
6. Failure or refusal to attend appointments (Standard 609)
7. Maintaining staff skill levels - minimum colposcopy volumes (Standard 611)

Some of these indicators (7.6 and 7.7) have not been developed. It is envisioned that all indicators will be reviewed as part of the planned transition to primary HPV screening, and so these may be included in future monitoring reports after the programme transitions. The current colposcopy standard was published in July 2013 (available at <https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/policies-and-standards>).

Colposcopy data has been recorded on the NCSP Register for a relatively short time, compared to cytology and histology data. There is incomplete reporting of colposcopy data to the NCSP Register, and therefore results for these indicators may need to be interpreted with some caution. However, it was and is felt that colposcopy indicators were an important quality measure of the NCSP, and reporting on them should not be unduly delayed. This was also a recommendation of the 2011 Parliamentary Review into the NCSP.[19](#_ENREF_19) It is anticipated that completeness of colposcopy data on the NCSP Register will continue to improve over time. The 2015 Parliamentary Review again emphasised that achieving complete recording of colposcopy data on the NCSP Register is essential. [20](#_ENREF_20)

Additionally, not all DHBs were yet reporting the full data required by Colposcopy Policies and Standards 2013 for the full-time periods reported on in this report (as all indicators in this section other than 7.3 can report on colposcopy which occurred earlier than the current monitoring period); the last three DHBs went live with the 2013 Standards in August 2016. This means that in many cases performance indicators are not directly compared to the targets or have had to rely on proxy data to measure performance. Where relevant, this is described in the sections relating to the individual indicators.

### Indicator 7.1 – Timeliness of colposcopic assessment – high-grade cytology

|  |  |
| --- | --- |
| **Definition** | This indicator measures performance against Standard 602. It relates to the proportion of women seen at colposcopy within the recommended time period, from the time of the receipt of a referral from the sample taker for a high-grade cytology.  Timeliness is calculated using the time from the referral following the high-grade cytology result being accepted by the colposcopy unit, to the time of the woman’s first colposcopic assessment at that colposcopy unit.  As in Indicator 6, high-grade cytology results are included if the cytology sample was collected in the six months preceding the current monitoring period (i.e. 1 July - 31 December 2017). High-grade cytology is defined as that associated with any of the TBS codes ASH, HS1, HS2, SC, AG1-AG5, AIS, AC1-AC5. Where a woman has more than one high-grade cytology result in the relevant time period, the result from the first high-grade cytology sample collected is used. Timeliness of colposcopic assessment is calculated separately for those women with clinical suspicion of invasive carcinoma, or a suspicion of invasive carcinoma (based on either cytological interpretation TBS codes HS2, SC, AC1-AC5 or recommendation codes R10 or R14 that may be used in the context of symptoms); and for women with other high-grade cytology results (TBS codes ASH, HS1, AG1-AG5, AIS), since the timeframes differ for these two groups.  Referrals and colposcopy visits for these women were retrieved from the NCSP Register. The standard requires that a woman be seen within a time period from when the colposcopy unit received the referral. However due to the completeness of the accepted referral date compared to the received date, referral accepted date is used in this indicator as a proxy for the date the referral was received, and the start date for calculating timeliness. Referrals were retrieved where the date on which the referral was accepted occurred after the date the cytology sample was collected, and the referral was accepted no later than four weeks prior to the end of the current monitoring period. Colposcopy visits recorded on the NCSP Register were retrieved if they occurred after an accepted referral (to the same DHB) and no later than the end of the current monitoring period. The difference of four weeks between the two was to ensure that there were at least four weeks of data following every accepted referral which could be searched for colposcopy visits. In the current report, histology data are also used to supplement colposcopy data and help ascertain if a colposcopy visit occurred. Women with a histology sample collected after their cytology sample are assumed to have attended a colposcopy clinic for follow-up on the date the histology sample was collected, even if a colposcopy visit is not explicitly recorded on the NCSP Register.  Histology results have been used by the NCSP Register to follow up missing colposcopy visit data to improve the quality of colposcopy data on the Register. During the previous and current monitoring periods all DHBs adopted electronic reporting of the 2013 Standards, with the last three DHBs going live in August 2016. This has greatly improved the data on the Register and for public DHBs and when data are sufficiently complete future reports will be able to report directly against the 2013 Standards without using the current proxies for DHBs (with limited exceptions). Whereas, for private clinics complete reporting against the 2013 Standards is taking more time with the majority still reporting against 2008 standards. Therefore, values reported for the private aggregate will need to continue to use histology proxies (where necessary) until all private data is in accordance with the 2013 Standards.  Results are reported by ethnicity and DHB. For women who attended colposcopy, DHB is assigned on the basis of the DHB of the colposcopy facility where they attended for colposcopy. The date on which the referral to that DHB was accepted is used to calculate timeliness. If there are multiple referrals for the same woman to that DHB, the date of the first accepted referral following the cytology sample is used. Women who attended colposcopy but had no relevant referral to that DHB recorded on the NCSP Register were excluded from the calculations of timeliness (since the time between the acceptance of the referral and the colposcopy visit could not be calculated). However, these women were reported on separately.  For women who did not attend colposcopy prior to the end of the current monitoring period, DHB is assigned based on the DHB of the facility which accepted the referral for that woman (where the referral was accepted no later than four weeks prior to the end of the current monitoring period). If there were multiple referrals for the same woman which occurred after the cytology sample, the most recently accepted referral within the timeframe was used.  For women who neither attended colposcopy nor had an accepted referral with any DHB, DHB is assigned on the basis of the health facility where their high-grade cytology sample was collected.  Since cytology samples were collected in the six months prior to the current monitoring period, this allows a follow-up period of at least six months for all women (and up to 12 months for some women) where a woman can attend colposcopy and be assigned to a DHB, or alternately have a referral accepted by a DHB.  High-grade cytology tests indicating that a woman was already under specialist management (TBS=R13) were excluded from this measure. |
| **Target** | ***Timeliness – high -grade cytology indicating suspicion of invasive disease***  95% or more of women who have evidence of clinical suspicion of invasive carcinoma, or a laboratory report indicating ‘features suspicious for invasion’, or ‘changes consistent with squamous cell carcinoma’ (TBS codes HS2, SC, AC1-AC5), or similar, must receive a date for a colposcopy appointment or a gynaecological assessment that is within 10 working days from when the colposcopy unit received the referral from the smear taker/ referrer.  ***Timeliness – high -grade cytology (no suspicion of invasive disease)***  95% or more of women who have high-grade cervical smear abnormalities (but no suspicion of invasive disease; TBS codes ASH, HS1, AG1-AG5, AIS) must receive a date for a colposcopy within 20 working days from when the colposcopy unit received the referral from the smear taker/ referrer.  The targets for this indicator rely on records of colposcopy appointments on the NCSP Register. As advised by the Ministry and NCSP Advisory Group for all women with a high-grade cytology test in the six months prior to the current monitoring period, timeliness is instead measured from the time between a referral is accepted to when women *have their first subsequent* colposcopy visit, acknowledging that this is not exactly as stated in the Standard target above. |
| **Current Situation** | In the period 1 July - 31 December 2017, there were 1,706 women with high-grade cytology results who were not already under specialist management. This comprised 43 women who had results indicating suspicion of invasive disease, and 1,663 women who had other high-grade cytology results. In total, accepted referrals were found for 1,539 (90.2%) of the 1,706 women (Table 66).  ***Timeliness – high-grade cytology indicating suspicion of invasive disease***  Accepted referrals for colposcopy were found for 30 (69.8%) of the 43 women who had high-grade cytology indicating suspicion of invasive disease. For those with an accepted colposcopy referral recorded, referrals are broken down by the detailed cytological result in Table 69. Of these 30 women with a referral, 25 (83.3%) have a record of a colposcopy visit on the NCSP Register within ten working days of their referral, and 27 (90.0%) have a visit within 20 working days (Table 19).  Considering all 43 women with high-grade cytology indicating suspicion of invasive disease, regardless of whether or not a referral to colposcopy was recorded, a total of 41 (95.3%) have a record of a colposcopy visit prior to 30 June 2018 representing a follow-up period of at least six and up to 12 months after their high-grade cytology report.  ***Timeliness – high-grade cytology (no suspicion of invasive disease)***  Accepted referrals for colposcopy were found for 1,509 women (90.7%) of the 1,663 women who had high-grade cytology not indicating suspicion of invasive disease. Among the women with accepted referrals, 1,142 (75.7%) were seen at colposcopy within 20 working days of their referral, and 1,381 (91.5%) were seen within 40 working days (Table 67). The proportion of women seen within 20 working days varied by ethnicity, from 67.1% (Pacific women) to 78.1% (Asian women) (Figure 69, Table 67). This proportion also varied by DHB from 33.3% (West Coast) to all women (Wairarapa) (Figure 70, Table 68).  In total, 1,576 (94.8%) of the 1,663 women with high-grade cytology (but no suspicion of invasive disease) relating to a sample collected in the period 1 July - 31 December 2017 have a record of a colposcopy visit prior to 30 June 2018 (representing a follow-up period of at least six and up to 12 months after their high-grade cytology). |
| **Trends** | Nationally, the proportion of women with high-grade cytology indicating suspicion of invasive disease and an accepted colposcopy referral who were seen within the target timeframe (10 working days) has increased from 65.0% to 83.3%. The percentage of women with high-grade cytology indicating suspicion of invasive disease and an accepted colposcopy referral who were seen within 20 working days (90.0%) is also higher than the previous report (82.5%).  The proportion of women with high-grade cytology (but no suspicion of invasive disease) and an accepted colposcopy referral who were seen within 20 working days is similar between the previous report (75.6%) and the current report (75.7%). This trend was also representative when investigated by ethnicity, with similar proportions of women with high-grade cytology and no suspicion of invasive disease seen within 20 working days in Pacific, Asian and European/ Other women in this monitoring period and the previous monitoring period. An increase was seen in Māori women (from 68.5% to 69.9%) (Figure 71). The proportion of all women with high-grade results for whom an accepted referral was available on the NCSP Register was higher in the current report compared to the previous report (90.2% in the current report; 88.2% in the previous report). |
| **Comments** | Since this indicator relies on colposcopy data in the NCSP Register, any incompleteness in reporting of referrals and colposcopy visits as at the time of the data extract from the NCSP Register (August 2018 for the current report) would lead to an underestimate of the number of women with referrals and/or follow-up colposcopy visits. In order to help address this, in the current report, histology data are also used to help ascertain if a colposcopy visit occurred. Women with a histology sample collected after their cytology sample are assumed to have attended a colposcopy clinic for follow-up, even if a colposcopy visit is not explicitly recorded on the NCSP Register. Among the 1,486 women (with or without a referral) who had a colposcopy visit by the end of the current monitoring period, there were 57 (3.8%) women where the colposcopy visit was not explicitly recorded on the NCSP Register and was inferred by using the histology result proxy.  For women with high-grade cytology indicating suspicion of invasive disease, the number referred for colposcopy is likely to be an underestimation of women with appropriate follow-up. Many women referred with suspicion of invasive disease are referred directly to gynae-oncology for a cone biopsy instead of colposcopy. This likely explains the comparatively low proportion of women with SC or AC1-5 results who have a record of colposcopy referral (50% or less). Therefore, the proportion with colposcopy in this group does not fully reflect the level of performance.  Additional information about follow-up tests performed in women with high -grade cytology is included in Indicator 6. The same 1,706 women (43 with suspicion of invasive disease, 1,663 with other high-grade cytology) are included in both this measure and Indicator 6. In Indicator 6, it was found that 1,520 (89.1%) had histology within 180 days and 1,612 (94.5%) had a follow-up test of some sort within 180 days. While in this indicator, colposcopy and histology records indicate that 1,617 (94.8%) women had attended colposcopy prior to 30 June 2018 (i.e. in a period of at least 181 days and up to one year after their high-grade cytology sample). Note that there may be some differences in results by DHB, however, since in Indicator 6 the DHB assigned to a woman is her own DHB (or, where this information is not available on the NCSP Register, the DHB of her responsible health facility, based on the clinic’s geographic location). In this indicator, women are assigned to a DHB based on either the DHB where they attended colposcopy, or the most recent DHB to which they have been referred (for women without colposcopy visits), or to the DHB of the health facility where the high-grade cytology sample was collected (for women with no referral and no colposcopy visit). Additionally, only public clinics are assigned a DHB within Indicator 7.1; private clinics are separated out and reported on as a group.  Reasons why a woman may not attend colposcopy within the recommended timeframe include both capacity limitations within the clinic, and potentially factors related to the woman requiring follow-up. Currently there is incomplete information available on the NCSP Register about colposcopy appointments which are scheduled for women where the woman reschedules or does not attend. Therefore, in this indicator it is not possible to distinguish delays in attending colposcopy following high-grade cytology which are due to capacity constraints which restrict the clinic’s ability to offer timely appointments, and delays which may be due to an individual woman’s need to reschedule an appointment or failure to attend. Factors which may lead a woman to delay a recommended visit include caring responsibilities, planned travel, competing prior commitments, illness, or menstruation. |

Table 19 - Women with a high-grade cytology report (suspicion of invasive disease), accepted referral and colposcopy visit, by ethnicity

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **HG women (suspicion of invasion)** | **Urgent referrals received** | **Women seen within:** | | | |
| **10 working days** | | **20 working days** | |
| **N** | **N** | **N** | **%** | **N** | **%** |
| Māori | 12 | 10 | 8 | 80.0 | 10 | 100.0 |
| Pacific | 11 | 10 | 10 | 100.0 | 10 | 100.0 |
| Asian | 14 | 5 | 3 | 60.0 | 3 | 60.0 |
| European/ Other | 6 | 5 | 4 | 80.0 | 4 | 80.0 |
| **Total** | **43** | **30** | **25** | **83.3** | **27** | **90.0** |

Figure 69 - Percentage of women with a high-grade cytology (no suspicion of invasive disease) with a colposcopy visit within 20 and 40 working days, by ethnicity




*95% target relates to colposcopy visits within 20 working days*

Figure 70 - Percentage of women with a high-grade cytology (no suspicion of invasive disease) with a colposcopy visit within 20 and 40 working days, by DHB



*95% target relates to colposcopy visits within 20 working days*

Figure 71 – Trends of the proportion of women with a high -grade cytology report (no suspicion of invasive disease) seen within 4 weeks (20 working days), by ethnicity




*95% target relates to colposcopy visits within 20 working days*

### Indicator 7.2 – Timeliness of colposcopic assessment – low-grade cytology


|  |  |
| --- | --- |
| **Definition** | This indicator measures performance against Standard 602. It reports on the timeliness of colposcopic assessment of women with either persistent low-grade cytology, or low-grade cytology and concurrent positive hrHPV test.  Women were included in this measure if they had a cytology sample collected in the 6-month period ending 12 months prior to the end of the current monitoring period (1 January – 30 June 2017 for the current report) where the results were low-grade (ASC-US or LSIL), and either a positive hrHPV test (within four weeks of the cytology result) or a previous low-grade cytology result (within the previous five years). Women undergoing test-of-cure management for a recent treatment of a high-grade squamous lesion (within the previous 4 years) were excluded.  Referrals and colposcopy visits for these women were retrieved from the NCSP Register. Referrals were retrieved where the date on which the referral was accepted occurred after the date the cytology sample was collected, and at least 26 weeks before the end of the current monitoring period (i.e. 26 weeks before 30 June 2018, to allow at least 26 weeks following the referral for colposcopy to occur). Colposcopy visits recorded on the NCSP Register were retrieved if they occurred after the cytology test and no later than the end of the current monitoring period. In addition to explicit colposcopy visit records, histology samples in the same timeframe were used as a proxy for a colposcopy visit, to supplement colposcopy visit data.  Results are reported by ethnicity and DHB. DHB is assigned in the same way as in Indicator 7.1. For women who attended colposcopy, DHB is assigned on the basis of the DHB of the colposcopy facility where they attended for colposcopy (or where the histology sample was collected if a visit is not explicitly recorded). If there are multiple referrals for the same woman to that DHB, the date of the first accepted referral following the cytology sample is used.  For women who did not attend colposcopy prior to the end of the current monitoring period, DHB is assigned based on the DHB of the facility which accepted the referral for that woman. If there were multiple referrals for the same woman which occurred after the cytology sample, the most recently accepted referral within the timeframe was used.  For women who neither attended colposcopy nor had an accepted referral with any DHB, DHB is assigned on the basis of the geographic region of the health facility where their low-grade cytology sample was collected.  Since cytology samples were collected in the 6-month period ending 12 months prior to the end of the current monitoring period, this allows a follow-up period of at least twelve months for all women (and up to 18 months for some women) where a woman can attend colposcopy and be assigned to a DHB. |
| **Target** | 95% of women who have persistent low-grade abnormalities, or a low-grade abnormality and positive HPV test, must receive a date for a colposcopy appointment that does not exceed 26 weeks of receipt of the referral.  At present, this indicator reports on aspects of follow-up, but not specifically on timeliness in relation to the standard, as the date of the first colposcopic assessment is not yet available for all women with a low-grade cytology test in the 6-month period 12-months prior to the end of the current monitoring period. In the interim, it reports on the number and percentage of women for whom a subsequent accepted referral and/ or a colposcopy visit are recorded, and the number and proportion of women who attended colposcopy within 26 weeks of an accepted referral. |
| **Current situation** | There were 3,488 women with either persistent low-grade cytology or low-grade cytology and a positive hrHPV test collected in the period 1 January – 30 June 2017. Nationally, subsequent accepted referrals are recorded for 3,017 (86.5%) of these women, and subsequent colposcopy for 3,198 (91.7%). The proportion of women for whom a subsequent referral and colposcopy visit are recorded are shown by DHB in Figure 72, and by ethnicity in Figure 73. The proportion of women for whom an accepted referral was recorded on the NCSP Register ranged from 80.0% (South Canterbury) to all women (Whanganui; Figure 72). The proportion of women with a subsequent colposcopy visit (which occurred by the end of the current monitoring period) recorded on the NCSP Register ranged from 66.7% (South Canterbury) to 98.0% of women (Whanganui; Figure 72). For ethnicity, the proportion of women for whom an accepted referral was recorded on the NCSP Register ranged from 85.0% for Asian women to 92.8% for Māori women (Figure 73). The proportion of women with a subsequent colposcopy visit recorded on the NCSP Register (regardless of whether or not a referral was recorded) ranged from 85.9% (Pacific women) to 92.6% (European/ Other women) (Figure 73).  Timeliness of colposcopic assessment is provided by examining the time between when a referral is accepted for a colposcopy and when a woman attended for colposcopy. Among the 3,017 women with an accepted referral nationally, 2,679 (88.8%) women attended for colposcopy within 26 weeks of their accepted referral (Table 70). By DHB, the proportion of women who attended for colposcopy within 26 weeks of their accepted referral ranged from 56.3% (Hawke's Bay) to 98.0% women (Whanganui) (Figure 74, Table 70). By ethnicity, this figure ranged from 82.5% of Māori women attending for colposcopy within 26 weeks of their accepted referral, to 90.1% of European/ Other women (Figure 75, Table 71)  Overall 2,845 women attended colposcopy following an accepted referral on the NCSP Register, and by the end of the current monitoring period (a follow-up period of 12 - 18 months after their cytology sample). This is equivalent to 81.6% of all women with persistent low-grade cytology or low-grade cytology and a positive hrHPV test, and 94.3% of women who had an accepted referral following their low-grade cytology. |
| **Trends** | Nationally, the proportion of women with colposcopy within 26 weeks of being referred has increased (88.8% in the current report, compared to 85.1% in the previous report). This increase has been seen in Māori and European/ Other women (an increase of 8.6% and 3.5%, respectively) (Figure 77). The proportion of women seen within 26 weeks has increased since the previous report in eleven out of 20 DHBs (Figure 76). A substantial decrease (greater than 10 percentage points) in the proportion seen within 26 weeks was observed in two DHBs (South Canterbury and Wairarapa). Conversely, a substantial increase (greater than 10 percentage points) in the proportion of women with colposcopy within 26 weeks compared to the previous report was seen in two DHBs (Bay of Plenty and Waikato). |
| **Comments** | Since this indicator relies on colposcopy data in the NCSP Register, any incompleteness in reporting of referrals and colposcopy visits at the time of the data extract from the NCSP Register (late February 2018 for the current report) would lead to an underestimate of the number of women with referrals and/ or follow-up colposcopy visits. In order to help address this, in the current report, histology data are also used to help ascertain if a colposcopy visit occurred. Women with a histology sample collected after their cytology sample are assumed to have attended a colposcopy clinic for follow-up, even if a colposcopy visit is not explicitly recorded on the NCSP Register.  As has been the case for previous monitoring periods, it is evident that referrals are incompletely recorded on the NCSP Register, as some women have a record of a colposcopy visit, but no record of an accepted referral. |

Figure 72 - Follow-up recorded\* for women with persistent LG cytology/ LG cytology and positive hrHPV test, by DHB



*\* For colposcopies ‘follow-up’ includes colposcopies recorded on the NCSP Register which occurred no later than the end of the current monitoring period, regardless of whether there is a referral or not. Referrals includes those recorded on the NCSP Register that were accepted no later than 26 weeks prior to the end of the current monitoring period. A colposcopy is assumed to have occurred if a histology sample is recorded in the relevant timeframe.*

Figure 73 - Follow-up recorded\* for women with persistent LG cytology/ LG cytology and positive hrHPV test, by ethnicity



*\* For colposcopies ‘follow-up’ includes colposcopies recorded on the NCSP Register which occurred no later than the end of the current monitoring period, regardless of whether there is a referral or not. Referrals includes those recorded on the NCSP Register that were accepted no later than 26 weeks prior to the end of the current monitoring period. A colposcopy is assumed to have occurred if a histology sample is recorded in the relevant timeframe.*

Figure 74 - Women with persistent LG cytology/ LG cytology and positive hrHPV test and an accepted referral for colposcopy: percentage with a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by DHB




Figure 75 - Women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy: percentage with a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by ethnicity





Figure 76 - Trends in the proportion of women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy who have a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by DHB

Figure 77 - Trends in proportion of women with persistent LG cytology or LG cytology and positive hrHPV test and an accepted referral for colposcopy who have a colposcopy visit recorded within 26 weeks of the date the referral was accepted, by ethnicity



### Indicator 7.3 – Adequacy of documenting colposcopy assessment

|  |  |
| --- | --- |
| **Definition** | This indicator measures performance against Standard 603.  The proportion of colposcopies which occurred within the monitoring period with complete reporting of   1. visibility of the squamo-columnar junction 2. presence or absence of a visible lesion 3. colposcopic opinion regarding the nature of the abnormality 4. recommended management and follow-up 5. timeframe recommended for follow-up 6. items i), ii), and iii) completed   Results are reported by DHB, based on the DHB of the facility where colposcopy was performed. |
| **Target** | 100% of medical notes will accurately record colposcopic findings at first and any subsequent assessments, including:   1. visibility of the squamo-columnar junction 2. presence or absence of a visible lesion 3. visibility of the limits of lesion 4. colposcopic opinion regarding the nature of the abnormality and the requirement for treatment 5. recommended management and follow-up 6. timeframe recommended for follow-up.   Items i), ii), v), vi) and the first of the items in iv) can be assessed using data in the NCSP Register, and are reported on below. Item iii) and the second half of item iv) cannot currently be assessed as although all DHBs have transitioned to reporting using 2013 Standards these fields cannot be fully utilised due to a lack of completeness. For private clinics, however, complete reporting against the 2013 Standards is likely to take more time with the majority still reporting against 2008 standards. Therefore, values reported for the private aggregate will continue to use proxies for a much longer period until complete 2013 reporting occurs.  When calculating the completeness of recording of the colposcopic opinion regarding the nature of the abnormality, this was restricted to those colposcopy visits where the presence of a lesion was either noted (colposcopic appearance recorded as abnormal), or could not be ruled out (colposcopic appearance recorded as inconclusive).  When calculating the overall completeness of items i), ii), and iii), colposcopic opinion regarding the nature of the abnormality was only required where colposcopic appearance was recorded as either abnormal or inconclusive. |
| **Current Situation** | There were 12,198 colposcopy visits within the current monitoring period recorded on the NCSP Register. Documentation relating to these visits was analysed (Table 72).  Nationally, the visibility of the squamo-columnar junction was documented for 97.3% of visits; the presence or absence of a lesion was documented for all visits; and an opinion regarding the lesion grade was documented for 91.6% of visits where the presence of a lesion could not be ruled out. Additionally, the type of follow-up was documented for 95.6% of visits and the timeframe for follow-up was documented for 94.9% of visits. The visibility of the squamo-columnar junction, presence or absence of a visible lesion, and the colposcopic opinion regarding the nature of the abnormality (where relevant) were all documented for 92.6% of visits.  The colposcopic appearance was reported to be abnormal in 54.0% of colposcopies, and inconclusive in 4.9% of colposcopies (Table 73). Biopsies were taken at 92.0% of colposcopies when the colposcopic appearance was abnormal; 33.7% of colposcopies where the colposcopic appearance was reported as inconclusive, and 19.2% of colposcopies where colposcopic appearance was reported as normal (Table 74).  Documentation varied by DHB, as shown in Figure 78 and Table 72. Documentation of visibility of the squamo-columnar junction varied from 94.4% (West Coast) to 99.9% of cases in Capital & Coast. In all DHBs, all colposcopy reports documented the presence or absence of a lesion. Recording of the opinion regarding the abnormality grade (which was only assessed if the colposcopic appearance was recorded as abnormal or inconclusive), ranged from 84.2% (South Canterbury) to 98.9% (Hutt Valley). Recording of the recommended type of follow-up ranged from 86.7% (Waitemata) to all cases (Whanganui) and recording of the recommended timeframe for follow-up ranged from 85.3% (Waitemata) to all women (Whanganui). Complete documentation of the visibility of the squamo-columnar junction, presence or absence of a visible lesion, and the colposcopic opinion regarding the nature of the abnormality (where required) ranged from 86.5% (West Coast) to 98.4% (Hutt Valley) (Figure 79, Table 72).  Abnormal colposcopic appearance ranged from 36.1% of colposcopies (Northland) to 68.5% of colposcopies (West Coast). Inconclusive colposcopic appearance ranged from 0.8% of colposcopies (Hutt Valley) to 9.0% of colposcopies (West Coast) (Table 73). The proportion of colposcopies where a biopsy was taken also varied by DHB. This proportion ranged from 86.0% of visits in Auckland, up to 96.6% (Whanganui) when the colposcopic appearance was abnormal, and from 10.6% (Bay of Plenty) up to 38.2% (Wairarapa) when the colposcopic appearance was normal (Table 74).  Colposcopies performed in private practice accounted for 11.6% of all colposcopies recorded on the NCSP Register in New Zealand in the current monitoring period. The documentation rate varied according to the recorded section in private practice when compared with public clinics overall (Table 72); The proportion complete was higher in public clinics overall when compared to the private clinics overall for documenting follow-up timeframe (95.3% for public clinics; 91.8% for private practice) and follow-up type (95.8% for public clinics and 94.4%for private practice). Documentation completion rate was also higher in public clinics overall than for private clinics overall for lesion grade (91.7% for public clinics and 90.9% for private practice). The completion rate for documenting the presence or absence of a lesion was 100% in both private and public clinics. Documentation completion rate was also similar in private clinics and public clinics overall for the proportion of colposcopies documenting visibility of the squamo-columnar junction (96.7% for private practice vs 97.4% for public clinics overall). Complete documentation of the visibility of the squamo-columnar junction, presence or absence of a visible lesion, and the colposcopic opinion regarding the nature of the abnormality was higher in public clinics than in private clinics overall (92.7% for public clinics overall vs. 91.3% for private practice). |
| **Trends** | For New Zealand as a whole, documentation of colposcopy visit items has remained fairly consistent over the last four monitoring periods. In the current period visibility of the squamo-columnar junction was documented for 97.3% of colposcopies, compared with between 96.9% and 97.4% for the previous three monitoring periods. The presence or absence of a lesion was documented for all visits in both the current and previous three periods. In the current period an opinion regarding the lesion grade was documented for 91.6% of visits where the presence of a lesion could not be ruled out, compared with between 91.5% and 92.0% for the previous three monitoring periods. Recording of recommended follow-up type was documented for 95.6% of visits in the current period, which is similar to the range seen for the previous three periods (94.8% - 95.5%). This was also the case for recommended timeframe for follow-up, which was recorded for 94.9% of visits in the current period compared with 94.0% - 94.8% in the previous three periods.  Trends in the completion of all required fields by DHB are shown in Figure 79.  In total 59.2% of colposcopies had an associated biopsy compared to 59.5% in the previous report. Of these, biopsies were taken in 92.0% of colposcopies with an abnormal appearance in this report and 92.1% in the previous report. 19.2% of colposcopies with a normal appearance also had documentation of a biopsy taken in this period and 18.9% in the previous reporting periods.  Trends in the number of colposcopies recorded on the NCSP Register by DHB are shown in Figure 80. The number of colposcopies decreased in the current monitoring period in seven of the 20 DHBs with an overall decrease in the number of colposcopies of 0.7%. |
| **Comments** | This indicator is only able to assess adequacy of documentation where colposcopy visits have been entered onto the NCSP Register in accordance with the 2013 Colposcopy Standard. Therefore, it cannot provide an absolute estimate of adequacy if these data are incomplete on the NCSP Register (that is, if the colposcopy visit itself is not recorded on the NCSP Register).  Some items required by the standard, such as the recording of recommended follow-up type and timeframe, cannot necessarily be completed at the time of the colposcopy visit – for example because they will depend on results of histology tests or other reviews. For DHBs that electronically report data to the NCSP Register, the completeness of these fields is likely to lag behind that of other fields, because the colposcopy visit data will be loaded onto the NCSP Register soon after the visit and before this information is available. As more DHBs have moved to electronic reporting, this lag could explain the reduction in the percentage of colposcopies where these items are complete, compared to previous reports. Additionally, since there is a lag in reporting recommended type and timeframe for follow-up, these two items were removed from the calculation of ‘all items complete’ in Report 43 and this has remained the case in subsequent reports. These are often not the fields with the lowest completion rates however, and therefore removing them from the calculation made a relatively small difference to ‘all items complete’. In 18 out of the 20 DHBs, the field with the lowest completion rate is the documentation of the opinion regarding the nature of abnormality grade (only required where the presence of a lesion could not be ruled out). It is possible that the low completion rate for predicted abnormality grade could be because some clinics are incorrectly interpreting the requirement to document a *predicted* abnormality grade (which should be documented at the time of colposcopy) as a requirement to document the *diagnosed* abnormality grade, which can only be done after histology results are available.  Some items in the 2013 colposcopy standard are not included in the 2008 colposcopy visit form or on the NCSP Register, in particular the visibility of the limits of the lesion, the biopsy site, and an explicit colposcopic opinion regarding the need for treatment (although a recommended follow-up timeframe is recorded, and whether follow-up is recommended with a colposcopist, oncology services, or sample taker). It is also not possible to determine the reason for the visit from the colposcopy visit form, for example if this is a first visit or a follow-up visit; or whether it was prompted by a high-grade cytology result, a low -grade cytology result which is either persistent or accompanied by a positive high-risk HPV test result, a request for referral regardless of cytology results, or another reason. As most private colposcopists were still reporting to the NCSP Register using the 2008 standard and due to the low completeness of the fields required to calculate the additional items for those DHBs using 2013 Standards, these items could not be taken into account in this indicator for the current report. |

Figure 78 - Completion of colposcopic assessment fields, by DHB




Figure 79 - Trends in the completion of all required colposcopic assessment fields, by DHB






Figure 80 - Trends in the number of colposcopies recorded on the NCSP Register, by DHB



### Indicator 7.4 – Timeliness and appropriateness of treatment

|  |  |
| --- | --- |
| **Definition** | This indicator measures performance against Standard 605.  It reports on the proportion of women with histological high-grade squamous intraepithelial lesions (HSIL) who are treated within eight weeks of histological confirmation. Histological HSIL is defined as CIN 2, CIN 3, CIN 2/3 or HSIL not otherwise specified (SNOMED codes M74007, M74008, M80102, M80702 and M67017).  Histological LSIL is not routinely treated, as treatment is not recommended for women with low-grade abnormalities in the 2013 Colposcopy Standards (consistent with 2008 NCSP *Guidelines for Cervical Screening in New Zealand*). The 2013 Colposcopy Standard recommends that the number of women who are treated with low-grade lesions (less than CIN 2 on histology) be minimised. Therefore, treatment of LSIL is included in this report for descriptive purposes and to examine the appropriateness (not timeliness) of treatment. This report describes the number and proportion of women with histological low-grade squamous intraepithelial lesions (LSIL) who are treated. To ensure consistency in the follow-up time examined for each woman and in order to allow timely reporting, treatments are included if they occur within 26 weeks of histological confirmation. Histological LSIL is defined as CIN 1 or CIN not otherwise specified (SNOMED codes M74006, M67016, M74000 and M67015). Women with histological LSIL who are treated but who also have a record of histological HSIL in the six-month period prior to their treatment are excluded, as their treatment in considered appropriate.  Women are included in this indicator if they have a histology sample where the result is HSIL or LSIL (as previously defined, above), and the sample was collected in the six-month period immediately prior to the current monitoring period (i.e. in the period 1 July - 31 December 2017). HSIL results must have been reported at least 8 weeks prior to the end of the current monitoring period, and LSIL results must have been reported at least 26 weeks prior to the end of the current monitoring period, in order to allow sufficient follow-up time for this indicator.  Treatment was defined as a colposcopy visit where there was a record of electrosurgical excision, laser ablation or excision, cold knife cone biopsy, or total hysterectomy. Colposcopy visits involving punch biopsies only are not included.  DHB is assigned based on the clinic where the histology sample was collected. |
| **Target** | 90% or more of women with HSIL are treated within 8 weeks of histological confirmation of CIN 2/3.  There is no explicit target relating to low-grade lesions, but the standard recommends that the number of women who are treated with low-grade lesions (less than CIN 2 on histology) be minimised. |
| **Current Situation** | There were 2,130 women with a histological diagnosis of CIN 2/3 (associated with histology samples collected in the previous six months, and reported at least eight weeks prior to 30 June 2018). Of these women, 1,359 women (63.8%) were treated within eight weeks of HSIL being histologically confirmed. The proportion of women treated within eight weeks varied widely by DHB, from 50.0% (South Canterbury and West Coast) to 92.3% of women (Tairawhiti). One DHB met the target of at least 90% of women treated within eight weeks of histological confirmation of HSIL (Figure 81, Table 20).  There were 1,724 women with a histological diagnosis of LSIL (associated with histology samples collected in the previous six months, and reported at least 26 weeks prior to 30 June 2018). Treatment for histological LSIL is not routinely recommended in the 2013 Colposcopy Standards or the 2008 NCSP *Guidelines for Cervical Screening in* New *Zealand*[21](#_ENREF_21), and so timeliness of treatment is not examined or compared to a target for LSIL. However, for descriptive purposes and to examine appropriateness of treatment, follow-up records were retrieved for the 1,724 women with histological LSIL. Of these women, 112 (6.5%) women were subsequently treated within 26 weeks of LSIL being histologically confirmed and had no additional record of high-grade histology in the six months preceding their treatment. The proportion of women subsequently treated varied widely by DHB, from no women (Hutt Valley, South Canterbury, Waikato and Wairarapa) to 22.2% (Hawke's Bay) (Table 20). The DHB where the largest number of women were treated was Canterbury (31 women). |
| **Trends** | Nationally, the proportion of women with histological HSIL who were treated within eight weeks of histological confirmation is similar to the previous monitoring report; 63.2% in the previous report, 63.8% in the current report. The proportion of women with histological HSIL who were treated within eight weeks for the current report period increased in five of the 20 DHBs when compared with the previous report period (Figure 82). The proportion treated within eight weeks has decreased over the last two monitoring periods in fourteen DHBs (Auckland, Bay of Plenty, Canterbury, Capital & Coast, Counties Manukau, Hawke's Bay, Hutt Valley, Lakes, South Canterbury, Taranaki, Waikato, Waitemata, West Coast and Whanganui) and remained similar in one DHB (Wairarapa).  The proportion of women with histological LSIL who were subsequently treated (within 26 weeks of LSIL being histologically confirmed) has decreased, from 7.3% for the previous report to 6.5% in the current report. |
| **Comments** | Whether or not treatment has occurred is determined for this indicator via colposcopy data in the NCSP Register. Trends may reflect changes in the completeness of colposcopy data recording treatment within a DHB rather than necessarily true increases or decreases in the proportion of women treated. This incomplete recording of treatment potentially affects the results for treatments for both HSIL and LSIL. In some cases, treatment may have occurred in a different clinic to that where the original histology sample was collected. Facilities not explicitly defined as DHB (public) clinics are aggregated together as private practice. It is possible that women whose original HSIL (or LSIL) histology sample was collected outside a DHB clinic may in practice have been treated at a DHB clinic (or conversely a woman whose histology sample was collected at a DHB clinic may have been treated outside a DHB clinic). Note, however, that timeliness is assessed here by including any treatment visits, regardless of where they occurred.  The 2013 National Cervical Screening Programme Policies and Standards: ‘Section 6 – Providing a Colposcopy Service’ requires colposcopy clinics to provide information about the “decision to treat date” and “date histology result is received”. At present, these dates are not available to use due to low completeness of this item on the NCSP Register. It is envisioned that when this information is available for all DHBs for a full monitoring period, it will be used to calculate timeliness of treatment for women with histological HSIL. |

Figure 81 - Proportion of women treated within eight weeks of histological confirmation of HSIL, by DHB



*Date that histology results were reported to requesting clinician is used as the date of histological confirmation. DHB is assigned based on the clinic where the original HSIL histology sample was collected, however treatments will be included regardless of where they occurred.*

Figure 82 - Trends in the proportion of women treated within eight weeks of histological confirmation of HSIL, by DHB




Table 20 - Timeliness and appropriateness of treatment, by DHB

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **Women with CIN 2/3** | **Treated within 8 weeks** | | **Women with histological LSIL\*** | **Women subsequently treated†** | |
|  | **N** | **N** | **%** | **N** | **N** | **%** |
| *Public clinics (overall)* | *1,824* | *1,228* | *67.3* | *1,391* | *101* | *7.3* |
| Auckland | 129 | 78 | 60.5 | 91 | 7 | 7.7 |
| Bay of Plenty | 89 | 63 | 70.8 | 72 | 7 | 9.7 |
| Canterbury | 274 | 176 | 64.2 | 474 | 31 | 6.5 |
| Capital & Coast | 79 | 51 | 64.6 | 54 | 9 | 16.7 |
| Counties Manukau | 173 | 118 | 68.2 | 264 | 20 | 7.6 |
| Hawke's Bay | 76 | 46 | 60.5 | 9 | 2 | 22.2 |
| Hutt Valley | 50 | 30 | 60.0 | 15 | - | - |
| Lakes | 46 | 29 | 63.0 | 32 | 5 | 15.6 |
| Mid Central | 98 | 73 | 74.5 | 47 | 1 | 2.1 |
| Nelson Marlborough | 53 | 42 | 79.2 | 12 | 1 | 8.3 |
| Northland | 91 | 64 | 70.3 | 12 | 1 | 8.3 |
| South Canterbury | 18 | 9 | 50.0 | 3 | - | - |
| Southern | 132 | 101 | 76.5 | 34 | 2 | 5.9 |
| Tairawhiti | 39 | 36 | 92.3 | 20 | 3 | 15.0 |
| Taranaki | 69 | 37 | 53.6 | 21 | 2 | 9.5 |
| Waikato | 166 | 117 | 70.5 | 45 | - | - |
| Wairarapa | 15 | 10 | 66.7 | 4 | - | - |
| Waitemata | 170 | 107 | 62.9 | 138 | 7 | 5.1 |
| West Coast | 20 | 10 | 50.0 | 29 | 2 | 6.9 |
| Whanganui | 37 | 31 | 83.8 | 15 | 1 | 6.7 |
| *Private Practice* | *306* | *131* | *42.8* | *333* | *11* | *3.3* |
| **Total** | **2,130** | **1,359** | **63.8** | **1,724** | **112** | **6.5** |

*DHB is assigned based on the clinic where the original HSIL histology sample was collected, however treatments will be included regardless of where they occurred.*

*\* CIN1, CIN not otherwise specified (SNOMED codes M67015, M67016, M74000 and M74006). CIN1 is not routinely treated (consistent with 2008 NCSP Guidelines for Cervical Screening in New Zealand), so these results are not compared to a target. They appear here for descriptive purposes and to show how frequently the women with histologically confirmed LSIL were treated. † Includes women treated within 26 weeks of LSIL histology. Date that histology results were reported to requesting clinician is used as the date of histological confirmation.*

### Indicator 7.5 – Timely discharging of women after treatment

|  |  |
| --- | --- |
| **Definition** | This indicator measures performance against Standard 608.  It reports on the proportion of women treated for a high -grade lesion who:   * receive colposcopy within the period up to nine months after their treatment * receive colposcopy and cytology within the period up to nine months after their treatment * are discharged appropriately within 12 months of their treatment.   Treatment was defined as a colposcopy visit where there was a record of electrosurgical excision, laser ablation or excision, cold knife cone biopsy, or total hysterectomy. Colposcopy visits involving punch biopsies only are not included. Treatment was included if it was for a high-grade lesion (CIN 2 or CIN 3), based on histology results for any histology specimen collected concurrent with or up to six months prior to treatment.  To allow for 12 months of follow-up information to be available, this indicator reports on women treated in the six-month period ending 12 months prior to the end of the current monitoring period (i.e. 1 January - 30 June 2017). Records for each woman treated in the six-month period ending 12 months prior to the end of current monitoring period were retrieved from the NCSP Register. Among these treated women, the number of women with a colposcopy visit, and with both a colposcopy visits and a cytology sample was calculated. Follow-up colposcopy visits were not restricted to only those within the same DHB as where initial treatment occurred; rather any colposcopy visit recorded on the NCSP Register for that woman was included. Follow-up visits were retrieved for the period up to nine months after the treatment visit.  Eligibility for discharge is not explicitly defined in the NCSP Colposcopy Standard, so based on advice from the NCSP Advisory Group, women were defined as eligible for discharge if they had a colposcopy visit and cytology test following their treatment, and their cytology result was negative.  Women were defined as having been discharged when their colposcopy report form recommended follow-up by their sample taker/ referring practitioner.  Results are reported by DHB, based on the DHB of the facility where the treatment colposcopy was performed. Therefore, for the purpose of this indicator, the DHB where treatment occurred was regarded as the DHB responsible for ensuring a treated woman was followed up. However, as previously described, the follow-up colposcopy visit need not have occurred within that DHB. |
| **Target** | 90% or more of women treated for CIN 2 or 3 should have a colposcopy and smear within the nine-month period post-treatment  90% or more of women treated for CIN 2 or 3 should be discharged back to the sample taker as appropriate. |
| **Current Situation** | There were 1,392 women treated for CIN 2 or CIN 3 lesions in the six-month period from 1 January - 30 June 2017. These women were followed up for 12 months from the date of their treatment visit.  ***Follow-up post treatment***  There were 1,079 women (77.5%) with a follow-up colposcopy, and 1,063 women (76.4%) with both a follow-up colposcopy and a cytology sample in the nine month period after their treatment visit.  Figure 83 shows the percentage of treated women with a record of follow-up colposcopy, and both follow-up colposcopy and a cytology sample, in the period up to nine months post-treatment by DHB. Generally, the number of women with both cytology and colposcopy was very similar to the number of women with at least colposcopy (Table 76). The number of women with colposcopy only and no record of a cytology sample in the timeframe was at most three in Bay of Plenty.  Nationally, the percentage of women treated for high-grade lesions with a record of colposcopy and cytology within the nine-month period post-treatment (76.4%) is below the target value of 90%.  One DHB met the target of at least 90% of women receiving cytology and colposcopy within nine months post-treatment (Figure 83, Table 76). The percentage of treated women with a record of both follow-up colposcopy and a cytology sample in the period up to nine months post-treatment varied by DHB from 33.3% (South Canterbury) to all women (Wairarapa).  ***Women discharged appropriately***  In total, 1,021 women (73.3% of those treated) were eligible to be discharged by 12 months after their treatment visit, and 879 of these women (86.1%) were discharged within 12 months of treatment (Table 75). Figure 84 shows how these percentages varied by DHB. The percentage of women eligible for discharge who were discharged within 12 months of treatment ranged from 37.5% (South Canterbury) to all eligible women (Wairarapa and West Coast) (Table 75). In some cases, the number of women eligible for discharge was small, so these results should be interpreted with caution (13 or fewer women in Wairarapa, South Canterbury and West Coast).  Ten DHBs met the target of discharging 90% of women where appropriate within 12 months (Capital & Coast, Counties Manukau, Hawke's Bay, Hutt Valley, Nelson Marlborough, Tairawhiti, Waikato, Wairarapa, West Coast and Whanganui).  In total (that is, without considering whether or not women met the criteria suggested by the NCSP Advisory Group to be eligible for discharge), 1,020 women were discharged within 12 months of being treated for a high-grade lesion (73.3% of all women treated for a high-grade lesion). |
| **Trends** | The proportion of women with follow-up has been consistent between the last two reports (from 77.5% for colposcopy for both reports, and from 76.5% to 76.4% for both cytology and colposcopy). One DHB met the target of 90% of women having colposcopy and cytology within nine months of treatment, compared to no DHBs in the previous report.  The proportion of women discharged appropriately to their sample taker by 12 months has increased (85.8% in the previous report; 86.1% in the current report). The number of DHBs meeting the target of 90% increased from eight to ten. |
| **Comments** | Since this indicator relies on colposcopy data in the NCSP Register, there is the possibility that incomplete reporting of colposcopy visits has led to an underestimate of the number of women with follow-up colposcopy visits and the number discharged in a given time period. The data used in this analysis was extracted from the NCSP Register in late February 2018.  The target that 90% or more of women treated for CIN 2 or 3 should be discharged back to the sample taker as appropriate was assessed in this monitoring report, based on guidance from the NCSP Advisory Group as to when discharge would be appropriate. However, it should be noted that neither the 2008 NCSP Guidelines for Cervical Screening in New Zealand nor the 2013 Colposcopy Standards themselves provide explicit guidance for when discharge back to the sample taker is appropriate.  In some circumstances, women may be treated within one DHB, but referred to another DHB for follow-up. This information is not always recorded in the NCSP Register, however this measure does take into account all follow-up visits which women attend, regardless of the DHB in which they occurred. For clarity in this report, women remain assigned to the DHB where their treatment was performed. |

Figure 83 - Percentage of women treated with colposcopy, and both colposcopy and cytology, within nine months post-treatment, by DHB





Figure 84 - Percentage of women discharged appropriately within 12 months of treatment, by DHB



## Indicator 8 – HPV tests

The indicators report on the use of HPV testing. At present, they incorporate the following indicators:

1. Triage of low-grade cytology
2. HPV test volumes (including purpose for which the test was performed)
3. HPV tests for follow-up of women with a historical high-grade abnormality


Other than HPV test volumes (indicator 8.2) specific monitoring of the other uses of HPV testing is not yet included. These other purposes include:

* Management of women previously treated for CIN
* Management of women with a high-grade squamous cytology result in the past followed by negative cytology
* Resolution of discordant cytology, colposcopy and histology

### Indicator 8.1 – Triage of low-grade cytology

|  |  |
| --- | --- |
| **Definition** | For women with an ASC-US or LSIL (low-grade) cytology result relating to a cervical sample taken in the monitoring period, and with no recent abnormal cytology (i.e. abnormal cytology results relating to specimens taken in the preceding five years), the following are reported on as follows:   * The number and proportion of women with a subsequent HPV triage test (by age group, and cytology laboratory) * Women with positive HPV triage result, as a proportion of women with a valid HPV test (by age group, and cytology laboratory) * Histological outcomes in women with a positive triage test, where this information is available within 12 months following a positive HPV triage test   Where a woman has two different low-grade cytology results, relating to a sample or samples collected on the same date, she is grouped in accordance with the most serious result (i.e. LSIL).  A subsequent HPV triage test is defined as an HPV test where the sample was collected at the same time or after the cytology sample, and where there is a result available (including invalid results).  Women whose ASC-US or LSIL cytology test is associated with a recommendation code of R14 (refer regardless of cytology result) are excluded, as they may be symptomatic.  Women who are aged less than 30 years are excluded from this indicator if they have ever had either a high-grade squamous cytology result (ASC-H, HSIL) or a high-grade squamous histology result (CIN 2/3), as they may be having an HPV test in order to follow-up a previous high-grade squamous abnormality (cytology or histology, i.e. historical testing or as a test-of-cure following treatment for CIN2/3).  If a laboratory which performed the cytology refers the HPV test to a different laboratory, measures are based on the laboratory which performed the cytology test.  Measures reported by age are based on the age of the women on the date that the cytology sample was collected. |
| **Target** | Targets have not yet been set. |
| **Current Situation** | There were 708 women aged less than 30 years and 1,580 women aged 30 years or more with an ASC-US cytology result relating to a sample collected in the current monitoring period, and who had no abnormal cytology results relating to samples taken in the previous five years. The corresponding figures for LSIL are 2,411 women aged less than 30 years and 1,594 women aged 30 years or more.  ***HPV triage***  NCSP Guidelines (2008) recommend that women aged 30 years or more who have not had an abnormal cytology report in the previous five years are offered a HPV triage test following ASC-US or LSIL cytology. Among these eligible women, 97.3% of women aged 30 years or more with an ASC-US cytology result, and 96.7% of women aged 30 years or more with an LSIL cytology result are recorded as having a subsequent HPV test (Table 77, Table 78). These proportions ranged from 87.1% (Medlab Central Ltd.) to 99.7 (Anatomical Pathology Services) for ASC-US cytology results and from 86.6% (Medlab Central Ltd.) to 99.4% (Pathlab) for LSIL cytology results (Figure 85, Table 77, Table 78).  HPV triage is not included in the recommendations for women aged less than 30 years, and accordingly the proportions of women aged less than 30 years with a subsequent HPV test are very small. Subsequent HPV tests are recorded in the NCSP Register for 1.0% of women aged less than 30 years with ASC-US results (7 women), and 0.6% of women aged less than 30 years with LSIL results (15 women). These proportions ranged from no women (LabPLUS and Pathlab) to 2.9% (Canterbury Health Laboratories) for women with ASC-US results, and from no women (Canterbury Health Laboratories and Medlab Central Ltd.) to 1.0% (LabPLUS and Southern Community Laboratories) for women with LSIL results (Table 77, Table 78).  ***Positive triage tests***  Among women aged 30 years or more with a valid HPV triage test results, the proportion who were positive for high risk HPV (hrHPV) was 24.5% for women with ASC-US results, and 58.5% for women with LSIL results. These proportions varied by laboratory from 13.5% (Canterbury Health Laboratories) to 29.7% (Anatomical Pathology Services) for women with ASC-US cytology (Figure 86), and from 38.5% (LabPLUS) to 67.1% (Canterbury Health Laboratories) for women with LSIL cytology (Figure 87).  The proportion of women whose HPV triage test was positive also varied by age. Among women aged 30-69 years, HPV positivity rates were highest for those aged 30-39 years for women with ASC-US cytology (34.9%), and for those with LSIL cytology (65.1%). HPV positivity rates generally decreased with increasing age, but were broadly similar for women with ASC-US cytology in each of the 10-year age groups between 40 and 69 years. For women with ASC-US results, the positivity rates in the 10-year age groups between 40 and 69 years ranged between 18.6% and 20.3% (Figure 88, Table 21). For women with LSIL results, the positivity rates were between 46.7% and 56.0% for these 10-year age groups (Figure 88, Table 22).  ***Histological outcomes in triage-positive women who attended colposcopy***  In order to allow sufficient time for women to have attended colposcopy following a positive triage test, histological outcomes were assessed in women with low-grade cytology and a positive HPV triage test in the six-month period 1 January – 30 June 2017. In this period, there were 329 women with an ASC-US cytology result and positive HPV triage test, and 796 who had an LSIL cytology result and positive HPV triage test. 314 (95.4%) of the women with ASC-US who were triage-positive and 728 (91.5%) of the women with LSIL who were triage-positive had a record of colposcopy and/or histology within the 12 months following their initial test results. Among the women with a record of colposcopy, 209 (66.6%) and 533 (73.2%) of the women with ASC-US and LSIL respectively have a histology record.  Histological outcomes in these women were initially considered in an analogous manner to Indicator 5.2 – that is, the number of women with CIN 2 or worse histology (CIN 2+; also see Appendix D), as a percentage of women who had a histology result available. The percentage of women with histology whose histology result was CIN 2+ was 23.0% for HPV triage-positive ASC-US and 19.3% for HPV triage-positive LSIL (Table 79, Table 80). These percentages varied by laboratory from 18.5% (Anatomical Pathology Services) to 31.6% (Canterbury Health Laboratories) for HPV triage-positive ASC-US and from 12.1% (Anatomical Pathology Services) to 26.8% (Pathlab) for HPV triage-positive LSIL (Figure 89).  We additionally considered histological outcomes as a percentage of women who attended colposcopy (rather than only those with a histology result), as some women may have no histology because colposcopic impression was normal. The corresponding percentages of women with CIN 2+ histology was 15.3% for HPV triage-positive ASC-US and 14.1% for HPV triage-positive LSIL (Table 79, Table 80). These percentages varied by laboratory from 12.2% (Anatomical Pathology Services) to 26.1% (Canterbury Health Laboratories) for HPV triage-positive ASC-US and from 8.9% (Anatomical Pathology Services) to 17.3% (Pathlab) for HPV triage-positive LSIL (Figure 90). For context, these are also compared with the corresponding percentages for women with ASC-H and HSIL cytology with CIN 2+ histology (among women who attended colposcopy within six months), by laboratory, in Figure 90.  Histological outcomes within 12 months in women with triage-positive test results are shown by age, as a percentage of women with histology recorded (Figure 92), and as a percentage of women with colposcopy recorded (Figure 93). Among women aged 30-69 years, the percentage of women with CIN 2+ histology within 12 months generally decreased with increasing age for HPV triage-positive ASC-US and LSIL. There were no cases of CIN 2+ among women aged 70+ years with ASC-US or LSIL and a positive HPV triage test. The age group with the highest proportion of triage positive women with CIN2+ histology was 30-39 years for both ASC-US and LSIL (33.0% and 24.3%, respectively). |
| **Trends** | ***HPV triage***  The proportion of women aged 30 years or more with low-grade cytology (and no recent abnormal cytology in the preceding five years) who received a subsequent HPV test is similar to the previous report for women with ASC-US results (97.4% in the previous period compared to 97.3% in the current period), but decreased for women with LSIL results (97.6% in the previous period compared to 96.7% in the current period). The proportion of women aged less than 30 years with a subsequent HPV test is slightly lower than the previous monitoring period for ASC-US results (1.8% in the previous period compared to 1.0% in the current period for ASC-US) and similar to the previous period for LSIL results (0.7% in the previous period and 0.6% in the current period for LSIL).  ***Positive triage tests***  The proportion of women aged 30 years or more who tested positive for a high-risk HPV type is lower in the current report for both ASC-US (25.5% in the previous report; 24.5% in the current report), and LSIL (60.1% in the previous report; 58.5% in the current report).  ***Histological outcomes in triage-positive women who attended colposcopy***  95.4% of women with ASC-US cytology and a positive HPV triage test in the six-month reference period for the current report had a record of colposcopy and/or histology within the 12 months following their test result, which has increased since the previous report (91.1%). For the current report, 66.6% of these women with colposcopy also had a histology record, which is similar to the previous report (66.6%). Of these women with a histology record, the histology result was CIN 2+ for 23.0% of women in the current report, compared with 26.9% in the previous report. When histological CIN 2+ outcomes were considered as a proportion of women with colposcopy, rather than histology, the corresponding figures were 15.3% in the current report versus 17.9% in the previous report. The proportion of triage-positive ASC-US women with CIN 2+ histology (among those who attended colposcopy) also decreased compared to the previous report at four of the six laboratories (LabPLUS, Medlab Central Ltd., Pathlab and Southern Community Laboratories; Figure 94). Caution must be taken when interpreting differences at LabPLUS due to frequently having small numbers of triage-positive womenand therefore highly variable percentages).  For women with LSIL cytology and a positive HPV triage test in the reference period for the current report, 91.5% had a record of colposcopy and/ or histology within 12 months of their result, which is lower than the 93.5% of women in the previous report. For the current report 73.2% of these women with colposcopy also had a histology record, compared with 71.8% in the previous report. Of those women with a histology record, the histology result was CIN 2+ for 19.3% of women in the current report, compared with 21.2% in the previous report. When histological CIN 2+ outcomes were considered as a proportion of women with colposcopy, rather than histology, the corresponding figures were 14.1% for the current report and 15.2% for the previous report. Trends in this proportion of LSIL triage-positive women with CIN 2+ histology (among those who attended colposcopy) are shown in Figure 95. The proportion with CIN2+ histology decreased in four laboratories (Anatomical Pathology Services, Canterbury Health Laboratories, LabPLUS and Medlab Central Ltd). |
| **Comments** | A small number of women aged less than 30 years with low-grade results, no recent abnormalities (in the previous five years) and no record at any time of a previous high-grade squamous abnormality (cytological or histological), have a record of a subsequent HPV test (22 women). This is lower than the number of women in the previous report (27 women). It is uncertain whether these HPV tests were performed for the purpose of triage, or for other reasons. In this report, we excluded women aged less than 30 years from this indicator if they had ever had a previous high-grade squamous abnormality (either ASC-H/ HSIL cytology, or CIN 2/3 histology). This was done in order to avoid potential inadvertent inclusion in this group of women being tested for HPV in concordance with the guidelines as part of “historical testing”. This could occur as a result of a previous high-grade squamous abnormality (either ASC-H/ HSIL cytology, or CIN 2/3 histology) currently managed by annual cytology, which occurred more than five years earlier (since abnormalities within the previous five years are already taken into account). It is also possible that some women were aged 29 years at the time of their cytology sample, but 30 years at the time of the cytology result, although previous exploration has suggested that the extent of this is likely to be small.[22](#_ENREF_22), [23](#_ENREF_23) Another possible explanation is that these women are being followed up for a previous high-grade result but this is not recorded on the NCSP Register (for example because this occurred overseas). The HPV test may also have been ordered by a specialist. However note that inadvertent inclusion of HPV tests ordered by a specialist to resolve discordant results (or for historical testing) should be minimised since women were excluded from this indicator if they had any recent abnormalities (past five years, any abnormality grade); if they had ever had a high-grade squamous abnormality (but no glandular abnormality) recorded on the NCSP Register; if the sample for HPV testing was collected on the same day as a recorded colposcopy visit for that woman; or if the sample for HPV testing was collected more than five weeks after the cytology sample. |

Figure 85 - Proportion of women (aged 30 years or more) with low-grade cytology who have a subsequent HPV test, by laboratory and cytology result



*Excludes women with abnormal cytology in the five years preceding their low -grade cytology sample.*

Figure 86 - Proportion of HPV triage tests which are positive following ASC-US cytology (women aged 30 years or more), by cytology laboratory




Figure 87 - Proportion of HPV triage tests which are positive following LSIL cytology (women aged 30 years or more), by cytology laboratory





Figure 88 - Proportion of women with an HPV triage test who are HPV positive, by age and cytology result



*Note: Excludes results for women aged less than 30 years and aged 70 years or more, since these are based on very small numbers of women with valid HPV test results.*

Table 21 - HPV triage test results following ASC-US cytology, by age and cytology laboratory

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Women with valid HPV test results** | | **Women with positive HPV test results (number and % within each age group)** | | | | | | | | | | | |
| **<30yrs\*** | **30+ yrs** | **< 30yrs\*** | | **30-39 yrs** | | **40-49 yrs** | | **50-59 yrs** | | **60-69 yrs** | | **70+ yrs** | |
| **N** | **N** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| Anatomical Pathology Services | 4 | 354 | 3 | 75.0 | 55 | 44.7 | 24 | 23.3 | 18 | 20.2 | 7 | 21.2 | 1 | 16.7 |
| Canterbury Health Laboratories | 1 | 111 | 0 | 0.0 | 6 | 15.0 | 8 | 20.0 | 1 | 5.3 | 0 | 0.0 | 0 | 0.0 |
| LabPLUS | 0 | 170 | 0 | 0.0 | 11 | 25.6 | 11 | 18.6 | 8 | 18.6 | 1 | 4.2 | 0 | 0.0 |
| Medlab Central Ltd. | 1 | 155 | 0 | 0.0 | 17 | 29.3 | 7 | 16.3 | 5 | 13.2 | 1 | 6.7 | 0 | 0.0 |
| Pathlab | 0 | 294 | 0 | 0.0 | 30 | 33.3 | 18 | 19.6 | 10 | 16.4 | 13 | 28.3 | 1 | 20.0 |
| Southern Community Laboratories | 1 | 452 | 0 | 0.0 | 55 | 37.9 | 30 | 20.7 | 25 | 22.5 | 13 | 27.1 | 0 | 0.0 |
| **Total** | **7** | **1536** | **3** | **42.9** | **174** | **34.9** | **98** | **20.3** | **67** | **18.6** | **35** | **19.8** | **2** | **11.8** |

*Excludes women with abnormal cytology in the five years preceding their low -grade cytology sample.*

*\* Additionally excludes women with any previous squamous high -grade (cytology or histology)*


Table 22 - HPV triage test results following LSIL cytology, by age and cytology laboratory

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Women with valid HPV test results** | | **Women with positive HPV test results (number and % within each age group)** | | | | | | | | | | | | | |
| **< 30yrs\*** | **30+ yrs** | **< 30yrs\*** | | **30-39 yrs** | | | **40-49 yrs** | | **50-59 yrs** | | | **60-69 yrs** | | **70+ yrs** | |
| **N** | **N** | **N** | **%** | | **N** | **%** | **N** | **%** | | **N** | **%** | **N** | **%** | **N** | **%** |
| Anatomical Pathology Services | 2 | 369 | 0 | 0.0 | | 124 | 67.0 | 64 | 59.8 | | 30 | 52.6 | 7 | 35.0 | 0 | 0.0 |
| Canterbury Health Laboratories | 0 | 70 | - | - | | 28 | 75.7 | 12 | 66.7 | | 5 | 38.5 | 2 | 100.0 | 0 | 0.0 |
| LabPLUS | 1 | 65 | 0 | 0.0 | | 14 | 51.9 | 9 | 37.5 | | 1 | 11.1 | 1 | 20.0 | 0 | 0.0 |
| Medlab Central Ltd. | 0 | 97 | - | - | | 23 | 59.0 | 14 | 50.0 | | 8 | 40.0 | 6 | 60.0 | 0 | 0.0 |
| Pathlab | 1 | 313 | 1 | 100.0 | | 78 | 61.4 | 61 | 51.7 | | 25 | 56.8 | 8 | 42.1 | 3 | 60.0 |
| Southern Community Laboratories | 11 | 627 | 9 | 81.8 | | 204 | 66.0 | 102 | 59.0 | | 52 | 49.1 | 18 | 52.9 | 3 | 60.0 |
| **Total** | **15** | **1541** | **10** | **66.7** | | **471** | **65.1** | **262** | **56.0** | | **121** | **48.6** | **42** | **46.7** | **6** | **60.0** |

*Excludes women with abnormal cytology in the five years preceding their low -grade cytology sample*


*\* Additionally excludes women with any previous squamous high -grade (cytology or histology)*

Figure 89 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of all women with histology, by laboratory



*Note that LabPLUS results are based in very small numbers of triage-positive women (see Table 79 and Table 80).*

Figure 90 – Triage-positive *women with histologically-confirmed* CIN 2+ within 12 months, as a percentage of all women who attended colposcopy, by laboratory



*Note that LabPLUS results are based in very small numbers of triage-positive women (see Table 79 and Table 80).*

Figure 91 - Women with histologically-confirmed CIN 2+ within 12 months, as a percentage of all women who attended colposcopy, by laboratory and referral cytology




Figure 92 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with histology recorded, by age




Figure 93 – Triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by age






Figure 94 –Trends in ASC-US triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by laboratory



*Time periods relate to monitoring report periods; results relate to samples collected in the 6-month period* *12 months prior to the monitoring period, to allow for sufficient follow-up time for colposcopy/ histology. See Table 79.*

Figure 95 – Trends in LSIL triage-positive women with histologically-confirmed CIN 2+ within 12 months, as a percentage of women with colposcopy recorded, by laboratory



*Time periods relate to monitoring report periods; results relate to samples collected in the 6-month period* *12 months prior to the monitoring period, to allow for sufficient follow-up time for colposcopy/ histology. Note that this graph excludes LabPLUS due to frequently having small numbers of triage-positive women and highly variable percentages. See Table 80.*

### Indicator 8.2 – HPV test volumes

|  |  |
| --- | --- |
| **Definition** | All HPV tests received by laboratories within the monitoring period were retrieved. This volume of HPV tests (performed for any purpose) is reported on by:   * Laboratory * Ethnicity * Age group * Purpose   Purpose is defined as one of the following categories:   1. Post-treatment *(women treated for high-grade squamous lesions (specifically CIN 2/3) in the period six months to four years prior to the HPV sample date, to capture two rounds of testing)* 2. Historical *(high-grade squamous cytology (ASC-H/ HSIL) or histology (CIN 2/3) more than three years prior to the HPV test sample)* 3. Taken at colposcopy (*HPV sample collected on the same date as a colposcopy visit or a histology sample in the same woman)* 4. HPV triage *(as defined in Indicator 8.1, but restricted to women aged 30 years or more at the time of the cytology specimen, and where the low -grade cytology (ASC-US or LSIL) was no more than six months prior to the HPV test)* 5. Other *(tests which do not fit into any of the above categories)*   These categories are defined hierarchically in the order shown; that is, a test cannot fit into more than one category, and tests are only considered for inclusion in a category if no previous categories in the list apply. The purpose of tests is not at its final stage of development and is an item that is under ongoing review.  Tests in the ‘Other’ category were explored further. The number of tests that fell into the ‘Other’ category was found to be relatively high in this report, but this analysis is nonetheless indicative of the appropriate purposes. It is also useful to report the extent of hrHPV tests for other purposes and the need to eliminate hrHPV tests for other purposes that are not within the NCSP guidelines. For this reason, the purpose of hrHPV tests are discussed in this report.  Rates of invalid HPV tests are also reported on.  Measures reported by age are based on the age of the women on the date that the HPV test sample was collected. |
| **Target** | Targets have not yet been set. |
| **Current Situation** | ***Overall volumes***  There were 18,302 samples received by laboratories for HPV testing within the current monitoring period. These are reported on further in Table 81 to Table 87.  Virtually all (98.3%) samples for HPV testing were from women aged 20-69 years. The large majority of women (86.0%) were aged 30 years or more (Figure 96, Table 85).  The number of samples received by laboratories for HPV testing ranged from 798 (LabPLUS; 4.4% of all HPV tests) to 7,915 (Southern Community Laboratories; 43.2% of all HPV tests) (Figure 97, Table 81). Figure 98 and Table 81 show for each laboratory the ratio of the number of HPV tests received, divided by the number of cytology tests received (expressed as a percentage). This measure provides some correction for the variation in workloads between different laboratories. It is likely, for example, that laboratories which process a larger volume of cytology tests would also undertake a larger volume of HPV tests. The ratio of HPV tests to cytology tests reported was on average 8.4% across New Zealand – that is, on average 8.4% of cytology tests are associated with an HPV test. This ratio varied by laboratory from 7.2% (Southern Community Labs; i.e. fewer HPV tests processed in relation to cytology tests processed than the national average) to 12.6% (Canterbury Health Laboratories; i.e. more HPV tests processed in relation to cytology tests processed than the national average).  The distribution of HPV tests by ethnicity is shown in Table 84.  The overall proportion of HPV tests with invalid results was 0.07% (Table 82). The proportion was small for the HPV test technologies reported (Table 83).  ***Purpose of HPV tests***  These HPV tests were further analysed in order to ascertain the purpose for which they were performed. Nationally, it was calculated that 2,694 (14.7%) were for post-treatment management for women treated in the past four years; 6,701 (36.6%) were for follow-up management of women with high-grade squamous cytology or histology more than three years previously (historical testing); 1,388 (7.6%) were on samples collected at a colposcopy visit which did not fit into a previous category (possibly for resolution of discordant results); and 2,878 (15.7%) were for triage of low-grade cytology in women aged 30 years or more. There were 4,641 (25.4%) HPV tests that did not fit into any of the previously described categories, identified as Other (Figure 99).  Further breakdowns of HPV tests by purpose are presented by age (Figure 100, Table 85), laboratory (Figure 101), and ethnicity (Table 84, Table 86).  There were variations in HPV test purpose by age (Figure 100, Table 85). HPV triage (by the definition used here, and consistent with NCSP Guidelines) did not occur in women aged less than 30 years. In women aged less than 30 years, a comparatively larger proportion were taken for post-treatment management (31.0%). Follow up of women with historical high-grade squamous abnormalities (more than three years ago) was the most common reason that HPV tests were performed among women in the five-year age groups between 30 and 54 years. Tests which did not fit into the prescribed categories, and were therefore classified as ‘Other’, were the most common classification among women aged 20-24 years and in the five-year age groups aged 55 years and older. Having an equal proportion, the most common reason for a HPV test for women aged <20 was at colposcopy and for ‘Other’ tests (although based on a very small number of HPV tests in women this age).  HPV test purpose also varied by laboratory (Figure 101, Table 86). Among tests for which the purpose could be determined, the most common reason for HPV testing was historical testing in five of the six laboratories (Anatomical Pathology Services, Canterbury Health Laboratories, Medlab Central Ltd., Pathlab and Southern Community Laboratories). HPV triage was the most common HPV test reason for LabPLUS. In all laboratories, however, tests for which the purpose was unclear were quite common, varying from 13.4% at LabPLUS to 33.1% Southern Community Laboratories. The proportion of tests performed for post-treatment management varied from 11.9% (Pathlab) to 24.9% (Canterbury Health Laboratories), while the proportion performed to follow up women with historical high-grade squamous abnormalities varied from 20.8% (LabPLUS) to 43.1% (Anatomical Pathology Services). The proportion of tests where the sample was collected at colposcopy but not for one of the previous purposes ranged from 2.7% (Anatomical Pathology Services) to 22.9% (LabPLUS). The proportion of tests performed for HPV triage ranged from 12.5% (Southern Community Labs) to 28.2% (LabPLUS).  Follow up of women with historical high-grade squamous abnormalities (more than three years ago) was the most common reason that HPV tests were performed among Māori, Pacific and European/ Other women. HPV triage was the most common reason for HPV tests in Asian women (Table 84).  Tests in the ‘Other’ category were further explored. A proportion of the ‘Other’ tests (2.6%; 120 tests) were potentially tests performed for post-treatment management, because the same woman had CIN 2/3 histology recorded on the NCSP Register, however there was no explicit record of treatment available on the NCSP Register, potentially due to incomplete colposcopy data on the NCSP Register. Another 5.0% occurred after treatment, but did not meet the criteria for post-treatment management because they occurred within 6 months of treatment (0.9%; 42 tests), or after treatment of a non-squamous high-grade (1.1%; 51 tests), or a non-high-grade (2.9%; 134 tests) or cervical cancer (0.13%; 6 tests). A further 18.0% of the ‘Other’ HPV tests occurred after a previous abnormality but one which did not meet the criteria for historical testing either because it was non-squamous (9.5%; 443 tests), the high-grade squamous cytology was less than three years ago (8.3%; 385 tests), or the histology diagnosis was cervical cancer (0.2%; 7 tests).  A larger proportion of the ‘Other’ tests (26.6%; 1,236 tests) occurred in women who did not have any specific high-grade abnormality recorded on the NCSP Register, but who did have a record on the NCSP Register suggesting that they had a previous high-grade abnormality (although the Register does not record whether it was a squamous abnormality or not; consequently, HPV testing is not indicated in these women by the NCSP guidelines). These records predominantly indicated prior high-grade cytology (22.2%; 1,030 tests), but some suggested prior high-grade histology (4.4%; 206 tests). Smaller proportions of HPV tests were associated with a low-grade abnormality, including either a current low-grade cytology result which did not meet the criteria for triage because the woman had another recent abnormality and triage was not required (2.1%; 99 tests), a record suggesting a previous low-grade cytology not explicitly recorded on the NCSP Register (3.0%; 137 tests), or collected by a specialist where none of the other reasons applied (5.5%; 255 tests). After this exploration, there remained 1,726 tests (37.2% of ‘Other’ tests; 9.4% of all HPV tests in the monitoring period) where purpose still could not be determined.  ***HPV tests at colposcopy***  HPV tests taken at colposcopy, were further explored based on the DHB of the colposcopy clinic where the sample was taken and whether or not it was a public or a private clinic. This included only HPV tests where a colposcopy record exists and not those inferred by a histology result. Nationally, more of the HPV tests that were taken at colposcopy came from public facilities (86.1%; 1,009 tests) than from private facilities (13.9%; 163 tests). As the number of HPV tests collected at a colposcopy clinic is potentially reflective of the number of colposcopies performed there, a rate of HPV tests at colposcopy which takes this variation into account was derived, in order to provide more information. The rate of HPV tests at colposcopy was calculated by dividing the number of HPV tests collected at colposcopy by the total number of colposcopies within that DHB or across private colposcopy clinics, expressed as a percentage. This rate can be broadly interpreted as the percentage of colposcopies (within a given DHB or sector) where an HPV test sample is collected. Across New Zealand, HPV test samples were collected in approximately 9.6% of colposcopies. In DHBs where HPV tests were collected at colposcopy, this value ranged from 2.3% (Auckland) to 30.4% (Lakes), and was 9.4% overall across all public DHB clinics (Figure 102, Table 87). In private practice, this rate was 11.6%. No HPV test samples were collected in the Tairawhiti DHB clinic. |
| **Trends** | A similar volume of HPV samples was received at laboratories for testing in the current (18,302) and the previous monitoring period (18,230; an increase of 0.4%). Three laboratories experienced an increase in the number of samples received between the current monitoring period compared with the previous report period. The laboratory with the largest percentage increase in the number of tests between the previous and current period was Southern Community Laboratories (from 7,380 to 7,915 tests; 7.2% increase) and the largest decrease was at LabPLUS (from 915 to 798 tests; 12.8% decrease) and Medlab Central Ltd. (from 1,816 to 1,588 tests; 12.6% decrease). Trends by laboratory can be seen in Figure 103.  Changes in HPV test volumes varied across all test purpose categories. The greatest increase in the number of tests performed for the four guidelines categories (post-treatment, historical testing, HPV triage or tests at colposcopy) occurred at colposcopy (9.8% increase; 124 tests) and the only relative decrease was seen in HPV tests taken for historical reasons (decrease of 1.0% or 68 tests) (Figure 104). A decrease was also seen in both the number of HPV tests in the ‘Other’ category (310 tests) and also the percent of all HPV tests in this category (from 27.2% to 25.4%). The proportion of tests in each of the other four categories was broadly similar to that seen in the previous report (from 14.1% to 14.7% for post-treatment management; from 37.1% to 36.6% for historical testing; and from 6.9% to 7.6% for tests taken at colposcopy; and increased from 14.7% to 15.7% for triage of low-grade cytology,).  The proportion of colposcopies where an HPV test sample was collected increased somewhat in this report (from 8.9% to 9.6%). DHBs where this proportion is higher are generally the same as in previous reports, although the proportion has been increasing over the previous three reports in South Canterbury, and also across private practice overall (Figure 105).  The proportion of HPV tests which are invalid remains very small (Table 83). |
| **Comments** | HPV volumes by laboratory will vary for a number of reasons, one of which being the general volume of work in that laboratory. In order to provide some correction for the variation in workloads between different laboratories, we calculated the ratio of HPV tests received to cytology tests reported on (Figure 98, Table 81). Other reasons for variations in the rate of HPV testing by laboratory (which are not taken into account in this ratio) may include differences in the population they serve, because HPV testing is performed in specific subgroups of women. For example, HPV triage testing is performed in women with low-grade (ASC-US/ LSIL) cytology results (but without recent abnormalities), therefore laboratories reporting higher rates of low-grade abnormalities may also have higher rates of triage testing. Conversely, laboratories reporting on a larger proportion of cytology from colposcopy clinics may be more likely to perform HPV tests arising from colposcopy (for example LabPLUS) but less likely to perform HPV triage testing, because women attending colposcopy have generally had a recent abnormality and therefore do not require triage. These issues may for example partly explain differences in the ratios between different Laboratories. To understand in more detail, the reasons for the differences, an explicit exploration of the purpose for which the HPV test was performed has been examined here.  Exploration is ongoing into the potential reason for tests in the ‘Other’ category, as is the refinement of specifications for the analysis of purpose. Some possible explanations include follow-up of women previously treated for high-grade squamous abnormalities where these abnormalities occurred outside New Zealand, prior to the woman being enrolled on the NCSP Register, or prior to the inception of the NCSP Register. The latter may potentially explain why the proportion of ‘Other’ tests is higher in older women than in younger women (except for women aged 20-24). Synopses held on the NCSP Register of previous (self-reported) high-grade abnormalities have been used in this report to explore this possibility further (although these synopses do not distinguish between squamous abnormalities and glandular abnormalities; HPV testing is currently only recommended for the management of women with previous squamous abnormalities). The proportion associated with a synopsis reflecting a previous high-grade abnormality (cytological or historical) reported here (26.6%) is slightly less than that in the previous report (29.7%), and the number of tests in this category has also decreased since the previous report (from 1,470 to 1,236). In a June 2015 newsletter, the NCSP reminded laboratories that women with a previous glandular lesion, or a high-grade synopsis code on their screening history but no confirmation that the previous abnormality was squamous, should remain on annual screening and HPV testing is not indicated for these women.  In reports prior to Number 49 (July – December 2017), some HPV tests that were collected at colposcopy were incorrectly classified in the ‘Other’ category (generally within the sub-category of a recent high-grade abnormality that therefore did not meet the criteria for post-treatment management or historical testing). This has been corrected in the current report and the increase in tests collected at colposcopy is explained by this change. |

Figure 96 - Volume of HPV test samples received by laboratories during the monitoring period, by age




Figure 97 - Volume of HPV test samples received by laboratories during the monitoring period, by laboratory





Figure 98 - HPV test samples as a percentage of cytology test samples received during the monitoring period, by laboratory



*HPV tests/ colposcopy can be interpreted as the percentage of cytology tests which have an associated HPV test*

Figure 99 - Volume of HPV test samples received during the monitoring period, by purpose




Figure 100 - HPV test samples received during the monitoring period, by purpose and age




Figure 101 - HPV test samples received during the monitoring period, by purpose and laboratory





Figure 102 - HPV test samples collected at colposcopy, in relation to total colposcopies\* performed in the period, by DHB



*HPV tests/ colposcopy can be interpreted broadly as the percentage of colposcopies within this DHB/ sector where a sample is collected for HPV testing. \*the number of HPV tests here includes only HPV test samples where a colposcopy report record exists and is not inferred by a histology result.*

Figure 103 - Trends in volumes of HPV test samples received, by laboratory



Figure 104 - Trends in volumes of HPV test samples received, by purpose



**

Figure 105 - Trends in HPV test samples collected at colposcopy, in relation to total colposcopies\* performed in the period, by DHB


**

*HPV tests/ colposcopy can be interpreted broadly as the percentage of colposcopies within this DHB/ sector where a sample is collected for HPV testing. \*the number of HPV tests here includes only HPV test samples where a colposcopy report record exists and is not inferred by a histology result.*

### Indicator 8.3 – HPV tests for follow-up of women with a historical high -grade abnormality

|  |  |
| --- | --- |
| **Definition** | NCSP Guidelines for Cervical Screening in New Zealand state that women with a previous high-grade squamous abnormality (ASC-H, HSIL, CIN 2/3) more than three years ago may benefit from two rounds of dual cytology and hrHPV testing (“historical testing”). If women test negative on both tests over two years, they can safely be screened according to the routine screening recommendations (cytology alone every three years until 70). HPV testing is not recommended for management of women with a historic non-squamous high-grade abnormality.  The purpose of this indicator is to examine the extent to which historical testing is being used for women who are eligible for it, and the outcomes of these tests.  Predominantly, women who are eligible for historical testing will be those who were eligible for it at the time it was introduced (1 October 2009), because women with more recent high-grade squamous abnormalities will be followed up with hrHPV testing in other ways (as part of standard post-treatment management and/ or use of hrHPV testing to assist in resolving discordant cytology and colposcopy/ histology). Women are considered to have been eligible for historical testing as at 1 October 2009 if:   1. They had a high-grade squamous abnormality (cytology or histology) more than three years prior to 1 October 2009, as per the definition of historical testing (i.e. prior to 1 October 2006) and 2. They had no previous glandular abnormality (i.e. prior to 1 October 2009); and 3. Between their historical high-grade squamous abnormality and 1 October 2009, they had *either* no cytology OR only negative cytology OR three consecutive negative cytology tests as their most recent cytology results; and 4. They were alive on 1 October 2009.   Women were excluded, however, if they had been treated for a high-grade squamous abnormality within the three years prior to 1 October 2009, because this meant they met the criteria for *post-treatment women*, rather than *historical testing.* Note that this indicator also does not report on historical testing in any women who became eligible for it after 1 October 2009 (although as noted above, this should be a small group as women with more recent high-grade squamous abnormalities will be followed up with hrHPV testing in other ways).  Within the current report, Round 1 and Round 2 historical tests are only considered for women who were both eligible for historical testing on 1 October 2009 *and* who also remained eligible for it throughout the current monitoring period. Therefore, in the current report, women were excluded if:   1. They were not still alive at the end of the current monitoring period *(follow-up no longer possible)*; or 2. They had a non-squamous high -grade abnormality between becoming eligible (on 1 October 2009) and the end of the current monitoring period *(no longer eligible for historical testing)*   HPV tests in these women from 1 October 2009 were retrieved. HPV tests which appeared to have been carried out for other recommended uses of HPV testing (such as HPV triage of low-grade cytology; HPV tests taken at colposcopy; or HPV tests performed to follow-up treatment of a high-grade squamous abnormality within the previous three years) were excluded since they were not performed for the purpose of historical testing. After excluding those tests, the first HPV test in each woman was defined as her Round 1 historical test. A Round 2 historical test was defined as the first HPV test which occurred at least 9 months after a Round 1 historical test.  Measures reported by age are based on the age of the women at the end of the current monitoring period (i.e. a woman’s age at 30 June 2018). Measures reported by DHB are based on the geographic area relating to the woman’s residence (or if this information is not available, that of her responsible health provider). |
| **Target** | Targets have not yet been set. |
| **Current Situation** | ***Overall women eligible for historical testing***  There were 50,503 women who, at 1 October 2009, were eligible for HPV testing to follow-up a historical squamous high-grade abnormality (“historical testing”). Of these women, 49,193 are considered in the current report (the remaining women were excluded because they were no longer alive at the end of the current monitoring period, or were no longer eligible for historical testing because they had a non-squamous high-grade abnormality since 1 October 2009). There were no women eligible for historical testing who were aged less than 25 years at the end of the current monitoring period; however, this is not unexpected, as women in this age group would have been aged less than 18 years old on 1 October 2009 and few women this age are screened or treated for high-grade abnormalities (Table 88).    ***HPV tests performed for historical reasons***  Overall, 33,472 (68.0%) of the women eligible for historical testing have a Round 1 historical test recorded on the NCSP Register. There were 28,102 women who also have a Round 2 historical tests (57.1% of eligible women; 84.0% of those with a Round 1 test).  The proportion of women with historical tests varied by age. Among women aged 25 to 69 years at the end of the current monitoring period, the proportion of eligible women with a historical test varied from 43.2% (25-29 years) to 71.0% (60-64 years) for Round 1 tests, and from 37.8% (25-29 years) to 61.1% (60-64 years) for Round 2 tests (Figure 106, Table 88).  The proportion of eligible women with historical tests also varied by DHB, from 56.3% (Counties Manukau) to 79.8% (Nelson Marlborough) for Round 1 tests, and from 43.5% (Counties Manukau) to 72.5% (Nelson Marlborough) for Round 2 tests (Figure 107, Table 89). The number of women eligible for historical testing in a given DHB did not appear to have any relationship with the proportion who had received a historical test (Figure 115).  The proportion of eligible women with Round 1 historical tests ranged from 48.4% in Pacific women to 70.1% in European/ Other women (Figure 108, Table 90). For Round 2 tests, this proportion ranged from 37.9% in Pacific women to 59.8% in European/ Other women.  We explored whether the proportion of women with a historical HPV test was influenced by screening participation within the previous five years (asking the question does higher screening participation for any test, increase the likelihood of initiating a historical test). The variation in the proportion of women with historical tests recorded did not appear to be fully explained by variations in screening participation, either by DHB (Figure 116, Table 91) or by ethnicity (Figure 117). |
| **Trends** | As this Indicator is reporting on the cumulative proportion of women who were eligible for HPV testing for the management of a historical high-grade squamous lesion as at 1 October 2009, the proportion is generally expected to increase over time. The proportion of eligible women with an HPV test recorded has increased since the previous report from 66.5% to 68.0% for Round 1 tests, and from 54.8% to 57.1% for Round 2 tests. It has also done so in every DHB (Figure 109), ethnicity (Figure 110) and most age groups (Figure 111) between this and the previous report. Women aged between 25-29 saw a drop in women with a Round 1 test recorded (from 53.2% to 43.2%) and Round 2 test recorded (from 40.3% to 37.8%) in the current reporting period. |
| **Comments** | This indicator currently only considers women who had a high-grade squamous abnormality more than three years prior to 1 October 2009. It is anticipated that women with more recent high-grade squamous abnormalities will be followed up via standard post-treatment management which also includes hrHPV testing. It was intended that future monitoring reports would also incorporate reporting on the use of hrHPV tests for the purpose of post-treatment management as a separate sub-indicator within Indicator 8. However, development of additional indicators has been suspended prior to the programme’s planned transition to primary HPV screening, as indicators will be reviewed as part of the transition process.  Planned future refinements include reporting on the proportion of the Round 1 and Round 2 historical tests where hrHPV was detected, and on how many women are able to be returned to routine screening after two rounds of negative cytology and hrHPV tests; considering women with a historical high-grade squamous abnormality who became eligible for historical testing after 1 October 2009; and taking into account whether women have attended for any screening test, since women who have not attended for any testing could not be offered historical testing. This last point has been partially explored within the current report, by considering whether there was any relationship between the variations in women with Round 1 and Round 2 historical tests by DHB or ethnicity and the variations in screening participation within the previous five years by DHB or ethnicity. An extended period of five-years was examined for screening participation (rather than three, which is the usual measure), since it corresponds more closely than three-year participation during which we searched for HPV tests in this group of women (i.e. from 1 October 2009 to the time of the data download from NCSP Register used within this report, late February 2018). However, as women with a previous abnormality are recommended to re-attend for screening more frequently than the routine interval, the variations in overall attendance by DHB or by ethnicity may differ from the variations by DHB or ethnicity in this subgroup of women who have had a previous abnormality.  It is possible that in some cases eligible women were offered historical HPV testing, but did not consent to the test. It has not been possible to take this into account within the current report. While this affects Round 1 tests, this should be less of an issue for Round 2 tests, because in June 2015 the NCSP requested that laboratories prompt sample takers to add on an HPV test where this is indicated by the Guidelines, but was not requested by the sample taker. Additionally, for women who had already consented to the Round 1 HPV test, separate consent was not required for a Round 2 HPV test.  It is also possible that the reason some women underwent Round 1 tests, but not Round 2 tests, is because their concurrent cytology result indicated that other management (for example colposcopy referral) was required. This might be explored when this indicator is further refined to report on the test results in women who have undergone historical testing. |

Figure 106 - Proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by age at 30 June 2018



*No women aged less than 25 years at the end of the current monitoring period were eligible for historical testing on 1 October 2009.*

Figure 107 - Proportion of eligible women with squamous high -grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by DHB at 30 June 2018




Figure 108 - Proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom an historical test is recorded on the NCSP Register, by ethnicity at 30 June 2018


**

Figure 109 – Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by DHB




Figure 110 - Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by ethnicity



**

Figure 111 - Trends in the proportion of eligible women with squamous high-grade abnormality more than 3 years ago for whom a round 1 historical test is recorded on the NCSP Register, by age



*No women aged less than 25 years at the end of the current monitoring period were eligible for historical testing on 1 October 2009.*

Appendix A – Additional data

## Indicator 1 - Coverage

### Indicator 1.1 – Three-year coverage

Table 23 - Three-year coverage by DHB (women 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Hysterectomy adjusted population** | | **Women screened in the last 3 years** |
|  | **N** | **N** | **%** |
| Auckland | 154,408 | 104,423 | 67.6 |
| Bay of Plenty | 60,880 | 47,746 | 78.4 |
| Canterbury | 145,913 | 105,570 | 72.4 |
| Capital & Coast | 86,673 | 65,547 | 75.6 |
| Counties Manukau | 147,703 | 100,423 | 68.0 |
| Hawke's Bay | 42,409 | 30,979 | 73.0 |
| Hutt Valley | 40,248 | 29,551 | 73.4 |
| Lakes | 28,281 | 21,510 | 76.1 |
| Mid Central | 45,137 | 32,403 | 71.8 |
| Nelson Marlborough | 39,661 | 30,801 | 77.7 |
| Northland | 45,235 | 31,375 | 69.4 |
| South Canterbury | 15,284 | 11,474 | 75.1 |
| Southern | 83,960 | 63,217 | 75.3 |
| Tairawhiti | 12,378 | 9,122 | 73.7 |
| Taranaki | 30,966 | 24,404 | 78.8 |
| Waikato | 105,944 | 77,681 | 73.3 |
| Wairarapa | 11,725 | 8,340 | 71.1 |
| Waitemata | 169,982 | 119,038 | 70.0 |
| West Coast | 8,600 | 6,208 | 72.2 |
| Whanganui | 16,193 | 11,734 | 72.5 |
| **Total** | **1,291,580** | **931,546** | **72.1** |

*Excludes 1 women for whom DHB could not be determined*

Table 24 - Three-year coverage by ethnicity (women 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **Ethnicity** | **Hysterectomy adjusted population** | **Women screened in the last 3 years (ages 25-69 years)** | |
|  | **(ages 25-69 years)** | **N** | **%** |
| Māori | 171,061 | 105,631 | 61.8 |
| Pacific | 73,920 | 50,722 | 68.6 |
| Asian | 217,924 | 128,806 | 59.1 |
| European/ Other | 828,675 | 646,387 | 78.0 |
| **Total** | **1,291,580** | **931,546** | **72.1** |

Table 25 – Three-year coverage by age (women 20-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **Age** | **Hysterectomy adjusted population** | **Women screened in the last 3 years** | |
|  | **N** | **N** | **%** |
| 20-24 | 171,787 | 78,780 | 45.9 |
| 25-29 | 185,876 | 109,485 | 58.9 |
| 30-34 | 167,487 | 113,201 | 67.6 |
| 35-39 | 149,850 | 111,004 | 74.1 |
| 40-44 | 142,822 | 110,191 | 77.2 |
| 45-49 | 154,838 | 121,252 | 78.3 |
| 50-54 | 142,297 | 110,891 | 77.9 |
| 55-59 | 138,392 | 105,404 | 76.2 |
| 60-64 | 114,892 | 84,567 | 73.6 |
| 65-69 | 95,126 | 65,551 | 68.9 |
| **20-69** | **1,463,367** | **1,010,326** | **69.0** |

Table 26 – Three-year coverage (women aged 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and DHB

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Māori** | | **Pacific** | | **Asian** | | **European/ Other** | |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| Auckland | 5,664 | 52.3 | 9,565 | 67.8 | 29,050 | 52.3 | 60,144 | 81.4 |
| Bay of Plenty | 8,440 | 64.0 | 579 | 64.9 | 2,705 | 53.3 | 36,022 | 86.3 |
| Canterbury | 5,707 | 53.9 | 2,206 | 75.9 | 10,524 | 64.2 | 87,133 | 75.1 |
| Capital & Coast | 4,985 | 57.8 | 3,412 | 62.5 | 8,392 | 58.6 | 48,758 | 83.7 |
| Counties Manukau | 12,021 | 60.2 | 19,810 | 71.1 | 27,239 | 64.2 | 41,353 | 72.0 |
| Hawke's Bay | 6,731 | 71.5 | 878 | 73.9 | 1,418 | 58.0 | 21,952 | 74.8 |
| Hutt Valley | 3,741 | 64.5 | 1,791 | 65.3 | 3,724 | 70.4 | 20,295 | 76.9 |
| Lakes | 6,130 | 69.8 | 457 | 80.2 | 1,420 | 50.5 | 13,503 | 83.8 |
| Mid Central | 5,082 | 66.8 | 772 | 73.6 | 2,231 | 53.6 | 24,318 | 75.3 |
| Nelson Marlborough | 2,261 | 66.7 | 382 | 75.8 | 1,363 | 63.7 | 26,795 | 79.7 |
| Northland | 8,516 | 63.2 | 430 | 53.2 | 1,169 | 48.5 | 21,260 | 74.5 |
| South Canterbury | 581 | 54.4 | 110 | 91.7 | 465 | 69.1 | 10,318 | 76.9 |
| Southern | 3,869 | 56.5 | 959 | 73.1 | 3,109 | 45.6 | 55,280 | 80.1 |
| Tairawhiti | 4,005 | 69.3 | 164 | 64.6 | 238 | 58.8 | 4,715 | 79.4 |
| Taranaki | 3,231 | 67.6 | 214 | 72.5 | 1,035 | 64.5 | 19,924 | 82.0 |
| Waikato | 12,970 | 62.3 | 1,815 | 64.3 | 7,256 | 62.1 | 55,640 | 78.8 |
| Wairarapa | 1,141 | 67.9 | 144 | 82.8 | 230 | 52.6 | 6,825 | 72.4 |
| Waitemata | 7,402 | 54.3 | 6,766 | 64.8 | 26,626 | 63.3 | 78,244 | 75.3 |
| West Coast | 549 | 60.6 | 53 | 59.6 | 209 | 60.4 | 5,397 | 74.3 |
| Whanganui | 2,605 | 68.0 | 215 | 66.0 | 403 | 48.4 | 8,511 | 76.0 |
| **NZ Overall** |  | **61.8** |  | **68.6** |  | **59.1** |  | **78.0** |

*Ethnicity-specific estimates for some DHBs exceed 100%. This is potentially due in part to limitations in the hysterectomy prevalence estimators which are used to adjust the eligible population.*

Table 27 – Three-year coverage (women aged 25-69 years screened in the three years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and age

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Māori** | | **Pacific** | | **Asian** | | **European/ Other** | |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| 25-29 | 16,939 | 57.6 | 7,337 | 52.7 | 14,870 | 40.3 | 70,339 | 66.6 |
| 30-34 | 14,399 | 60.5 | 6,800 | 62.6 | 22,608 | 60.1 | 69,394 | 72.9 |
| 35-39 | 12,810 | 60.2 | 6,703 | 69.3 | 21,782 | 66.0 | 69,709 | 81.1 |
| 40-44 | 12,792 | 62.1 | 6,409 | 71.4 | 15,823 | 63.9 | 75,167 | 85.0 |
| 45-49 | 13,571 | 64.6 | 6,357 | 72.6 | 15,158 | 63.9 | 86,166 | 85.0 |
| 50-54 | 11,973 | 66.2 | 5,986 | 76.9 | 12,588 | 62.8 | 80,344 | 83.3 |
| 55-59 | 10,887 | 65.2 | 4,902 | 79.2 | 10,884 | 62.3 | 78,731 | 80.3 |
| 60-64 | 7,409 | 62.5 | 3,632 | 82.7 | 9,271 | 64.1 | 64,255 | 76.3 |
| 65-69 | 4,851 | 58.3 | 2,596 | 77.7 | 5,822 | 58.3 | 52,282 | 71.1 |
| **NZ Overall** |  | **61.8** |  | **68.6** |  | **59.1** |  | **78.0** |

Table 28 – Five-year coverage by DHB (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Hysterectomy adjusted population** | **Women screened in the last 5 years** | |
|  | **N** | **N** | **%** |
| Auckland | 154,408 | 125,581 | 81.3 |
| Bay of Plenty | 60,880 | 55,362 | 90.9 |
| Canterbury | 145,913 | 125,160 | 85.8 |
| Capital & Coast | 86,673 | 77,974 | 90.0 |
| Counties Manukau | 147,703 | 121,823 | 82.5 |
| Hawke's Bay | 42,409 | 37,243 | 87.8 |
| Hutt Valley | 40,248 | 35,437 | 88.0 |
| Lakes | 28,281 | 25,302 | 89.5 |
| Mid Central | 45,137 | 38,294 | 84.8 |
| Nelson Marlborough | 39,661 | 36,099 | 91.0 |
| Northland | 45,235 | 37,922 | 83.8 |
| South Canterbury | 15,284 | 13,362 | 87.4 |
| Southern | 83,960 | 74,802 | 89.1 |
| Tairawhiti | 12,378 | 10,865 | 87.8 |
| Taranaki | 30,966 | 28,205 | 91.1 |
| Waikato | 105,944 | 90,891 | 85.8 |
| Wairarapa | 11,725 | 10,013 | 85.4 |
| Waitemata | 169,982 | 142,596 | 83.9 |
| West Coast | 8,600 | 7,423 | 86.3 |
| Whanganui | 16,193 | 13,984 | 86.4 |
| **Total** | ***1,291,580*** | ***1,108,338*** | ***85.8*** |

*Excludes 3 women for whom DHB could not be determined*

Table 29 – Five-year coverage by ethnicity (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **Ethnicity** | **Hysterectomy adjusted population** | **Women screened in the last 5 years** | |
|  | **N** | **N** | **%** |
| Māori | 171,061 | 131,210 | 76.7 |
| Pacific | 73,920 | 64,596 | 87.4 |
| Asian | 217,924 | 151,551 | 69.5 |
| European/ Other | 828,675 | 760,981 | 91.8 |
| **Total** | **1,291,580** | **1,108,338** | **85.8** |

Table 30 - Five-year coverage by age (women 20-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted)

|  |  |  |  |
| --- | --- | --- | --- |
| **Age** | **Hysterectomy adjusted population** | **Women screened in the last 5 years** | |
|  |  | **N** | **%** |
| 20-24 | 171,787 | 83,863 | 48.8 |
| 25-29 | 185,876 | 133,435 | 71.8 |
| 30-34 | 167,487 | 136,000 | 81.2 |
| 35-39 | 149,850 | 132,633 | 88.5 |
| 40-44 | 142,822 | 130,979 | 91.7 |
| 45-49 | 154,838 | 143,947 | 93.0 |
| 50-54 | 142,297 | 131,610 | 92.5 |
| 55-59 | 138,392 | 123,694 | 89.4 |
| 60-64 | 114,892 | 98,931 | 86.1 |
| 65-69 | 95,126 | 77,109 | 81.1 |
| **20-69** | **1,463,367** | **1,192,201** | **81.5** |

Table 31 - Five-year coverage (women aged 25-69 years screened in the five years prior to 30 June 2018, hysterectomy adjusted), by ethnicity and DHB

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Māori** | | **Pacific** | | **Asian** | | **European/ Other** | |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |
| Auckland | 7,045 | 65.0 | 12,213 | 86.6 | 34,986 | 62.9 | 71,337 | 96.6 |
| Bay of Plenty | 10,461 | 79.3 | 690 | 77.4 | 3,086 | 60.8 | 41,125 | 98.6 |
| Canterbury | 7,037 | 66.5 | 2,777 | 95.5 | 12,180 | 74.3 | 103,166 | 88.9 |
| Capital & Coast | 6,191 | 71.7 | 4,389 | 80.5 | 9,856 | 68.8 | 57,538 | 98.8 |
| Counties Manukau | 15,156 | 75.9 | 25,475 | 91.4 | 31,952 | 75.3 | 49,240 | 85.7 |
| Hawke's Bay | 8,507 | 90.3 | 1,114 | 93.8 | 1,604 | 65.7 | 26,018 | 88.6 |
| Hutt Valley | 4,743 | 81.7 | 2,308 | 84.1 | 4,374 | 82.7 | 24,012 | 90.9 |
| Lakes | 7,501 | 85.4 | 548 | 96.1 | 1,635 | 58.1 | 15,618 | 96.9 |
| Mid Central | 6,206 | 81.6 | 944 | 90.0 | 2,535 | 60.8 | 28,609 | 88.5 |
| Nelson Marlborough | 2,764 | 81.5 | 453 | 89.9 | 1,548 | 72.3 | 31,334 | 93.2 |
| Northland | 10,809 | 80.2 | 527 | 65.2 | 1,367 | 56.7 | 25,219 | 88.4 |
| South Canterbury | 703 | 65.8 | 135 | 112.5 | 515 | 76.5 | 12,009 | 89.5 |
| Southern | 4,758 | 69.5 | 1,185 | 90.3 | 3,634 | 53.3 | 65,225 | 94.6 |
| Tairawhiti | 4,939 | 85.5 | 199 | 78.3 | 273 | 67.4 | 5,454 | 91.8 |
| Taranaki | 3,920 | 82.1 | 256 | 86.8 | 1,187 | 74.0 | 22,842 | 94.0 |
| Waikato | 15,804 | 75.9 | 2,233 | 79.1 | 8,259 | 70.7 | 64,595 | 91.5 |
| Wairarapa | 1,429 | 85.0 | 182 | 104.6 | 269 | 61.6 | 8,133 | 86.2 |
| Waitemata | 9,331 | 68.5 | 8,641 | 82.8 | 31,606 | 75.2 | 93,018 | 89.6 |
| West Coast | 683 | 75.4 | 62 | 69.7 | 231 | 66.8 | 6,447 | 88.8 |
| Whanganui | 3,223 | 84.1 | 265 | 81.3 | 454 | 54.6 | 10,042 | 89.6 |
| **NZ Overall** | **131,210** | **76.7** | **64,596** | **87.4** | **151,551** | **69.5** | **760,981** | **91.8** |

*Ethnicity-specific estimates for some DHBs exceed 100%. This is potentially due in part to limitations in the hysterectomy prevalence estimators which are used to adjust the eligible population.*

Table 32 - Women under 20 years of age, and aged 15-19 years, screened in the three years prior to 30 June 2018, by DHB.

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Number of women screened in last 3 years** | | **% of population aged 15-19 years screened** |
| **aged 10-20 years** | **aged 15-19 years** |
| Auckland | 457 | 457 | 2.9 |
| Bay of Plenty | 240 | 240 | 3.5 |
| Canterbury | 999 | 997 | 5.7 |
| Capital & Coast | 428 | 428 | 3.9 |
| Counties Manukau | 386 | 385 | 2.0 |
| Hawke's Bay | 171 | 171 | 3.3 |
| Hutt Valley | 128 | 127 | 2.8 |
| Lakes | 92 | 90 | 2.6 |
| Mid Central | 156 | 156 | 2.6 |
| Nelson Marlborough | 140 | 140 | 3.5 |
| Northland | 107 | 106 | 2.1 |
| South Canterbury | 69 | 69 | 4.4 |
| Southern | 487 | 487 | 4.1 |
| Tairawhiti | 30 | 30 | 1.9 |
| Taranaki | 146 | 146 | 4.3 |
| Waikato | 401 | 400 | 2.9 |
| Wairarapa | 46 | 46 | 3.7 |
| Waitemata | 722 | 720 | 3.9 |
| West Coast | 42 | 42 | 5.4 |
| Whanganui | 61 | 61 | 3.3 |
| *Unspecified* |  | - | - |
| **Total** | **5,308** | ***5,298*** | ***3.5*** |

Table 33 - Women screened under 20 years of age, as a proportion of all women screened in the three years to 30 June 2018, by DHB

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Women screened in last 3 years** | | **Proportion of women screened who were aged < 20 years (%)** |
| **aged < 20 years** | **all ages** |
| Auckland | 457 | 115,176 | 0.4 |
| Bay of Plenty | 240 | 52,913 | 0.5 |
| Canterbury | 999 | 118,803 | 0.8 |
| Capital & Coast | 428 | 74,539 | 0.6 |
| Counties Manukau | 386 | 110,843 | 0.3 |
| Hawke's Bay | 171 | 34,497 | 0.5 |
| Hutt Valley | 128 | 32,422 | 0.4 |
| Lakes | 92 | 23,688 | 0.4 |
| Mid Central | 156 | 36,544 | 0.4 |
| Nelson Marlborough | 140 | 33,884 | 0.4 |
| Northland | 107 | 34,649 | 0.3 |
| South Canterbury | 69 | 12,750 | 0.5 |
| Southern | 487 | 72,375 | 0.7 |
| Tairawhiti | 30 | 10,160 | 0.3 |
| Taranaki | 146 | 27,066 | 0.5 |
| Waikato | 401 | 87,445 | 0.5 |
| Wairarapa | 46 | 9,315 | 0.5 |
| Waitemata | 722 | 131,368 | 0.5 |
| West Coast | 42 | 6,861 | 0.6 |
| Whanganui | 61 | 13,080 | 0.5 |
| *Unspecified* | - | - | - |
| **Total** | **5,308** | **1,038,378** | **0.5** |

Table 34 - Women screened under 20 years of age, and women aged 18-19 years when they were screened, in the three years to 30 June 2018, by DHB

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Number of women screened in last 3 years** | | |
| **aged 10-19 years** | **aged 18-19 years** | **% aged 18-19 years** |
| Auckland | 457 | 429 | 93.9 |
| Bay of Plenty | 240 | 220 | 91.7 |
| Canterbury | 999 | 869 | 87.0 |
| Capital & Coast | 428 | 406 | 94.9 |
| Counties Manukau | 386 | 338 | 87.6 |
| Hawke's Bay | 171 | 150 | 87.7 |
| Hutt Valley | 128 | 113 | 88.3 |
| Lakes | 92 | 80 | 87.0 |
| Mid Central | 156 | 147 | 94.2 |
| Nelson Marlborough | 140 | 121 | 86.4 |
| Northland | 107 | 91 | 85.0 |
| South Canterbury | 69 | 59 | 85.5 |
| Southern | 487 | 438 | 89.9 |
| Tairawhiti | 30 | 25 | 83.3 |
| Taranaki | 146 | 133 | 91.1 |
| Waikato | 401 | 370 | 92.3 |
| Wairarapa | 46 | 41 | 89.1 |
| Waitemata | 722 | 628 | 87.0 |
| West Coast | 42 | 36 | 85.7 |
| Whanganui | 61 | 54 | 88.5 |
| *Unspecified* | *#N/A* | *#N/A* | *#N/A* |
| **Total** | ***5,308*** | ***4,748*** | ***89.4*** |

Table 35 – Estimated age-specific prevalence of hysterectomy in New Zealand, used to perform hysterectomy adjustment

|  |  |  |
| --- | --- | --- |
| **Age group** | **Estimated hysterectomy prevalence (%)** | |
| **Report 49** | **Report 48** |
| 20-24 | 0.016% | 0.344% |
| 25-29 | 0.171% | 0.913% |
| 30-34 | 0.781% | 1.789% |
| 35-39 | 2.406% | 3.503% |
| 40-44 | 5.447% | 6.561% |
| 45-49 | 8.494% | 10.030% |
| 50-54 | 12.135% | 13.283% |
| 55-59 | 14.428% | 17.529% |
| 60-64 | 18.282% | 23.689% |
| 65-69 | 21.916% | 29.103% |

*Based on estimates from Cleary and Wright*[*1*](#_ENREF_1) *(Report 49) and Gray[2](#_ENREF_2" \o "Gray, 2011 #9020) (Report 48)*

Table 36 - Women (25-69 years) screened in the three years to 30 June 2018, as a percentage of the i) hysterectomy-adjustment NZ female population and ii) total NZ female population, by DHB

|  |  |  |
| --- | --- | --- |
| **DHB** | **Women screened in the last 3 years** | |
|  | **(hysterectomy-adjusted)** | **(no hysterectomy adjustment)** |
| Auckland | 67.6 | 62.8 |
| Bay of Plenty | 78.4 | 70.9 |
| Canterbury | 72.4 | 65.9 |
| Capital & Coast | 75.6 | 69.5 |
| Counties Manukau | 68.0 | 62.6 |
| Hawke's Bay | 73.0 | 65.9 |
| Hutt Valley | 73.4 | 67.0 |
| Lakes | 76.1 | 69.1 |
| Mid Central | 71.8 | 65.1 |
| Nelson Marlborough | 77.7 | 69.7 |
| Northland | 69.4 | 62.4 |
| South Canterbury | 75.1 | 67.4 |
| Southern | 75.3 | 68.4 |
| Tairawhiti | 73.7 | 66.9 |
| Taranaki | 78.8 | 71.5 |
| Waikato | 73.3 | 66.8 |
| Wairarapa | 71.1 | 63.9 |
| Waitemata | 70.0 | 64.2 |
| West Coast | 72.2 | 65.0 |
| Whanganui | 72.5 | 65.4 |
| **Total** | ***72.1*** | ***65.8*** |

Table 37 - Trends in three-year coverage by DHB (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DHB** | **To 31 Dec 2016** | **T0 30 Jun 2017** | **To 31 Dec 2017** | **To 30 Jun 2018** |
| Auckland | 78.5% | 77.4% | 70.6% | 67.6% |
| Bay of Plenty | 81.3% | 81.1% | 80.3% | 78.4% |
| Canterbury | 74.6% | 74.5% | 73.7% | 72.4% |
| Capital & Coast | 80.1% | 79.3% | 78.3% | 75.6% |
| Counties Manukau | 74.0% | 73.2% | 71.8% | 68.0% |
| Hawke's Bay | 75.7% | 75.9% | 76.3% | 73.0% |
| Hutt Valley | 77.7% | 76.7% | 76.0% | 73.4% |
| Lakes | 78.5% | 78.1% | 77.0% | 76.1% |
| Mid Central | 75.1% | 74.9% | 73.9% | 71.8% |
| Nelson Marlborough | 79.9% | 80.0% | 80.4% | 77.7% |
| Northland | 73.0% | 73.0% | 71.8% | 69.4% |
| South Canterbury | 77.0% | 76.2% | 76.9% | 75.1% |
| Southern | 79.6% | 79.9% | 78.5% | 75.3% |
| Tairawhiti | 73.7% | 74.3% | 75.8% | 73.7% |
| Taranaki | 79.3% | 78.9% | 81.0% | 78.8% |
| Waikato | 76.2% | 76.5% | 75.6% | 73.3% |
| Wairarapa | 73.6% | 73.6% | 75.2% | 71.1% |
| Waitemata | 75.9% | 75.2% | 73.4% | 70.0% |
| West Coast | 72.3% | 71.1% | 75.3% | 72.2% |
| Whanganui | 75.8% | 74.8% | 75.1% | 72.5% |
| **Total** | **76.8%** | **76.4%** | **74.8%** | **72.1%** |

*Note:*

*Updated hysterectomy estimates and population projections were used to calculate coverage for 31 December 2017 and 30 June 2018 (2017 update 2013 Census and 2018 update 2013 Census, respectively). Original population projection estimates were used to calculate coverage for 30 June 2017 and prior.*

Table 38 - Trends in three-year coverage by age (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Age** | **To 31 Dec 2016** | **T0 30 Jun 2017** | **To 31 Dec 2017** | **To 30 Jun 2018** |
| 20-24 | 51.0% | 50.3% | 47.5% | 45.9% |
| 25-29 | 65.5% | 65.0% | 60.8% | 58.9% |
| 30-34 | 72.5% | 72.1% | 69.4% | 67.6% |
| 35-39 | 78.0% | 77.8% | 76.1% | 74.1% |
| 40-44 | 79.9% | 79.9% | 78.7% | 77.2% |
| 45-49 | 81.4% | 81.0% | 80.5% | 78.3% |
| 50-54 | 80.7% | 80.1% | 79.5% | 77.9% |
| 55-59 | 80.1% | 79.6% | 79.4% | 76.2% |
| 60-64 | 79.9% | 79.3% | 79.1% | 73.6% |
| 65-69 | 75.5% | 75.2% | 75.8% | 68.9% |
| **Total** | **73.7%** | **73.3%** | **71.6%** | **69.0%** |

*Note:*

*Updated hysterectomy estimates and population projections were used to calculate coverage for 31 December 2017 and 30 June 2018 (2017 update 2013 Census and 2018 update 2013 Census, respectively). Original population projection estimates were used to calculate coverage for 30 June 2017 and prior.*

Table 39 - Trends in three-year coverage by ethnicity (women screened in the previous three years, as a percentage of the hysterectomy-adjusted female population)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ethnicity** | **To 31 Dec 2016** | **T0 30 Jun 2017** | **To 31 Dec 2017** | **To 30 Jun 2018** |
| Māori | 64.1% | 64.0% | 62.0% | 61.8% |
| Pacific | 75.1% | 74.3% | 73.4% | 68.6% |
| Asian | 66.6% | 67.2% | 63.4% | 59.1% |
| European/ Other | 81.7% | 81.1% | 80.4% | 78.0% |
| **Total** | **76.8%** | **76.4%** | **74.8*%*** | ***72.1%*** |

*Note:*

*Updated hysterectomy estimates and population projections were used to calculate coverage for 31 December 2017 and 30 June 2018 (2017 update 2013 Census and 2018 update 2013 Census, respectively). Original population projection estimates were used to calculate coverage for 30 June 2017 and prior.*


## Indicator 2 – First screening events

Table 40 - Age distribution of first screening events for period 1 January – 30 June 2018

|  |  |  |
| --- | --- | --- |
| **Age** | **Women with first events** | **% of first events (ages 20-69 yrs) which occurred in that age group** |
|
| 20-24 | 10,546 | 44.1 |
| 25-29 | 4,695 | 19.6 |
| 30-34 | 3,407 | 14.2 |
| 35-39 | 1,977 | 8.3 |
| 40-44 | 1,093 | 4.6 |
| 45-49 | 755 | 3.2 |
| 50-54 | 462 | 1.9 |
| 55-59 | 373 | 1.6 |
| 60-64 | 381 | 1.6 |
| 65-69 | 222 | 0.9 |
| **20-69 yrs** | **23,911** | 100.0 |

*Percentage = number of first screens in age group divided by total number of first screens x 100*

Figure 112 - Proportion of population\* in that age group with their first screening event during the monitoring period (women aged 20-69 years at 30 June 2018)



*\*Hysterectomy adjusted, 2013 Census data projected to 30 June 2018.*

Table 41 - Women (aged 20-69 years) with first screening events as a proportion of i) total number of women with screening events, and ii) eligible women, by DHB, for period 1 January – 30 June 2018

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **DHB** | **Women with first events**  **N** | **As a proportion of women with a screening event** | | **As a proportion of eligible population** | |
| **N** | **%** | **N** | **%** |
| Auckland | 3,639 | 24,808 | 14.7 | 180,032 | 2.0 |
| Bay of Plenty | 971 | 11,377 | 8.5 | 67,109 | 1.4 |
| Canterbury | 2,850 | 25,615 | 11.1 | 165,750 | 1.7 |
| Capital & Coast | 1,983 | 15,537 | 12.8 | 101,161 | 2.0 |
| Counties Manukau | 2,913 | 22,352 | 13.0 | 168,799 | 1.7 |
| Hawke's Bay | 571 | 6,829 | 8.4 | 46,689 | 1.2 |
| Hutt Valley | 580 | 6,600 | 8.8 | 44,647 | 1.3 |
| Lakes | 514 | 5,342 | 9.6 | 31,581 | 1.6 |
| Mid Central | 732 | 8,041 | 9.1 | 52,016 | 1.4 |
| Nelson Marlborough | 533 | 6,910 | 7.7 | 42,801 | 1.2 |
| Northland | 561 | 6,991 | 8.0 | 49,755 | 1.1 |
| South Canterbury | 160 | 2,392 | 6.7 | 16,589 | 1.0 |
| Southern | 1,741 | 14,781 | 11.8 | 97,268 | 1.8 |
| Tairawhiti | 173 | 2,114 | 8.2 | 13,803 | 1.3 |
| Taranaki | 377 | 5,380 | 7.0 | 33,856 | 1.1 |
| Waikato | 1,918 | 18,209 | 10.5 | 120,391 | 1.6 |
| Wairarapa | 120 | 1,886 | 6.4 | 12,815 | 0.9 |
| Waitemata | 3,237 | 27,891 | 11.6 | 191,067 | 1.7 |
| West Coast | 91 | 1,243 | 7.3 | 9,310 | 1.0 |
| Whanganui | 247 | 2,837 | 8.7 | 17,928 | 1.4 |
| **Total** | **23,911** | **217,135** | **11.0** | **1,463,367** | **1.6** |

*Note: Proportions shown are women with first screening event within a DHB, divided by i) all women with a screening event within that DHB (first or subsequent events) and ii) the hysterectomy-adjusted 2013 Census population projected to 30 June 2018 for that DHB, as a percent. Total women screened and women with first events exclude those for whom DHB could not be ascertained.*

Table 42 - Women (ages 20-69 years) with first screening events as a proportion of i) total number of women with screening events, and ii) eligible women, by ethnicity, for period 1 January – 30 June 2018

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **Women with first events** | **As a proportion of women with a screening eventi** | | **As a proportion of eligible populationii** | |
| **N** | **%** | **N** | **%** |
| Māori | 2,593 | 26,195 | 9.9 | 204,537 | 1.3 |
| Pacific | 1,522 | 10,879 | 14.0 | 88,743 | 1.7 |
| Asian | 6,703 | 29,713 | 22.6 | 246,780 | 2.7 |
| European/ Other | 13,093 | 150,348 | 8.7 | 923,307 | 1.4 |
| **Total** | **23,911** | **217,135** | **11.0** | **1,463,367** | **1.6** |

*Note: Proportions shown are women with first screening event in an ethnicity group, divided by i) all women with a screening event within that ethnicity group (first or subsequent events) and ii) the hysterectomy-adjusted 2013 Census population projected to 30 June 2018 for that ethnicity group, as a percent.*

Table 43 - Median age of women with a first screening event, by ethnicity, for period 1 January – 30 June 2018

|  |  |  |
| --- | --- | --- |
| **Ethnic Group** | **Median Age** | **Mean Age** |
| Māori | 22 | *24.4* |
| Pacific | 25 | *28.8* |
| Asian | 31 | *33.3* |
| European/ Other | 24 | *27.9* |

## Indicator 3 – Withdrawal rates

Table 44 - Number of women who withdrew from the NCSP Register 1 January – 30 June 2018 by age, and proportion of women who were enrolled at the start of the monitoring period who withdrew

|  |  |  |  |
| --- | --- | --- | --- |
| **Age** | **Enrolled at start** | **Women withdrawn** | |
|  | **N** | **N** | **%** |
| <20 | 785 | - | 0 |
| 20-24 | 73,493 | 1 | 0.001 |
| 25-29 | 144,966 | 2 | 0.001 |
| 30-34 | 169,010 | 1 | 0.001 |
| 35-39 | 179,598 | 2 | 0.001 |
| 40-44 | 185,351 | 2 | 0.001 |
| 45-49 | 205,349 | 3 | 0.001 |
| 50-54 | 191,941 | 2 | 0.001 |
| 55-59 | 183,251 | 4 | 0.002 |
| 60-64 | 149,388 | 4 | 0.003 |
| 65-69 | 120,935 | 1 | 0.001 |
| 70+ | 277,942 | - | <0.001 |
| **Total (all ages)** | **1,882,009** | **22** | **0.001** |
| **Total (20-69)** | **1,603,282** | **22** | **0.001** |

*\* As a proportion of women enrolled at the start of the monitoring period*

Table 45 - Number of women (aged 20-69 years) who withdrew from the NCSP Register 1 January – 30 June 2018 by ethnicity, and proportion of women who were enrolled at the start of the monitoring period who withdrew

|  |  |  |  |
| --- | --- | --- | --- |
| **Ethnicity** | **Enrolled at start** | **Women withdrawn** | |
|  | **N** | **N** | **%** |
| Māori | 200,575 | 1 | 0.000 |
| Pacific | 102,093 | 1 | 0.001 |
| Asian | 198,132 | 2 | 0.001 |
| European/ Other | 1,102,482 | 18 | 0.002 |
| **Total** | **1,603,282** | **22** | **0.001** |

*\* As a proportion of women enrolled at the start of the monitoring period*

## Indicator 4 – Early re-screening

Table 46 - Early re-screening by five-year age group

|  |  |  |  |
| --- | --- | --- | --- |
| **Age** | **Women recommended to return in 3 years** | **Women with >1 subsequent test** | |
|  | **N** | **%** |
| 20-24 | 1,077 | 171 | 15.9 |
| 25-29 | 4,125 | 585 | 14.2 |
| 30-34 | 4,551 | 599 | 13.2 |
| 35-39 | 4,942 | 643 | 13.0 |
| 40-44 | 5,436 | 702 | 12.9 |
| 45-49 | 6,104 | 755 | 12.4 |
| 50-54 | 5,635 | 708 | 12.6 |
| 55-59 | 5,480 | 649 | 11.8 |
| 60-64 | 4,468 | 407 | 9.1 |
| 65-69 | 3,219 | 247 | 7.7 |
| **All ages** | **45,037** | **5,466** | **12.1** |

Table 47 - Early re-screening by DHB

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Women recommended to return in 3 years** | **Women with >1 subsequent test** | |
| **N** | **%** |
| Auckland | 4,875 | 684 | 14.0 |
| Bay of Plenty | 2,394 | 335 | 14.0 |
| Canterbury | 5,164 | 742 | 14.4 |
| Capital & Coast | 3,329 | 298 | 9.0 |
| Counties Manukau | 4,136 | 509 | 12.3 |
| Hawke's Bay | 1,723 | 181 | 10.5 |
| Hutt Valley | 1,512 | 116 | 7.7 |
| Lakes | 1,031 | 118 | 11.4 |
| Mid Central | 1,678 | 146 | 8.7 |
| Nelson Marlborough | 1,518 | 157 | 10.3 |
| Northland | 1,569 | 154 | 9.8 |
| South Canterbury | 615 | 69 | 11.2 |
| Southern | 3,179 | 381 | 12.0 |
| Tairawhiti | 433 | 36 | 8.3 |
| Taranaki | 1,214 | 147 | 12.1 |
| Waikato | 3,785 | 368 | 9.7 |
| Wairarapa | 420 | 70 | 16.7 |
| Waitemata | 5,499 | 891 | 16.2 |
| West Coast | 310 | 20 | 6.5 |
| Whanganui | 653 | 44 | 6.7 |
| *Unspecified* | - | - | 0.0 |
| **Total** | **45,037** | **5,466** | **12.1** |

Table 48 - Early re-screening by ethnicity

|  |  |  |  |
| --- | --- | --- | --- |
| **Ethnicity** | **Women recommended to return in 3 years** | **Women with >1 subsequent test** | |
| **N** | **%** |
| Māori | 5,008 | 572 | 11.4 |
| Pacific | 2,150 | 180 | 8.4 |
| Asian | 5,190 | 617 | 11.9 |
| European/ Other | 32,689 | 4,097 | 12.5 |
| **Total** | **45,037** | **5,466** | **12.1** |

## Indicator 5 – Laboratory indicators

### Indicator 5.1 – Laboratory cytology reporting

Table 49 - Age-standardised percentage of satisfactory smears reported as HSIL, by laboratory

|  |  |  |
| --- | --- | --- |
|  | **% satisfactory smears reported as HSIL** | |
| **Laboratory** | **Age-standardised rate\***  **(20-69 years)** | **Crude rate** |
| Anatomical Pathology Services | 0.52% | 0.57% |
| Canterbury Health Laboratories | 0.88% | 1.00% |
| LabPLUS | 2.14% | 2.32% |
| Medlab Central Ltd. | 0.99% | 1.05% |
| Pathlab | 0.43% | 0.46% |
| Southern Community Laboratories | 0.78% | 0.83% |
| **Total** | **0.75%** | **0.81%** |

*\* Age-standardised to the NZ 2013 Census population (females, ages 20-69 years)*

### Indicator 5.2 – Accuracy of cytology predicting HSIL

Table 50 - Positive predictive value of a report of HSIL + SC cytology, excluding samples from colposcopy, by laboratory

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | | **No histology** | | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | | **%** | **N** | |
| Anatomical Pathology Services | 137 | 93.2 | 106 | 77.4 | 10 | | 6.8 | 147 | |
| Canterbury Health Laboratories | 29 | 93.5 | 24 | 82.8 | 2 | | 6.5 | 31 | |
| LabPLUS | 27 | 84.4 | 21 | 77.8 | 5 | | 15.6 | 32 | |
| Medlab Central Ltd | 99 | 93.4 | 85 | 85.9 | 7 | | 6.6 | 106 | |
| Pathlab | 82 | 94.3 | 67 | 81.7 | 5 | | 5.7 | 87 | |
| Southern Community Labs Dunedin | 498 | 93.6 | 396 | 79.5 | 34 | | 6.4 | 532 | |
| **Total** | **872** | **93.3** | **699** | **80.2** | **63** | | **6.7** | **935** | |

*Target: 65% - 85%*

Table – Comparison of PPV based on original method vs updated method excluding samples from colposcopy, by cytology category and laboratory

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HSIL+SC** | | | | **ASC-H** | | | | **HSIL + SC + ASC-H** | | | |
|  | ***Original method*** | | **Updated (ex colp)** | | ***Original method*** | | **Updated (ex colp)** | | ***Original Method*** | | **Updated (ex colp)** | |
| **Lab** | ***PPV (%)*** | ***Based on (N)\**** | **PPV** | **Based on (N)\*** | ***PPV*** | ***Based on (N)\**** | **PPV** | **Based on (N)\*** | ***PPV*** | ***Based on (N)\**** | **PPV** | **Based on (N)\*** |
| Anatomical Pathology Services | *77.4* | *155* | 77.4 | 137 | *50.0* | *136* | 54.7 | 139 | *64.6* | *291* | 65.9 | 276 |
| Canterbury Health Laboratories | *87.7* | *65* | 82.8 | 29 | *63.2* | *106* | 62.7 | 59 | *72.5* | *171* | 69.3 | 88 |
| LabPLUS | *85.7* | *147* | 77.8 | 27 | *44.0* | *150* | 53.2 | 47 | *64.6* | *297* | 62.2 | 74 |
| Medlab Central Ltd | *86.9* | *130* | 85.9 | 99 | *56.6* | *83* | 54.7 | 75 | *75.1* | *213* | 72.4 | 174 |
| Pathlab | *82.5* | *114* | 81.7 | 82 | *42.1* | *95* | 53.3 | 92 | *64.1* | *209* | 66.7 | 174 |
| Southern Community Labs | *81.2* | *693* | 79.5 | 498 | *52.3* | *155* | 55.6 | 144 | *75.9* | *848* | 74.1 | 642 |
| **Total** | ***82.3*** | ***1,304*** | **80.2** | **872** | ***50.9*** | ***725*** | **55.4** | **556** | ***71.1*** | ***2,029*** | **70.5** | **1,428** |

\* Number of women with histology within 6 months of cytology sample

Table 52 - Positive predictive value of a report of HSIL + SC cytology (original method), by laboratory

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | | **No histology** | | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | | **%** | **N** | |
| Anatomical Pathology Services | 155 | 93.9 | 120 | 77.4 | 10 | | 6.1 | 165 | |
| Canterbury Health Laboratories | 65 | 92.9 | 57 | 87.7 | 5 | | 7.1 | 70 | |
| LabPLUS | 147 | 90.2 | 126 | 85.7 | 16 | | 9.8 | 163 | |
| Medlab Central Ltd. | 130 | 92.9 | 113 | 86.9 | 10 | | 7.1 | 140 | |
| Pathlab | 114 | 95.0 | 94 | 82.5 | 6 | | 5.0 | 120 | |
| Southern Community Laboratories | 693 | 92.9 | 563 | 81.2 | 53 | | 7.1 | 746 | |
| **Total** | **1,304** | **92.9** | **1,073** | **82.3** | **100** | | **7.1** | **1,404** | |

*Target: 65% - 85%*

Table 53 - Positive predictive value of a report of ASC-H cytology, excluding samples from colposcopy, by laboratory

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | **No histology** | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | **%** | **N** |
| Anatomical Pathology Services | 139 | 84.2 | 76 | 54.7 | 26 | 15.8 | 165 |
| Canterbury Health Laboratories | 59 | 90.8 | 37 | 62.7 | 6 | 9.2 | 65 |
| LabPLUS | 47 | 78.3 | 25 | 53.2 | 13 | 21.7 | 60 |
| Medlab Central Ltd | 75 | 82.4 | 41 | 54.7 | 16 | 17.6 | 91 |
| Pathlab | 92 | 77.3 | 49 | 53.3 | 27 | 22.7 | 119 |
| Southern Community Labs Dunedin | 144 | 86.2 | 80 | 55.6 | 23 | 13.8 | 167 |
| **Total** | **556** | **83.4** | **308** | **55.4** | **111** | **16.6** | **667** |

Table 54 - Positive predictive value of a report of ASC-H cytology (original method), by laboratory

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | **No histology** | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | **%** | **N** |
| Anatomical Pathology Services | 136 | 84.0 | 68 | 50.0 | 26 | 16.0 | 162 |
| Canterbury Health Laboratories | 106 | 86.9 | 67 | 63.2 | 16 | 13.1 | 122 |
| LabPLUS | 150 | 72.8 | 66 | 44.0 | 56 | 27.2 | 206 |
| Medlab Central Ltd. | 83 | 80.6 | 47 | 56.6 | 20 | 19.4 | 103 |
| Pathlab | 95 | 77.9 | 40 | 42.1 | 27 | 22.1 | 122 |
| Southern Community Laboratories | 155 | 82.4 | 81 | 52.3 | 33 | 17.6 | 188 |
| **Total** | **725** | **80.3** | **369** | **50.9** | **178** | **19.7** | **903** |

Table 55 - Positive predictive value of a report of ASC-H + HSIL + SC cytology, excluding samples from colposcopy, by laboratory

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | **No histology** | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | **%** | **N** |
| Anatomical Pathology Services | 276 | 88.5 | 182 | 65.9 | 36 | 11.5 | 312 |
| Canterbury Health Laboratories | 88 | 91.7 | 61 | 69.3 | 8 | 8.3 | 96 |
| LabPLUS | 74 | 80.4 | 46 | 62.2 | 18 | 19.6 | 92 |
| Medlab Central Ltd | 174 | 88.3 | 126 | 72.4 | 23 | 11.7 | 197 |
| Pathlab | 174 | 84.5 | 116 | 66.7 | 32 | 15.5 | 206 |
| Southern Community Labs Dunedin | 642 | 91.8 | 476 | 74.1 | 57 | 8.2 | 699 |
| **Total** | **1,428** | **89.1** | **1,007** | **70.5** | **174** | **10.9** | **1,602** |

Table 56 - Positive predictive value of a report of ASC-H + HSIL + SC cytology (original method), by laboratory

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Histology available** | | **HSIL confirmed by histology** | | **No histology** | | **Total reports** |
|  | **N** | **%** | **N** | **%** | **N** | **%** | **N** |
| Anatomical Pathology Services | 291 | 89.0 | 188 | 64.6 | 36 | 11.0 | 327 |
| Canterbury Health Laboratories | 171 | 89.1 | 124 | 72.5 | 21 | 10.9 | 192 |
| LabPLUS | 297 | 80.5 | 192 | 64.6 | 72 | 19.5 | 369 |
| Medlab Central Ltd. | 213 | 87.7 | 160 | 75.1 | 30 | 12.3 | 243 |
| Pathlab | 209 | 86.4 | 134 | 64.1 | 33 | 13.6 | 242 |
| Southern Community Laboratories | 848 | 90.8 | 644 | 75.9 | 86 | 9.2 | 934 |
| **Total** | **2,029** | **87.9** | **1,442** | **71.1** | **278** | **12.1** | **2,307** |

Table – Change in categorisation of women with high grade cytology results between the original and updated method excluding samples from colposcopy

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **Original method** | | | |  |
|  |  | **ASC-H** | | **HSIL + SC** | | **Total** |
|  |  | **<CIN2** | **CIN2+** | **<CIN2** | **CIN2+** |
| **Updated method** | **ASC-H** | 242 | 243 | 5 | 66 | **556** |
| **HSIL + SC** | 0 | 0 | 173 | 699 | **872** |
| **Excluded\*** | 114 | 126 | 53 | 308 | **601** |
|  | **Total** | **356** | **369** | **231** | **1,073** | **2,029** |

\* cytology samples were excluded if they collected at the same facility and on the same date as either a colposcopy visit or a histology sample for the same woman (presumed to have been collected at a colposcopy visit)

### Indicator 5.4 – Histology Reporting

Figure 113 - Trends in histologically-confirmed HSIL as a percentage of all women with histology (to 1 January – 30 June 2018)




Figure 114 - Rate of women with CIN 2/3 per 1,000 women screened, by age, 1 January 2008 – 30 June 2018




Table 58 - Rate of women with CIN 2/3 per 1,000 women screened, by age and ethnicity and for NZ overall, 1 January – 30 June 2018

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Ethnicity** | | | |  |
| **DHB** | **Māori** | **Pacific** | **Asian** | **European/ Other** | **NZ overall** |
| <20 | 10.8 | 0.0 | 0.0 | 4.7 | 5.5 |
| 20-24 | 14.1 | 7.0 | 7.5 | 15.2 | 14.0 |
| 25-29 | 22.7 | 11.2 | 5.2 | 21.8 | 18.7 |
| 30-34 | 22.9 | 14.1 | 7.9 | 20.1 | 17.6 |
| 35-39 | 12.6 | 11.5 | 9.5 | 10.9 | 10.9 |
| 40-44 | 9.1 | 4.1 | 7.2 | 7.3 | 7.3 |
| 45-49 | 7.0 | 5.8 | 4.2 | 5.2 | 5.3 |
| 50-54 | 4.1 | 3.7 | 4.0 | 2.9 | 3.2 |
| 55-59 | 6.1 | 6.7 | 4.2 | 2.4 | 3.2 |
| 60-64 | 2.0 | 6.2 | 2.2 | 2.2 | 2.4 |
| 65-69 | 1.1 | 2.2 | 4.8 | 2.4 | 2.5 |
| 70+ | 14.6 | 14.9 | 7.4 | 6.2 | 6.8 |
| **ASR (20-69 years)^** | **12.0** | **7.9** | **6.1** | **10.8** | **10.0** |

*^Age Standardised to the WHO population (ages 20-69 years)*

Table 59 - Rate of women, per 1,000 women screened, with CIN 2/3 histology, by age and ethnicity, July-Dec 2008 to Jan-Jun 2018

| **Ethnicity name** | **Age Group** | **Period** | | | | | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Jul-Dec 2008** | **Jan-Jun 2009** | **Jul-Dec 2009** | **Jan-Jun 2010** | **Jul-Dec 2010** | **Jan-Jun 2011** | **Jul-Dec 2011** | **Jan-Jun 2012** | **Jul-Dec 2012** | **Jan-Jun 2013** | **Jul-Dec 2013** | **Jan-Jun 2014** | **Jul-Dec 2014** | **Jan-Jun 2015** | **Jul-Dec 2015** | **Jan-Jun 2016** | **Jul-Dec 2016** | **Jan-Jun 2017** | **Jul-Dec 2017** | **Jan-Jun 2018** |
| Māori | <20 | 18.9 | 21.5 | 23.0 | 8.6 | 19.5 | 14.4 | 24.1 | 16.8 | 12.2 | 0.0 | 0.0 | 0.0 | 14.6 | 7.2 | 15.7 | 7.6 | 0.0 | 20.8 | 14.5 | 10.8 |
| Māori | 20-24 | 25.7 | 29.0 | 30.7 | 25.5 | 27.7 | 23.4 | 30.7 | 31.5 | 29.3 | 27.5 | 30.7 | 24.6 | 23.4 | 19.7 | 20.3 | 20.1 | 18.8 | 19.5 | 16.7 | 14.1 |
| Māori | 25-29 | 30.4 | 33.4 | 32.3 | 28.9 | 28.1 | 30.1 | 34.9 | 33.7 | 41.2 | 39.3 | 38.3 | 37.0 | 40.0 | 32.1 | 33.5 | 27.4 | 33.6 | 25.0 | 29.1 | 22.7 |
| Māori | 30-34 | 26.8 | 20.8 | 19.3 | 24.6 | 31.4 | 26.9 | 22.0 | 27.3 | 33.4 | 29.3 | 30.3 | 28.7 | 24.7 | 30.9 | 30.0 | 23.5 | 30.1 | 22.3 | 26.8 | 22.9 |
| Māori | 35-39 | 13.7 | 16.1 | 16.0 | 19.7 | 17.4 | 14.9 | 17.4 | 16.9 | 13.7 | 18.2 | 20.2 | 17.1 | 16.8 | 17.3 | 21.7 | 18.2 | 18.1 | 19.2 | 19.3 | 12.6 |
| Māori | 40-44 | 10.5 | 9.5 | 9.0 | 10.6 | 10.1 | 12.6 | 11.3 | 10.9 | 9.5 | 10.2 | 13.0 | 9.9 | 13.8 | 12.5 | 10.9 | 14.4 | 14.9 | 14.4 | 8.9 | 9.1 |
| Māori | 45-49 | 6.6 | 11.6 | 9.2 | 4.7 | 7.9 | 6.2 | 6.7 | 6.4 | 6.0 | 8.7 | 7.4 | 7.2 | 9.5 | 8.8 | 10.1 | 5.5 | 7.0 | 5.9 | 7.3 | 7.0 |
| Māori | 50-54 | 7.7 | 6.5 | 2.4 | 4.5 | 5.1 | 4.6 | 2.2 | 8.1 | 8.6 | 6.0 | 3.9 | 5.1 | 8.1 | 8.0 | 5.4 | 5.0 | 8.4 | 4.0 | 4.4 | 4.1 |
| Māori | 55-59 | 4.4 | 3.3 | 5.3 | 0.7 | 4.1 | 2.6 | 8.5 | 4.5 | 3.8 | 2.5 | 1.9 | 3.5 | 2.9 | 3.3 | 2.0 | 4.2 | 3.9 | 4.3 | 4.9 | 6.1 |
| Māori | 60-64 | 5.8 | 4.9 | 2.2 | 4.6 | 2.8 | 2.0 | 4.0 | 3.9 | 2.8 | 3.7 | 2.7 | 5.2 | 9.3 | 7.1 | 3.9 | 5.4 | 4.6 | 2.4 | 3.0 | 2.0 |
| Māori | 65-69 | 6.0 | 1.9 | 3.8 | 5.6 | 1.7 | 1.7 | 3.4 | 0.0 | 6.4 | 6.4 | 1.6 | 1.4 | 1.4 | 3.8 | 3.8 | 3.8 | 11.0 | 1.2 | 1.2 | 1.1 |
| Māori | 70+ | 8.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.0 | 7.5 | 7.5 | 8.6 | 17.7 | 13.3 | 0.0 | 0.0 | 7.9 | 9.0 | 0.0 | 0.0 | 7.8 | 14.6 |
| Pacific | <20 | 11.0 | 11.6 | 7.2 | 0.0 | 0.0 | 0.0 | 0.0 | 10.6 | 0.0 | 0.0 | 27.8 | 21.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 52.6 | 0.0 | 0.0 |
| Pacific | 20-24 | 10.9 | 11.2 | 12.9 | 13.7 | 15.1 | 12.3 | 10.2 | 15.0 | 16.9 | 14.1 | 14.0 | 7.5 | 9.9 | 8.9 | 12.7 | 6.8 | 9.6 | 5.7 | 5.0 | 7.0 |
| Pacific | 25-29 | 12.5 | 6.2 | 7.5 | 8.8 | 16.2 | 16.0 | 14.3 | 13.6 | 15.1 | 13.2 | 14.7 | 16.3 | 22.9 | 17.6 | 12.3 | 14.3 | 15.0 | 16.3 | 14.7 | 11.2 |
| Pacific | 30-34 | 10.5 | 9.3 | 11.4 | 11.9 | 10.5 | 10.7 | 6.2 | 18.4 | 18.7 | 11.8 | 13.0 | 13.7 | 16.5 | 16.0 | 14.4 | 13.1 | 20.4 | 17.1 | 14.8 | 14.1 |
| Pacific | 35-39 | 3.4 | 8.8 | 6.6 | 7.2 | 9.5 | 7.1 | 8.1 | 10.4 | 14.2 | 12.8 | 11.7 | 10.0 | 13.3 | 8.0 | 8.5 | 6.6 | 9.8 | 6.3 | 12.4 | 11.5 |
| Pacific | 40-44 | 8.2 | 4.6 | 3.0 | 4.2 | 4.8 | 5.3 | 8.3 | 7.4 | 10.2 | 8.1 | 7.4 | 6.2 | 9.3 | 4.5 | 3.5 | 8.5 | 11.3 | 7.6 | 6.4 | 4.1 |
| Pacific | 45-49 | 7.5 | 7.8 | 4.1 | 3.3 | 4.7 | 4.2 | 4.8 | 7.4 | 8.1 | 5.7 | 3.7 | 4.6 | 4.7 | 5.1 | 5.2 | 5.8 | 6.8 | 3.3 | 3.4 | 5.8 |
| Pacific | 50-54 | 4.4 | 1.2 | 2.4 | 1.1 | 6.1 | 3.2 | 2.0 | 5.7 | 8.2 | 6.1 | 2.7 | 3.9 | 1.8 | 5.2 | 3.4 | 5.0 | 2.7 | 2.5 | 4.9 | 3.7 |
| Pacific | 55-59 | 2.8 | 1.6 | 4.3 | 1.4 | 2.7 | 1.4 | 1.5 | 2.7 | 2.8 | 6.5 | 3.9 | 4.0 | 3.3 | 2.1 | 1.2 | 1.1 | 2.3 | 4.7 | 5.5 | 6.7 |
| Pacific | 60-64 | 2.4 | 2.3 | 4.1 | 2.1 | 5.7 | 8.3 | 3.8 | 5.2 | 3.6 | 1.7 | 1.6 | 0.0 | 3.3 | 1.5 | 1.5 | 2.8 | 3.0 | 3.1 | 4.5 | 6.2 |
| Pacific | 65-69 | 3.6 | 0.0 | 0.0 | 0.0 | 0.0 | 3.2 | 3.1 | 2.8 | 0.0 | 2.7 | 5.0 | 2.4 | 2.5 | 2.3 | 0.0 | 2.2 | 7.0 | 7.1 | 4.7 | 2.2 |
| Pacific | 70+ | 0.0 | 15.9 | 15.6 | 15.6 | 13.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17.5 | 0.0 | 0.0 | 15.2 | 0.0 | 0.0 | 12.7 | 15.4 | 14.1 | 14.9 |
| Asian | <20 | 0.0 | 13.5 | 19.2 | 0.0 | 19.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 62.5 | 0.0 | 0.0 | 0.0 |
| Asian | 20-24 | 8.4 | 4.9 | 8.2 | 5.7 | 6.8 | 7.9 | 6.6 | 9.2 | 14.3 | 10.8 | 9.7 | 9.1 | 11.6 | 4.8 | 10.1 | 14.0 | 10.8 | 11.6 | 7.1 | 7.5 |
| Asian | 25-29 | 8.1 | 9.0 | 6.6 | 6.0 | 7.1 | 9.2 | 10.7 | 8.1 | 12.9 | 9.8 | 8.1 | 8.7 | 11.4 | 7.9 | 13.9 | 11.9 | 10.6 | 4.4 | 6.9 | 5.2 |
| Asian | 30-34 | 7.3 | 6.5 | 6.7 | 9.0 | 7.9 | 9.5 | 14.5 | 9.4 | 11.3 | 9.8 | 10.0 | 9.1 | 7.4 | 9.2 | 11.0 | 12.6 | 11.0 | 9.1 | 9.9 | 7.9 |
| Asian | 35-39 | 8.0 | 8.8 | 6.7 | 7.5 | 10.6 | 10.1 | 11.3 | 7.7 | 12.9 | 7.8 | 10.4 | 10.0 | 8.0 | 8.9 | 6.9 | 7.8 | 9.9 | 7.4 | 6.8 | 9.5 |
| Asian | 40-44 | 7.1 | 5.3 | 4.2 | 8.5 | 8.8 | 5.4 | 5.8 | 8.7 | 11.4 | 8.7 | 9.6 | 4.9 | 9.9 | 5.3 | 7.9 | 9.7 | 8.5 | 6.0 | 4.6 | 7.2 |
| Asian | 45-49 | 4.3 | 3.9 | 4.8 | 3.5 | 6.2 | 4.4 | 5.6 | 2.2 | 9.6 | 6.0 | 4.6 | 6.5 | 6.1 | 4.4 | 6.4 | 5.6 | 4.7 | 4.0 | 4.2 | 4.2 |
| Asian | 50-54 | 3.3 | 1.2 | 3.6 | 3.2 | 2.5 | 3.5 | 1.9 | 3.8 | 5.0 | 4.0 | 5.9 | 3.0 | 3.6 | 4.3 | 6.4 | 4.8 | 5.7 | 4.8 | 4.5 | 4.0 |
| Asian | 55-59 | 0.0 | 3.6 | 2.4 | 4.0 | 1.5 | 6.4 | 6.4 | 3.8 | 4.2 | 2.3 | 3.2 | 3.4 | 3.9 | 3.3 | 1.0 | 2.0 | 4.2 | 1.9 | 3.2 | 4.2 |
| Asian | 60-64 | 8.8 | 4.4 | 1.2 | 1.2 | 2.2 | 5.5 | 4.1 | 5.2 | 2.8 | 4.3 | 3.1 | 3.1 | 4.2 | 2.6 | 1.3 | 5.8 | 2.8 | 4.1 | 3.8 | 2.2 |
| Asian | 65-69 | 5.1 | 0.0 | 2.3 | 2.2 | 8.4 | 0.0 | 3.8 | 3.9 | 0.0 | 1.6 | 0.0 | 3.0 | 1.3 | 0.0 | 3.7 | 3.1 | 6.3 | 6.0 | 1.9 | 4.8 |
| Asian | 70+ | 12.5 | 0.0 | 10.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.8 | 9.5 | 28.6 | 0.0 | 0.0 | 9.4 | 8.4 | 0.0 | 0.0 | 0.0 | 0.0 | 7.4 |
| European/ Other | <20 | 23.0 | 18.6 | 22.9 | 7.9 | 11.5 | 11.7 | 19.7 | 20.5 | 17.5 | 21.7 | 16.5 | 11.8 | 6.8 | 8.7 | 22.9 | 6.8 | 7.7 | 16.8 | 15.3 | 4.7 |
| European/ Other | 20-24 | 27.5 | 28.3 | 26.5 | 24.6 | 25.8 | 28.4 | 27.7 | 31.3 | 28.5 | 26.6 | 24.1 | 23.4 | 22.3 | 20.5 | 21.6 | 20.3 | 21.1 | 18.6 | 17.7 | 15.2 |
| European/ Other | 25-29 | 27.2 | 27.3 | 25.3 | 25.1 | 27.0 | 27.3 | 30.0 | 29.3 | 30.6 | 30.8 | 33.0 | 30.1 | 30.2 | 27.9 | 31.0 | 30.5 | 29.0 | 24.4 | 23.8 | 21.8 |
| European/ Other | 30-34 | 16.1 | 16.4 | 17.8 | 16.4 | 20.2 | 19.5 | 17.6 | 18.2 | 22.8 | 22.5 | 21.0 | 21.5 | 21.6 | 19.6 | 22.4 | 21.7 | 22.2 | 20.5 | 18.9 | 20.1 |
| European/ Other | 35-39 | 10.5 | 10.6 | 9.9 | 10.1 | 11.9 | 10.9 | 12.1 | 11.6 | 14.2 | 10.7 | 13.0 | 12.9 | 13.4 | 11.4 | 12.3 | 13.3 | 13.6 | 11.6 | 14.8 | 10.9 |
| European/ Other | 40-44 | 6.5 | 5.8 | 5.9 | 6.5 | 7.2 | 7.4 | 6.9 | 7.9 | 8.6 | 9.3 | 8.6 | 8.4 | 8.8 | 7.4 | 7.3 | 8.6 | 7.7 | 7.1 | 7.3 | 7.3 |
| European/ Other | 45-49 | 5.1 | 3.7 | 3.9 | 4.6 | 4.6 | 3.4 | 4.5 | 4.6 | 5.5 | 5.3 | 5.8 | 5.3 | 6.0 | 4.5 | 5.1 | 5.6 | 6.1 | 4.1 | 4.4 | 5.2 |
| European/ Other | 50-54 | 2.6 | 2.5 | 2.4 | 2.7 | 3.2 | 2.2 | 2.9 | 2.7 | 2.8 | 3.6 | 3.2 | 3.1 | 3.6 | 2.4 | 3.1 | 3.4 | 4.2 | 3.2 | 3.6 | 2.9 |
| European/ Other | 55-59 | 2.0 | 1.2 | 1.3 | 1.9 | 1.9 | 1.6 | 1.9 | 2.2 | 2.0 | 2.1 | 1.9 | 2.1 | 2.6 | 1.9 | 2.9 | 3.3 | 2.8 | 2.7 | 2.2 | 2.4 |
| European/ Other | 60-64 | 2.0 | 2.2 | 1.7 | 0.7 | 1.5 | 1.2 | 1.7 | 1.7 | 2.2 | 2.0 | 1.4 | 1.7 | 2.7 | 2.7 | 2.5 | 1.4 | 2.3 | 2.6 | 2.8 | 2.2 |
| European/ Other | 65-69 | 1.4 | 1.8 | 1.3 | 0.9 | 2.2 | 1.6 | 1.1 | 1.2 | 1.5 | 1.6 | 1.7 | 1.8 | 1.7 | 1.8 | 1.9 | 1.8 | 2.4 | 2.6 | 2.2 | 2.4 |
| European/ Other | 70+ | 2.1 | 4.9 | 2.4 | 2.6 | 5.0 | 3.8 | 2.0 | 3.0 | 1.7 | 7.9 | 5.1 | 1.8 | 3.6 | 1.8 | 4.5 | 7.6 | 2.6 | 4.3 | 5.5 | 6.2 |

Table 60 - Number of women screened, by age and ethnicity, July-Dec 2008 to Jan-Jun 2018

| Ethnicity | Age Group | Period | | | | | | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Jul-Dec 2008 | Jan-Jun 2009 | Jul-Dec 2009 | Jan-Jun 2010 | Jul-Dec 2010 | Jan-Jun 2011 | Jul-Dec 2011 | Jan-Jun 2012 | Jul-Dec 2012 | Jan-Jun 2013 | Jul-Dec 2013 | Jan-Jun 2014 | Jul-Dec 2014 | Jan-Jun 2015 | Jul-Dec 2015 | Jan-Jun 2016 | Jul-Dec 2016 | Jan-Jun 2017 | Jul-Dec 2017 | Jan-Jun 2018 |
| Māori | <20 | 635 | 606 | 434 | 464 | 359 | 348 | 290 | 297 | 246 | 204 | 150 | 150 | 137 | 139 | 127 | 131 | 97 | 96 | 69 | 93 |
| Māori | 20-24 | 4049 | 4306 | 4395 | 4548 | 4649 | 4743 | 4663 | 4478 | 4668 | 4501 | 4494 | 4393 | 4230 | 4371 | 4476 | 4321 | 3878 | 3900 | 3768 | 3961 |
| Māori | 25-29 | 3096 | 3354 | 3064 | 3288 | 3304 | 3460 | 3212 | 3265 | 3204 | 3256 | 3397 | 3355 | 3354 | 3485 | 3707 | 3720 | 3361 | 3446 | 3398 | 3699 |
| Māori | 30-34 | 3027 | 3220 | 2961 | 3050 | 3121 | 3120 | 3001 | 3002 | 2937 | 2726 | 2772 | 2783 | 2712 | 2909 | 2864 | 2982 | 2628 | 2645 | 2837 | 3192 |
| Māori | 35-39 | 3206 | 3113 | 3059 | 3144 | 3267 | 3148 | 3049 | 2836 | 2851 | 2697 | 2669 | 2689 | 2621 | 2713 | 2814 | 2694 | 2484 | 2494 | 2493 | 2767 |
| Māori | 40-44 | 2939 | 2828 | 2885 | 2838 | 2979 | 3098 | 3017 | 2946 | 3057 | 2846 | 2842 | 2727 | 2904 | 2880 | 2940 | 2704 | 2558 | 2570 | 2478 | 2746 |
| Māori | 45-49 | 2716 | 2665 | 2729 | 2765 | 2798 | 2764 | 2687 | 2656 | 2665 | 2521 | 2562 | 2629 | 2622 | 2734 | 2778 | 2717 | 2577 | 2526 | 2603 | 2857 |
| Māori | 50-54 | 1945 | 1844 | 2082 | 2015 | 2166 | 2193 | 2262 | 2214 | 2338 | 2315 | 2289 | 2368 | 2470 | 2378 | 2572 | 2403 | 2275 | 2253 | 2288 | 2431 |
| Māori | 55-59 | 1370 | 1213 | 1319 | 1389 | 1462 | 1513 | 1527 | 1548 | 1600 | 1573 | 1621 | 1711 | 1695 | 1844 | 1980 | 1902 | 1809 | 1856 | 2022 | 2148 |
| Māori | 60-64 | 856 | 818 | 902 | 874 | 1060 | 985 | 1010 | 1013 | 1088 | 1076 | 1097 | 1146 | 1188 | 1271 | 1289 | 1300 | 1314 | 1269 | 1327 | 1474 |
| Māori | 65-69 | 496 | 514 | 521 | 533 | 599 | 593 | 582 | 642 | 621 | 629 | 630 | 694 | 725 | 785 | 789 | 788 | 817 | 842 | 851 | 920 |
| Māori | 70+ | 118 | 118 | 117 | 129 | 135 | 117 | 125 | 134 | 134 | 116 | 113 | 150 | 124 | 132 | 127 | 111 | 144 | 129 | 128 | 137 |
| Pacific | <20 | 181 | 173 | 138 | 134 | 108 | 126 | 90 | 94 | 50 | 60 | 36 | 47 | 40 | 36 | 27 | 26 | 25 | 19 | 18 | 12 |
| Pacific | 20-24 | 1463 | 1434 | 1474 | 1535 | 1721 | 1624 | 1673 | 1728 | 1540 | 1632 | 1648 | 1593 | 1521 | 1569 | 1576 | 1772 | 1458 | 1406 | 1392 | 1292 |
| Pacific | 25-29 | 1438 | 1446 | 1341 | 1476 | 1417 | 1372 | 1397 | 1473 | 1324 | 1443 | 1431 | 1468 | 1438 | 1534 | 1627 | 1679 | 1468 | 1410 | 1363 | 1432 |
| Pacific | 30-34 | 1530 | 1503 | 1400 | 1434 | 1525 | 1398 | 1441 | 1469 | 1281 | 1355 | 1308 | 1317 | 1331 | 1437 | 1457 | 1601 | 1275 | 1230 | 1288 | 1346 |
| Pacific | 35-39 | 1457 | 1472 | 1355 | 1383 | 1468 | 1402 | 1353 | 1345 | 1337 | 1254 | 1285 | 1306 | 1281 | 1371 | 1417 | 1522 | 1229 | 1277 | 1211 | 1310 |
| Pacific | 40-44 | 1460 | 1309 | 1322 | 1412 | 1468 | 1329 | 1328 | 1343 | 1277 | 1232 | 1358 | 1285 | 1285 | 1320 | 1429 | 1414 | 1243 | 1185 | 1098 | 1231 |
| Pacific | 45-49 | 1193 | 1151 | 1207 | 1206 | 1281 | 1203 | 1245 | 1224 | 1233 | 1218 | 1360 | 1299 | 1264 | 1384 | 1354 | 1383 | 1182 | 1221 | 1179 | 1209 |
| Pacific | 50-54 | 910 | 807 | 841 | 889 | 985 | 933 | 996 | 1056 | 980 | 991 | 1106 | 1029 | 1120 | 1146 | 1182 | 1193 | 1093 | 1183 | 1017 | 1067 |
| Pacific | 55-59 | 708 | 609 | 700 | 703 | 749 | 691 | 674 | 743 | 712 | 767 | 777 | 743 | 900 | 934 | 855 | 945 | 853 | 854 | 909 | 897 |
| Pacific | 60-64 | 418 | 426 | 484 | 477 | 530 | 481 | 521 | 573 | 562 | 585 | 622 | 603 | 607 | 677 | 657 | 703 | 673 | 635 | 668 | 648 |
| Pacific | 65-69 | 274 | 278 | 287 | 269 | 293 | 315 | 319 | 363 | 359 | 377 | 397 | 418 | 407 | 433 | 461 | 460 | 429 | 424 | 429 | 447 |
| Pacific | 70+ | 55 | 63 | 64 | 64 | 76 | 58 | 57 | 43 | 55 | 57 | 57 | 65 | 65 | 66 | 77 | 76 | 79 | 65 | 71 | 67 |
| Asian | <20 | 80 | 74 | 52 | 61 | 51 | 55 | 39 | 42 | 35 | 26 | 31 | 26 | 21 | 34 | 26 | 25 | 16 | 22 | 20 | 21 |
| Asian | 20-24 | 1662 | 1625 | 1471 | 1590 | 1463 | 1392 | 1507 | 1528 | 1540 | 1580 | 1642 | 1643 | 1638 | 1669 | 1678 | 1712 | 1672 | 1725 | 1696 | 1742 |
| Asian | 25-29 | 2978 | 3205 | 3166 | 3312 | 3222 | 3246 | 3171 | 3322 | 3175 | 3154 | 3207 | 3087 | 3325 | 3543 | 3465 | 3794 | 3500 | 3616 | 3895 | 4039 |
| Asian | 30-34 | 2593 | 2764 | 2844 | 3009 | 3052 | 3145 | 3234 | 3518 | 3620 | 3887 | 4084 | 4159 | 4319 | 4905 | 4639 | 5017 | 4799 | 5140 | 5046 | 5339 |
| Asian | 35-39 | 2988 | 2856 | 2983 | 2922 | 2931 | 2977 | 2835 | 2969 | 2872 | 2948 | 3068 | 3104 | 3266 | 3698 | 3609 | 3862 | 3931 | 4165 | 4435 | 4727 |
| Asian | 40-44 | 2830 | 2804 | 2889 | 2834 | 2953 | 2941 | 2910 | 2972 | 2890 | 2991 | 3036 | 3051 | 3045 | 3232 | 3048 | 3303 | 3176 | 3170 | 3293 | 3332 |
| Asian | 45-49 | 2570 | 2546 | 2682 | 2599 | 2729 | 2702 | 2663 | 2709 | 2703 | 2675 | 2809 | 2773 | 2788 | 2957 | 2820 | 2863 | 2983 | 3027 | 3072 | 3067 |
| Asian | 50-54 | 1808 | 1719 | 1922 | 1850 | 1961 | 1974 | 2072 | 2095 | 2184 | 2234 | 2389 | 2305 | 2510 | 2577 | 2511 | 2509 | 2470 | 2475 | 2466 | 2513 |
| Asian | 55-59 | 1126 | 1122 | 1259 | 1259 | 1344 | 1405 | 1573 | 1566 | 1661 | 1707 | 1875 | 1780 | 2068 | 2105 | 2023 | 2006 | 2121 | 2055 | 2178 | 2137 |
| Asian | 60-64 | 685 | 684 | 803 | 849 | 906 | 916 | 972 | 954 | 1061 | 1152 | 1304 | 1272 | 1429 | 1539 | 1549 | 1563 | 1755 | 1704 | 1839 | 1785 |
| Asian | 65-69 | 395 | 394 | 435 | 454 | 478 | 499 | 526 | 517 | 568 | 639 | 713 | 660 | 766 | 885 | 814 | 968 | 951 | 1002 | 1035 | 1032 |
| Asian | 70+ | 80 | 86 | 95 | 93 | 103 | 87 | 100 | 98 | 93 | 105 | 105 | 110 | 112 | 106 | 119 | 93 | 127 | 133 | 134 | 136 |
| Eur/Other | <20 | 1999 | 1994 | 1444 | 1517 | 1221 | 1287 | 1065 | 1022 | 856 | 829 | 666 | 676 | 584 | 574 | 524 | 592 | 392 | 476 | 392 | 424 |
| Eur/Other | 20-24 | 17847 | 18684 | 17865 | 18551 | 18846 | 18916 | 19222 | 18908 | 18719 | 18652 | 18609 | 18125 | 17975 | 18452 | 17886 | 18195 | 16418 | 16748 | 15909 | 16334 |
| Eur/Other | 25-29 | 15215 | 16606 | 14694 | 15797 | 14988 | 15228 | 15024 | 15312 | 14774 | 15206 | 15015 | 15231 | 15046 | 16038 | 15740 | 16352 | 14882 | 15792 | 14916 | 16344 |
| Eur/Other | 30-34 | 16868 | 17853 | 15773 | 16912 | 15822 | 15762 | 15441 | 15738 | 15031 | 15316 | 14806 | 14712 | 14459 | 15231 | 14621 | 15258 | 14248 | 14738 | 14268 | 16031 |
| Eur/Other | 35-39 | 20691 | 21710 | 19825 | 20191 | 19483 | 18782 | 18039 | 18041 | 16884 | 16666 | 15734 | 15638 | 14825 | 15547 | 14990 | 15309 | 14289 | 14416 | 13738 | 14934 |
| Eur/Other | 40-44 | 20557 | 20705 | 20015 | 20385 | 20443 | 19891 | 20319 | 19987 | 19562 | 18871 | 18950 | 18240 | 17988 | 18553 | 17472 | 16811 | 15924 | 15627 | 14585 | 15718 |
| Eur/Other | 45-49 | 20808 | 20278 | 20649 | 19993 | 20267 | 19137 | 19483 | 18693 | 18827 | 17820 | 17992 | 17103 | 17634 | 17692 | 17900 | 17415 | 16864 | 16788 | 16782 | 17495 |
| Eur/Other | 50-54 | 16642 | 16519 | 17099 | 16828 | 17609 | 16943 | 17855 | 17543 | 17743 | 17178 | 17783 | 16709 | 17338 | 17346 | 17361 | 16262 | 15916 | 15441 | 15518 | 15869 |
| Eur/Other | 55-59 | 13515 | 13102 | 13936 | 13579 | 13939 | 13427 | 14117 | 14007 | 14240 | 13613 | 14423 | 13902 | 14463 | 14476 | 15134 | 14461 | 14559 | 14662 | 14746 | 15338 |
| Eur/Other | 60-64 | 10822 | 10657 | 11443 | 11414 | 11652 | 11230 | 11949 | 11341 | 11607 | 11086 | 11699 | 11075 | 11874 | 11752 | 12001 | 11725 | 11565 | 11585 | 11871 | 12244 |
| Eur/Other | 65-69 | 7327 | 7196 | 7598 | 7632 | 7648 | 7393 | 7937 | 8173 | 8624 | 8580 | 9074 | 8931 | 9572 | 9757 | 9774 | 9575 | 9451 | 9299 | 9514 | 10042 |
| Eur/Other | 70+ | 2400 | 2250 | 2488 | 2338 | 2381 | 2356 | 2463 | 2358 | 2328 | 2159 | 2343 | 2191 | 2249 | 2165 | 2201 | 2230 | 2351 | 2351 | 2383 | 2584 |

### Indicator 5.5 – Laboratory turnaround time

Table 61 - Timeliness of cytology reporting by laboratory, 1 January – 30 June 2018

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Laboratory turnaround time - cytology** | | | | | | | | | | | |
| **Within 7 days** | | | **8-15 days** | | | **Total within 15 days** | | **More than 15 days** | | **Total** | |
| **N** | **%** | **N** | | **%** | **N** | | **%** | **N** | **%** | | **N** |
| Anatomical Pathology Services | 44,846 | 97.7 | 960 | | 2.1 | 45,806 | | 99.8 | 111 | 0.2 | | 45,917 |
| Canterbury Health Laboratories | 9,795 | 93.1 | 689 | | 6.5 | 10,484 | | 99.6 | 40 | 0.4 | | 10,524 |
| LabPLUS | 7,449 | 89.3 | 735 | | 8.8 | 8,184 | | 98.2 | 154 | 1.8 | | 8,338 |
| Medlab Central Ltd. | 11,274 | 70.9 | 4,394 | | 27.6 | 15,668 | | 98.5 | 234 | 1.5 | | 15,902 |
| Pathlab | 27,779 | 98.7 | 321 | | 1.1 | 28,100 | | 99.9 | 42 | 0.1 | | 28,142 |
| Southern Community Laboratories | 106,455 | 96.8 | 1,857 | | 1.7 | 108,312 | | 98.5 | 1,620 | 1.5 | | 109,932 |
| **Total** | **207,598** | **94.9** | **8,956** | | **4.1** | **216,554** | | **99.0** | **2,201** | **1.0** | | **218,755** |

*Target: 90% within seven working days and 98% within 15 working days.*

*Note: total samples reported on for this Indicator is different from that reported in Indicator 5.1. Here, ‘total samples’ refers to all cytology samples received by laboratories within the monitoring period. Indicator 5.1 shows the total number of cytology samples taken during the period.*

Table 62 - Timeliness of histology reporting by laboratory, 1 January – 30 June 2018

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Laboratory turnaround time - histology** | | | | | | | | | | | |
| **Within 10 days** | | **10-15 days** | | | **Total within 15 days** | | | **More than 15 days** | | **Total** | |
| **N** | **%** | | **N** | **%** | | **N** | **%** | **N** | **%** | | **N** |
| Anatomical Pathology Services | 1,456 | 96.7 | | 31 | 2.1 | | 1,487 | 98.7 | 19 | 1.3 | | 1,506 |
| Canterbury Health Laboratories | 1,327 | 88.3 | | 146 | 9.7 | | 1,473 | 98.0 | 30 | 2.0 | | 1,503 |
| LabPLUS | 527 | 70.4 | | 108 | 14.4 | | 635 | 84.8 | 114 | 15.2 | | 749 |
| Medlab Central Ltd. | 779 | 95.2 | | 8 | 1.0 | | 787 | 96.2 | 31 | 3.8 | | 818 |
| Memorial Hospital Hastings Laboratory | 53 | 85.5 | | 2 | 3.2 | | 55 | 88.7 | 7 | 11.3 | | 62 |
| Middlemore Hospital Laboratory | 929 | 91.0 | | 57 | 5.6 | | 986 | 96.6 | 35 | 3.4 | | 1,021 |
| Nelson Hospital Laboratory | 108 | 94.7 | | 3 | 2.6 | | 111 | 97.4 | 3 | 2.6 | | 114 |
| North Shore Hospital Laboratory | 859 | 94.5 | | 27 | 3.0 | | 886 | 97.5 | 23 | 2.5 | | 909 |
| Northland Pathology Laboratory | 223 | 85.8 | | 24 | 9.2 | | 247 | 95.0 | 13 | 5.0 | | 260 |
| Pathlab | 945 | 83.6 | | 143 | 12.7 | | 1,088 | 96.3 | 42 | 3.7 | | 1,130 |
| Southern Community Laboratories Dunedin | 2,768 | 99.4 | | 4 | 0.1 | | 2,772 | 99.6 | 12 | 0.4 | | 2,784 |
| Southern Community Laboratories Wellington | 950 | 97.7 | | 21 | 2.2 | | 971 | 99.9 | 1 | 0.1 | | 972 |
| Taranaki Medlab | 375 | 100.0 | | - | 0.0 | | 375 | 100.0 | - | 0.0 | | 375 |
| Waikato Hospital Laboratory | 190 | 78.2 | | 3 | 1.2 | | 193 | 79.4 | 50 | 20.6 | | 243 |
| **Total** | **11,489** | **92.3** | | **577** | **4.6** | | **12,066** | **96.9** | **380** | **3.1** | | **12,446** |

Target: 90% within ten working days and 98% within 15 working days of receipt of the sample

Note: total histology samples reported on for this Indicator is different from that reported in Indicator 5.4. Indicator 5.5 includes all histology samples received by laboratories within the monitoring period, while 5.4 includes all histology samples taken within the monitoring period

Table 63 - Timeliness of reporting for cytology with associated HPV testing by laboratory, 1 January – 30 June 2018

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Laboratory turnaround time - cytology with HPV testing** | | | | | |
| **Within 15 days** | | **More than 15 days** | | | **Total** |
| **N** | **%** | **N** | **%** | **N** | |
| Anatomical Pathology Services | 719 | 99.9 | 1 | 0.1 | 720 | |
| Canterbury Health Laboratories | 183 | 99.5 | 1 | 0.5 | 184 | |
| LabPLUS | 239 | 97.6 | 6 | 2.4 | 245 | |
| Medlab Central Ltd. | 252 | 97.7 | 6 | 2.3 | 258 | |
| Pathlab | 601 | 99.8 | 1 | 0.2 | 602 | |
| Southern Community Laboratories | 1,049 | 99.5 | 5 | 0.5 | 1,054 | |
| **Total** | **3,043** | **99.3** | **20** | **0.7** | **3,063** | |

## Indicator 6 – Follow-up of women with high-grade cytology

Table 64 - Women with a histology report within 90 days of a high-grade cytology report, by DHB and age

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **<20** | | **20-24** | | | **25-29** | | **30-34** | | | **35-39** | | **40-44** | | **45-49** | | **50-54** | | | **55-59** | | **60-64** | | **65-69** | | **70+** | | **Total** |
| **DHB** | **N** | **%** | | **N** | **%** | **N** | **%** | | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |  | |
| Auckland | - | - | | 22 | 78.6 | 38 | 80.9 | | 29 | 82.9 | 19 | 86.4 | 15 | 78.9 | 8 | 72.7 | | 5 | 71.4 | 9 | 75.0 | 3 | 37.5 | 4 | 80.0 | 2 | 40.0 | 154 | |
| Bay of Plenty | - | - | | 10 | 83.3 | 19 | 95.0 | | 11 | 78.6 | 7 | 77.8 | 5 | 100.0 | 4 | 50.0 | | 5 | 100.0 | 1 | 50.0 | 2 | 100.0 | 2 | 66.7 | 4 | 100.0 | 70 | |
| Canterbury | - | - | | 34 | 91.9 | 46 | 88.5 | | 27 | 93.1 | 16 | 84.2 | 12 | 100.0 | 15 | 93.8 | | 9 | 75.0 | 7 | 87.5 | 4 | 66.7 | 2 | 100.0 | 2 | 50.0 | 174 | |
| Capital & Coast | - | - | | 15 | 100.0 | 14 | 82.4 | | 10 | 71.4 | 11 | 78.6 | 5 | 100.0 | 3 | 100.0 | | 4 | 50.0 | 3 | 75.0 | 1 | 25.0 | 3 | 100.0 | - | - | 69 | |
| Counties Manukau | - | - | | 13 | 68.4 | 25 | 92.6 | | 27 | 71.1 | 18 | 78.3 | 12 | 100.0 | 6 | 66.7 | | 7 | 77.8 | 5 | 83.3 | 2 | 50.0 | 3 | 42.9 | - | - | 118 | |
| Hawke's Bay | - | - | | 8 | 66.7 | 15 | 100.0 | | 13 | 92.9 | 7 | 100.0 | 5 | 83.3 | 4 | 80.0 | | 2 | 66.7 | 6 | 85.7 | 2 | 66.7 | - | - | 3 | 100.0 | 65 | |
| Hutt Valley | - | - | | 5 | 83.3 | 7 | 87.5 | | 8 | 88.9 | 4 | 80.0 | 3 | 100.0 | 3 | 100.0 | | 1 | 50.0 | 1 | 50.0 | - | - | 0 | 0.0 | - | - | 32 | |
| Lakes | - | - | | 1 | 100.0 | 8 | 100.0 | | 6 | 100.0 | 6 | 100.0 | 1 | 33.3 | 2 | 66.7 | | 2 | 100.0 | 4 | 80.0 | 1 | 50.0 | 2 | 100.0 | 1 | 100.0 | 34 | |
| Mid Central | - | - | | 17 | 77.3 | 8 | 88.9 | | 13 | 100.0 | 10 | 90.9 | 6 | 100.0 | 3 | 100.0 | | 3 | 100.0 | - | - | 1 | 50.0 | 1 | 100.0 | 0 | 0.0 | 62 | |
| Nelson Marlborough | - | - | | 8 | 100.0 | 12 | 100.0 | | 10 | 100.0 | 6 | 85.7 | 11 | 100.0 | 1 | 25.0 | | 4 | 100.0 | 4 | 100.0 | 2 | 66.7 | 4 | 80.0 | - | - | 62 | |
| Northland | 1 | 100.0 | | 2 | 100.0 | 3 | 100.0 | | 13 | 100.0 | 8 | 88.9 | 4 | 80.0 | 1 | 33.3 | | 1 | 50.0 | 2 | 28.6 | 1 | 50.0 | 0 | 0.0 | - | - | 36 | |
| South Canterbury | 1 | 100.0 | | 1 | 100.0 | 1 | 100.0 | | 2 | 100.0 | 4 | 100.0 | 1 | 100.0 | 1 | 100.0 | | - | - | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 0 | 0.0 | 15 | |
| Southern | - | - | | 16 | 94.1 | 26 | 100.0 | | 21 | 84.0 | 17 | 100.0 | 11 | 100.0 | 5 | 100.0 | | 5 | 62.5 | 3 | 50.0 | 3 | 75.0 | 1 | 50.0 | 3 | 75.0 | 111 | |
| Tairawhiti | - | - | | 2 | 66.7 | 4 | 80.0 | | 8 | 61.5 | 2 | 100.0 | 2 | 100.0 | 1 | 50.0 | | - | - | 3 | 100.0 | - | - | 1 | 100.0 | - | - | 23 | |
| Taranaki | - | - | | 4 | 100.0 | 13 | 92.9 | | 5 | 71.4 | 8 | 100.0 | 5 | 71.4 | 5 | 100.0 | | 2 | 66.7 | 2 | 100.0 | 1 | 50.0 | 1 | 100.0 | 0 | 0.0 | 46 | |
| Waikato | - | - | | 24 | 100.0 | 19 | 86.4 | | 32 | 94.1 | 15 | 93.8 | 11 | 91.7 | 10 | 90.9 | | 7 | 77.8 | 7 | 63.6 | 4 | 50.0 | 2 | 66.7 | 3 | 60.0 | 134 | |
| Wairarapa | - | - | | 3 | 100.0 | 2 | 100.0 | | 1 | 100.0 | 3 | 100.0 | 1 | 100.0 | 1 | 100.0 | | 1 | 100.0 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 12 | |
| Waitemata | - | - | | 28 | 82.4 | 30 | 83.3 | | 24 | 88.9 | 23 | 92.0 | 19 | 95.0 | 11 | 84.6 | | 14 | 82.4 | 10 | 100.0 | 3 | 75.0 | 11 | 91.7 | 3 | 60.0 | 176 | |
| West Coast | - | - | | 2 | 100.0 | 1 | 100.0 | | 1 | 50.0 | - | - | 1 | 100.0 | 2 | 66.7 | | 1 | 100.0 | 0 | 0.0 | - | - | - | - | - | - | 8 | |
| Whanganui | - | - | | 5 | 100.0 | 4 | 80.0 | | 9 | 100.0 | 5 | 100.0 | 1 | 50.0 | 1 | 100.0 | | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 1 | 100.0 | 0 | 0.0 | 32 | |
| **Total** | **2** | **100.0** | | **220** | **86.3** | **295** | **89.4** | | **270** | **85.7** | **189** | **89.2** | **131** | **91.0** | **87** | **79.1** | | **75** | **76.5** | **71** | **74.7** | **33** | **57.9** | **39** | **75.0** | **21** | **58.3** | **1,433** | |

*‘ – ‘ indicates there were no women in this sub-category with a high -grade cytology report*

Table 65 - Women with a histology report within 180 days of a high-grade cytology report, by DHB and age

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **<20** | | **20-24** | | **25-29** | | **30-34** | | **35-39** | | **40-44** | | **45-49** | | **50-54** | | **55-59** | | **60-64** | | **65-69** | | **70+** | | **Total** |
| **DHB** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** |  |
| Auckland | - | - | 25 | 89.3 | 40 | 85.1 | 32 | 91.4 | 19 | 86.4 | 16 | 84.2 | 10 | 90.9 | 6 | 85.7 | 10 | 83.3 | 4 | 50.0 | 4 | 80.0 | 3 | 60.0 | 169 |
| Bay of Plenty | - | - | 10 | 83.3 | 20 | 100.0 | 12 | 85.7 | 7 | 77.8 | 5 | 100.0 | 5 | 62.5 | 5 | 100.0 | 1 | 50.0 | 2 | 100.0 | 2 | 66.7 | 4 | 100.0 | 73 |
| Canterbury | - | - | 35 | 94.6 | 47 | 90.4 | 27 | 93.1 | 17 | 89.5 | 12 | 100.0 | 16 | 100.0 | 10 | 83.3 | 7 | 87.5 | 6 | 100.0 | 2 | 100.0 | 3 | 75.0 | 182 |
| Capital & Coast | - | - | 15 | 100.0 | 15 | 88.2 | 10 | 71.4 | 14 | 100.0 | 5 | 100.0 | 3 | 100.0 | 5 | 62.5 | 3 | 75.0 | 2 | 50.0 | 3 | 100.0 | - | - | 75 |
| Counties Manukau | - | - | 15 | 78.9 | 26 | 96.3 | 30 | 78.9 | 18 | 78.3 | 12 | 100.0 | 6 | 66.7 | 7 | 77.8 | 5 | 83.3 | 2 | 50.0 | 5 | 71.4 | - | - | 126 |
| Hawke's Bay | - | - | 11 | 91.7 | 15 | 100.0 | 14 | 100.0 | 7 | 100.0 | 5 | 83.3 | 4 | 80.0 | 2 | 66.7 | 6 | 85.7 | 2 | 66.7 | - | - | 3 | 100.0 | 69 |
| Hutt Valley | - | - | 6 | 100.0 | 7 | 87.5 | 9 | 100.0 | 4 | 80.0 | 3 | 100.0 | 3 | 100.0 | 1 | 50.0 | 1 | 50.0 | - | - | 1 | 100.0 | - | - | 35 |
| Lakes | - | - | 1 | 100.0 | 8 | 100.0 | 6 | 100.0 | 6 | 100.0 | 2 | 66.7 | 3 | 100.0 | 2 | 100.0 | 4 | 80.0 | 1 | 50.0 | 2 | 100.0 | 1 | 100.0 | 36 |
| Mid Central | - | - | 18 | 81.8 | 8 | 88.9 | 13 | 100.0 | 11 | 100.0 | 6 | 100.0 | 3 | 100.0 | 3 | 100.0 | - | - | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 66 |
| Nelson Marlborough | - | - | 8 | 100.0 | 12 | 100.0 | 10 | 100.0 | 6 | 85.7 | 11 | 100.0 | 3 | 75.0 | 4 | 100.0 | 4 | 100.0 | 2 | 66.7 | 4 | 80.0 | - | - | 64 |
| Northland | 1 | 100.0 | 2 | 100.0 | 3 | 100.0 | 13 | 100.0 | 9 | 100.0 | 4 | 80.0 | 1 | 33.3 | 1 | 50.0 | 4 | 57.1 | 2 | 100.0 | 1 | 100.0 | - | - | 41 |
| South Canterbury | 1 | 100.0 | 1 | 100.0 | 1 | 100.0 | 2 | 100.0 | 4 | 100.0 | 1 | 100.0 | 1 | 100.0 | - | - | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 0 | 0.0 | 15 |
| Southern | - | - | 16 | 94.1 | 26 | 100.0 | 23 | 92.0 | 17 | 100.0 | 11 | 100.0 | 5 | 100.0 | 7 | 87.5 | 4 | 66.7 | 3 | 75.0 | 1 | 50.0 | 3 | 75.0 | 116 |
| Tairawhiti | - | - | 3 | 100.0 | 4 | 80.0 | 10 | 76.9 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | - | - | 3 | 100.0 | - | - | 1 | 100.0 | - | - | 27 |
| Taranaki | - | - | 4 | 100.0 | 13 | 92.9 | 6 | 85.7 | 8 | 100.0 | 5 | 71.4 | 5 | 100.0 | 2 | 66.7 | 2 | 100.0 | 2 | 100.0 | 1 | 100.0 | 2 | 100.0 | 50 |
| Waikato | - | - | 24 | 100.0 | 19 | 86.4 | 32 | 94.1 | 15 | 93.8 | 12 | 100.0 | 10 | 90.9 | 7 | 77.8 | 7 | 63.6 | 5 | 62.5 | 2 | 66.7 | 4 | 80.0 | 137 |
| Wairarapa | - | - | 3 | 100.0 | 2 | 100.0 | 1 | 100.0 | 3 | 100.0 | 1 | 100.0 | 1 | 100.0 | 1 | 100.0 | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 13 |
| Waitemata | - | - | 28 | 82.4 | 33 | 91.7 | 25 | 92.6 | 23 | 92.0 | 19 | 95.0 | 11 | 84.6 | 15 | 88.2 | 10 | 100.0 | 4 | 100.0 | 11 | 91.7 | 4 | 80.0 | 183 |
| West Coast | - | - | 2 | 100.0 | 1 | 100.0 | 1 | 50.0 | - | - | 1 | 100.0 | 2 | 66.7 | 1 | 100.0 | 1 | 100.0 | - | - | - | - | - | - | 9 |
| Whanganui | - | - | 5 | 100.0 | 4 | 80.0 | 9 | 100.0 | 5 | 100.0 | 2 | 100.0 | 1 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 34 |
| **Total** | **2** | **100.0** | **232** | **91.0** | **304** | **92.1** | **285** | **90.5** | **195** | **92.0** | **135** | **93.8** | **95** | **86.4** | **81** | **82.7** | **76** | **80.0** | **42** | **73.7** | **44** | **84.6** | **29** | **80.6** | **1,520** |

*‘ – ‘ indicates there were no women in this sub-category with a high-grade cytology report*

## Indicator 7 – Colposcopy indicators

### Indicator 7.1 – Timeliness of colposcopic assessment – high-grade cytology

Table 66 - Women with high -grade cytology (including cytological suspicion of invasive disease), by DHB

|  |  |  |
| --- | --- | --- |
| **DHB** | **HG women** | **HG women with referral recorded on the NCSP Register** |
|  | **N** | **N** |
| Auckland | 147 | 131 |
| Bay of Plenty | 68 | 64 |
| Canterbury | 169 | 161 |
| Capital & Coast | 78 | 71 |
| Counties Manukau | 130 | 124 |
| Hawke's Bay | 68 | 64 |
| Hutt Valley | 38 | 36 |
| Lakes | 40 | 39 |
| Mid Central | 75 | 74 |
| Nelson Marlborough | 61 | 56 |
| Northland | 42 | 38 |
| South Canterbury | 14 | 13 |
| Southern | 102 | 96 |
| Tairawhiti | 28 | 25 |
| Taranaki | 45 | 45 |
| Waikato | 132 | 126 |
| Wairarapa | 13 | 12 |
| Waitemata | 152 | 145 |
| West Coast | 12 | 12 |
| Whanganui | 30 | 30 |
| *Private practice* | *262* | *177* |
| **Total** | **1,706** | **1,539** |

Table 67 - Women with a high -grade cytology report (no suspicion of invasive disease), accepted referral and a colposcopy visit within 20 and 40 working days, by ethnicity

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **HG women** | **Accepted referrals recorded on NCSP Register** | **Women seen within 20 working days** | | **Women seen within 40 working days** | |
|  | **N** | **N** | **N** | **%** | **N** | **%** |
| Māori | 264 | 246 | 172 | 69.9 | 216 | 87.8 |
| Pacific | 83 | 73 | 49 | 67.1 | 60 | 82.2 |
| Asian | 162 | 146 | 114 | 78.1 | 133 | 91.1 |
| European/ Other | 1,154 | 1,044 | 807 | 77.3 | 972 | 93.1 |
| **Total** | **1,663** | **1,509** | **1,142** | **75.7** | **1,381** | **91.5** |

Table 68 - Women with a high-grade cytology report (no suspicion of invasive disease), accepted referral and a colposcopy visit within 20 and 40 working days, by DHB

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **HG women** | **Accepted referrals recorded on NCSP Register** | **Women seen within 20 working days** | | **Women seen within 40 working  days** | | |
|  | **N** | **N** | **N** | **%** | | **N** | **%** |
| *Public clinics overall* | *1,407* | *1,334* | *1,036* | *77.7* | | *1,253* | *93.9* |
| Auckland | 144 | 131 | 107 | 81.7 | | 122 | 93.1 |
| Bay of Plenty | 64 | 60 | 52 | 86.7 | | 55 | 91.7 |
| Canterbury | 165 | 159 | 119 | 74.8 | | 153 | 96.2 |
| Capital & Coast | 75 | 71 | 60 | 84.5 | | 67 | 94.4 |
| Counties Manukau | 130 | 124 | 96 | 77.4 | | 115 | 92.7 |
| Hawke's Bay | 66 | 62 | 33 | 53.2 | | 55 | 88.7 |
| Hutt Valley | 38 | 36 | 31 | 86.1 | | 35 | 97.2 |
| Lakes | 38 | 37 | 21 | 56.8 | | 36 | 97.3 |
| Mid Central | 74 | 73 | 59 | 80.8 | | 70 | 95.9 |
| Nelson Marlborough | 60 | 55 | 34 | 61.8 | | 52 | 94.5 |
| Northland | 41 | 37 | 34 | 91.9 | | 37 | 100.0 |
| South Canterbury | 12 | 11 | 10 | 90.9 | | 10 | 90.9 |
| Southern | 101 | 95 | 69 | 72.6 | | 91 | 95.8 |
| Tairawhiti | 28 | 25 | 18 | 72.0 | | 21 | 84.0 |
| Taranaki | 45 | 45 | 34 | 75.6 | | 41 | 91.1 |
| Waikato | 127 | 121 | 113 | 93.4 | | 118 | 97.5 |
| Wairarapa | 13 | 12 | 12 | 100.0 | | 12 | 100.0 |
| Waitemata | 145 | 139 | 103 | 74.1 | | 126 | 90.6 |
| West Coast | 12 | 12 | 4 | 33.3 | | 8 | 66.7 |
| Whanganui | 29 | 29 | 27 | 93.1 | | 29 | 100.0 |
| *Private Practice* | *256* | *175* | *106* | *60.6* | | *128* | *73.1* |
| **Total** | **1,663** | **1,509** | **1,142** | **75.7** | | **1,381** | **91.5** |

Table 69 - Women with cytological suspicion of invasive disease, by cytology result subcategory

|  |  |  |
| --- | --- | --- |
| **Cytology result sub-category** | **Total women** | **Accepted referrals recorded on NCSP Register\*** |
| **N** | **N** |
| HS2 | 12 | 10 |
| SC | 11 | 10 |
| AC1-AC5 | 14 | 5 |
| R10, R14 | 6 | 5 |
| **Total** | **43** | **30** |

*\* Referral accepted date no later than four weeks prior to the end of the current monitoring period, in order to allow at least four weeks of follow-up time available.*

### Indicator 7.2 – Timeliness of colposcopic assessment – low-grade cytology

Table 70 - Follow-up of women with persistent low -grade cytology/ low -grade cytology and positive hrHPV test, by DHB

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **LG women** | **Women with subsequent referral recorded** | | | **Women with subsequent colposcopy visit recorded** | | | | **Women with colposcopy subsequent to referral recorded** | | | **Women with colposcopy subsequent to referral recorded AND referral:colposcopy interval <= 26 weeks** | |
|  | **N** | **N** | **%\*** | | **N** | | **% \*** | **N** | | **% †** | **N** | | **% †** |
| Auckland | 403 | 368 | | 91.3 | | 359 | 89.1 | 354 | | 96.2 | 335 | | 91.0 |
| Bay of Plenty | 229 | 206 | | 90.0 | | 210 | 91.7 | 198 | | 96.1 | 168 | | 81.6 |
| Canterbury | 288 | 278 | | 96.5 | | 274 | 95.1 | 272 | | 97.8 | 269 | | 96.8 |
| Capital & Coast | 130 | 121 | | 93.1 | | 115 | 88.5 | 113 | | 93.4 | 105 | | 86.8 |
| Counties Manukau | 291 | 275 | | 94.5 | | 259 | 89.0 | 251 | | 91.3 | 247 | | 89.8 |
| Hawke's Bay | 73 | 64 | | 87.7 | | 64 | 87.7 | 61 | | 95.3 | 36 | | 56.3 |
| Hutt Valley | 63 | 59 | | 93.7 | | 57 | 90.5 | 57 | | 96.6 | 55 | | 93.2 |
| Lakes | 77 | 73 | | 94.8 | | 72 | 93.5 | 71 | | 97.3 | 60 | | 82.2 |
| Mid Central | 124 | 116 | | 93.5 | | 116 | 93.5 | 113 | | 97.4 | 110 | | 94.8 |
| Nelson Marlborough | 59 | 56 | | 94.9 | | 57 | 96.6 | 55 | | 98.2 | 39 | | 69.6 |
| Northland | 72 | 66 | | 91.7 | | 63 | 87.5 | 62 | | 93.9 | 57 | | 86.4 |
| South Canterbury | 15 | 12 | | 80.0 | | 10 | 66.7 | 9 | | 75.0 | 9 | | 75.0 |
| Southern | 132 | 122 | | 92.4 | | 121 | 91.7 | 116 | | 95.1 | 107 | | 87.7 |
| Tairawhiti | 51 | 43 | | 84.3 | | 41 | 80.4 | 38 | | 88.4 | 38 | | 88.4 |
| Taranaki | 44 | 42 | | 95.5 | | 43 | 97.7 | 42 | | 100.0 | 41 | | 97.6 |
| Waikato | 313 | 302 | | 96.5 | | 286 | 91.4 | 283 | | 93.7 | 267 | | 88.4 |
| Wairarapa | 21 | 19 | | 90.5 | | 19 | 90.5 | 17 | | 89.5 | 17 | | 89.5 |
| Waitemata | 397 | 381 | | 96.0 | | 364 | 91.7 | 357 | | 93.7 | 353 | | 92.7 |
| West Coast | 26 | 25 | | 96.2 | | 24 | 92.3 | 23 | | 92.0 | 23 | | 92.0 |
| Whanganui | 49 | 49 | | 100.0 | | 48 | 98.0 | 48 | | 98.0 | 48 | | 98.0 |
| *Private practice* | *631* | *340* | | *53.9* | | *596* | *94.5* | *305* | | *89.7* | *295* | | *86.8* |
| **Total** | **3,488** | **3,017** | | **86.5** | | **3,198** | **91.7** | **2,845** | | **94.3** | **2,679** | | **88.8** |

*LG women = women with persistent LG/ who are LG & hrHPV positive*

*\* Percentage of women with persistent LG/ who are LG & hrHPV positive; † percentage of women with a referral*

Table 71 - Follow-up of women with persistent low -grade cytology/ low-grade cytology and positive hrHPV test, by ethnicity

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **LG women** | **Women with subsequent referral recorded** | | | **Women with subsequent colposcopy visit recorded** | | | | | **Women with colposcopy subsequent to referral recorded** | | **Women with colposcopy subsequent to referral recorded AND referral: colposcopy interval <= 26 weeks** | | |
|  | **N** | **N** | **%\*** | | | **N** | | **% \*** | **N** | | **% †** | | **N** | **% †** |
| Māori | 363 | 337 | | 92.8 | | | 322 | 88.7 | 308 | | 91.4 | | 278 | 82.5 |
| Pacific | 156 | 143 | | 91.7 | | | 134 | 85.9 | 127 | | 88.8 | | 123 | 86.0 |
| Asian | 414 | 352 | | 85.0 | | | 377 | 91.1 | 330 | | 93.8 | | 309 | 87.8 |
| European/ Other | 2,555 | 2,185 | | 85.5 | | | 2,365 | 92.6 | 2,080 | | 95.2 | | 1,969 | 90.1 |
| **Total** | **3,488** | **3,017** | | **86.5** | | | **3,198** | **91.7** | **2,845** | | **94.3** | | **2,679** | **88.8** |

*LG women = women with persistent LG/ who are LG & hrHPV positive*

*\* Percentage of women with persistent LG/ who are LG & hrHPV positive; † percentage of women with a referral*

### Indicator 7.3 – Adequacy of documenting colposcopic assessment

Table 72 - Completion of colposcopic assessment fields, by DHB

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **Total colposcopies**  **N** | **% of colposcopies performed where items are completed** | | | | | |
| **SCJ visibility(i)** | **Presence/ absence lesion(ii)** | **Opinion re abnormality grade(iii)** | **Follow-up type** | **Follow-up timeframe** | **Items i, ii, & iii complete** |
| *Public clinics overall* | *10,789* | *97.4* | *100.0* | *91.7* | *95.8* | *95.3* | *92.7* |
| Auckland | 918 | 98.3 | 100.0 | 92.6 | 98.7 | 98.4 | 93.6 |
| Bay of Plenty | 646 | 96.7 | 100.0 | 89.3 | 90.6 | 89.9 | 89.6 |
| Canterbury | 1,653 | 97.4 | 100.0 | 92.7 | 96.9 | 96.7 | 92.8 |
| Capital & Coast | 711 | 99.9 | 100.0 | 92.3 | 94.0 | 93.4 | 96.2 |
| Counties Manukau | 930 | 96.6 | 100.0 | 93.3 | 99.0 | 98.5 | 92.3 |
| Hawke's Bay | 329 | 97.9 | 100.0 | 92.4 | 97.3 | 97.0 | 93.6 |
| Hutt Valley | 256 | 99.2 | 100.0 | 98.9 | 96.1 | 96.1 | 98.4 |
| Lakes | 296 | 98.0 | 100.0 | 89.7 | 94.6 | 94.6 | 91.2 |
| Mid Central | 543 | 95.0 | 100.0 | 89.5 | 98.3 | 98.2 | 90.1 |
| Nelson Marlborough | 325 | 98.5 | 100.0 | 91.8 | 94.5 | 93.8 | 92.9 |
| Northland | 363 | 97.2 | 100.0 | 85.6 | 98.6 | 98.1 | 91.5 |
| South Canterbury | 123 | 97.6 | 100.0 | 84.2 | 95.1 | 95.1 | 91.1 |
| Southern | 702 | 96.9 | 100.0 | 88.1 | 96.6 | 96.3 | 90.3 |
| Tairawhiti | 161 | 98.8 | 100.0 | 94.7 | 96.9 | 96.3 | 97.5 |
| Taranaki | 389 | 96.1 | 100.0 | 88.8 | 99.7 | 99.7 | 90.2 |
| Waikato | 859 | 98.4 | 100.0 | 96.5 | 99.1 | 97.6 | 96.4 |
| Wairarapa | 73 | 98.6 | 100.0 | 89.7 | 97.3 | 97.3 | 93.2 |
| Waitemata | 1,222 | 96.6 | 100.0 | 91.1 | 86.7 | 85.3 | 92.5 |
| West Coast | 89 | 94.4 | 100.0 | 88.4 | 98.9 | 98.9 | 86.5 |
| Whanganui | 201 | 95.0 | 100.0 | 90.8 | 100.0 | 100.0 | 89.1 |
| *Private practice* | *1,409* | *96.7* | *100.0* | *90.9* | *94.4* | *91.8* | *91.3* |
| **Total** | **12,198** | **97.3** | **100.0** | **91.6** | **95.6** | **94.9** | **92.6** |

Table 73 - Summary of colposcopic appearance findings, by DHB

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DHB** | **Total colposcopies** | **SCJ visible\*** | **Colposcopic appearance (as % of colposcopies where items are completed)** | |
| **N** | **N** | **Abnormal** | **Inconclusive** |
| *Public clinics overall* | *10,789* | *10,505* | *53.9* | *4.8* |
| Auckland | 918 | 902 | 58.5 | 4.7 |
| Bay of Plenty | 646 | 625 | 60.7 | 7.3 |
| Canterbury | 1,653 | 1,610 | 60.3 | 4.8 |
| Capital & Coast | 711 | 710 | 43.7 | 3.7 |
| Counties Manukau | 930 | 898 | 59.6 | 4.3 |
| Hawke's Bay | 329 | 322 | 52.0 | 4.3 |
| Hutt Valley | 256 | 254 | 67.6 | 0.8 |
| Lakes | 296 | 290 | 59.1 | 6.8 |
| Mid Central | 543 | 516 | 43.8 | 5.2 |
| Nelson Marlborough | 325 | 320 | 65.5 | 5.8 |
| Northland | 363 | 353 | 36.1 | 6.1 |
| South Canterbury | 123 | 120 | 39.0 | 7.3 |
| Southern | 702 | 680 | 52.7 | 7.1 |
| Tairawhiti | 161 | 159 | 44.7 | 2.5 |
| Taranaki | 389 | 374 | 47.0 | 5.9 |
| Waikato | 859 | 845 | 53.9 | 2.0 |
| Wairarapa | 73 | 72 | 47.9 | 5.5 |
| Waitemata | 1,222 | 1,180 | 46.8 | 4.6 |
| West Coast | 89 | 84 | 68.5 | 9.0 |
| Whanganui | 201 | 191 | 58.7 | 6.0 |
| *Private practice* | 1,409 | *1,363* | *54.6* | *5.5* |
| **Total** | **12,198** | **11,868** | **54.0** | **4.9** |

*\* Field has been completed*

Table 74 - Biopsies by colposcopic appearance and DHB

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **Colposcopic appearance** | | | | | | | | | | |
| **Abnormal** | | |  | **Inconclusive** | | |  | **Normal** | | |
| **Total** | **Biopsy taken** | |  | **Total** | **Biopsy taken** | |  | **Total** | **Biopsy taken** | |
| **N** | **N** | **%** |  | **N** | **N** | **%** |  | **N** | **N** | **%** |
| *Public clinics overall* | *5,813* | *5,397* | *92.8* |  | *523* | *156* | *29.8* |  | *4,453* | *842* | *18.9* |
| Auckland | 537 | 462 | 86.0 |  | 43 | 17 | 39.5 |  | 338 | 42 | 12.4 |
| Bay of Plenty | 392 | 361 | 92.1 |  | 47 | 10 | 21.3 |  | 207 | 22 | 10.6 |
| Canterbury | 996 | 938 | 94.2 |  | 79 | 29 | 36.7 |  | 578 | 136 | 23.5 |
| Capital & Coast | 311 | 293 | 94.2 |  | 26 | 4 | 15.4 |  | 374 | 118 | 31.6 |
| Counties Manukau | 554 | 522 | 94.2 |  | 40 | 11 | 27.5 |  | 336 | 47 | 14.0 |
| Hawke's Bay | 171 | 157 | 91.8 |  | 14 | 2 | 14.3 |  | 144 | 22 | 15.3 |
| Hutt Valley | 173 | 157 | 90.8 |  | 2 | 1 | 50.0 |  | 81 | 10 | 12.3 |
| Lakes | 175 | 158 | 90.3 |  | 20 | 5 | 25.0 |  | 101 | 11 | 10.9 |
| Mid Central | 238 | 222 | 93.3 |  | 28 | 9 | 32.1 |  | 277 | 67 | 24.2 |
| Nelson Marlborough | 213 | 205 | 96.2 |  | 19 | 9 | 47.4 |  | 93 | 28 | 30.1 |
| Northland | 131 | 123 | 93.9 |  | 22 | 3 | 13.6 |  | 210 | 39 | 18.6 |
| South Canterbury | 48 | 46 | 95.8 |  | 9 | 3 | 33.3 |  | 66 | 10 | 15.2 |
| Southern | 370 | 353 | 95.4 |  | 50 | 18 | 36.0 |  | 282 | 83 | 29.4 |
| Tairawhiti | 72 | 67 | 93.1 |  | 4 | 0 | 0.0 |  | 85 | 22 | 25.9 |
| Taranaki | 183 | 166 | 90.7 |  | 23 | 7 | 30.4 |  | 183 | 27 | 14.8 |
| Waikato | 463 | 443 | 95.7 |  | 17 | 1 | 5.9 |  | 379 | 49 | 12.9 |
| Wairarapa | 35 | 33 | 94.3 |  | 4 | 2 | 50.0 |  | 34 | 13 | 38.2 |
| Waitemata | 572 | 519 | 90.7 |  | 56 | 14 | 25.0 |  | 594 | 82 | 13.8 |
| West Coast | 61 | 58 | 95.1 |  | 8 | 2 | 25.0 |  | 20 | 4 | 20.0 |
| Whanganui | 118 | 114 | 96.6 |  | 12 | 9 | 75.0 |  | 71 | 10 | 14.1 |
| *Private practice* | *770* | *657* | *85.3* |  | *77* | *46* | *59.7* |  | *562* | *121* | *21.5* |
| **Total** | **6,583** | **6,054** | **92.0** |  | **600** | **202** | **33.7** |  | **5,015** | **963** | **19.2** |

### Indicator 7.5 – Timely discharge of women after treatment

Table 75 - Follow-up of treated women with colposcopy and cytology in the period up to nine months post-treatment, and discharge of eligible women

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Total treatments** | **Eligible for discharge\*** | | **Women discharged appropriately** | |
| **DHB** | **N** | **N** | **% of women treated** | **N** | **% of eligible** |
| Auckland | 126 | 81 | 64.3 | 69 | 85.2 |
| Bay of Plenty | 63 | 43 | 68.3 | 38 | 88.4 |
| Canterbury | 181 | 136 | 75.1 | 104 | 76.5 |
| Capital & Coast | 45 | 39 | 86.7 | 36 | 92.3 |
| Counties Manukau | 153 | 100 | 65.4 | 94 | 94.0 |
| Hawke's Bay | 56 | 41 | 73.2 | 39 | 95.1 |
| Hutt Valley | 23 | 20 | 87.0 | 19 | 95.0 |
| Lakes | 38 | 33 | 86.8 | 27 | 81.8 |
| Mid Central | 83 | 56 | 67.5 | 49 | 87.5 |
| Nelson Marlborough | 37 | 27 | 73.0 | 26 | 96.3 |
| Northland | 54 | 37 | 68.5 | 30 | 81.1 |
| South Canterbury | 9 | 8 | 88.9 | 3 | 37.5 |
| Southern | 69 | 61 | 88.4 | 54 | 88.5 |
| Tairawhiti | 24 | 21 | 87.5 | 19 | 90.5 |
| Taranaki | 39 | 31 | 79.5 | 25 | 80.6 |
| Waikato | 117 | 94 | 80.3 | 91 | 96.8 |
| Wairarapa | 7 | 5 | 71.4 | 5 | 100.0 |
| Waitemata | 126 | 89 | 70.6 | 74 | 83.1 |
| West Coast | 16 | 13 | 81.3 | 13 | 100.0 |
| Whanganui | 34 | 21 | 61.8 | 20 | 95.2 |
| *Private Practice* | *92* | *65* | *70.7* | *44* | *67.7* |
| **Total** | **1,392** | **1,021** | **73.3** | **879** | **86.1** |

*\* Based on advice from the NCSP Advisory Group, women were defined as eligible for discharge if they had a cytology test following their treatment, and their cytology result was negative*

Table 76 - Follow-up of treated women in the period up to nine months post-treatment

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **DHB** | **Total treatments** | **Colposcopy within 9 months post-treatment** | | **Colposcopy & cytology within 9 months post-treatment** | |
| **N** | **N** | **%** | **N** | **%** |
| Auckland | 126 | 106 | 84.1 | 106 | 84.1 |
| Bay of Plenty | 63 | 27 | 42.9 | 24 | 38.1 |
| Canterbury | 181 | 142 | 78.5 | 140 | 77.3 |
| Capital & Coast | 45 | 39 | 86.7 | 39 | 86.7 |
| Counties Manukau | 153 | 112 | 73.2 | 111 | 72.5 |
| Hawke's Bay | 56 | 35 | 62.5 | 33 | 58.9 |
| Hutt Valley | 23 | 18 | 78.3 | 18 | 78.3 |
| Lakes | 38 | 26 | 68.4 | 25 | 65.8 |
| Mid Central | 83 | 67 | 80.7 | 66 | 79.5 |
| Nelson Marlborough | 37 | 30 | 81.1 | 30 | 81.1 |
| Northland | 54 | 47 | 87.0 | 45 | 83.3 |
| South Canterbury | 9 | 3 | 33.3 | 3 | 33.3 |
| Southern | 69 | 59 | 85.5 | 59 | 85.5 |
| Tairawhiti | 24 | 18 | 75.0 | 17 | 70.8 |
| Taranaki | 39 | 32 | 82.1 | 32 | 82.1 |
| Waikato | 117 | 98 | 83.8 | 98 | 83.8 |
| Wairarapa | 7 | 7 | 100.0 | 7 | 100.0 |
| Waitemata | 126 | 112 | 88.9 | 112 | 88.9 |
| West Coast | 16 | 11 | 68.8 | 11 | 68.8 |
| Whanganui | 34 | 29 | 85.3 | 27 | 79.4 |
| *Private practice* | *92* | *61* | *66.3* | *60* | *65.2* |
| **Total** | **1,392** | **1,079** | **77.5** | **1,063** | **76.4** |

## Indicator 8 – HPV tests

### Indicator 8.1 – Triage of low-grade cytology

Table 77 - Triage testing of women with ASC-US cytology

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Total ASC-US results** | | **Women with an HPV test** | | | |
| **aged < 30yrs** | **aged 30+ yrs** | **aged < 30yrs** | | **aged 30+ yrs** | |
| **N** | **N** | **N** | **%** | **N** | **%** |
| Anatomical Pathology Services | 185 | 355 | 4 | 2.2 | 354 | 99.7 |
| Canterbury Health Laboratories | 34 | 113 | 1 | 2.9 | 111 | 98.2 |
| LabPLUS | 71 | 178 | 0 | 0.0 | 171 | 96.1 |
| Medlab Central Ltd. | 94 | 178 | 1 | 1.1 | 155 | 87.1 |
| Pathlab | 123 | 298 | 0 | 0.0 | 294 | 98.7 |
| Southern Community Laboratories | 201 | 458 | 1 | 0.5 | 452 | 98.7 |
| **Total** | **708** | **1,580** | **7** | **1.0** | **1,537** | **97.3** |

*\* Where the laboratory which performed the cytology test differs from the laboratory which performed the HPV test, classification is according to the laboratory which performed the cytology test*

Table 78 - Triage testing of women with LSIL cytology

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Total LSIL results** | | **Women with an HPV test** | | | |
| **aged < 30yrs** | **aged 30+ yrs** | **aged < 30yrs** | | **aged 30+ yrs** | |
| **N** | **N** | **N** | **%** | **N** | **%** |
| Anatomical Pathology Services | 537 | 372 | 2 | 0.4 | 369 | 99.2 |
| Canterbury Health Laboratories | 122 | 73 | 0 | 0.0 | 70 | 95.9 |
| LabPLUS | 103 | 67 | 1 | 1.0 | 65 | 97.0 |
| Medlab Central Ltd. | 150 | 112 | 0 | 0.0 | 97 | 86.6 |
| Pathlab | 370 | 315 | 1 | 0.3 | 313 | 99.4 |
| Southern Community Laboratories | 1,129 | 655 | 11 | 1.0 | 627 | 95.7 |
| **Total** | **2,411** | **1,594** | **15** | **0.6** | **1,541** | **96.7** |

*\* Where the laboratory which performed the cytology test differs from the laboratory which performed the HPV test, classification is according to the laboratory which performed the cytology test*

Table 79 - Histological outcomes within 12 months in women with ASC-US cytology and positive HPV triage test

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Women with ASC-US cytology & positive HPV triage test** | **Triage-positive women who attended colposcopy** | | **Triage-positive women with histology recorded** | | | **Triage-positive women with CIN 2+ histology** | | |
|  | **N** | **N** | **%\*** | | **N** | **%\*** | **N** | **%†** | **%‡** |
| Anatomical Pathology Services | 85 | 82 | 96.5 | | 54 | 63.5 | 10 | 12.2 | 18.5 |
| Canterbury Health Laboratories | 24 | 23 | 95.8 | | 19 | 79.2 | 6 | 26.1 | 31.6 |
| LabPLUS | 18 | 16 | 88.9 | | 10 | 55.6 | 1 | 6.3 | 10.0 |
| Medlab Central Ltd. | 30 | 28 | 93.3 | | 20 | 66.7 | 6 | 21.4 | 30.0 |
| Pathlab | 87 | 86 | 98.9 | | 56 | 64.4 | 14 | 16.3 | 25.0 |
| Southern Community Laboratories | 85 | 79 | 92.9 | | 50 | 58.8 | 11 | 13.9 | 22.0 |
| **Total** | **329** | **314** | **95.4** | | **209** | **63.5** | **48** | **15.3** | **23.0** |

*\* % of women with ASC-US cytology and positive triage test † expressed as a percentage of women with colposcopy ‡ expressed as a percentage of women with histology. Results are for ASC-US cytology collected in the 6-month period 12 months prior to the current monitoring period (i.e. in 1 July – 31 December 2016), to allow for sufficient follow-up time for colposcopy/ histology.*

Table 80 - Histological outcomes within 12 months in women with LSIL cytology and positive HPV triage test

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Women with LSIL cytology & positive HPV triage test** | **Triage -positive women who attended colposcopy** | | **Triage -positive women with histology recorded** | | **Triage -positive women with CIN 2+ histology** | | |
|  | **N** | **N** | **%\*** | **N** | **%\*** | **N** | **%†** | **%‡** |
| Anatomical Pathology Services | 235 | 214 | 91.1 | 157 | 66.8 | 19 | 8.9 | 12.1 |
| Canterbury Health Laboratories | 26 | 24 | 92.3 | 19 | 73.1 | 4 | 16.7 | 21.1 |
| LabPLUS | 23 | 20 | 87.0 | 17 | 73.9 | 3 | 15.0 | 17.6 |
| Medlab Central Ltd. | 40 | 37 | 92.5 | 22 | 55.0 | 4 | 10.8 | 18.2 |
| Pathlab | 121 | 110 | 90.9 | 71 | 58.7 | 19 | 17.3 | 26.8 |
| Southern Community Laboratories | 351 | 323 | 92.0 | 247 | 70.4 | 54 | 16.7 | 21.9 |
| **Total** | **796** | **728** | **91.5** | **533** | **67.0** | **103** | **14.1** | **19.3** |

*\* % of women with LSIL cytology and positive triage test † expressed as a percentage of women with colposcopy ‡ expressed as a percentage of women with histology. Results are for ASC-US cytology collected in the 6-month period 12 months prior to the current monitoring period (i.e. in 1 July – 31 December 2016), to allow for sufficient follow-up time for colposcopy/ histology.*

### Indicator 8.2 – HPV test volumes

Table 81 - Volume of HPV test samples received during the monitoring period, by laboratory

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HPV tests received** | | **Ratio HPV tests: smears received (%)** |
| **Laboratory** | **N** | **% of  national total** |
| Anatomical Pathology Services | 4,110 | 22.5 | 9.0 |
| Canterbury Health Laboratories | 1,326 | 7.2 | 12.6 |
| LabPLUS | 798 | 4.4 | 9.6 |
| Medlab Central Ltd. | 1,588 | 8.7 | 10.0 |
| Pathlab | 2,565 | 14.0 | 9.1 |
| Southern Community Laboratories | 7,915 | 43.2 | 7.2 |
| **Total** | **18,302** | **100.0** | **8.4** |

Table 82 - Invalid HPV tests, by laboratory

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory** | **Total** | **Valid** | | | | **Invalid** | |
| **N** | | **N** | **%** | **N** | | **%** |
| Anatomical Pathology Services | 4,110 | | 4,107 | 99.9 | 3 | | 0.07 |
| Canterbury Health Laboratories | 1,326 | | 1,324 | 99.8 | 2 | | 0.15 |
| LabPLUS | 798 | | 797 | 99.9 | 1 | | 0.13 |
| Medlab Central Ltd. | 1,588 | | 1,587 | 99.9 | 1 | | 0.06 |
| Pathlab | 2,565 | | 2,560 | 99.8 | 5 | | 0.19 |
| Southern Community Laboratories | 7,915 | | 7,914 | 100.0 | 1 | | 0.01 |
| **Total** | **18,302** | | **18,289** | **99.9** | **13** | | **0.07** |

Table 83 - Validity of HPV triage tests, by test technology

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Test technology** | **Total HPV tests** | | **Valid** | | **Invalid** | |
|  | **N** | **%** | **N** | **%** | **N** | **%** |
| Abbott RealTime | 9,241 | *50.5* | 9,238 | 100.0 | 3 | 0.03 |
| Roche COBAS4800 | 7,302 | *39.9* | 7,297 | 99.9 | 5 | 0.07 |
| BD Onclarity | 1,759 | *9.6* | 1,754 | 99.7 | 5 | 0.28 |
| **Total** | **18,302** | ***100.0*** | **18,289** | **99.9** | **13** | **0.07** |

Table 84 - Volume of HPV test samples received during the monitoring period, by purpose and ethnicity

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Post-treatment** | | | **Historical** | | **Taken at colposcopy** | | | **HPV triage** | | **Other** | | | **Total** |
| **Ethnicity** | **N** | **%** | **N** | | **%** | | **N** | **%** | **N** | **%** | **N** | **%** | **N** | |
| Māori | 400 | 15.0 | 1,117 | | 42.0 | | 156 | 5.9 | 333 | 12.5 | 655 | 24.6 | 2,661 | |
| Pacific | 90 | 14.1 | 226 | | 35.4 | | 39 | 6.1 | 158 | 24.8 | 125 | 19.6 | 638 | |
| Asian | 255 | 17.5 | 368 | | 25.2 | | 123 | 8.4 | 438 | 30.0 | 274 | 18.8 | 1,458 | |
| European/ Other | 1,949 | 14.4 | 4,990 | | 36.8 | | 1,070 | 7.9 | 1,949 | 14.4 | 3,587 | 26.5 | 13,545 | |
| **Total** | **2,694** | **14.7** | **6,701** | | **36.6** | | **1,388** | **7.6** | **2,878** | **15.7** | **4,641** | **25.4** | **18,302** | |

Table 85 - Volume of HPV test samples received during the monitoring period, by purpose and age

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Post-treatment** | | **Historical** | | **Taken at colposcopy** | | | **HPV triage** | | **Other** | | | **Total** |
| **Age** | **N** | **%** | **N** | **%** | | **N** | **%** | **N** | **%** | | **N** | **%** | **N** |
| <20 | 1 | 14.3 | - | - | | 3 | 42.9 | - | 0.0 | | 3 | 42.9 | 7 |
| 20-24 | 184 | 25.9 | 55 | 7.7 | | 197 | 27.7 | - | 0.0 | | 274 | 38.6 | 710 |
| 25-29 | 612 | 33.1 | 648 | 35.0 | | 168 | 9.1 | - | 0.0 | | 422 | 22.8 | 1,850 |
| 30-34 | 626 | 20.7 | 1,068 | 35.3 | | 186 | 6.1 | 628 | 20.8 | | 517 | 17.1 | 3,025 |
| 35-39 | 426 | 17.3 | 1,014 | 41.1 | | 143 | 5.8 | 497 | 20.1 | | 387 | 15.7 | 2,467 |
| 40-44 | 293 | 12.9 | 996 | 44.0 | | 136 | 6.0 | 425 | 18.8 | | 415 | 18.3 | 2,265 |
| 45-49 | 211 | 9.0 | 1,014 | 43.5 | | 116 | 5.0 | 447 | 19.2 | | 544 | 23.3 | 2,332 |
| 50-54 | 131 | 6.9 | 709 | 37.6 | | 139 | 7.4 | 318 | 16.9 | | 589 | 31.2 | 1,886 |
| 55-59 | 90 | 5.7 | 545 | 34.8 | | 119 | 7.6 | 256 | 16.3 | | 556 | 35.5 | 1,566 |
| 60-64 | 59 | 5.5 | 342 | 31.7 | | 88 | 8.2 | 165 | 15.3 | | 424 | 39.3 | 1,078 |
| 65-69 | 40 | 4.9 | 216 | 26.5 | | 60 | 7.4 | 110 | 13.5 | | 389 | 47.7 | 815 |
| 70+ | 21 | 7.0 | 94 | 31.2 | | 33 | 11.0 | 32 | 10.6 | | 121 | 40.2 | 301 |
| **Total** | **2,694** | **14.7** | **6,701** | **36.6** | | **1,388** | **7.6** | **2,878** | **15.7** | | **4,641** | **25.4** | **18,302** |

Table 86 - Volume of HPV test samples received during the monitoring period, by purpose and laboratory

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Post-treatment** | | **Historical** | | **Taken at colposcopy** | | **HPV triage** | | | **Other** | | **Total** |
| **Laboratory** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | **%** | **N** | | **%** | **N** |
| Anatomical Pathology Services | 566 | 13.8 | 1,771 | 43.1 | 109 | 2.7 | 702 | 17.1 | 962 | | 23.4 | 4,110 |
| Canterbury Health Laboratories | 330 | 24.9 | 347 | 26.2 | 280 | 21.1 | 169 | 12.7 | 200 | | 15.1 | 1,326 |
| LabPLUS | 117 | 14.7 | 166 | 20.8 | 183 | 22.9 | 225 | 28.2 | 107 | | 13.4 | 798 |
| Medlab Central Ltd. | 304 | 19.1 | 596 | 37.5 | 63 | 4.0 | 242 | 15.2 | 383 | | 24.1 | 1,588 |
| Pathlab | 305 | 11.9 | 1,089 | 42.5 | 255 | 9.9 | 550 | 21.4 | 366 | | 14.3 | 2,565 |
| Southern Community Laboratories | 1,072 | 13.5 | 2,732 | 34.5 | 498 | 6.3 | 990 | 12.5 | 2,623 | | 33.1 | 7,915 |
| **Total** | **2,694** | **14.7** | **6,701** | **36.6** | **1,388** | **7.6** | **2,878** | **15.7** | **4,641** | | **25.4** | **18,302** |

Table 87 - HPV test samples collected at colposcopy, in relation to total colposcopies performed in the period, by DHB

|  |  |  |  |
| --- | --- | --- | --- |
| **Laboratory** | **HPV tests**  **N** | **Colposcopies**  **N** | **HPV tests / colposcopies**  **%** |
| *Public clinics overall* | *1,009* | *10,789* | *9.4* |
| Auckland | 21 | 918 | 2.3 |
| Bay of Plenty | 128 | 646 | 19.8 |
| Canterbury | 186 | 1,653 | 11.3 |
| Capital & Coast | 57 | 711 | 8.0 |
| Counties Manukau | 70 | 930 | 7.5 |
| Hawke's Bay | 37 | 329 | 11.2 |
| Hutt Valley | 21 | 256 | 8.2 |
| Lakes | 90 | 296 | 30.4 |
| Mid Central | 16 | 543 | 2.9 |
| Nelson Marlborough | 36 | 325 | 11.1 |
| Northland | 29 | 363 | 8.0 |
| South Canterbury | 33 | 123 | 26.8 |
| Southern | 57 | 702 | 8.1 |
| Tairawhiti | - | 161 | - |
| Taranaki | 36 | 389 | 9.3 |
| Waikato | 96 | 859 | 11.2 |
| Wairarapa | 15 | 73 | 20.5 |
| Waitemata | 59 | 1,222 | 4.8 |
| West Coast | 6 | 89 | 6.7 |
| Whanganui | 16 | 201 | 8.0 |
| *Private practice* | 163 | 1,409 | 11.6 |
| **Total** | **1,172** | **12,198** | **9.6** |

*HPV tests/ colposcopy can be interpreted broadly as the percentage of colposcopies within this DHB/ sector where a sample is collected for HPV testing. Consistent with the count of colposcopies column, the number of HPV tests here includes only HPV test samples where a colposcopy report record exists.*

### Indicator 8.3 –HPV tests for follow-up of women with a historical high-grade abnormality

Table 88 - Women eligible for and proportion who have received HPV testing for a historical high-grade abnormality, by age at 30 June 2018

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Age group** | **Number of women eligible for testing as at 1 Oct 2009** | | **Round 1 test recorded** | | **Round 2 test recorded** | |
|  | **All** | **In current report\*** | **N** | **%** | **N** | **%** |
| <20 | - | - | - | 0.0 | - | 0.0 |
| 20-24 | - | - | - | 0.0 | - | 0.0 |
| 25-29 | 37 | 37 | 16 | 43.2 | 14 | 37.8 |
| 30-34 | 1,646 | 1,634 | 1,063 | 65.1 | 831 | 50.9 |
| 35-39 | 5,907 | 5,865 | 3,903 | 66.5 | 3,241 | 55.3 |
| 40-44 | 9,405 | 9,331 | 6,491 | 69.6 | 5,432 | 58.2 |
| 45-49 | 10,890 | 10,772 | 7,586 | 70.4 | 6,385 | 59.3 |
| 50-54 | 8,060 | 7,925 | 5,558 | 70.1 | 4,691 | 59.2 |
| 55-59 | 5,967 | 5,790 | 4,056 | 70.1 | 3,448 | 59.6 |
| 60-64 | 3,653 | 3,528 | 2,506 | 71.0 | 2,155 | 61.1 |
| 65-69 | 2,178 | 2,037 | 1,397 | 68.6 | 1,204 | 59.1 |
| 70+ | 2,760 | 2,274 | 896 | 39.4 | 701 | 30.8 |
| **Total** | **50,503** | **49,193** | **33,472** | **68.0** | **28,102** | **57.1** |

*\* Women are not followed up in the current report if they are no longer alive at the end of the current monitoring period; or if they have since had a non-squamous high -grade abnormality (no longer eligible for HPV testing to follow-up historical high -grade abnormality).*

Table 89 - Women eligible for and proportion who have received historical HPV testing, by DHB

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **DHB** | **Number of women eligible for historical testing as at 1 Oct 2009** | | **Round 1 test recorded** | | **Round 2 test recorded** | |
|  | **All** | **In current report\*** | **N** | **%** | **N** | **%** |
| Auckland | 3,986 | 3,919 | 2,247 | 57.3 | 1,756 | 44.8 |
| Bay of Plenty | 3,025 | 2,937 | 2,076 | 70.7 | 1,673 | 57.0 |
| Canterbury | 6,018 | 5,879 | 4,048 | 68.9 | 3,553 | 60.4 |
| Capital & Coast | 2,804 | 2,761 | 1,876 | 67.9 | 1,663 | 60.2 |
| Counties Manukau | 3,535 | 3,432 | 1,932 | 56.3 | 1,493 | 43.5 |
| Hawke's Bay | 2,240 | 2,172 | 1,576 | 72.6 | 1,346 | 62.0 |
| Hutt Valley | 1,537 | 1,497 | 1,029 | 68.7 | 885 | 59.1 |
| Lakes | 1,612 | 1,573 | 973 | 61.9 | 765 | 48.6 |
| Mid Central | 2,242 | 2,172 | 1,624 | 74.8 | 1,433 | 66.0 |
| Nelson Marlborough | 1,902 | 1,849 | 1,475 | 79.8 | 1,340 | 72.5 |
| Northland | 1,925 | 1,852 | 1,155 | 62.4 | 881 | 47.6 |
| South Canterbury | 844 | 818 | 617 | 75.4 | 544 | 66.5 |
| Southern | 4,765 | 4,658 | 3,349 | 71.9 | 2,906 | 62.4 |
| Tairawhiti | 910 | 876 | 568 | 64.8 | 467 | 53.3 |
| Taranaki | 2,220 | 2,145 | 1,591 | 74.2 | 1,414 | 65.9 |
| Waikato | 4,029 | 3,921 | 2,920 | 74.5 | 2,512 | 64.1 |
| Wairarapa | 514 | 500 | 332 | 66.4 | 284 | 56.8 |
| Waitemata | 5,128 | 5,008 | 3,197 | 63.8 | 2,452 | 49.0 |
| West Coast | 433 | 425 | 337 | 79.3 | 300 | 70.6 |
| Whanganui | 822 | 789 | 550 | 69.7 | 435 | 55.1 |
| Unspecified | *12* | *10* | *-* | *0.0* | *-* | *0.0* |
| **Total** | **50,503** | **49,193** | **33,472** | **68.0** | **28,102** | **57.1** |


*\* Women are not followed up in the current report if they are no longer alive at the end of the current monitoring period; or if they have since had a non-squamous high -grade abnormality (no longer eligible for historical HPV testing).*

Table 90 - Women eligible for and proportion who have received historical HPV testing, by ethnicity

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ethnicity** | **Number of women eligible for historical testing as at 1 Oct 2009** | | **Round 1 test recorded** | | | **Round 2 test recorded** | |
|  | **All** | **In current report\*** | **N** | **%** | **N** | | **%** |
| Māori | 7,950 | 7,651 | 4,866 | 63.6 | 3,773 | | 49.3 |
| Pacific | 1,240 | 1,203 | 582 | 48.4 | 456 | | 37.9 |
| Asian | 1,696 | 1,677 | 912 | 54.4 | 756 | | 45.1 |
| European/ Other | 39,617 | 38,662 | 27,112 | 70.1 | 23,117 | | 59.8 |
| **Total** | **50,503** | **49,193** | **33,472** | **68.0** | **28,102** | | **57.1** |

*\* Women are not followed up in the current report if they are no longer alive at the end of the current monitoring period; or if they have since had a non-squamous high -grade abnormality (no longer eligible for historical HPV testing).*


Figure 115 - Number of women eligible for historical testing within a DHB versus the percentage with a Round 1 historical HPV test recorded



*Each dot represents a DHB.*


*This chart does not suggest that there is any relationship between the number of women eligible for testing and percent of women who have been tested, therefore this does not seem a likely explanation for the variation in women tested in different DHBs.*

Figure 116 - Relationship between women screened in the previous five years and proportion of women with historical tests recorded, by DHB



*Each dot represents a DHB. See also Table 91*

Figure 117 - Relationship between women screened in the previous five years and proportion of women with historical tests recorded, by ethnicity



*Each dot represents an ethnicity*

Table 91 - Women screened in the previous five years and proportion of women with historical round 1 and 2 tests recorded, by DHB

|  |  |  |  |
| --- | --- | --- | --- |
| **DHB** | **Women screened in the last 5 years** | **Round 1 test recorded** | **Round 2 test recorded** |
|  | **%** | **%** | **%** |
| Auckland | *81.8%* | 57.3% | 44.8% |
| Bay of Plenty | *93.3%* | 70.7% | 57.0% |
| Canterbury | *88.0%* | 68.9% | 60.4% |
| Capital & Coast | *92.3%* | 67.9% | 60.2% |
| Counties Manukau | *83.5%* | 56.3% | 43.5% |
| Hawke's Bay | *90.5%* | 72.6% | 62.0% |
| Hutt Valley | *90.3%* | 68.7% | 59.1% |
| Lakes | *91.1%* | 61.9% | 48.6% |
| Mid Central | *87.7%* | 74.8% | 66.0% |
| Nelson Marlborough | *93.8%* | 79.8% | 72.5% |
| Northland | *86.6%* | 62.4% | 47.6% |
| South Canterbury | *89.6%* | 75.4% | 66.5% |
| Southern | *91.9%* | 71.9% | 62.4% |
| Tairawhiti | *90.0%* | 64.8% | 53.3% |
| Taranaki | *93.7%* | 74.2% | 65.9% |
| Waikato | *87.7%* | 74.5% | 64.1% |
| Wairarapa | *89.3%* | 66.4% | 56.8% |
| Waitemata | *84.9%* | 63.8% | 49.0% |
| West Coast | *89.0%* | 79.3% | 70.6% |
| Whanganui | *89.3%* | 69.7% | 55.1% |

# Appendix B – Bethesda 2001 New Zealand Modified

| **TBS code** | **Descriptor** |
| --- | --- |
| Specimen type | |
| CPS | Conventional pap smear |
| LBC | Liquid based cytology |
| COM | Combined (conventional and liquid based) |
| Specimen site | |
| T | Vault |
| R | Cervical |
| V | Vaginal |
| Adequacy | |
| S1 | The specimen is satisfactory for evaluation (optional free text) |
| S2 | The specimen is satisfactory for evaluation (optional free text). No endocervical/ transformation zone component present |
| UA | The specimen is unsatisfactory for evaluation because of insufficient squamous cells |
| UB | The specimen is unsatisfactory for evaluation because of poor fixation/preservation |
| UC | The specimen is unsatisfactory for evaluation because foreign material obscures the cells |
| UD | The specimen is unsatisfactory for evaluation because inflammation obscures the cells |
| UE | The specimen is unsatisfactory for evaluation because blood obscures the cells |
| UF | The specimen is unsatisfactory for evaluation because of cytolysis/autolysis |
| UG | The specimen is unsatisfactory for evaluation because … (free text) |
| General | |
| G1 | Negative for intraepithelial lesion or malignancy |
| G2 | Epithelial cell abnormality: See interpretation/result |
| G3 | Other: See interpretation/result |
| Interpretation | |
| O1 | There are organisms consistent with Trichomonas species |
| O2 | There are fungal organisms morphologically consistent with Candida species |
| O3 | There is a shift in microbiological flora that may represent bacterial vaginosis |
| O4 | There are bacteria morphologically consistent with Actinomyces species |
| O5 | There are cellular changes consistent with Herpes simplex virus |
| OT1 | There are reactive cellular changes present (optional free text) |
| OT2 | There are endometrial cells present in a woman over the age of 40 years |
| OT3 | There are atrophic cellular changes present |
| ASL | There are atypical squamous cells of undetermined significance (ASC-US) present |
| ASH | There are atypical squamous cells present. A high -grade squamous intraepithelial lesion cannot be excluded (ASC-H) |
| LS | There are abnormal squamous cells consistent with a low -grade squamous intraepithelial lesion (LSIL; CIN1/HPV) |
| HS1 | There are abnormal squamous cells consistent with a high -grade squamous intraepithelial lesion (HSIL). The features are consistent with CINII or CINIII |
| HS2 | There are abnormal squamous cells consistent with a high -grade squamous intraepithelial lesion (HSIL) with features suspicious for invasion |
| SC | There are abnormal squamous cells showing changes consistent with squamous cell carcinoma |
| AG1 | There are atypical endocervical cells present |
| AG2 | There are atypical endometrial cells present |
| AG3 | There are atypical glandular cells present |
| AG4 | There are atypical endocervical cells favouring a neoplastic process |
| AG5 | There are atypical glandular cells favouring a neoplastic process |
| AIS | There are abnormal endocervical cells consistent with adenocarcinoma in-situ (AIS) |
| AC1 | There are abnormal glandular cells consistent with endocervical adenocarcinoma |
| AC2 | There are abnormal glandular cells consistent with endometrial adenocarcinoma |
| AC3 | There are abnormal glandular cells consistent with extrauterine adenocarcinoma |
| AC4 | There are abnormal glandular cells consistent with adenocarcinoma |
| AC5 | There are abnormal cells consistent with a malignant neoplasm |
| Recommendation | |
| R1 | The next smear should be taken in three years, based on the information held on the NCSP Register |
| R2 | Please repeat the smear within three months |
| R3 | Please repeat the smear within three months of the end of pregnancy |
| R4 | Please repeat the smear in three months |
| R5 | Please repeat the smear in six months |
| R6 | Please repeat the smear in 12 months |
| R7 | Because a previous smear showed atypical squamous cells or low -grade changes, please repeat the smear in 12 months |
| R8 | Annual smears are indicated because of previous high -grade abnormality |
| R9 | Referral for specialist assessment is indicated |
| R10 | Urgent referral for specialist assessment is indicated |
| R11 | [not in use] |
| R12 | Please repeat the smear shortly after a course of oestrogen treatment |
| R13 | Under specialist care |
| R14 | In view of the abnormal clinical history provided, urgent referral for assessment is recommended regardless of cytological findings |

Appendix C – SNOMED categories for histological samples

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Adequacy of specimen** | | **1986 Code** | **1993 Code** |  |  |
| Insufficient or unsatisfactory material for diagnosis | | M09000 | M09010 |  |  |
| There is no code for satisfactory materials. | |  |  |  |  |
| **Site (topography) of specimen** | | **1986 Code** | **1993 Code** |  |  |
| Vagina | | T81 | T82000 |  |  |
| Cervix (includes endocervix and exocervix) | | T83 | T83200 |  |  |
| **Summary diagnosis** | **Code stored on register** | **1986 Code** | **1993 Code** | **Diagnostic category** | **Rank\*** |
| ***There will be a maximum of four M codes transmitted to the register.*** | | | | |  |
| Negative result - normal tissue | | M00100 | M60000 | Negative/benign | 1 |
| Inflammation | | M40000 | M40000 | Negative/benign | 2 |
| Microglandular hyperplasia | | M72480 | M72480 | Negative/benign | 3 |
| Squamous Metaplasia | | M73000 | M73000 | Negative/benign | 4 |
| Polyp | | M76800 | M76800 | Negative/benign | 5 |
| Other (Morphologic abnormality, not dysplastic or malignant) | | M01000 | M01000 | Negative/benign | 6 |
| Atypia | | M69700 | M67000 | CIN 1 | 7 |
| Benign glandular atypia | | M81400 | M67030 | Negative/benign | 8 |
| HPV, koilocytosis, condyloma (NOS)  Condyloma acuminatum | M76700 | M76700  M76720 | M76700  M76720 | HPV | 9 |
| CIN I (LSIL)  (VAIN I when used with T81/ T82000) | | M74006 | M67016 | CIN 1 | 10 |
| Dysplasia / CIN NOS | | M74000 | M67015 | CIN 1 | 11 |
| Glandular dysplasia | | M81401 | M67031 | Glandular dysplasia | 12 |
| CIN II (HSIL)  (VAIN II when used with T81/ T82000) | | M74007 |  | CIN 2 | 13 |
| HSIL NOS | | M67017 | M67017 | HSIL | 14 |
| CIN III (HSIL) | | M74008 |  | CIN 3 | 17 |
| (VAIN III when used with T81/ T82000)  Carcinoma in situ | | M80102  M80702 | M80102  M80702 |  | 15  16 |
| Adenocarcinoma in situ | | M81402 | M81402 | Adenocarc. in situ | 18 |
| Microinvasive squamous cell carcinoma | | M80765 | M80763 | Micro-invasive | 19 |
| Invasive squamous cell carcinoma | | M80703 | M80703 | Invasive SCC | 20 |
| Adenocarcinoma (endocervical type) | | M83843 | M83843 | Adenocarcinoma (endocervical type) | 21 |
| Adenosquamous carcinoma | | M85603 | M85603 | Adenosquamous carcinoma | 22 |
| Invasive adenocarcinoma (not endocervical type) | | M81403 | M81403 | Invasive adenocarcinoma  (not endocervical type) | 23 |
| Metastatic tumour | | M80006 | M80006 | Other cancer | 29 |
| Undifferentiated carcinoma | | M80203 | M80203 | Other cancer | 24 |
| Sarcoma |  | M88003 | M88003 | Other cancer | 25 |
| **Other codes accepted** | **Code stored on register** | **1986 Code** | **1993 Code** | **Diagnostic category** | **Rank** |
| Carcinosarcoma | M88003 | M89803 | M89803 | Other cancer | 26 |
| Choriocarcinoma | M80003 | M91003 | M91003 | Other cancer | 27 |
| Miscellaneous primary tumour | M80003 | M80003 | M80003 | Other cancer | 28 |
| Small cell carcinoma | M80003 | M80413 | M80413 | Other cancer | 30 |
| Malignant tumour, Small cell type | M80003 | M80023 | M80023 | Other cancer | 31 |
| **Other codes accepted** | **Code stored on register** | **1986 Code** | **1993 Code** | **Diagnostic category** | **Rank** |
| Melanoma | M80003 | M87203 | M87203 | Other cancer | 32 |
| Other primary epithelial malignancy | M80003 | M80103 | M80103 | Other cancer | 33 |

Appendix D – Indicator Definitions Targets and Reporting Details

## Positive predictive value calculations

Table 92 - Definition used for positive predictive value calculations

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Histology Diagnosis** | **G1** | **Squamous (G2)** | | | | | **Glandular (G2)** | | | **Other (G3)** | **Total** |
|  | **G1** | **ASL** | **LS** | **ASH** | **HS1/2** | **SC** | **AG1-5** | **AIS** | **AC1-4** | **AC5** |  |
| Negative |  |  |  | **q** | **y** | **y** | **a** | **a** | **a** |  |  |
| Squam-Atypia NOS |  |  |  | **q** | **y** | **y** | **a** | **a** | **a** |  |  |
| Squam-Low-grade/CIN1/HPV |  |  |  | **q** | **y** | **y** | **a** | **a** | **a** |  |  |
| Squam-High-grade/CIN 2-3 |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Squam Microinvasive SCC |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Squam-Invasive SCC |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Gland-Benign Atypia |  |  |  | **q** | **y** | **y** | **a** | **a** | **a** |  |  |
| Gland-Dyplasia |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Gland-AIS |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Gland-Invasive Adeno |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |
| Other Malignant Neoplasm |  |  |  | **p** | **x** | **x** | **b** | **b** | **b** |  |  |

PPV% (ASC-H)= sum(p) / (sum(p)+sum(q))

PPV% (HSIL)= sum(x) / (sum(x)+sum(y))

PPV% (ASC-H + HSIL + SC)= (sum(p) + sum(x))/ (sum(p)+sum(q) +sum(x) + sum(y)

Appendix E – DHB assignment for colposcopy clinics

Where results in Indicator 7 (colposcopy indicators) are provided by DHB, the clinics included in each DHB are as listed below. Assignment of individual facilities to specific DHBs was provided by the NCSP. All other colposcopy clinics were grouped together as “Private practice”.

| **DHB** | **Colposcopy clinics included\*** |
| --- | --- |
| Auckland | Ward 97 - Gynae Inpatient Auckland City Hospital  General Surgery – Auckland City Hospital  Colposcopy Clinic - Greenlane Clinical Centre  Gynae Outpatient Clinic – Greenlane Clinical Centre  Short Stay Surgical Unit – Greenlane Clinical Centre  Emergency Medicine – North Shore Hospital |
| Bay of Plenty | Whakatane Hospital (G)  Opotiki Hospital Outpatients’ Department  Tauranga Hospital (G) |
| Canterbury | Ashburton Hospital  Christchurch Hospital  Christchurch Sexual Health Centre  Christchurch Women's Hospital - Colposcopy  Christchurch Women's Hospital - Gynaecology |
| Capital & Coast | Colposcopy Clinic – Wellington Women’s Hospital Outpatients Department  Kenepuru Women's Outpatients’ Department  Women's Clinic – Wellington Regional Hospital |
| Counties Manukau | Manukau Super Clinic  Gynaecology Clinic – [Middlemore Hospital]  Colposcopy Clinic – Manukau Super Clinic |
| Hawke's Bay | Chatham Islands Health Centre  Outpatients Dept – Napier Health Centre  Villa 4, Gynaecology, Hawke’s Bay Hospital  Hawkes Bay Regional Hospital  Wairoa Cervical Screening  Wairoa Hospital |
| Hutt Valley | Women's Health Clinic – Hutt Hospital  Gynaecology Clinic - Hutt Hospital |
| Lakes | Rotorua Hospital (Gynae Dept)  Taupo Hospital |
| Mid Central | Colposcopy Clinic – Palmerston North Hospital  Gynaecology Clinic - Palmerston North Hospital  Gynaecology Clinic Horowhenua Hospital |
| Nelson Marlborough | Marlborough Maternity & Gynae  Nelson Outpatients Department |
| Northland | Colposcopy Clinic Whangarei Hospital  Kaitaia Hospital Colp Outpatients’ Department  Bay Of Islands Hospital Outpatients’ Department  Gynaecology Clinic Whangarei Hospital |
| South Canterbury | Timaru Hospital - Colp/Gynae |
| Southern | General Gynae Department – Dunedin Hospital  Dunedin Public Hospital  Dunedin Colposcopy Clinic  Southland Hospital Gynaecology |
| Tairawhiti | Gisborne Hospital |
| Taranaki | Taranaki Health Base Hospital - Outpatients Department  Hawera Outpatients |
| Waikato | Te Kuiti Hospital  Womens Outpatient Services – Waikato Hospital  Tokoroa Hospital - Bev Thorn |
| Wairarapa | Gynaecology Clinic – Wairarapa Hospital |
| Waitemata | Colposcopy Clinic- Waitakere Hospital  Gynaecology Clinic –North Shore Hospital  Colposcopy Clinic- North Shore Hospital  Peri-Operative Department - North Shore Hospital |
| West Coast | Greymouth Hospital  Gynaecology Clinic Greymouth |
| Whanganui | Wanganui Hospital  Gynaecology Clinic – Good Health Wanganui |

*\* Assignment of specific facilities to a DHB was provided by the NCSP, in order to distinguish between DHB clinics and private practice, because the NCSP Register records geographic DHB and does not record public vs private clinic.*

Appendix F – Glossary

|  |  |
| --- | --- |
| **Term** | **Definition** |
| AGC | Atypical glandular cells |
| AIS | Adenocarcinoma in situ. High-grade changes to the glandular (endocervical) cells of the cervix |
| ASC-H | Atypical squamous cells of undetermined significance, cannot exclude high -grade |
| ASC-US | Atypical squamous cells of undetermined significance |
| ASR | Age standardised rate |
| CI | Confidence interval |
| CIN | Cervical intra-epithelial neoplasia; CINI: low -grade; CIN 2 or 3: high -grade |
| CIS | Carcinoma in situ. An older classification of CIN 3. Abnormal cells that are confined to the surface epithelium of the cervix. |
| CPS | Conventional Pap (Papanicolaou) Smear |
| DHB | District Health Board |
| European/ Other | European women and women from non-Māori ,non-Pacific and non-Asian ethnic groups |
| HPV | Human papillomavirus |
| HPV test | Testing for a high risk (oncogenic) subtype of human papillomavirus |
| hrHPV | A high risk (oncogenic) subtype of human papillomavirus |
| HSIL | High -grade squamous intra-epithelial lesion |
| ISC | Invasive squamous carcinoma |
| LBC | Liquid based cytology |
| LSIL | Low -grade squamous intra-epithelial lesion |
| NCSP | National Cervical Screening Programme |
| NHI | National Health Index |
| NILM | Negative for intraepithelial lesion or malignancy (a negative cytology report) |
| NSU | National Screening Unit of the Ministry of Health |
| NPV | Negative predictive value. The proportion of the screened population with negative test results who do not have the disease being tested for. |
| OR | Odds ratio |
| PCR | Polymerase chain reaction. A technique in molecular genetics used in many types of HPV testing |
| PPV | Positive predictive value. The proportion of the screened population with positive test results who have the disease being tested for. |
| RR | Relative risk |
| SC | Squamous cell carcinoma (TBS 2001) |
| SCC | Squamous cell carcinoma |
| SNOMED | Systematised Nomenclature of Medicine. A systematically organised collection of medical terminology including histopathological diagnoses. |
| TBS 2001 (NZ Modified) | The Bethesda System 2001 New Zealand Modified. A management system based on categorising the cytological interpretation of cellular abnormality as negative, low-grade or high-grade. |
| TZ | Transformation zone. The region of the cervix where the glandular precursor cells change to squamous cells |

References

1. Cleary L, Wright C. Estimating hysterectomy prevalence in New Zealand 2010-2018: Report on methods, 2018.

2. Gray A. Methodology for estimating hysterectomy prevalence in women 20-69. Wellington, New Zealand, 2011.

3. Ministry of Health. HISO 10001:2017 Ethnicity Data Protocols. 2017. <https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocolslast> updated 6th October 2017).

4. Ministry of Health. Ethnicity Data Protocols for the Health and Disability Sector. 2004. <http://www.health.govt.nz/publication/ethnicity-data-protocols-health-and-disability-sectorlast>).

5. Ministry of Health. Asian Health Chart Book. 2006. <http://www.health.govt.nz/publication/asian-health-chart-book-2006last>).

6. National Screening Unit. Age range change for cervical screening. 2018. <https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/age-range-change-cervical-screening> (accessed 4th July 2018; last updated 7th June 2018).

7. Simonella L, Lewis H, Smith M, Neal H, Bromhead C, Canfell K. The prevalence of type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. *BMC Infect Dis* 2013; **13**(114).

8. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int J Cancer* 2007; **121**(3): 621-32.

9. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. *J Med Virol* 2009; **81**(7): 1283-91.

10. Brestovac B, Harnett GB, Smith DW, Shellam GR, Frost FA. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. *J Med Virol* 2005; **76**(1): 106-10.

11. Porras C, Rodriguez AC, Hildesheim A, et al. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. *Cancer Epidemiol Biomarkers Prev* 2009; **18**(3): 863-5.

12. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjaer SK. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. *Gynecol Oncol* 2012; **124**(2): 281-5.

13. Miyamoto J, Berkowitz Z, Unger E, et al. Vaccine-type HPV distribution in CIN3/AIS: 3 U.S. cancer registries, 1994-2005. International Papillomavirus Conference and Clinical Workshop; 2011 17-22/9/2011; Berlin, Germany; 2011.

14. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. *The Lancet* 2019.

15. Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. *Cancer Epidemiol Biomarkers Prev* 2013; **22**(8): 1446-50.

16. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and Indigenous Australian population following a national HPV vaccination program: analysis of routinely collected national hospital data. *J Infect Dis* 2015; **211**(1): 91-9.

17. National Cervical Screening Programme. NCSP Operational Policy and Quality Standards, Section 5.

18. National Cervical Screening Programme. Bethesda 2001 (NZ Modified) codes for Cytology Laboratories: Codes, descriptors and assessment of sample adequacy for cytology laboratories. Wellington, 2014.

19. Ministry of Health. Report of the Parliamentary Review Committee regarding the New Zealand Cervical Screening Programme Wellington: Ministry of Health, 2011.

20. Parliamentary Review Committee. Report of the Parliamentary Review Committee regarding the New Zealand Cervical Screening Programme, June 2015. Wellington, 2015.

21. National Screening Unit. Guidelines for Cervical Screening in New Zealand: Incorporating the management of women with abnormal cervical smears. Wellington: National Screening Unit, Ministry of Health, 2008.

22. Smith M, Walker R, Canfell K. National Cervical Screening Programme Monitoring Report Number 33. Wellington, 2012.

23. Smith M, Walker R, Canfell K. National Cervical Screening Programme Monitoring Report Number 34. Wellington, 2012.